Level/ Type | Code | Display Name | Code System | Designations | Description |
---|
0‑L | A | ALIMENTARY TRACT AND METABOLISM | WHO Anatomical Therapeutic Chemical classification | | ALIMENTARY TRACT AND METABOLISM |
0‑L | A01 | STOMATOLOGICAL PREPARATIONS | WHO Anatomical Therapeutic Chemical classification | | STOMATOLOGICAL PREPARATIONS |
0‑L | A01A | STOMATOLOGICAL PREPARATIONS | WHO Anatomical Therapeutic Chemical classification | | STOMATOLOGICAL PREPARATIONS |
0‑L | A01AA | Caries prophylactic agents | WHO Anatomical Therapeutic Chemical classification | | Caries prophylactic agents |
0‑L | A01AA01 | sodium fluoride | WHO Anatomical Therapeutic Chemical classification | | sodium fluoride |
0‑L | A01AA02 | sodium monofluorophosphate | WHO Anatomical Therapeutic Chemical classification | | sodium monofluorophosphate |
0‑L | A01AA03 | olaflur | WHO Anatomical Therapeutic Chemical classification | | olaflur |
0‑L | A01AA04 | stannous fluoride | WHO Anatomical Therapeutic Chemical classification | | stannous fluoride |
0‑L | A01AA30 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | A01AA51 | sodium fluoride, combinations | WHO Anatomical Therapeutic Chemical classification | | sodium fluoride, combinations |
0‑L | A01AB | Antiinfectives and antiseptics for local oral treatment | WHO Anatomical Therapeutic Chemical classification | | Antiinfectives and antiseptics for local oral treatment |
0‑L | A01AB02 | hydrogen peroxide | WHO Anatomical Therapeutic Chemical classification | | hydrogen peroxide |
0‑L | A01AB03 | chlorhexidine | WHO Anatomical Therapeutic Chemical classification | | chlorhexidine |
0‑L | A01AB04 | amphotericin B | WHO Anatomical Therapeutic Chemical classification | | amphotericin B |
0‑L | A01AB05 | polynoxylin | WHO Anatomical Therapeutic Chemical classification | | polynoxylin |
0‑L | A01AB06 | domiphen | WHO Anatomical Therapeutic Chemical classification | | domiphen |
0‑L | A01AB07 | oxyquinoline | WHO Anatomical Therapeutic Chemical classification | | oxyquinoline |
0‑L | A01AB08 | neomycin | WHO Anatomical Therapeutic Chemical classification | | neomycin |
0‑L | A01AB09 | miconazole | WHO Anatomical Therapeutic Chemical classification | | miconazole |
0‑L | A01AB10 | natamycin | WHO Anatomical Therapeutic Chemical classification | | natamycin |
0‑L | A01AB11 | various | WHO Anatomical Therapeutic Chemical classification | | various |
0‑L | A01AB12 | hexetidine | WHO Anatomical Therapeutic Chemical classification | | hexetidine |
0‑L | A01AB13 | tetracycline | WHO Anatomical Therapeutic Chemical classification | | tetracycline |
0‑L | A01AB14 | benzoxonium chloride | WHO Anatomical Therapeutic Chemical classification | | benzoxonium chloride |
0‑L | A01AB15 | tibezonium iodide | WHO Anatomical Therapeutic Chemical classification | | tibezonium iodide |
0‑L | A01AB16 | mepartricin | WHO Anatomical Therapeutic Chemical classification | | mepartricin |
0‑L | A01AB17 | metronidazole | WHO Anatomical Therapeutic Chemical classification | | metronidazole |
0‑L | A01AB18 | clotrimazole | WHO Anatomical Therapeutic Chemical classification | | clotrimazole |
0‑L | A01AB19 | sodium perborate | WHO Anatomical Therapeutic Chemical classification | | sodium perborate |
0‑L | A01AB21 | chlortetracycline | WHO Anatomical Therapeutic Chemical classification | | chlortetracycline |
0‑L | A01AB22 | doxycycline | WHO Anatomical Therapeutic Chemical classification | | doxycycline |
0‑L | A01AB23 | minocycline | WHO Anatomical Therapeutic Chemical classification | | minocycline |
0‑L | A01AC | Corticosteroids for local oral treatment | WHO Anatomical Therapeutic Chemical classification | | Corticosteroids for local oral treatment |
0‑L | A01AC01 | triamcinolone | WHO Anatomical Therapeutic Chemical classification | | triamcinolone |
0‑L | A01AC02 | dexamethasone | WHO Anatomical Therapeutic Chemical classification | | dexamethasone |
0‑L | A01AC03 | hydrocortisone | WHO Anatomical Therapeutic Chemical classification | | hydrocortisone |
0‑L | A01AC54 | prednisolone, combinations | WHO Anatomical Therapeutic Chemical classification | | prednisolone, combinations |
0‑L | A01AD | Other agents for local oral treatment | WHO Anatomical Therapeutic Chemical classification | | Other agents for local oral treatment |
0‑L | A01AD01 | epinephrine | WHO Anatomical Therapeutic Chemical classification | | epinephrine |
0‑L | A01AD02 | benzydamine | WHO Anatomical Therapeutic Chemical classification | | benzydamine |
0‑L | A01AD05 | acetylsalicylic acid | WHO Anatomical Therapeutic Chemical classification | | acetylsalicylic acid |
0‑L | A01AD06 | adrenalone | WHO Anatomical Therapeutic Chemical classification | | adrenalone |
0‑L | A01AD07 | amlexanox | WHO Anatomical Therapeutic Chemical classification | | amlexanox |
0‑L | A01AD08 | becaplermin | WHO Anatomical Therapeutic Chemical classification | | becaplermin |
0‑L | A01AD11 | various | WHO Anatomical Therapeutic Chemical classification | | various |
0‑L | A02 | DRUGS FOR ACID RELATED DISORDERS | WHO Anatomical Therapeutic Chemical classification | | DRUGS FOR ACID RELATED DISORDERS |
0‑L | A02A | ANTACIDS | WHO Anatomical Therapeutic Chemical classification | | ANTACIDS |
0‑L | A02AA | Magnesium compounds | WHO Anatomical Therapeutic Chemical classification | | Magnesium compounds |
0‑L | A02AA01 | magnesium carbonate | WHO Anatomical Therapeutic Chemical classification | | magnesium carbonate |
0‑L | A02AA02 | magnesium oxide | WHO Anatomical Therapeutic Chemical classification | | magnesium oxide |
0‑L | A02AA03 | magnesium peroxide | WHO Anatomical Therapeutic Chemical classification | | magnesium peroxide |
0‑L | A02AA04 | magnesium hydroxide | WHO Anatomical Therapeutic Chemical classification | | magnesium hydroxide |
0‑L | A02AA05 | magnesium silicate | WHO Anatomical Therapeutic Chemical classification | | magnesium silicate |
0‑L | A02AA10 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | A02AB | Aluminium compounds | WHO Anatomical Therapeutic Chemical classification | | Aluminium compounds |
0‑L | A02AB01 | aluminium hydroxide | WHO Anatomical Therapeutic Chemical classification | | aluminium hydroxide |
0‑L | A02AB02 | algeldrate | WHO Anatomical Therapeutic Chemical classification | | algeldrate |
0‑L | A02AB03 | aluminium phosphate | WHO Anatomical Therapeutic Chemical classification | | aluminium phosphate |
0‑L | A02AB04 | dihydroxialumini sodium carbonate | WHO Anatomical Therapeutic Chemical classification | | dihydroxialumini sodium carbonate |
0‑L | A02AB05 | aluminium acetoacetate | WHO Anatomical Therapeutic Chemical classification | | aluminium acetoacetate |
0‑L | A02AB06 | aloglutamol | WHO Anatomical Therapeutic Chemical classification | | aloglutamol |
0‑L | A02AB07 | aluminium glycinate | WHO Anatomical Therapeutic Chemical classification | | aluminium glycinate |
0‑L | A02AB10 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | A02AC | Calcium compounds | WHO Anatomical Therapeutic Chemical classification | | Calcium compounds |
0‑L | A02AC01 | calcium carbonate | WHO Anatomical Therapeutic Chemical classification | | calcium carbonate |
0‑L | A02AC02 | calcium silicate | WHO Anatomical Therapeutic Chemical classification | | calcium silicate |
0‑L | A02AC10 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | A02AD | Combinations and complexes of aluminium, calcium and magnesium compounds | WHO Anatomical Therapeutic Chemical classification | | Combinations and complexes of aluminium, calcium and magnesium compounds |
0‑L | A02AD01 | ordinary salt combinations | WHO Anatomical Therapeutic Chemical classification | | ordinary salt combinations |
0‑L | A02AD02 | magaldrate | WHO Anatomical Therapeutic Chemical classification | | magaldrate |
0‑L | A02AD03 | almagate | WHO Anatomical Therapeutic Chemical classification | | almagate |
0‑L | A02AD04 | hydrotalcite | WHO Anatomical Therapeutic Chemical classification | | hydrotalcite |
0‑L | A02AD05 | almasilate | WHO Anatomical Therapeutic Chemical classification | | almasilate |
0‑L | A02AF | Antacids with antiflatulents | WHO Anatomical Therapeutic Chemical classification | | Antacids with antiflatulents |
0‑L | A02AF01 | magaldrate and antiflatulents | WHO Anatomical Therapeutic Chemical classification | | magaldrate and antiflatulents |
0‑L | A02AF02 | ordinary salt combinations and antiflatulents | WHO Anatomical Therapeutic Chemical classification | | ordinary salt combinations and antiflatulents |
0‑L | A02AG | Antacids with antispasmodics | WHO Anatomical Therapeutic Chemical classification | | Antacids with antispasmodics |
0‑L | A02AH | Antacids with sodium bicarbonate | WHO Anatomical Therapeutic Chemical classification | | Antacids with sodium bicarbonate |
0‑L | A02AX | Antacids, other combinations | WHO Anatomical Therapeutic Chemical classification | | Antacids, other combinations |
0‑L | A02B | DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) | WHO Anatomical Therapeutic Chemical classification | | DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) |
0‑L | A02BA | H2-receptor antagonists | WHO Anatomical Therapeutic Chemical classification | | H2-receptor antagonists |
0‑L | A02BA01 | cimetidine | WHO Anatomical Therapeutic Chemical classification | | cimetidine |
0‑L | A02BA02 | ranitidine | WHO Anatomical Therapeutic Chemical classification | | ranitidine |
0‑L | A02BA03 | famotidine | WHO Anatomical Therapeutic Chemical classification | | famotidine |
0‑L | A02BA04 | nizatidine | WHO Anatomical Therapeutic Chemical classification | | nizatidine |
0‑L | A02BA05 | niperotidine | WHO Anatomical Therapeutic Chemical classification | | niperotidine |
0‑L | A02BA06 | roxatidine | WHO Anatomical Therapeutic Chemical classification | | roxatidine |
0‑L | A02BA07 | ranitidine bismuth citrate | WHO Anatomical Therapeutic Chemical classification | | ranitidine bismuth citrate |
0‑L | A02BA08 | lafutidine | WHO Anatomical Therapeutic Chemical classification | | lafutidine |
0‑L | A02BA51 | cimetidine, combinations | WHO Anatomical Therapeutic Chemical classification | | cimetidine, combinations |
0‑L | A02BA53 | famotidine, combinations | WHO Anatomical Therapeutic Chemical classification | | famotidine, combinations |
0‑L | A02BB | Prostaglandins | WHO Anatomical Therapeutic Chemical classification | | Prostaglandins |
0‑L | A02BB01 | misoprostol | WHO Anatomical Therapeutic Chemical classification | | misoprostol |
0‑L | A02BB02 | enprostil | WHO Anatomical Therapeutic Chemical classification | | enprostil |
0‑L | A02BC | Proton pump inhibitors | WHO Anatomical Therapeutic Chemical classification | | Proton pump inhibitors |
0‑L | A02BC01 | omeprazole | WHO Anatomical Therapeutic Chemical classification | | omeprazole |
0‑L | A02BC02 | pantoprazole | WHO Anatomical Therapeutic Chemical classification | | pantoprazole |
0‑L | A02BC03 | lansoprazole | WHO Anatomical Therapeutic Chemical classification | | lansoprazole |
0‑L | A02BC04 | rabeprazole | WHO Anatomical Therapeutic Chemical classification | | rabeprazole |
0‑L | A02BC05 | esomeprazole | WHO Anatomical Therapeutic Chemical classification | | esomeprazole |
0‑L | A02BC06 | dexlansoprazole | WHO Anatomical Therapeutic Chemical classification | | dexlansoprazole |
0‑L | A02BC07 | dexrabeprazole | WHO Anatomical Therapeutic Chemical classification | | dexrabeprazole |
0‑L | A02BC53 | lansoprazole, combinations | WHO Anatomical Therapeutic Chemical classification | | lansoprazole, combinations |
0‑L | A02BC54 | rabeprazole, combinations | WHO Anatomical Therapeutic Chemical classification | | rabeprazole, combinations |
0‑L | A02BD | Combinations for eradication of Helicobacter pylori | WHO Anatomical Therapeutic Chemical classification | | Combinations for eradication of Helicobacter pylori |
0‑L | A02BD01 | omeprazole, amoxicillin and metronidazole | WHO Anatomical Therapeutic Chemical classification | | omeprazole, amoxicillin and metronidazole |
0‑L | A02BD02 | lansoprazole, tetracycline and metronidazole | WHO Anatomical Therapeutic Chemical classification | | lansoprazole, tetracycline and metronidazole |
0‑L | A02BD03 | lansoprazole, amoxicillin and metronidazole | WHO Anatomical Therapeutic Chemical classification | | lansoprazole, amoxicillin and metronidazole |
0‑L | A02BD04 | pantoprazole, amoxicillin and clarithromycin | WHO Anatomical Therapeutic Chemical classification | | pantoprazole, amoxicillin and clarithromycin |
0‑L | A02BD05 | omeprazole, amoxicillin and clarithromycin | WHO Anatomical Therapeutic Chemical classification | | omeprazole, amoxicillin and clarithromycin |
0‑L | A02BD06 | esomeprazole, amoxicillin and clarithromycin | WHO Anatomical Therapeutic Chemical classification | | esomeprazole, amoxicillin and clarithromycin |
0‑L | A02BD07 | lansoprazole, amoxicillin and clarithromycin | WHO Anatomical Therapeutic Chemical classification | | lansoprazole, amoxicillin and clarithromycin |
0‑L | A02BD08 | bismuth subcitrate, tetracycline and metronidazole | WHO Anatomical Therapeutic Chemical classification | | bismuth subcitrate, tetracycline and metronidazole |
0‑L | A02BD09 | lansoprazole, clarithromycin and tinidazole | WHO Anatomical Therapeutic Chemical classification | | lansoprazole, clarithromycin and tinidazole |
0‑L | A02BD10 | lansoprazole, amoxicillin and levofloxacin | WHO Anatomical Therapeutic Chemical classification | | lansoprazole, amoxicillin and levofloxacin |
0‑L | A02BD11 | pantoprazole, amoxicillin, clarithromycin and metronidazole | WHO Anatomical Therapeutic Chemical classification | | pantoprazole, amoxicillin, clarithromycin and metronidazole |
0‑L | A02BX | Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) | WHO Anatomical Therapeutic Chemical classification | | Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) |
0‑L | A02BX01 | carbenoxolone | WHO Anatomical Therapeutic Chemical classification | | carbenoxolone |
0‑L | A02BX02 | sucralfate | WHO Anatomical Therapeutic Chemical classification | | sucralfate |
0‑L | A02BX03 | pirenzepine | WHO Anatomical Therapeutic Chemical classification | | pirenzepine |
0‑L | A02BX04 | methiosulfonium chloride | WHO Anatomical Therapeutic Chemical classification | | methiosulfonium chloride |
0‑L | A02BX05 | bismuth subcitrate | WHO Anatomical Therapeutic Chemical classification | | bismuth subcitrate |
0‑L | A02BX06 | proglumide | WHO Anatomical Therapeutic Chemical classification | | proglumide |
0‑L | A02BX07 | gefarnate | WHO Anatomical Therapeutic Chemical classification | | gefarnate |
0‑L | A02BX08 | sulglicotide | WHO Anatomical Therapeutic Chemical classification | | sulglicotide |
0‑L | A02BX09 | acetoxolone | WHO Anatomical Therapeutic Chemical classification | | acetoxolone |
0‑L | A02BX10 | zolimidine | WHO Anatomical Therapeutic Chemical classification | | zolimidine |
0‑L | A02BX11 | troxipide | WHO Anatomical Therapeutic Chemical classification | | troxipide |
0‑L | A02BX12 | bismuth subnitrate | WHO Anatomical Therapeutic Chemical classification | | bismuth subnitrate |
0‑L | A02BX13 | alginic acid | WHO Anatomical Therapeutic Chemical classification | | alginic acid |
0‑L | A02BX51 | carbenoxolone, combinations excl. psycholeptics | WHO Anatomical Therapeutic Chemical classification | | carbenoxolone, combinations excl. psycholeptics |
0‑L | A02BX71 | carbenoxolone, combinations with psycholeptics | WHO Anatomical Therapeutic Chemical classification | | carbenoxolone, combinations with psycholeptics |
0‑L | A02BX77 | gefarnate, combinations with psycholeptics | WHO Anatomical Therapeutic Chemical classification | | gefarnate, combinations with psycholeptics |
0‑L | A02X | OTHER DRUGS FOR ACID RELATED DISORDERS | WHO Anatomical Therapeutic Chemical classification | | OTHER DRUGS FOR ACID RELATED DISORDERS |
0‑L | A03 | DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS | WHO Anatomical Therapeutic Chemical classification | | DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS |
0‑L | A03A | DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS | WHO Anatomical Therapeutic Chemical classification | | DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS |
0‑L | A03AA | Synthetic anticholinergics, esters with tertiary amino group | WHO Anatomical Therapeutic Chemical classification | | Synthetic anticholinergics, esters with tertiary amino group |
0‑L | A03AA01 | oxyphencyclimine | WHO Anatomical Therapeutic Chemical classification | | oxyphencyclimine |
0‑L | A03AA03 | camylofin | WHO Anatomical Therapeutic Chemical classification | | camylofin |
0‑L | A03AA04 | mebeverine | WHO Anatomical Therapeutic Chemical classification | | mebeverine |
0‑L | A03AA05 | trimebutine | WHO Anatomical Therapeutic Chemical classification | | trimebutine |
0‑L | A03AA06 | rociverine | WHO Anatomical Therapeutic Chemical classification | | rociverine |
0‑L | A03AA07 | dicycloverine | WHO Anatomical Therapeutic Chemical classification | | dicycloverine |
0‑L | A03AA08 | dihexyverine | WHO Anatomical Therapeutic Chemical classification | | dihexyverine |
0‑L | A03AA09 | difemerine | WHO Anatomical Therapeutic Chemical classification | | difemerine |
0‑L | A03AA30 | piperidolate | WHO Anatomical Therapeutic Chemical classification | | piperidolate |
0‑L | A03AB | Synthetic anticholinergics, quaternary ammonium compounds | WHO Anatomical Therapeutic Chemical classification | | Synthetic anticholinergics, quaternary ammonium compounds |
0‑L | A03AB01 | benzilone | WHO Anatomical Therapeutic Chemical classification | | benzilone |
0‑L | A03AB02 | glycopyrronium bromide | WHO Anatomical Therapeutic Chemical classification | | glycopyrronium bromide |
0‑L | A03AB03 | oxyphenonium | WHO Anatomical Therapeutic Chemical classification | | oxyphenonium |
0‑L | A03AB04 | penthienate | WHO Anatomical Therapeutic Chemical classification | | penthienate |
0‑L | A03AB05 | propantheline | WHO Anatomical Therapeutic Chemical classification | | propantheline |
0‑L | A03AB06 | otilonium bromide | WHO Anatomical Therapeutic Chemical classification | | otilonium bromide |
0‑L | A03AB07 | methantheline | WHO Anatomical Therapeutic Chemical classification | | methantheline |
0‑L | A03AB08 | tridihexethyl | WHO Anatomical Therapeutic Chemical classification | | tridihexethyl |
0‑L | A03AB09 | isopropamide | WHO Anatomical Therapeutic Chemical classification | | isopropamide |
0‑L | A03AB10 | hexocyclium | WHO Anatomical Therapeutic Chemical classification | | hexocyclium |
0‑L | A03AB11 | poldine | WHO Anatomical Therapeutic Chemical classification | | poldine |
0‑L | A03AB12 | mepenzolate | WHO Anatomical Therapeutic Chemical classification | | mepenzolate |
0‑L | A03AB13 | bevonium | WHO Anatomical Therapeutic Chemical classification | | bevonium |
0‑L | A03AB14 | pipenzolate | WHO Anatomical Therapeutic Chemical classification | | pipenzolate |
0‑L | A03AB15 | diphemanil | WHO Anatomical Therapeutic Chemical classification | | diphemanil |
0‑L | A03AB16 | (2-benzhydryloxyethyl)diethyl-methylammonium iodide | WHO Anatomical Therapeutic Chemical classification | | (2-benzhydryloxyethyl)diethyl-methylammonium iodide |
0‑L | A03AB17 | tiemonium iodide | WHO Anatomical Therapeutic Chemical classification | | tiemonium iodide |
0‑L | A03AB18 | prifinium bromide | WHO Anatomical Therapeutic Chemical classification | | prifinium bromide |
0‑L | A03AB19 | timepidium bromide | WHO Anatomical Therapeutic Chemical classification | | timepidium bromide |
0‑L | A03AB21 | fenpiverinium | WHO Anatomical Therapeutic Chemical classification | | fenpiverinium |
0‑L | A03AB53 | oxyphenonium, combinations | WHO Anatomical Therapeutic Chemical classification | | oxyphenonium, combinations |
0‑L | A03AC | Synthetic antispasmodics, amides with tertiary amines | WHO Anatomical Therapeutic Chemical classification | | Synthetic antispasmodics, amides with tertiary amines |
0‑L | A03AC02 | dimethylaminopropionylphenothiazine | WHO Anatomical Therapeutic Chemical classification | | dimethylaminopropionylphenothiazine |
0‑L | A03AC04 | nicofetamide | WHO Anatomical Therapeutic Chemical classification | | nicofetamide |
0‑L | A03AC05 | tiropramide | WHO Anatomical Therapeutic Chemical classification | | tiropramide |
0‑L | A03AD | Papaverine and derivatives | WHO Anatomical Therapeutic Chemical classification | | Papaverine and derivatives |
0‑L | A03AD01 | papaverine | WHO Anatomical Therapeutic Chemical classification | | papaverine |
0‑L | A03AD02 | drotaverine | WHO Anatomical Therapeutic Chemical classification | | drotaverine |
0‑L | A03AD30 | moxaverine | WHO Anatomical Therapeutic Chemical classification | | moxaverine |
0‑L | A03AE | Serotonin receptor antagonists | WHO Anatomical Therapeutic Chemical classification | | Serotonin receptor antagonists |
0‑L | A03AE01 | alosetron | WHO Anatomical Therapeutic Chemical classification | | alosetron |
0‑L | A03AE03 | cilansetron | WHO Anatomical Therapeutic Chemical classification | | cilansetron |
0‑L | A03AX | Other drugs for functional gastrointestinal disorders | WHO Anatomical Therapeutic Chemical classification | | Other drugs for functional gastrointestinal disorders |
0‑L | A03AX01 | fenpiprane | WHO Anatomical Therapeutic Chemical classification | | fenpiprane |
0‑L | A03AX02 | diisopromine | WHO Anatomical Therapeutic Chemical classification | | diisopromine |
0‑L | A03AX03 | chlorbenzoxamine | WHO Anatomical Therapeutic Chemical classification | | chlorbenzoxamine |
0‑L | A03AX04 | pinaverium | WHO Anatomical Therapeutic Chemical classification | | pinaverium |
0‑L | A03AX05 | fenoverine | WHO Anatomical Therapeutic Chemical classification | | fenoverine |
0‑L | A03AX06 | idanpramine | WHO Anatomical Therapeutic Chemical classification | | idanpramine |
0‑L | A03AX07 | proxazole | WHO Anatomical Therapeutic Chemical classification | | proxazole |
0‑L | A03AX08 | alverine | WHO Anatomical Therapeutic Chemical classification | | alverine |
0‑L | A03AX09 | trepibutone | WHO Anatomical Therapeutic Chemical classification | | trepibutone |
0‑L | A03AX10 | isometheptene | WHO Anatomical Therapeutic Chemical classification | | isometheptene |
0‑L | A03AX11 | caroverine | WHO Anatomical Therapeutic Chemical classification | | caroverine |
0‑L | A03AX12 | phloroglucinol | WHO Anatomical Therapeutic Chemical classification | | phloroglucinol |
0‑L | A03AX13 | silicones | WHO Anatomical Therapeutic Chemical classification | | silicones |
0‑L | A03AX14 | valethamate | WHO Anatomical Therapeutic Chemical classification | | valethamate |
0‑L | A03AX30 | trimethyldiphenylpropylamine | WHO Anatomical Therapeutic Chemical classification | | trimethyldiphenylpropylamine |
0‑L | A03AX58 | alverine, combinations | WHO Anatomical Therapeutic Chemical classification | | alverine, combinations |
0‑L | A03B | BELLADONNA AND DERIVATIVES, PLAIN | WHO Anatomical Therapeutic Chemical classification | | BELLADONNA AND DERIVATIVES, PLAIN |
0‑L | A03BA | Belladonna alkaloids, tertiary amines | WHO Anatomical Therapeutic Chemical classification | | Belladonna alkaloids, tertiary amines |
0‑L | A03BA01 | atropine | WHO Anatomical Therapeutic Chemical classification | | atropine |
0‑L | A03BA03 | hyoscyamine | WHO Anatomical Therapeutic Chemical classification | | hyoscyamine |
0‑L | A03BA04 | belladonna total alkaloids | WHO Anatomical Therapeutic Chemical classification | | belladonna total alkaloids |
0‑L | A03BB | Belladonna alkaloids, semisynthetic, quaternary ammonium compounds | WHO Anatomical Therapeutic Chemical classification | | Belladonna alkaloids, semisynthetic, quaternary ammonium compounds |
0‑L | A03BB01 | butylscopolamine | WHO Anatomical Therapeutic Chemical classification | | butylscopolamine |
0‑L | A03BB02 | methylatropine | WHO Anatomical Therapeutic Chemical classification | | methylatropine |
0‑L | A03BB03 | methylscopolamine | WHO Anatomical Therapeutic Chemical classification | | methylscopolamine |
0‑L | A03BB04 | fentonium | WHO Anatomical Therapeutic Chemical classification | | fentonium |
0‑L | A03BB05 | cimetropium bromide | WHO Anatomical Therapeutic Chemical classification | | cimetropium bromide |
0‑L | A03C | ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS | WHO Anatomical Therapeutic Chemical classification | | ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS |
0‑L | A03CA | Synthetic anticholinergic agents in combination with psycholeptics | WHO Anatomical Therapeutic Chemical classification | | Synthetic anticholinergic agents in combination with psycholeptics |
0‑L | A03CA01 | isopropamide and psycholeptics | WHO Anatomical Therapeutic Chemical classification | | isopropamide and psycholeptics |
0‑L | A03CA02 | clidinium and psycholeptics | WHO Anatomical Therapeutic Chemical classification | | clidinium and psycholeptics |
0‑L | A03CA03 | oxyphencyclimine and psycholeptics | WHO Anatomical Therapeutic Chemical classification | | oxyphencyclimine and psycholeptics |
0‑L | A03CA04 | otilonium bromide and psycholeptics | WHO Anatomical Therapeutic Chemical classification | | otilonium bromide and psycholeptics |
0‑L | A03CA05 | glycopyrronium bromide and psycholeptics | WHO Anatomical Therapeutic Chemical classification | | glycopyrronium bromide and psycholeptics |
0‑L | A03CA06 | bevonium and psycholeptics | WHO Anatomical Therapeutic Chemical classification | | bevonium and psycholeptics |
0‑L | A03CA07 | ambutonium and psycholeptics | WHO Anatomical Therapeutic Chemical classification | | ambutonium and psycholeptics |
0‑L | A03CA08 | diphemanil and psycholeptics | WHO Anatomical Therapeutic Chemical classification | | diphemanil and psycholeptics |
0‑L | A03CA09 | pipenzolate and psycholeptics | WHO Anatomical Therapeutic Chemical classification | | pipenzolate and psycholeptics |
0‑L | A03CA30 | emepronium and psycholeptics | WHO Anatomical Therapeutic Chemical classification | | emepronium and psycholeptics |
0‑L | A03CA34 | propantheline and psycholeptics | WHO Anatomical Therapeutic Chemical classification | | propantheline and psycholeptics |
0‑L | A03CB | Belladonna and derivatives in combination with psycholeptics | WHO Anatomical Therapeutic Chemical classification | | Belladonna and derivatives in combination with psycholeptics |
0‑L | A03CB01 | methylscopolamine and psycholeptics | WHO Anatomical Therapeutic Chemical classification | | methylscopolamine and psycholeptics |
0‑L | A03CB02 | belladonna total alkaloids and psycholeptics | WHO Anatomical Therapeutic Chemical classification | | belladonna total alkaloids and psycholeptics |
0‑L | A03CB03 | atropine and psycholeptics | WHO Anatomical Therapeutic Chemical classification | | atropine and psycholeptics |
0‑L | A03CB04 | methylhomatropine and psycholeptics | WHO Anatomical Therapeutic Chemical classification | | methylhomatropine and psycholeptics |
0‑L | A03CB31 | hyoscyamine and psycholeptics | WHO Anatomical Therapeutic Chemical classification | | hyoscyamine and psycholeptics |
0‑L | A03CC | Other antispasmodics in combination with psycholeptics | WHO Anatomical Therapeutic Chemical classification | | Other antispasmodics in combination with psycholeptics |
0‑L | A03D | ANTISPASMODICS IN COMBINATION WITH ANALGESICS | WHO Anatomical Therapeutic Chemical classification | | ANTISPASMODICS IN COMBINATION WITH ANALGESICS |
0‑L | A03DA | Synthetic anticholinergic agents in combination with analgesics | WHO Anatomical Therapeutic Chemical classification | | Synthetic anticholinergic agents in combination with analgesics |
0‑L | A03DA01 | tropenzilone and analgesics | WHO Anatomical Therapeutic Chemical classification | | tropenzilone and analgesics |
0‑L | A03DA02 | pitofenone and analgesics | WHO Anatomical Therapeutic Chemical classification | | pitofenone and analgesics |
0‑L | A03DA03 | bevonium and analgesics | WHO Anatomical Therapeutic Chemical classification | | bevonium and analgesics |
0‑L | A03DA04 | ciclonium and analgesics | WHO Anatomical Therapeutic Chemical classification | | ciclonium and analgesics |
0‑L | A03DA05 | camylofin and analgesics | WHO Anatomical Therapeutic Chemical classification | | camylofin and analgesics |
0‑L | A03DA06 | trospium and analgesics | WHO Anatomical Therapeutic Chemical classification | | trospium and analgesics |
0‑L | A03DA07 | tiemonium iodide and analgesics | WHO Anatomical Therapeutic Chemical classification | | tiemonium iodide and analgesics |
0‑L | A03DB | Belladonna and derivatives in combination with analgesics | WHO Anatomical Therapeutic Chemical classification | | Belladonna and derivatives in combination with analgesics |
0‑L | A03DB04 | butylscopolamine and analgesics | WHO Anatomical Therapeutic Chemical classification | | butylscopolamine and analgesics |
0‑L | A03DC | Other antispasmodics in combination with analgesics | WHO Anatomical Therapeutic Chemical classification | | Other antispasmodics in combination with analgesics |
0‑L | A03E | ANTISPASMODICS AND ANTICHOLINERGICS IN COMBINATION WITH OTHER DRUGS | WHO Anatomical Therapeutic Chemical classification | | ANTISPASMODICS AND ANTICHOLINERGICS IN COMBINATION WITH OTHER DRUGS |
0‑L | A03EA | Antispasmodics, psycholeptics and analgesics in combination | WHO Anatomical Therapeutic Chemical classification | | Antispasmodics, psycholeptics and analgesics in combination |
0‑L | A03ED | Antispasmodics in combination with other drugs | WHO Anatomical Therapeutic Chemical classification | | Antispasmodics in combination with other drugs |
0‑L | A03F | PROPULSIVES | WHO Anatomical Therapeutic Chemical classification | | PROPULSIVES |
0‑L | A03FA | Propulsives | WHO Anatomical Therapeutic Chemical classification | | Propulsives |
0‑L | A03FA01 | metoclopramide | WHO Anatomical Therapeutic Chemical classification | | metoclopramide |
0‑L | A03FA02 | cisapride | WHO Anatomical Therapeutic Chemical classification | | cisapride |
0‑L | A03FA03 | domperidone | WHO Anatomical Therapeutic Chemical classification | | domperidone |
0‑L | A03FA04 | bromopride | WHO Anatomical Therapeutic Chemical classification | | bromopride |
0‑L | A03FA05 | alizapride | WHO Anatomical Therapeutic Chemical classification | | alizapride |
0‑L | A03FA06 | clebopride | WHO Anatomical Therapeutic Chemical classification | | clebopride |
0‑L | A03FA07 | itopride | WHO Anatomical Therapeutic Chemical classification | | itopride |
0‑L | A03FA08 | cinitapride | WHO Anatomical Therapeutic Chemical classification | | cinitapride |
0‑L | A04 | ANTIEMETICS AND ANTINAUSEANTS | WHO Anatomical Therapeutic Chemical classification | | ANTIEMETICS AND ANTINAUSEANTS |
0‑L | A04A | ANTIEMETICS AND ANTINAUSEANTS | WHO Anatomical Therapeutic Chemical classification | | ANTIEMETICS AND ANTINAUSEANTS |
0‑L | A04AA | Serotonin (5HT3) antagonists | WHO Anatomical Therapeutic Chemical classification | | Serotonin (5HT3) antagonists |
0‑L | A04AA01 | ondansetron | WHO Anatomical Therapeutic Chemical classification | | ondansetron |
0‑L | A04AA02 | granisetron | WHO Anatomical Therapeutic Chemical classification | | granisetron |
0‑L | A04AA03 | tropisetron | WHO Anatomical Therapeutic Chemical classification | | tropisetron |
0‑L | A04AA04 | dolasetron | WHO Anatomical Therapeutic Chemical classification | | dolasetron |
0‑L | A04AA05 | palonosetron | WHO Anatomical Therapeutic Chemical classification | | palonosetron |
0‑L | A04AA55 | palonosetron, combinations | WHO Anatomical Therapeutic Chemical classification | | palonosetron, combinations |
0‑L | A04AD | Other antiemetics | WHO Anatomical Therapeutic Chemical classification | | Other antiemetics |
0‑L | A04AD01 | scopolamine | WHO Anatomical Therapeutic Chemical classification | | scopolamine |
0‑L | A04AD02 | cerium oxalate | WHO Anatomical Therapeutic Chemical classification | | cerium oxalate |
0‑L | A04AD04 | chlorobutanol | WHO Anatomical Therapeutic Chemical classification | | chlorobutanol |
0‑L | A04AD05 | metopimazine | WHO Anatomical Therapeutic Chemical classification | | metopimazine |
0‑L | A04AD10 | dronabinol | WHO Anatomical Therapeutic Chemical classification | | dronabinol |
0‑L | A04AD11 | nabilone | WHO Anatomical Therapeutic Chemical classification | | nabilone |
0‑L | A04AD12 | aprepitant | WHO Anatomical Therapeutic Chemical classification | | aprepitant |
0‑L | A04AD13 | casopitant | WHO Anatomical Therapeutic Chemical classification | | casopitant |
0‑L | A04AD14 | rolapitant | WHO Anatomical Therapeutic Chemical classification | | rolapitant |
0‑L | A04AD51 | scopolamine, combinations | WHO Anatomical Therapeutic Chemical classification | | scopolamine, combinations |
0‑L | A04AD54 | chlorobutanol, combinations | WHO Anatomical Therapeutic Chemical classification | | chlorobutanol, combinations |
0‑L | A05 | BILE AND LIVER THERAPY | WHO Anatomical Therapeutic Chemical classification | | BILE AND LIVER THERAPY |
0‑L | A05A | BILE THERAPY | WHO Anatomical Therapeutic Chemical classification | | BILE THERAPY |
0‑L | A05AA | Bile acid preparations | WHO Anatomical Therapeutic Chemical classification | | Bile acid preparations |
0‑L | A05AA01 | chenodeoxycholic acid | WHO Anatomical Therapeutic Chemical classification | | chenodeoxycholic acid |
0‑L | A05AA02 | ursodeoxycholic acid | WHO Anatomical Therapeutic Chemical classification | | ursodeoxycholic acid |
0‑L | A05AA03 | cholic acid | WHO Anatomical Therapeutic Chemical classification | | cholic acid |
0‑L | A05AA04 | obeticholic acid | WHO Anatomical Therapeutic Chemical classification | | obeticholic acid |
0‑L | A05AB | Preparations for biliary tract therapy | WHO Anatomical Therapeutic Chemical classification | | Preparations for biliary tract therapy |
0‑L | A05AB01 | nicotinyl methylamide | WHO Anatomical Therapeutic Chemical classification | | nicotinyl methylamide |
0‑L | A05AX | Other drugs for bile therapy | WHO Anatomical Therapeutic Chemical classification | | Other drugs for bile therapy |
0‑L | A05AX01 | piprozolin | WHO Anatomical Therapeutic Chemical classification | | piprozolin |
0‑L | A05AX02 | hymecromone | WHO Anatomical Therapeutic Chemical classification | | hymecromone |
0‑L | A05AX03 | cyclobutyrol | WHO Anatomical Therapeutic Chemical classification | | cyclobutyrol |
0‑L | A05B | LIVER THERAPY, LIPOTROPICS | WHO Anatomical Therapeutic Chemical classification | | LIVER THERAPY, LIPOTROPICS |
0‑L | A05BA | Liver therapy | WHO Anatomical Therapeutic Chemical classification | | Liver therapy |
0‑L | A05BA01 | arginine glutamate | WHO Anatomical Therapeutic Chemical classification | | arginine glutamate |
0‑L | A05BA03 | silymarin | WHO Anatomical Therapeutic Chemical classification | | silymarin |
0‑L | A05BA04 | citiolone | WHO Anatomical Therapeutic Chemical classification | | citiolone |
0‑L | A05BA05 | epomediol | WHO Anatomical Therapeutic Chemical classification | | epomediol |
0‑L | A05BA06 | ornithine oxoglurate | WHO Anatomical Therapeutic Chemical classification | | ornithine oxoglurate |
0‑L | A05BA07 | tidiacic arginine | WHO Anatomical Therapeutic Chemical classification | | tidiacic arginine |
0‑L | A05BA08 | glycyrrhizic acid | WHO Anatomical Therapeutic Chemical classification | | glycyrrhizic acid |
0‑L | A05C | DRUGS FOR BILE THERAPY AND LIPOTROPICS IN COMBINATION | WHO Anatomical Therapeutic Chemical classification | | DRUGS FOR BILE THERAPY AND LIPOTROPICS IN COMBINATION |
0‑L | A06 | DRUGS FOR CONSTIPATION | WHO Anatomical Therapeutic Chemical classification | | DRUGS FOR CONSTIPATION |
0‑L | A06A | DRUGS FOR CONSTIPATION | WHO Anatomical Therapeutic Chemical classification | | DRUGS FOR CONSTIPATION |
0‑L | A06AA | Softeners, emollients | WHO Anatomical Therapeutic Chemical classification | | Softeners, emollients |
0‑L | A06AA01 | liquid paraffin | WHO Anatomical Therapeutic Chemical classification | | liquid paraffin |
0‑L | A06AA02 | docusate sodium | WHO Anatomical Therapeutic Chemical classification | | docusate sodium |
0‑L | A06AA51 | liquid paraffin, combinations | WHO Anatomical Therapeutic Chemical classification | | liquid paraffin, combinations |
0‑L | A06AB | Contact laxatives | WHO Anatomical Therapeutic Chemical classification | | Contact laxatives |
0‑L | A06AB01 | oxyphenisatine | WHO Anatomical Therapeutic Chemical classification | | oxyphenisatine |
0‑L | A06AB02 | bisacodyl | WHO Anatomical Therapeutic Chemical classification | | bisacodyl |
0‑L | A06AB03 | dantron | WHO Anatomical Therapeutic Chemical classification | | dantron |
0‑L | A06AB04 | phenolphthalein | WHO Anatomical Therapeutic Chemical classification | | phenolphthalein |
0‑L | A06AB05 | castor oil | WHO Anatomical Therapeutic Chemical classification | | castor oil |
0‑L | A06AB06 | senna glycosides | WHO Anatomical Therapeutic Chemical classification | | senna glycosides |
0‑L | A06AB07 | cascara | WHO Anatomical Therapeutic Chemical classification | | cascara |
0‑L | A06AB08 | sodium picosulfate | WHO Anatomical Therapeutic Chemical classification | | sodium picosulfate |
0‑L | A06AB09 | bisoxatin | WHO Anatomical Therapeutic Chemical classification | | bisoxatin |
0‑L | A06AB20 | contact laxatives in combination | WHO Anatomical Therapeutic Chemical classification | | contact laxatives in combination |
0‑L | A06AB30 | contact laxatives in combination with belladonna alkaloids | WHO Anatomical Therapeutic Chemical classification | | contact laxatives in combination with belladonna alkaloids |
0‑L | A06AB52 | bisacodyl, combinations | WHO Anatomical Therapeutic Chemical classification | | bisacodyl, combinations |
0‑L | A06AB53 | dantron, combinations | WHO Anatomical Therapeutic Chemical classification | | dantron, combinations |
0‑L | A06AB56 | senna glycosides, combinations | WHO Anatomical Therapeutic Chemical classification | | senna glycosides, combinations |
0‑L | A06AB57 | cascara, combinations | WHO Anatomical Therapeutic Chemical classification | | cascara, combinations |
0‑L | A06AB58 | sodium picosulfate, combinations | WHO Anatomical Therapeutic Chemical classification | | sodium picosulfate, combinations |
0‑L | A06AC | Bulk-forming laxatives | WHO Anatomical Therapeutic Chemical classification | | Bulk-forming laxatives |
0‑L | A06AC01 | ispaghula (psylla seeds) | WHO Anatomical Therapeutic Chemical classification | | ispaghula (psylla seeds) |
0‑L | A06AC02 | ethulose | WHO Anatomical Therapeutic Chemical classification | | ethulose |
0‑L | A06AC03 | sterculia | WHO Anatomical Therapeutic Chemical classification | | sterculia |
0‑L | A06AC05 | linseed | WHO Anatomical Therapeutic Chemical classification | | linseed |
0‑L | A06AC06 | methylcellulose | WHO Anatomical Therapeutic Chemical classification | | methylcellulose |
0‑L | A06AC07 | triticum (wheat fibre) | WHO Anatomical Therapeutic Chemical classification | | triticum (wheat fibre) |
0‑L | A06AC08 | polycarbophil calcium | WHO Anatomical Therapeutic Chemical classification | | polycarbophil calcium |
0‑L | A06AC51 | ispaghula, combinations | WHO Anatomical Therapeutic Chemical classification | | ispaghula, combinations |
0‑L | A06AC53 | sterculia, combinations | WHO Anatomical Therapeutic Chemical classification | | sterculia, combinations |
0‑L | A06AC55 | linseed, combinations | WHO Anatomical Therapeutic Chemical classification | | linseed, combinations |
0‑L | A06AD | Osmotically acting laxatives | WHO Anatomical Therapeutic Chemical classification | | Osmotically acting laxatives |
0‑L | A06AD01 | magnesium carbonate | WHO Anatomical Therapeutic Chemical classification | | magnesium carbonate |
0‑L | A06AD02 | magnesium oxide | WHO Anatomical Therapeutic Chemical classification | | magnesium oxide |
0‑L | A06AD03 | magnesium peroxide | WHO Anatomical Therapeutic Chemical classification | | magnesium peroxide |
0‑L | A06AD04 | magnesium sulfate | WHO Anatomical Therapeutic Chemical classification | | magnesium sulfate |
0‑L | A06AD10 | mineral salts in combination | WHO Anatomical Therapeutic Chemical classification | | mineral salts in combination |
0‑L | A06AD11 | lactulose | WHO Anatomical Therapeutic Chemical classification | | lactulose |
0‑L | A06AD12 | lactitol | WHO Anatomical Therapeutic Chemical classification | | lactitol |
0‑L | A06AD13 | sodium sulfate | WHO Anatomical Therapeutic Chemical classification | | sodium sulfate |
0‑L | A06AD14 | pentaerithrityl | WHO Anatomical Therapeutic Chemical classification | | pentaerithrityl |
0‑L | A06AD15 | macrogol | WHO Anatomical Therapeutic Chemical classification | | macrogol |
0‑L | A06AD16 | mannitol | WHO Anatomical Therapeutic Chemical classification | | mannitol |
0‑L | A06AD17 | sodium phosphate | WHO Anatomical Therapeutic Chemical classification | | sodium phosphate |
0‑L | A06AD18 | sorbitol | WHO Anatomical Therapeutic Chemical classification | | sorbitol |
0‑L | A06AD19 | magnesium citrate | WHO Anatomical Therapeutic Chemical classification | | magnesium citrate |
0‑L | A06AD21 | sodium tartrate | WHO Anatomical Therapeutic Chemical classification | | sodium tartrate |
0‑L | A06AD61 | lactulose, combinations | WHO Anatomical Therapeutic Chemical classification | | lactulose, combinations |
0‑L | A06AD65 | macrogol, combinations | WHO Anatomical Therapeutic Chemical classification | | macrogol, combinations |
0‑L | A06AG | Enemas | WHO Anatomical Therapeutic Chemical classification | | Enemas |
0‑L | A06AG01 | sodium phosphate | WHO Anatomical Therapeutic Chemical classification | | sodium phosphate |
0‑L | A06AG02 | bisacodyl | WHO Anatomical Therapeutic Chemical classification | | bisacodyl |
0‑L | A06AG03 | dantron, incl. combinations | WHO Anatomical Therapeutic Chemical classification | | dantron, incl. combinations |
0‑L | A06AG04 | glycerol | WHO Anatomical Therapeutic Chemical classification | | glycerol |
0‑L | A06AG06 | oil | WHO Anatomical Therapeutic Chemical classification | | oil |
0‑L | A06AG07 | sorbitol | WHO Anatomical Therapeutic Chemical classification | | sorbitol |
0‑L | A06AG10 | docusate sodium, incl. combinations | WHO Anatomical Therapeutic Chemical classification | | docusate sodium, incl. combinations |
0‑L | A06AG11 | sodium lauryl sulfoacetate, incl. combinations | WHO Anatomical Therapeutic Chemical classification | | sodium lauryl sulfoacetate, incl. combinations |
0‑L | A06AG20 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | A06AH | Peripheral opioid receptor antagonists | WHO Anatomical Therapeutic Chemical classification | | Peripheral opioid receptor antagonists |
0‑L | A06AH01 | methylnaltrexone bromide | WHO Anatomical Therapeutic Chemical classification | | methylnaltrexone bromide |
0‑L | A06AH02 | alvimopan | WHO Anatomical Therapeutic Chemical classification | | alvimopan |
0‑L | A06AH03 | naloxegol | WHO Anatomical Therapeutic Chemical classification | | naloxegol |
0‑L | A06AH04 | naloxone | WHO Anatomical Therapeutic Chemical classification | | naloxone |
0‑L | A06AX | Other drugs for constipation | WHO Anatomical Therapeutic Chemical classification | | Other drugs for constipation |
0‑L | A06AX01 | glycerol | WHO Anatomical Therapeutic Chemical classification | | glycerol |
0‑L | A06AX02 | carbon dioxide producing drugs | WHO Anatomical Therapeutic Chemical classification | | carbon dioxide producing drugs |
0‑L | A06AX03 | lubiprostone | WHO Anatomical Therapeutic Chemical classification | | lubiprostone |
0‑L | A06AX04 | linaclotide | WHO Anatomical Therapeutic Chemical classification | | linaclotide |
0‑L | A06AX05 | prucalopride | WHO Anatomical Therapeutic Chemical classification | | prucalopride |
0‑L | A06AX06 | tegaserod | WHO Anatomical Therapeutic Chemical classification | | tegaserod |
0‑L | A07 | ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS | WHO Anatomical Therapeutic Chemical classification | | ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS |
0‑L | A07A | INTESTINAL ANTIINFECTIVES | WHO Anatomical Therapeutic Chemical classification | | INTESTINAL ANTIINFECTIVES |
0‑L | A07AA | Antibiotics | WHO Anatomical Therapeutic Chemical classification | | Antibiotics |
0‑L | A07AA01 | neomycin | WHO Anatomical Therapeutic Chemical classification | | neomycin |
0‑L | A07AA02 | nystatin | WHO Anatomical Therapeutic Chemical classification | | nystatin |
0‑L | A07AA03 | natamycin | WHO Anatomical Therapeutic Chemical classification | | natamycin |
0‑L | A07AA04 | streptomycin | WHO Anatomical Therapeutic Chemical classification | | streptomycin |
0‑L | A07AA05 | polymyxin B | WHO Anatomical Therapeutic Chemical classification | | polymyxin B |
0‑L | A07AA06 | paromomycin | WHO Anatomical Therapeutic Chemical classification | | paromomycin |
0‑L | A07AA07 | amphotericin B | WHO Anatomical Therapeutic Chemical classification | | amphotericin B |
0‑L | A07AA08 | kanamycin | WHO Anatomical Therapeutic Chemical classification | | kanamycin |
0‑L | A07AA09 | vancomycin | WHO Anatomical Therapeutic Chemical classification | | vancomycin |
0‑L | A07AA10 | colistin | WHO Anatomical Therapeutic Chemical classification | | colistin |
0‑L | A07AA11 | rifaximin | WHO Anatomical Therapeutic Chemical classification | | rifaximin |
0‑L | A07AA12 | fidaxomicin | WHO Anatomical Therapeutic Chemical classification | | fidaxomicin |
0‑L | A07AA51 | neomycin, combinations | WHO Anatomical Therapeutic Chemical classification | | neomycin, combinations |
0‑L | A07AA54 | streptomycin, combinations | WHO Anatomical Therapeutic Chemical classification | | streptomycin, combinations |
0‑L | A07AB | Sulfonamides | WHO Anatomical Therapeutic Chemical classification | | Sulfonamides |
0‑L | A07AB02 | phthalylsulfathiazole | WHO Anatomical Therapeutic Chemical classification | | phthalylsulfathiazole |
0‑L | A07AB03 | sulfaguanidine | WHO Anatomical Therapeutic Chemical classification | | sulfaguanidine |
0‑L | A07AB04 | succinylsulfathiazole | WHO Anatomical Therapeutic Chemical classification | | succinylsulfathiazole |
0‑L | A07AC | Imidazole derivatives | WHO Anatomical Therapeutic Chemical classification | | Imidazole derivatives |
0‑L | A07AC01 | miconazole | WHO Anatomical Therapeutic Chemical classification | | miconazole |
0‑L | A07AX | Other intestinal antiinfectives | WHO Anatomical Therapeutic Chemical classification | | Other intestinal antiinfectives |
0‑L | A07AX01 | broxyquinoline | WHO Anatomical Therapeutic Chemical classification | | broxyquinoline |
0‑L | A07AX02 | acetarsol | WHO Anatomical Therapeutic Chemical classification | | acetarsol |
0‑L | A07AX03 | nifuroxazide | WHO Anatomical Therapeutic Chemical classification | | nifuroxazide |
0‑L | A07AX04 | nifurzide | WHO Anatomical Therapeutic Chemical classification | | nifurzide |
0‑L | A07B | INTESTINAL ADSORBENTS | WHO Anatomical Therapeutic Chemical classification | | INTESTINAL ADSORBENTS |
0‑L | A07BA | Charcoal preparations | WHO Anatomical Therapeutic Chemical classification | | Charcoal preparations |
0‑L | A07BA01 | medicinal charcoal | WHO Anatomical Therapeutic Chemical classification | | medicinal charcoal |
0‑L | A07BA51 | medicinal charcoal, combinations | WHO Anatomical Therapeutic Chemical classification | | medicinal charcoal, combinations |
0‑L | A07BB | Bismuth preparations | WHO Anatomical Therapeutic Chemical classification | | Bismuth preparations |
0‑L | A07BC | Other intestinal adsorbents | WHO Anatomical Therapeutic Chemical classification | | Other intestinal adsorbents |
0‑L | A07BC01 | pectin | WHO Anatomical Therapeutic Chemical classification | | pectin |
0‑L | A07BC02 | kaolin | WHO Anatomical Therapeutic Chemical classification | | kaolin |
0‑L | A07BC03 | crospovidone | WHO Anatomical Therapeutic Chemical classification | | crospovidone |
0‑L | A07BC04 | attapulgite | WHO Anatomical Therapeutic Chemical classification | | attapulgite |
0‑L | A07BC05 | diosmectite | WHO Anatomical Therapeutic Chemical classification | | diosmectite |
0‑L | A07BC30 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | A07BC54 | attapulgite, combinations | WHO Anatomical Therapeutic Chemical classification | | attapulgite, combinations |
0‑L | A07C | ELECTROLYTES WITH CARBOHYDRATES | WHO Anatomical Therapeutic Chemical classification | | ELECTROLYTES WITH CARBOHYDRATES |
0‑L | A07CA | Oral rehydration salt formulations | WHO Anatomical Therapeutic Chemical classification | | Oral rehydration salt formulations |
0‑L | A07D | ANTIPROPULSIVES | WHO Anatomical Therapeutic Chemical classification | | ANTIPROPULSIVES |
0‑L | A07DA | Antipropulsives | WHO Anatomical Therapeutic Chemical classification | | Antipropulsives |
0‑L | A07DA01 | diphenoxylate | WHO Anatomical Therapeutic Chemical classification | | diphenoxylate |
0‑L | A07DA02 | opium | WHO Anatomical Therapeutic Chemical classification | | opium |
0‑L | A07DA03 | loperamide | WHO Anatomical Therapeutic Chemical classification | | loperamide |
0‑L | A07DA04 | difenoxin | WHO Anatomical Therapeutic Chemical classification | | difenoxin |
0‑L | A07DA05 | loperamide oxide | WHO Anatomical Therapeutic Chemical classification | | loperamide oxide |
0‑L | A07DA06 | eluxadoline | WHO Anatomical Therapeutic Chemical classification | | eluxadoline |
0‑L | A07DA52 | morphine, combinations | WHO Anatomical Therapeutic Chemical classification | | morphine, combinations |
0‑L | A07DA53 | loperamide, combinations | WHO Anatomical Therapeutic Chemical classification | | loperamide, combinations |
0‑L | A07E | INTESTINAL ANTIINFLAMMATORY AGENTS | WHO Anatomical Therapeutic Chemical classification | | INTESTINAL ANTIINFLAMMATORY AGENTS |
0‑L | A07EA | Corticosteroids acting locally | WHO Anatomical Therapeutic Chemical classification | | Corticosteroids acting locally |
0‑L | A07EA01 | prednisolone | WHO Anatomical Therapeutic Chemical classification | | prednisolone |
0‑L | A07EA02 | hydrocortisone | WHO Anatomical Therapeutic Chemical classification | | hydrocortisone |
0‑L | A07EA03 | prednisone | WHO Anatomical Therapeutic Chemical classification | | prednisone |
0‑L | A07EA04 | betamethasone | WHO Anatomical Therapeutic Chemical classification | | betamethasone |
0‑L | A07EA05 | tixocortol | WHO Anatomical Therapeutic Chemical classification | | tixocortol |
0‑L | A07EA06 | budesonide | WHO Anatomical Therapeutic Chemical classification | | budesonide |
0‑L | A07EA07 | beclometasone | WHO Anatomical Therapeutic Chemical classification | | beclometasone |
0‑L | A07EB | Antiallergic agents, excl. corticosteroids | WHO Anatomical Therapeutic Chemical classification | | Antiallergic agents, excl. corticosteroids |
0‑L | A07EB01 | cromoglicic acid | WHO Anatomical Therapeutic Chemical classification | | cromoglicic acid |
0‑L | A07EC | Aminosalicylic acid and similar agents | WHO Anatomical Therapeutic Chemical classification | | Aminosalicylic acid and similar agents |
0‑L | A07EC01 | sulfasalazine | WHO Anatomical Therapeutic Chemical classification | | sulfasalazine |
0‑L | A07EC02 | mesalazine | WHO Anatomical Therapeutic Chemical classification | | mesalazine |
0‑L | A07EC03 | olsalazine | WHO Anatomical Therapeutic Chemical classification | | olsalazine |
0‑L | A07EC04 | balsalazide | WHO Anatomical Therapeutic Chemical classification | | balsalazide |
0‑L | A07F | ANTIDIARRHEAL MICROORGANISMS | WHO Anatomical Therapeutic Chemical classification | | ANTIDIARRHEAL MICROORGANISMS |
0‑L | A07FA | Antidiarrheal microorganisms | WHO Anatomical Therapeutic Chemical classification | | Antidiarrheal microorganisms |
0‑L | A07FA01 | lactic acid producing organisms | WHO Anatomical Therapeutic Chemical classification | | lactic acid producing organisms |
0‑L | A07FA02 | saccharomyces boulardii | WHO Anatomical Therapeutic Chemical classification | | saccharomyces boulardii |
0‑L | A07FA51 | lactic acid producing organisms, combinations | WHO Anatomical Therapeutic Chemical classification | | lactic acid producing organisms, combinations |
0‑L | A07X | OTHER ANTIDIARRHEALS | WHO Anatomical Therapeutic Chemical classification | | OTHER ANTIDIARRHEALS |
0‑L | A07XA | Other antidiarrheals | WHO Anatomical Therapeutic Chemical classification | | Other antidiarrheals |
0‑L | A07XA01 | albumin tannate | WHO Anatomical Therapeutic Chemical classification | | albumin tannate |
0‑L | A07XA02 | ceratonia | WHO Anatomical Therapeutic Chemical classification | | ceratonia |
0‑L | A07XA03 | calcium compounds | WHO Anatomical Therapeutic Chemical classification | | calcium compounds |
0‑L | A07XA04 | racecadotril | WHO Anatomical Therapeutic Chemical classification | | racecadotril |
0‑L | A07XA51 | albumin tannate, combinations | WHO Anatomical Therapeutic Chemical classification | | albumin tannate, combinations |
0‑L | A08 | ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS | WHO Anatomical Therapeutic Chemical classification | | ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS |
0‑L | A08A | ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS | WHO Anatomical Therapeutic Chemical classification | | ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS |
0‑L | A08AA | Centrally acting antiobesity products | WHO Anatomical Therapeutic Chemical classification | | Centrally acting antiobesity products |
0‑L | A08AA01 | phentermine | WHO Anatomical Therapeutic Chemical classification | | phentermine |
0‑L | A08AA02 | fenfluramine | WHO Anatomical Therapeutic Chemical classification | | fenfluramine |
0‑L | A08AA03 | amfepramone | WHO Anatomical Therapeutic Chemical classification | | amfepramone |
0‑L | A08AA04 | dexfenfluramine | WHO Anatomical Therapeutic Chemical classification | | dexfenfluramine |
0‑L | A08AA05 | mazindol | WHO Anatomical Therapeutic Chemical classification | | mazindol |
0‑L | A08AA06 | etilamfetamine | WHO Anatomical Therapeutic Chemical classification | | etilamfetamine |
0‑L | A08AA07 | cathine | WHO Anatomical Therapeutic Chemical classification | | cathine |
0‑L | A08AA08 | clobenzorex | WHO Anatomical Therapeutic Chemical classification | | clobenzorex |
0‑L | A08AA09 | mefenorex | WHO Anatomical Therapeutic Chemical classification | | mefenorex |
0‑L | A08AA10 | sibutramine | WHO Anatomical Therapeutic Chemical classification | | sibutramine |
0‑L | A08AA11 | lorcaserin | WHO Anatomical Therapeutic Chemical classification | | lorcaserin |
0‑L | A08AA56 | ephedrine, combinations | WHO Anatomical Therapeutic Chemical classification | | ephedrine, combinations |
0‑L | A08AA62 | bupropion and naltrexone | WHO Anatomical Therapeutic Chemical classification | | bupropion and naltrexone |
0‑L | A08AB | Peripherally acting antiobesity products | WHO Anatomical Therapeutic Chemical classification | | Peripherally acting antiobesity products |
0‑L | A08AB01 | orlistat | WHO Anatomical Therapeutic Chemical classification | | orlistat |
0‑L | A08AX | Other antiobesity drugs | WHO Anatomical Therapeutic Chemical classification | | Other antiobesity drugs |
0‑L | A08AX01 | rimonabant | WHO Anatomical Therapeutic Chemical classification | | rimonabant |
0‑L | A09 | DIGESTIVES, INCL. ENZYMES | WHO Anatomical Therapeutic Chemical classification | | DIGESTIVES, INCL. ENZYMES |
0‑L | A09A | DIGESTIVES, INCL. ENZYMES | WHO Anatomical Therapeutic Chemical classification | | DIGESTIVES, INCL. ENZYMES |
0‑L | A09AA | Enzyme preparations | WHO Anatomical Therapeutic Chemical classification | | Enzyme preparations |
0‑L | A09AA01 | diastase | WHO Anatomical Therapeutic Chemical classification | | diastase |
0‑L | A09AA02 | multienzymes (lipase, protease etc.) | WHO Anatomical Therapeutic Chemical classification | | multienzymes (lipase, protease etc.) |
0‑L | A09AA03 | pepsin | WHO Anatomical Therapeutic Chemical classification | | pepsin |
0‑L | A09AA04 | tilactase | WHO Anatomical Therapeutic Chemical classification | | tilactase |
0‑L | A09AB | Acid preparations | WHO Anatomical Therapeutic Chemical classification | | Acid preparations |
0‑L | A09AB01 | glutamic acid hydrochloride | WHO Anatomical Therapeutic Chemical classification | | glutamic acid hydrochloride |
0‑L | A09AB02 | betaine hydrochloride | WHO Anatomical Therapeutic Chemical classification | | betaine hydrochloride |
0‑L | A09AB03 | hydrochloric acid | WHO Anatomical Therapeutic Chemical classification | | hydrochloric acid |
0‑L | A09AB04 | citric acid | WHO Anatomical Therapeutic Chemical classification | | citric acid |
0‑L | A09AC | Enzyme and acid preparations, combinations | WHO Anatomical Therapeutic Chemical classification | | Enzyme and acid preparations, combinations |
0‑L | A09AC01 | pepsin and acid preparations | WHO Anatomical Therapeutic Chemical classification | | pepsin and acid preparations |
0‑L | A09AC02 | multienzymes and acid preparations | WHO Anatomical Therapeutic Chemical classification | | multienzymes and acid preparations |
0‑L | A10 | DRUGS USED IN DIABETES | WHO Anatomical Therapeutic Chemical classification | | DRUGS USED IN DIABETES |
0‑L | A10A | INSULINS AND ANALOGUES | WHO Anatomical Therapeutic Chemical classification | | INSULINS AND ANALOGUES |
0‑L | A10AB | Insulins and analogues for injection, fast-acting | WHO Anatomical Therapeutic Chemical classification | | Insulins and analogues for injection, fast-acting |
0‑L | A10AB01 | insulin (human) | WHO Anatomical Therapeutic Chemical classification | | insulin (human) |
0‑L | A10AB02 | insulin (beef) | WHO Anatomical Therapeutic Chemical classification | | insulin (beef) |
0‑L | A10AB03 | insulin (pork) | WHO Anatomical Therapeutic Chemical classification | | insulin (pork) |
0‑L | A10AB04 | insulin lispro | WHO Anatomical Therapeutic Chemical classification | | insulin lispro |
0‑L | A10AB05 | insulin aspart | WHO Anatomical Therapeutic Chemical classification | | insulin aspart |
0‑L | A10AB06 | insulin glulisine | WHO Anatomical Therapeutic Chemical classification | | insulin glulisine |
0‑L | A10AB30 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | A10AC | Insulins and analogues for injection, intermediate-acting | WHO Anatomical Therapeutic Chemical classification | | Insulins and analogues for injection, intermediate-acting |
0‑L | A10AC01 | insulin (human) | WHO Anatomical Therapeutic Chemical classification | | insulin (human) |
0‑L | A10AC02 | insulin (beef) | WHO Anatomical Therapeutic Chemical classification | | insulin (beef) |
0‑L | A10AC03 | insulin (pork) | WHO Anatomical Therapeutic Chemical classification | | insulin (pork) |
0‑L | A10AC04 | insulin lispro | WHO Anatomical Therapeutic Chemical classification | | insulin lispro |
0‑L | A10AC30 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | A10AD | Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting | WHO Anatomical Therapeutic Chemical classification | | Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting |
0‑L | A10AD01 | insulin (human) | WHO Anatomical Therapeutic Chemical classification | | insulin (human) |
0‑L | A10AD02 | insulin (beef) | WHO Anatomical Therapeutic Chemical classification | | insulin (beef) |
0‑L | A10AD03 | insulin (pork) | WHO Anatomical Therapeutic Chemical classification | | insulin (pork) |
0‑L | A10AD04 | insulin lispro | WHO Anatomical Therapeutic Chemical classification | | insulin lispro |
0‑L | A10AD05 | insulin aspart | WHO Anatomical Therapeutic Chemical classification | | insulin aspart |
0‑L | A10AD06 | insulin degludec and insulin aspart | WHO Anatomical Therapeutic Chemical classification | | insulin degludec and insulin aspart |
0‑L | A10AD30 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | A10AE | Insulins and analogues for injection, long-acting | WHO Anatomical Therapeutic Chemical classification | | Insulins and analogues for injection, long-acting |
0‑L | A10AE01 | insulin (human) | WHO Anatomical Therapeutic Chemical classification | | insulin (human) |
0‑L | A10AE02 | insulin (beef) | WHO Anatomical Therapeutic Chemical classification | | insulin (beef) |
0‑L | A10AE03 | insulin (pork) | WHO Anatomical Therapeutic Chemical classification | | insulin (pork) |
0‑L | A10AE04 | insulin glargine | WHO Anatomical Therapeutic Chemical classification | | insulin glargine |
0‑L | A10AE05 | insulin detemir | WHO Anatomical Therapeutic Chemical classification | | insulin detemir |
0‑L | A10AE06 | insulin degludec | WHO Anatomical Therapeutic Chemical classification | | insulin degludec |
0‑L | A10AE30 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | A10AE56 | insulin degludec and liraglutide | WHO Anatomical Therapeutic Chemical classification | | insulin degludec and liraglutide |
0‑L | A10AF | Insulins and analogues for inhalation | WHO Anatomical Therapeutic Chemical classification | | Insulins and analogues for inhalation |
0‑L | A10AF01 | insulin (human) | WHO Anatomical Therapeutic Chemical classification | | insulin (human) |
0‑L | A10B | BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS | WHO Anatomical Therapeutic Chemical classification | | BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS |
0‑L | A10BA | Biguanides | WHO Anatomical Therapeutic Chemical classification | | Biguanides |
0‑L | A10BA01 | phenformin | WHO Anatomical Therapeutic Chemical classification | | phenformin |
0‑L | A10BA02 | metformin | WHO Anatomical Therapeutic Chemical classification | | metformin |
0‑L | A10BA03 | buformin | WHO Anatomical Therapeutic Chemical classification | | buformin |
0‑L | A10BB | Sulfonylureas | WHO Anatomical Therapeutic Chemical classification | | Sulfonylureas |
0‑L | A10BB01 | glibenclamide | WHO Anatomical Therapeutic Chemical classification | | glibenclamide |
0‑L | A10BB02 | chlorpropamide | WHO Anatomical Therapeutic Chemical classification | | chlorpropamide |
0‑L | A10BB03 | tolbutamide | WHO Anatomical Therapeutic Chemical classification | | tolbutamide |
0‑L | A10BB04 | glibornuride | WHO Anatomical Therapeutic Chemical classification | | glibornuride |
0‑L | A10BB05 | tolazamide | WHO Anatomical Therapeutic Chemical classification | | tolazamide |
0‑L | A10BB06 | carbutamide | WHO Anatomical Therapeutic Chemical classification | | carbutamide |
0‑L | A10BB07 | glipizide | WHO Anatomical Therapeutic Chemical classification | | glipizide |
0‑L | A10BB08 | gliquidone | WHO Anatomical Therapeutic Chemical classification | | gliquidone |
0‑L | A10BB09 | gliclazide | WHO Anatomical Therapeutic Chemical classification | | gliclazide |
0‑L | A10BB10 | metahexamide | WHO Anatomical Therapeutic Chemical classification | | metahexamide |
0‑L | A10BB11 | glisoxepide | WHO Anatomical Therapeutic Chemical classification | | glisoxepide |
0‑L | A10BB12 | glimepiride | WHO Anatomical Therapeutic Chemical classification | | glimepiride |
0‑L | A10BB31 | acetohexamide | WHO Anatomical Therapeutic Chemical classification | | acetohexamide |
0‑L | A10BC | Sulfonamides (heterocyclic) | WHO Anatomical Therapeutic Chemical classification | | Sulfonamides (heterocyclic) |
0‑L | A10BC01 | glymidine | WHO Anatomical Therapeutic Chemical classification | | glymidine |
0‑L | A10BD | Combinations of oral blood glucose lowering drugs | WHO Anatomical Therapeutic Chemical classification | | Combinations of oral blood glucose lowering drugs |
0‑L | A10BD01 | phenformin and sulfonylureas | WHO Anatomical Therapeutic Chemical classification | | phenformin and sulfonylureas |
0‑L | A10BD02 | metformin and sulfonylureas | WHO Anatomical Therapeutic Chemical classification | | metformin and sulfonylureas |
0‑L | A10BD03 | metformin and rosiglitazone | WHO Anatomical Therapeutic Chemical classification | | metformin and rosiglitazone |
0‑L | A10BD04 | glimepiride and rosiglitazone | WHO Anatomical Therapeutic Chemical classification | | glimepiride and rosiglitazone |
0‑L | A10BD05 | metformin and pioglitazone | WHO Anatomical Therapeutic Chemical classification | | metformin and pioglitazone |
0‑L | A10BD06 | glimepiride and pioglitazone | WHO Anatomical Therapeutic Chemical classification | | glimepiride and pioglitazone |
0‑L | A10BD07 | metformin and sitagliptin | WHO Anatomical Therapeutic Chemical classification | | metformin and sitagliptin |
0‑L | A10BD08 | metformin and vildagliptin | WHO Anatomical Therapeutic Chemical classification | | metformin and vildagliptin |
0‑L | A10BD09 | pioglitazone and alogliptin | WHO Anatomical Therapeutic Chemical classification | | pioglitazone and alogliptin |
0‑L | A10BD10 | metformin and saxagliptin | WHO Anatomical Therapeutic Chemical classification | | metformin and saxagliptin |
0‑L | A10BD11 | metformin and linagliptin | WHO Anatomical Therapeutic Chemical classification | | metformin and linagliptin |
0‑L | A10BD12 | pioglitazone and sitagliptin | WHO Anatomical Therapeutic Chemical classification | | pioglitazone and sitagliptin |
0‑L | A10BD13 | metformin and alogliptin | WHO Anatomical Therapeutic Chemical classification | | metformin and alogliptin |
0‑L | A10BD14 | metformin and repaglinide | WHO Anatomical Therapeutic Chemical classification | | metformin and repaglinide |
0‑L | A10BD15 | metformin and dapagliflozin | WHO Anatomical Therapeutic Chemical classification | | metformin and dapagliflozin |
0‑L | A10BD16 | metformin and canagliflozin | WHO Anatomical Therapeutic Chemical classification | | metformin and canagliflozin |
0‑L | A10BD17 | metformin and acarbose | WHO Anatomical Therapeutic Chemical classification | | metformin and acarbose |
0‑L | A10BD18 | metformin and gemigliptin | WHO Anatomical Therapeutic Chemical classification | | metformin and gemigliptin |
0‑L | A10BD19 | linagliptin and empagliflozin | WHO Anatomical Therapeutic Chemical classification | | linagliptin and empagliflozin |
0‑L | A10BD20 | metformin and empagliflozin | WHO Anatomical Therapeutic Chemical classification | | metformin and empagliflozin |
0‑L | A10BD21 | saxagliptin and dapagliflozin | WHO Anatomical Therapeutic Chemical classification | | saxagliptin and dapagliflozin |
0‑L | A10BF | Alpha glucosidase inhibitors | WHO Anatomical Therapeutic Chemical classification | | Alpha glucosidase inhibitors |
0‑L | A10BF01 | acarbose | WHO Anatomical Therapeutic Chemical classification | | acarbose |
0‑L | A10BF02 | miglitol | WHO Anatomical Therapeutic Chemical classification | | miglitol |
0‑L | A10BF03 | voglibose | WHO Anatomical Therapeutic Chemical classification | | voglibose |
0‑L | A10BG | Thiazolidinediones | WHO Anatomical Therapeutic Chemical classification | | Thiazolidinediones |
0‑L | A10BG01 | troglitazone | WHO Anatomical Therapeutic Chemical classification | | troglitazone |
0‑L | A10BG02 | rosiglitazone | WHO Anatomical Therapeutic Chemical classification | | rosiglitazone |
0‑L | A10BG03 | pioglitazone | WHO Anatomical Therapeutic Chemical classification | | pioglitazone |
0‑L | A10BH | Dipeptidyl peptidase 4 (DPP-4) inhibitors | WHO Anatomical Therapeutic Chemical classification | | Dipeptidyl peptidase 4 (DPP-4) inhibitors |
0‑L | A10BH01 | sitagliptin | WHO Anatomical Therapeutic Chemical classification | | sitagliptin |
0‑L | A10BH02 | vildagliptin | WHO Anatomical Therapeutic Chemical classification | | vildagliptin |
0‑L | A10BH03 | saxagliptin | WHO Anatomical Therapeutic Chemical classification | | saxagliptin |
0‑L | A10BH04 | alogliptin | WHO Anatomical Therapeutic Chemical classification | | alogliptin |
0‑L | A10BH05 | linagliptin | WHO Anatomical Therapeutic Chemical classification | | linagliptin |
0‑L | A10BH06 | gemigliptin | WHO Anatomical Therapeutic Chemical classification | | gemigliptin |
0‑L | A10BH51 | sitagliptin and simvastatin | WHO Anatomical Therapeutic Chemical classification | | sitagliptin and simvastatin |
0‑L | A10BJ | Glucagon-like peptide-1 (GLP-1) analogues | WHO Anatomical Therapeutic Chemical classification | | Glucagon-like peptide-1 (GLP-1) analogues |
0‑L | A10BJ01 | exenatide | WHO Anatomical Therapeutic Chemical classification | | exenatide |
0‑L | A10BJ02 | liraglutide | WHO Anatomical Therapeutic Chemical classification | | liraglutide |
0‑L | A10BJ03 | lixisenatide | WHO Anatomical Therapeutic Chemical classification | | lixisenatide |
0‑L | A10BJ04 | albiglutide | WHO Anatomical Therapeutic Chemical classification | | albiglutide |
0‑L | A10BJ05 | dulaglutide | WHO Anatomical Therapeutic Chemical classification | | dulaglutide |
0‑L | A10BK | Sodium-glucose co-transporter 2 (SGLT2) inhibitors | WHO Anatomical Therapeutic Chemical classification | | Sodium-glucose co-transporter 2 (SGLT2) inhibitors |
0‑L | A10BK01 | dapagliflozin | WHO Anatomical Therapeutic Chemical classification | | dapagliflozin |
0‑L | A10BK02 | canagliflozin | WHO Anatomical Therapeutic Chemical classification | | canagliflozin |
0‑L | A10BK03 | empagliflozin | WHO Anatomical Therapeutic Chemical classification | | empagliflozin |
0‑L | A10BX | Other blood glucose lowering drugs, excl. insulins | WHO Anatomical Therapeutic Chemical classification | | Other blood glucose lowering drugs, excl. insulins |
0‑L | A10BX01 | guar gum | WHO Anatomical Therapeutic Chemical classification | | guar gum |
0‑L | A10BX02 | repaglinide | WHO Anatomical Therapeutic Chemical classification | | repaglinide |
0‑L | A10BX03 | nateglinide | WHO Anatomical Therapeutic Chemical classification | | nateglinide |
0‑L | A10BX05 | pramlintide | WHO Anatomical Therapeutic Chemical classification | | pramlintide |
0‑L | A10BX06 | benfluorex | WHO Anatomical Therapeutic Chemical classification | | benfluorex |
0‑L | A10BX08 | mitiglinide | WHO Anatomical Therapeutic Chemical classification | | mitiglinide |
0‑L | A10X | OTHER DRUGS USED IN DIABETES | WHO Anatomical Therapeutic Chemical classification | | OTHER DRUGS USED IN DIABETES |
0‑L | A10XA | Aldose reductase inhibitors | WHO Anatomical Therapeutic Chemical classification | | Aldose reductase inhibitors |
0‑L | A10XA01 | tolrestat | WHO Anatomical Therapeutic Chemical classification | | tolrestat |
0‑L | A11 | VITAMINS | WHO Anatomical Therapeutic Chemical classification | | VITAMINS |
0‑L | A11A | MULTIVITAMINS, COMBINATIONS | WHO Anatomical Therapeutic Chemical classification | | MULTIVITAMINS, COMBINATIONS |
0‑L | A11AA | Multivitamins with minerals | WHO Anatomical Therapeutic Chemical classification | | Multivitamins with minerals |
0‑L | A11AA01 | multivitamins and iron | WHO Anatomical Therapeutic Chemical classification | | multivitamins and iron |
0‑L | A11AA02 | multivitamins and calcium | WHO Anatomical Therapeutic Chemical classification | | multivitamins and calcium |
0‑L | A11AA03 | multivitamins and other minerals, incl. combinations | WHO Anatomical Therapeutic Chemical classification | | multivitamins and other minerals, incl. combinations |
0‑L | A11AA04 | multivitamins and trace elements | WHO Anatomical Therapeutic Chemical classification | | multivitamins and trace elements |
0‑L | A11AB | Multivitamins, other combinations | WHO Anatomical Therapeutic Chemical classification | | Multivitamins, other combinations |
0‑L | A11B | MULTIVITAMINS, PLAIN | WHO Anatomical Therapeutic Chemical classification | | MULTIVITAMINS, PLAIN |
0‑L | A11BA | Multivitamins, plain | WHO Anatomical Therapeutic Chemical classification | | Multivitamins, plain |
0‑L | A11C | VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO | WHO Anatomical Therapeutic Chemical classification | | VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO |
0‑L | A11CA | Vitamin A, plain | WHO Anatomical Therapeutic Chemical classification | | Vitamin A, plain |
0‑L | A11CA01 | retinol (vit A) | WHO Anatomical Therapeutic Chemical classification | | retinol (vit A) |
0‑L | A11CA02 | betacarotene | WHO Anatomical Therapeutic Chemical classification | | betacarotene |
0‑L | A11CB | Vitamin A and D in combination | WHO Anatomical Therapeutic Chemical classification | | Vitamin A and D in combination |
0‑L | A11CC | Vitamin D and analogues | WHO Anatomical Therapeutic Chemical classification | | Vitamin D and analogues |
0‑L | A11CC01 | ergocalciferol | WHO Anatomical Therapeutic Chemical classification | | ergocalciferol |
0‑L | A11CC02 | dihydrotachysterol | WHO Anatomical Therapeutic Chemical classification | | dihydrotachysterol |
0‑L | A11CC03 | alfacalcidol | WHO Anatomical Therapeutic Chemical classification | | alfacalcidol |
0‑L | A11CC04 | calcitriol | WHO Anatomical Therapeutic Chemical classification | | calcitriol |
0‑L | A11CC05 | colecalciferol | WHO Anatomical Therapeutic Chemical classification | | colecalciferol |
0‑L | A11CC06 | calcifediol | WHO Anatomical Therapeutic Chemical classification | | calcifediol |
0‑L | A11CC20 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | A11D | VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 | WHO Anatomical Therapeutic Chemical classification | | VITAMIN B1, PLAIN AND IN COMBINATION WITH VITAMIN B6 AND B12 |
0‑L | A11DA | Vitamin B1, plain | WHO Anatomical Therapeutic Chemical classification | | Vitamin B1, plain |
0‑L | A11DA01 | thiamine (vit B1) | WHO Anatomical Therapeutic Chemical classification | | thiamine (vit B1) |
0‑L | A11DA02 | sulbutiamine | WHO Anatomical Therapeutic Chemical classification | | sulbutiamine |
0‑L | A11DA03 | benfotiamine | WHO Anatomical Therapeutic Chemical classification | | benfotiamine |
0‑L | A11DB | Vitamin B1 in combination with vitamin B6 and/or vitamin B12 | WHO Anatomical Therapeutic Chemical classification | | Vitamin B1 in combination with vitamin B6 and/or vitamin B12 |
0‑L | A11E | VITAMIN B-COMPLEX, INCL. COMBINATIONS | WHO Anatomical Therapeutic Chemical classification | | VITAMIN B-COMPLEX, INCL. COMBINATIONS |
0‑L | A11EA | Vitamin B-complex, plain | WHO Anatomical Therapeutic Chemical classification | | Vitamin B-complex, plain |
0‑L | A11EB | Vitamin B-complex with vitamin C | WHO Anatomical Therapeutic Chemical classification | | Vitamin B-complex with vitamin C |
0‑L | A11EC | Vitamin B-complex with minerals | WHO Anatomical Therapeutic Chemical classification | | Vitamin B-complex with minerals |
0‑L | A11ED | Vitamin B-complex with anabolic steroids | WHO Anatomical Therapeutic Chemical classification | | Vitamin B-complex with anabolic steroids |
0‑L | A11EX | Vitamin B-complex, other combinations | WHO Anatomical Therapeutic Chemical classification | | Vitamin B-complex, other combinations |
0‑L | A11G | ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS | WHO Anatomical Therapeutic Chemical classification | | ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS |
0‑L | A11GA | Ascorbic acid (vitamin C), plain | WHO Anatomical Therapeutic Chemical classification | | Ascorbic acid (vitamin C), plain |
0‑L | A11GA01 | ascorbic acid (vit C) | WHO Anatomical Therapeutic Chemical classification | | ascorbic acid (vit C) |
0‑L | A11GB | Ascorbic acid (vitamin C), combinations | WHO Anatomical Therapeutic Chemical classification | | Ascorbic acid (vitamin C), combinations |
0‑L | A11GB01 | ascorbic acid (vit C) and calcium | WHO Anatomical Therapeutic Chemical classification | | ascorbic acid (vit C) and calcium |
0‑L | A11H | OTHER PLAIN VITAMIN PREPARATIONS | WHO Anatomical Therapeutic Chemical classification | | OTHER PLAIN VITAMIN PREPARATIONS |
0‑L | A11HA | Other plain vitamin preparations | WHO Anatomical Therapeutic Chemical classification | | Other plain vitamin preparations |
0‑L | A11HA01 | nicotinamide | WHO Anatomical Therapeutic Chemical classification | | nicotinamide |
0‑L | A11HA02 | pyridoxine (vit B6) | WHO Anatomical Therapeutic Chemical classification | | pyridoxine (vit B6) |
0‑L | A11HA03 | tocopherol (vit E) | WHO Anatomical Therapeutic Chemical classification | | tocopherol (vit E) |
0‑L | A11HA04 | riboflavin (vit B2) | WHO Anatomical Therapeutic Chemical classification | | riboflavin (vit B2) |
0‑L | A11HA05 | biotin | WHO Anatomical Therapeutic Chemical classification | | biotin |
0‑L | A11HA06 | pyridoxal phosphate | WHO Anatomical Therapeutic Chemical classification | | pyridoxal phosphate |
0‑L | A11HA07 | inositol | WHO Anatomical Therapeutic Chemical classification | | inositol |
0‑L | A11HA08 | tocofersolan | WHO Anatomical Therapeutic Chemical classification | | tocofersolan |
0‑L | A11HA30 | dexpanthenol | WHO Anatomical Therapeutic Chemical classification | | dexpanthenol |
0‑L | A11HA31 | calcium pantothenate | WHO Anatomical Therapeutic Chemical classification | | calcium pantothenate |
0‑L | A11HA32 | pantethine | WHO Anatomical Therapeutic Chemical classification | | pantethine |
0‑L | A11J | OTHER VITAMIN PRODUCTS, COMBINATIONS | WHO Anatomical Therapeutic Chemical classification | | OTHER VITAMIN PRODUCTS, COMBINATIONS |
0‑L | A11JA | Combinations of vitamins | WHO Anatomical Therapeutic Chemical classification | | Combinations of vitamins |
0‑L | A11JB | Vitamins with minerals | WHO Anatomical Therapeutic Chemical classification | | Vitamins with minerals |
0‑L | A11JC | Vitamins, other combinations | WHO Anatomical Therapeutic Chemical classification | | Vitamins, other combinations |
0‑L | A12 | MINERAL SUPPLEMENTS | WHO Anatomical Therapeutic Chemical classification | | MINERAL SUPPLEMENTS |
0‑L | A12A | CALCIUM | WHO Anatomical Therapeutic Chemical classification | | CALCIUM |
0‑L | A12AA | Calcium | WHO Anatomical Therapeutic Chemical classification | | Calcium |
0‑L | A12AA01 | calcium phosphate | WHO Anatomical Therapeutic Chemical classification | | calcium phosphate |
0‑L | A12AA02 | calcium glubionate | WHO Anatomical Therapeutic Chemical classification | | calcium glubionate |
0‑L | A12AA03 | calcium gluconate | WHO Anatomical Therapeutic Chemical classification | | calcium gluconate |
0‑L | A12AA04 | calcium carbonate | WHO Anatomical Therapeutic Chemical classification | | calcium carbonate |
0‑L | A12AA05 | calcium lactate | WHO Anatomical Therapeutic Chemical classification | | calcium lactate |
0‑L | A12AA06 | calcium lactate gluconate | WHO Anatomical Therapeutic Chemical classification | | calcium lactate gluconate |
0‑L | A12AA07 | calcium chloride | WHO Anatomical Therapeutic Chemical classification | | calcium chloride |
0‑L | A12AA08 | calcium glycerylphosphate | WHO Anatomical Therapeutic Chemical classification | | calcium glycerylphosphate |
0‑L | A12AA09 | calcium citrate lysine complex | WHO Anatomical Therapeutic Chemical classification | | calcium citrate lysine complex |
0‑L | A12AA10 | calcium glucoheptonate | WHO Anatomical Therapeutic Chemical classification | | calcium glucoheptonate |
0‑L | A12AA11 | calcium pangamate | WHO Anatomical Therapeutic Chemical classification | | calcium pangamate |
0‑L | A12AA13 | calcium citrate | WHO Anatomical Therapeutic Chemical classification | | calcium citrate |
0‑L | A12AA20 | calcium (different salts in combination) | WHO Anatomical Therapeutic Chemical classification | | calcium (different salts in combination) |
0‑L | A12AA30 | calcium laevulate | WHO Anatomical Therapeutic Chemical classification | | calcium laevulate |
0‑L | A12AX | Calcium, combinations with vitamin D and/or other drugs | WHO Anatomical Therapeutic Chemical classification | | Calcium, combinations with vitamin D and/or other drugs |
0‑L | A12B | POTASSIUM | WHO Anatomical Therapeutic Chemical classification | | POTASSIUM |
0‑L | A12BA | Potassium | WHO Anatomical Therapeutic Chemical classification | | Potassium |
0‑L | A12BA01 | potassium chloride | WHO Anatomical Therapeutic Chemical classification | | potassium chloride |
0‑L | A12BA02 | potassium citrate | WHO Anatomical Therapeutic Chemical classification | | potassium citrate |
0‑L | A12BA03 | potassium hydrogentartrate | WHO Anatomical Therapeutic Chemical classification | | potassium hydrogentartrate |
0‑L | A12BA04 | potassium hydrogencarbonate | WHO Anatomical Therapeutic Chemical classification | | potassium hydrogencarbonate |
0‑L | A12BA05 | potassium gluconate | WHO Anatomical Therapeutic Chemical classification | | potassium gluconate |
0‑L | A12BA30 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | A12BA51 | potassium chloride, combinations | WHO Anatomical Therapeutic Chemical classification | | potassium chloride, combinations |
0‑L | A12C | OTHER MINERAL SUPPLEMENTS | WHO Anatomical Therapeutic Chemical classification | | OTHER MINERAL SUPPLEMENTS |
0‑L | A12CA | Sodium | WHO Anatomical Therapeutic Chemical classification | | Sodium |
0‑L | A12CA01 | sodium chloride | WHO Anatomical Therapeutic Chemical classification | | sodium chloride |
0‑L | A12CA02 | sodium sulfate | WHO Anatomical Therapeutic Chemical classification | | sodium sulfate |
0‑L | A12CB | Zinc | WHO Anatomical Therapeutic Chemical classification | | Zinc |
0‑L | A12CB01 | zinc sulfate | WHO Anatomical Therapeutic Chemical classification | | zinc sulfate |
0‑L | A12CB02 | zinc gluconate | WHO Anatomical Therapeutic Chemical classification | | zinc gluconate |
0‑L | A12CB03 | zinc protein complex | WHO Anatomical Therapeutic Chemical classification | | zinc protein complex |
0‑L | A12CC | Magnesium | WHO Anatomical Therapeutic Chemical classification | | Magnesium |
0‑L | A12CC01 | magnesium chloride | WHO Anatomical Therapeutic Chemical classification | | magnesium chloride |
0‑L | A12CC02 | magnesium sulfate | WHO Anatomical Therapeutic Chemical classification | | magnesium sulfate |
0‑L | A12CC03 | magnesium gluconate | WHO Anatomical Therapeutic Chemical classification | | magnesium gluconate |
0‑L | A12CC04 | magnesium citrate | WHO Anatomical Therapeutic Chemical classification | | magnesium citrate |
0‑L | A12CC05 | magnesium aspartate | WHO Anatomical Therapeutic Chemical classification | | magnesium aspartate |
0‑L | A12CC06 | magnesium lactate | WHO Anatomical Therapeutic Chemical classification | | magnesium lactate |
0‑L | A12CC07 | magnesium levulinate | WHO Anatomical Therapeutic Chemical classification | | magnesium levulinate |
0‑L | A12CC08 | magnesium pidolate | WHO Anatomical Therapeutic Chemical classification | | magnesium pidolate |
0‑L | A12CC09 | magnesium orotate | WHO Anatomical Therapeutic Chemical classification | | magnesium orotate |
0‑L | A12CC10 | magnesium oxide | WHO Anatomical Therapeutic Chemical classification | | magnesium oxide |
0‑L | A12CC30 | magnesium (different salts in combination) | WHO Anatomical Therapeutic Chemical classification | | magnesium (different salts in combination) |
0‑L | A12CD | Fluoride | WHO Anatomical Therapeutic Chemical classification | | Fluoride |
0‑L | A12CD01 | sodium fluoride | WHO Anatomical Therapeutic Chemical classification | | sodium fluoride |
0‑L | A12CD02 | sodium monofluorophosphate | WHO Anatomical Therapeutic Chemical classification | | sodium monofluorophosphate |
0‑L | A12CD51 | fluoride, combinations | WHO Anatomical Therapeutic Chemical classification | | fluoride, combinations |
0‑L | A12CE | Selenium | WHO Anatomical Therapeutic Chemical classification | | Selenium |
0‑L | A12CE01 | sodium selenate | WHO Anatomical Therapeutic Chemical classification | | sodium selenate |
0‑L | A12CE02 | sodium selenite | WHO Anatomical Therapeutic Chemical classification | | sodium selenite |
0‑L | A12CX | Other mineral products | WHO Anatomical Therapeutic Chemical classification | | Other mineral products |
0‑L | A13 | TONICS | WHO Anatomical Therapeutic Chemical classification | | TONICS |
0‑L | A13A | TONICS | WHO Anatomical Therapeutic Chemical classification | | TONICS |
0‑L | A14 | ANABOLIC AGENTS FOR SYSTEMIC USE | WHO Anatomical Therapeutic Chemical classification | | ANABOLIC AGENTS FOR SYSTEMIC USE |
0‑L | A14A | ANABOLIC STEROIDS | WHO Anatomical Therapeutic Chemical classification | | ANABOLIC STEROIDS |
0‑L | A14AA | Androstan derivatives | WHO Anatomical Therapeutic Chemical classification | | Androstan derivatives |
0‑L | A14AA01 | androstanolone | WHO Anatomical Therapeutic Chemical classification | | androstanolone |
0‑L | A14AA02 | stanozolol | WHO Anatomical Therapeutic Chemical classification | | stanozolol |
0‑L | A14AA03 | metandienone | WHO Anatomical Therapeutic Chemical classification | | metandienone |
0‑L | A14AA04 | metenolone | WHO Anatomical Therapeutic Chemical classification | | metenolone |
0‑L | A14AA05 | oxymetholone | WHO Anatomical Therapeutic Chemical classification | | oxymetholone |
0‑L | A14AA06 | quinbolone | WHO Anatomical Therapeutic Chemical classification | | quinbolone |
0‑L | A14AA07 | prasterone | WHO Anatomical Therapeutic Chemical classification | | prasterone |
0‑L | A14AA08 | oxandrolone | WHO Anatomical Therapeutic Chemical classification | | oxandrolone |
0‑L | A14AA09 | norethandrolone | WHO Anatomical Therapeutic Chemical classification | | norethandrolone |
0‑L | A14AB | Estren derivatives | WHO Anatomical Therapeutic Chemical classification | | Estren derivatives |
0‑L | A14AB01 | nandrolone | WHO Anatomical Therapeutic Chemical classification | | nandrolone |
0‑L | A14AB02 | ethylestrenol | WHO Anatomical Therapeutic Chemical classification | | ethylestrenol |
0‑L | A14AB03 | oxabolone cipionate | WHO Anatomical Therapeutic Chemical classification | | oxabolone cipionate |
0‑L | A14B | OTHER ANABOLIC AGENTS | WHO Anatomical Therapeutic Chemical classification | | OTHER ANABOLIC AGENTS |
0‑L | A15 | APPETITE STIMULANTS | WHO Anatomical Therapeutic Chemical classification | | APPETITE STIMULANTS |
0‑L | A16 | OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS | WHO Anatomical Therapeutic Chemical classification | | OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS |
0‑L | A16A | OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS | WHO Anatomical Therapeutic Chemical classification | | OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS |
0‑L | A16AA | Amino acids and derivatives | WHO Anatomical Therapeutic Chemical classification | | Amino acids and derivatives |
0‑L | A16AA01 | levocarnitine | WHO Anatomical Therapeutic Chemical classification | | levocarnitine |
0‑L | A16AA02 | ademetionine | WHO Anatomical Therapeutic Chemical classification | | ademetionine |
0‑L | A16AA03 | glutamine | WHO Anatomical Therapeutic Chemical classification | | glutamine |
0‑L | A16AA04 | mercaptamine | WHO Anatomical Therapeutic Chemical classification | | mercaptamine |
0‑L | A16AA05 | carglumic acid | WHO Anatomical Therapeutic Chemical classification | | carglumic acid |
0‑L | A16AA06 | betaine | WHO Anatomical Therapeutic Chemical classification | | betaine |
0‑L | A16AA07 | metreleptin | WHO Anatomical Therapeutic Chemical classification | | metreleptin |
0‑L | A16AB | Enzymes | WHO Anatomical Therapeutic Chemical classification | | Enzymes |
0‑L | A16AB01 | alglucerase | WHO Anatomical Therapeutic Chemical classification | | alglucerase |
0‑L | A16AB02 | imiglucerase | WHO Anatomical Therapeutic Chemical classification | | imiglucerase |
0‑L | A16AB03 | agalsidase alfa | WHO Anatomical Therapeutic Chemical classification | | agalsidase alfa |
0‑L | A16AB04 | agalsidase beta | WHO Anatomical Therapeutic Chemical classification | | agalsidase beta |
0‑L | A16AB05 | laronidase | WHO Anatomical Therapeutic Chemical classification | | laronidase |
0‑L | A16AB06 | sacrosidase | WHO Anatomical Therapeutic Chemical classification | | sacrosidase |
0‑L | A16AB07 | alglucosidase alfa | WHO Anatomical Therapeutic Chemical classification | | alglucosidase alfa |
0‑L | A16AB08 | galsulfase | WHO Anatomical Therapeutic Chemical classification | | galsulfase |
0‑L | A16AB09 | idursulfase | WHO Anatomical Therapeutic Chemical classification | | idursulfase |
0‑L | A16AB10 | velaglucerase alfa | WHO Anatomical Therapeutic Chemical classification | | velaglucerase alfa |
0‑L | A16AB11 | taliglucerase alfa | WHO Anatomical Therapeutic Chemical classification | | taliglucerase alfa |
0‑L | A16AB12 | elosulfase alfa | WHO Anatomical Therapeutic Chemical classification | | elosulfase alfa |
0‑L | A16AB13 | asfotase alfa | WHO Anatomical Therapeutic Chemical classification | | asfotase alfa |
0‑L | A16AB14 | sebelipase alfa | WHO Anatomical Therapeutic Chemical classification | | sebelipase alfa |
0‑L | A16AX | Various alimentary tract and metabolism products | WHO Anatomical Therapeutic Chemical classification | | Various alimentary tract and metabolism products |
0‑L | A16AX01 | thioctic acid | WHO Anatomical Therapeutic Chemical classification | | thioctic acid |
0‑L | A16AX02 | anethole trithione | WHO Anatomical Therapeutic Chemical classification | | anethole trithione |
0‑L | A16AX03 | sodium phenylbutyrate | WHO Anatomical Therapeutic Chemical classification | | sodium phenylbutyrate |
0‑L | A16AX04 | nitisinone | WHO Anatomical Therapeutic Chemical classification | | nitisinone |
0‑L | A16AX05 | zinc acetate | WHO Anatomical Therapeutic Chemical classification | | zinc acetate |
0‑L | A16AX06 | miglustat | WHO Anatomical Therapeutic Chemical classification | | miglustat |
0‑L | A16AX07 | sapropterin | WHO Anatomical Therapeutic Chemical classification | | sapropterin |
0‑L | A16AX08 | teduglutide | WHO Anatomical Therapeutic Chemical classification | | teduglutide |
0‑L | A16AX09 | glycerol phenylbutyrate | WHO Anatomical Therapeutic Chemical classification | | glycerol phenylbutyrate |
0‑L | A16AX10 | eliglustat | WHO Anatomical Therapeutic Chemical classification | | eliglustat |
0‑L | A16AX11 | sodium benzoate | WHO Anatomical Therapeutic Chemical classification | | sodium benzoate |
0‑L | A16AX12 | trientine | WHO Anatomical Therapeutic Chemical classification | | trientine |
0‑L | A16AX13 | uridine triacetate | WHO Anatomical Therapeutic Chemical classification | | uridine triacetate |
0‑L | B | BLOOD AND BLOOD FORMING ORGANS | WHO Anatomical Therapeutic Chemical classification | | BLOOD AND BLOOD FORMING ORGANS |
0‑L | B01 | ANTITHROMBOTIC AGENTS | WHO Anatomical Therapeutic Chemical classification | | ANTITHROMBOTIC AGENTS |
0‑L | B01A | ANTITHROMBOTIC AGENTS | WHO Anatomical Therapeutic Chemical classification | | ANTITHROMBOTIC AGENTS |
0‑L | B01AA | Vitamin K antagonists | WHO Anatomical Therapeutic Chemical classification | | Vitamin K antagonists |
0‑L | B01AA01 | dicoumarol | WHO Anatomical Therapeutic Chemical classification | | dicoumarol |
0‑L | B01AA02 | phenindione | WHO Anatomical Therapeutic Chemical classification | | phenindione |
0‑L | B01AA03 | warfarin | WHO Anatomical Therapeutic Chemical classification | | warfarin |
0‑L | B01AA04 | phenprocoumon | WHO Anatomical Therapeutic Chemical classification | | phenprocoumon |
0‑L | B01AA07 | acenocoumarol | WHO Anatomical Therapeutic Chemical classification | | acenocoumarol |
0‑L | B01AA08 | ethyl biscoumacetate | WHO Anatomical Therapeutic Chemical classification | | ethyl biscoumacetate |
0‑L | B01AA09 | clorindione | WHO Anatomical Therapeutic Chemical classification | | clorindione |
0‑L | B01AA10 | diphenadione | WHO Anatomical Therapeutic Chemical classification | | diphenadione |
0‑L | B01AA11 | tioclomarol | WHO Anatomical Therapeutic Chemical classification | | tioclomarol |
0‑L | B01AA12 | fluindione | WHO Anatomical Therapeutic Chemical classification | | fluindione |
0‑L | B01AB | Heparin group | WHO Anatomical Therapeutic Chemical classification | | Heparin group |
0‑L | B01AB01 | heparin | WHO Anatomical Therapeutic Chemical classification | | heparin |
0‑L | B01AB02 | antithrombin III | WHO Anatomical Therapeutic Chemical classification | | antithrombin III |
0‑L | B01AB04 | dalteparin | WHO Anatomical Therapeutic Chemical classification | | dalteparin |
0‑L | B01AB05 | enoxaparin | WHO Anatomical Therapeutic Chemical classification | | enoxaparin |
0‑L | B01AB06 | nadroparin | WHO Anatomical Therapeutic Chemical classification | | nadroparin |
0‑L | B01AB07 | parnaparin | WHO Anatomical Therapeutic Chemical classification | | parnaparin |
0‑L | B01AB08 | reviparin | WHO Anatomical Therapeutic Chemical classification | | reviparin |
0‑L | B01AB09 | danaparoid | WHO Anatomical Therapeutic Chemical classification | | danaparoid |
0‑L | B01AB10 | tinzaparin | WHO Anatomical Therapeutic Chemical classification | | tinzaparin |
0‑L | B01AB11 | sulodexide | WHO Anatomical Therapeutic Chemical classification | | sulodexide |
0‑L | B01AB12 | bemiparin | WHO Anatomical Therapeutic Chemical classification | | bemiparin |
0‑L | B01AB51 | heparin, combinations | WHO Anatomical Therapeutic Chemical classification | | heparin, combinations |
0‑L | B01AC | Platelet aggregation inhibitors excl. heparin | WHO Anatomical Therapeutic Chemical classification | | Platelet aggregation inhibitors excl. heparin |
0‑L | B01AC01 | ditazole | WHO Anatomical Therapeutic Chemical classification | | ditazole |
0‑L | B01AC02 | cloricromen | WHO Anatomical Therapeutic Chemical classification | | cloricromen |
0‑L | B01AC03 | picotamide | WHO Anatomical Therapeutic Chemical classification | | picotamide |
0‑L | B01AC04 | clopidogrel | WHO Anatomical Therapeutic Chemical classification | | clopidogrel |
0‑L | B01AC05 | ticlopidine | WHO Anatomical Therapeutic Chemical classification | | ticlopidine |
0‑L | B01AC06 | acetylsalicylic acid | WHO Anatomical Therapeutic Chemical classification | | acetylsalicylic acid |
0‑L | B01AC07 | dipyridamole | WHO Anatomical Therapeutic Chemical classification | | dipyridamole |
0‑L | B01AC08 | carbasalate calcium | WHO Anatomical Therapeutic Chemical classification | | carbasalate calcium |
0‑L | B01AC09 | epoprostenol | WHO Anatomical Therapeutic Chemical classification | | epoprostenol |
0‑L | B01AC10 | indobufen | WHO Anatomical Therapeutic Chemical classification | | indobufen |
0‑L | B01AC11 | iloprost | WHO Anatomical Therapeutic Chemical classification | | iloprost |
0‑L | B01AC13 | abciximab | WHO Anatomical Therapeutic Chemical classification | | abciximab |
0‑L | B01AC15 | aloxiprin | WHO Anatomical Therapeutic Chemical classification | | aloxiprin |
0‑L | B01AC16 | eptifibatide | WHO Anatomical Therapeutic Chemical classification | | eptifibatide |
0‑L | B01AC17 | tirofiban | WHO Anatomical Therapeutic Chemical classification | | tirofiban |
0‑L | B01AC18 | triflusal | WHO Anatomical Therapeutic Chemical classification | | triflusal |
0‑L | B01AC19 | beraprost | WHO Anatomical Therapeutic Chemical classification | | beraprost |
0‑L | B01AC21 | treprostinil | WHO Anatomical Therapeutic Chemical classification | | treprostinil |
0‑L | B01AC22 | prasugrel | WHO Anatomical Therapeutic Chemical classification | | prasugrel |
0‑L | B01AC23 | cilostazol | WHO Anatomical Therapeutic Chemical classification | | cilostazol |
0‑L | B01AC24 | ticagrelor | WHO Anatomical Therapeutic Chemical classification | | ticagrelor |
0‑L | B01AC25 | cangrelor | WHO Anatomical Therapeutic Chemical classification | | cangrelor |
0‑L | B01AC26 | vorapaxar | WHO Anatomical Therapeutic Chemical classification | | vorapaxar |
0‑L | B01AC27 | selexipag | WHO Anatomical Therapeutic Chemical classification | | selexipag |
0‑L | B01AC30 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | B01AC56 | acetylsalicylic acid, combinations with proton pump inhibitors | WHO Anatomical Therapeutic Chemical classification | | acetylsalicylic acid, combinations with proton pump inhibitors |
0‑L | B01AD | Enzymes | WHO Anatomical Therapeutic Chemical classification | | Enzymes |
0‑L | B01AD01 | streptokinase | WHO Anatomical Therapeutic Chemical classification | | streptokinase |
0‑L | B01AD02 | alteplase | WHO Anatomical Therapeutic Chemical classification | | alteplase |
0‑L | B01AD03 | anistreplase | WHO Anatomical Therapeutic Chemical classification | | anistreplase |
0‑L | B01AD04 | urokinase | WHO Anatomical Therapeutic Chemical classification | | urokinase |
0‑L | B01AD05 | fibrinolysin | WHO Anatomical Therapeutic Chemical classification | | fibrinolysin |
0‑L | B01AD06 | brinase | WHO Anatomical Therapeutic Chemical classification | | brinase |
0‑L | B01AD07 | reteplase | WHO Anatomical Therapeutic Chemical classification | | reteplase |
0‑L | B01AD08 | saruplase | WHO Anatomical Therapeutic Chemical classification | | saruplase |
0‑L | B01AD09 | ancrod | WHO Anatomical Therapeutic Chemical classification | | ancrod |
0‑L | B01AD10 | drotrecogin alfa (activated) | WHO Anatomical Therapeutic Chemical classification | | drotrecogin alfa (activated) |
0‑L | B01AD11 | tenecteplase | WHO Anatomical Therapeutic Chemical classification | | tenecteplase |
0‑L | B01AD12 | protein C | WHO Anatomical Therapeutic Chemical classification | | protein C |
0‑L | B01AE | Direct thrombin inhibitors | WHO Anatomical Therapeutic Chemical classification | | Direct thrombin inhibitors |
0‑L | B01AE01 | desirudin | WHO Anatomical Therapeutic Chemical classification | | desirudin |
0‑L | B01AE02 | lepirudin | WHO Anatomical Therapeutic Chemical classification | | lepirudin |
0‑L | B01AE03 | argatroban | WHO Anatomical Therapeutic Chemical classification | | argatroban |
0‑L | B01AE04 | melagatran | WHO Anatomical Therapeutic Chemical classification | | melagatran |
0‑L | B01AE05 | ximelagatran | WHO Anatomical Therapeutic Chemical classification | | ximelagatran |
0‑L | B01AE06 | bivalirudin | WHO Anatomical Therapeutic Chemical classification | | bivalirudin |
0‑L | B01AE07 | dabigatran etexilate | WHO Anatomical Therapeutic Chemical classification | | dabigatran etexilate |
0‑L | B01AF | Direct factor Xa inhibitors | WHO Anatomical Therapeutic Chemical classification | | Direct factor Xa inhibitors |
0‑L | B01AF01 | rivaroxaban | WHO Anatomical Therapeutic Chemical classification | | rivaroxaban |
0‑L | B01AF02 | apixaban | WHO Anatomical Therapeutic Chemical classification | | apixaban |
0‑L | B01AF03 | edoxaban | WHO Anatomical Therapeutic Chemical classification | | edoxaban |
0‑L | B01AX | Other antithrombotic agents | WHO Anatomical Therapeutic Chemical classification | | Other antithrombotic agents |
0‑L | B01AX01 | defibrotide | WHO Anatomical Therapeutic Chemical classification | | defibrotide |
0‑L | B01AX04 | dermatan sulfate | WHO Anatomical Therapeutic Chemical classification | | dermatan sulfate |
0‑L | B01AX05 | fondaparinux | WHO Anatomical Therapeutic Chemical classification | | fondaparinux |
0‑L | B02 | ANTIHEMORRHAGICS | WHO Anatomical Therapeutic Chemical classification | | ANTIHEMORRHAGICS |
0‑L | B02A | ANTIFIBRINOLYTICS | WHO Anatomical Therapeutic Chemical classification | | ANTIFIBRINOLYTICS |
0‑L | B02AA | Amino acids | WHO Anatomical Therapeutic Chemical classification | | Amino acids |
0‑L | B02AA01 | aminocaproic acid | WHO Anatomical Therapeutic Chemical classification | | aminocaproic acid |
0‑L | B02AA02 | tranexamic acid | WHO Anatomical Therapeutic Chemical classification | | tranexamic acid |
0‑L | B02AA03 | aminomethylbenzoic acid | WHO Anatomical Therapeutic Chemical classification | | aminomethylbenzoic acid |
0‑L | B02AB | Proteinase inhibitors | WHO Anatomical Therapeutic Chemical classification | | Proteinase inhibitors |
0‑L | B02AB01 | aprotinin | WHO Anatomical Therapeutic Chemical classification | | aprotinin |
0‑L | B02AB02 | alfa1 antitrypsin | WHO Anatomical Therapeutic Chemical classification | | alfa1 antitrypsin |
0‑L | B02AB04 | camostat | WHO Anatomical Therapeutic Chemical classification | | camostat |
0‑L | B02B | VITAMIN K AND OTHER HEMOSTATICS | WHO Anatomical Therapeutic Chemical classification | | VITAMIN K AND OTHER HEMOSTATICS |
0‑L | B02BA | Vitamin K | WHO Anatomical Therapeutic Chemical classification | | Vitamin K |
0‑L | B02BA01 | phytomenadione | WHO Anatomical Therapeutic Chemical classification | | phytomenadione |
0‑L | B02BA02 | menadione | WHO Anatomical Therapeutic Chemical classification | | menadione |
0‑L | B02BB | Fibrinogen | WHO Anatomical Therapeutic Chemical classification | | Fibrinogen |
0‑L | B02BB01 | fibrinogen, human | WHO Anatomical Therapeutic Chemical classification | | fibrinogen, human |
0‑L | B02BC | Local hemostatics | WHO Anatomical Therapeutic Chemical classification | | Local hemostatics |
0‑L | B02BC01 | absorbable gelatin sponge | WHO Anatomical Therapeutic Chemical classification | | absorbable gelatin sponge |
0‑L | B02BC02 | oxidized cellulose | WHO Anatomical Therapeutic Chemical classification | | oxidized cellulose |
0‑L | B02BC03 | tetragalacturonic acid hydroxymethylester | WHO Anatomical Therapeutic Chemical classification | | tetragalacturonic acid hydroxymethylester |
0‑L | B02BC05 | adrenalone | WHO Anatomical Therapeutic Chemical classification | | adrenalone |
0‑L | B02BC06 | thrombin | WHO Anatomical Therapeutic Chemical classification | | thrombin |
0‑L | B02BC07 | collagen | WHO Anatomical Therapeutic Chemical classification | | collagen |
0‑L | B02BC08 | calcium alginate | WHO Anatomical Therapeutic Chemical classification | | calcium alginate |
0‑L | B02BC09 | epinephrine | WHO Anatomical Therapeutic Chemical classification | | epinephrine |
0‑L | B02BC30 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | B02BD | Blood coagulation factors | WHO Anatomical Therapeutic Chemical classification | | Blood coagulation factors |
0‑L | B02BD01 | coagulation factor IX, II, VII and X in combination | WHO Anatomical Therapeutic Chemical classification | | coagulation factor IX, II, VII and X in combination |
0‑L | B02BD02 | coagulation factor VIII | WHO Anatomical Therapeutic Chemical classification | | coagulation factor VIII |
0‑L | B02BD03 | factor VIII inhibitor bypassing activity | WHO Anatomical Therapeutic Chemical classification | | factor VIII inhibitor bypassing activity |
0‑L | B02BD04 | coagulation factor IX | WHO Anatomical Therapeutic Chemical classification | | coagulation factor IX |
0‑L | B02BD05 | coagulation factor VII | WHO Anatomical Therapeutic Chemical classification | | coagulation factor VII |
0‑L | B02BD06 | von Willebrand factor and coagulation factor VIII in combination | WHO Anatomical Therapeutic Chemical classification | | von Willebrand factor and coagulation factor VIII in combination |
0‑L | B02BD07 | coagulation factor XIII | WHO Anatomical Therapeutic Chemical classification | | coagulation factor XIII |
0‑L | B02BD08 | eptacog alfa (activated) | WHO Anatomical Therapeutic Chemical classification | | eptacog alfa (activated) |
0‑L | B02BD10 | von Willebrand factor | WHO Anatomical Therapeutic Chemical classification | | von Willebrand factor |
0‑L | B02BD11 | catridecacog | WHO Anatomical Therapeutic Chemical classification | | catridecacog |
0‑L | B02BD13 | coagulation factor X | WHO Anatomical Therapeutic Chemical classification | | coagulation factor X |
0‑L | B02BD14 | susoctocog alfa | WHO Anatomical Therapeutic Chemical classification | | susoctocog alfa |
0‑L | B02BD30 | thrombin | WHO Anatomical Therapeutic Chemical classification | | thrombin |
0‑L | B02BX | Other systemic hemostatics | WHO Anatomical Therapeutic Chemical classification | | Other systemic hemostatics |
0‑L | B02BX01 | etamsylate | WHO Anatomical Therapeutic Chemical classification | | etamsylate |
0‑L | B02BX02 | carbazochrome | WHO Anatomical Therapeutic Chemical classification | | carbazochrome |
0‑L | B02BX03 | batroxobin | WHO Anatomical Therapeutic Chemical classification | | batroxobin |
0‑L | B02BX04 | romiplostim | WHO Anatomical Therapeutic Chemical classification | | romiplostim |
0‑L | B02BX05 | eltrombopag | WHO Anatomical Therapeutic Chemical classification | | eltrombopag |
0‑L | B03 | ANTIANEMIC PREPARATIONS | WHO Anatomical Therapeutic Chemical classification | | ANTIANEMIC PREPARATIONS |
0‑L | B03A | IRON PREPARATIONS | WHO Anatomical Therapeutic Chemical classification | | IRON PREPARATIONS |
0‑L | B03AA | Iron bivalent, oral preparations | WHO Anatomical Therapeutic Chemical classification | | Iron bivalent, oral preparations |
0‑L | B03AA01 | ferrous glycine sulfate | WHO Anatomical Therapeutic Chemical classification | | ferrous glycine sulfate |
0‑L | B03AA02 | ferrous fumarate | WHO Anatomical Therapeutic Chemical classification | | ferrous fumarate |
0‑L | B03AA03 | ferrous gluconate | WHO Anatomical Therapeutic Chemical classification | | ferrous gluconate |
0‑L | B03AA04 | ferrous carbonate | WHO Anatomical Therapeutic Chemical classification | | ferrous carbonate |
0‑L | B03AA05 | ferrous chloride | WHO Anatomical Therapeutic Chemical classification | | ferrous chloride |
0‑L | B03AA06 | ferrous succinate | WHO Anatomical Therapeutic Chemical classification | | ferrous succinate |
0‑L | B03AA07 | ferrous sulfate | WHO Anatomical Therapeutic Chemical classification | | ferrous sulfate |
0‑L | B03AA08 | ferrous tartrate | WHO Anatomical Therapeutic Chemical classification | | ferrous tartrate |
0‑L | B03AA09 | ferrous aspartate | WHO Anatomical Therapeutic Chemical classification | | ferrous aspartate |
0‑L | B03AA10 | ferrous ascorbate | WHO Anatomical Therapeutic Chemical classification | | ferrous ascorbate |
0‑L | B03AA11 | ferrous iodine | WHO Anatomical Therapeutic Chemical classification | | ferrous iodine |
0‑L | B03AB | Iron trivalent, oral preparations | WHO Anatomical Therapeutic Chemical classification | | Iron trivalent, oral preparations |
0‑L | B03AB01 | ferric sodium citrate | WHO Anatomical Therapeutic Chemical classification | | ferric sodium citrate |
0‑L | B03AB02 | saccharated iron oxide | WHO Anatomical Therapeutic Chemical classification | | saccharated iron oxide |
0‑L | B03AB03 | sodium feredetate | WHO Anatomical Therapeutic Chemical classification | | sodium feredetate |
0‑L | B03AB04 | ferric hydroxide | WHO Anatomical Therapeutic Chemical classification | | ferric hydroxide |
0‑L | B03AB05 | ferric oxide polymaltose complexes | WHO Anatomical Therapeutic Chemical classification | | ferric oxide polymaltose complexes |
0‑L | B03AB07 | chondroitin sulfate-iron complex | WHO Anatomical Therapeutic Chemical classification | | chondroitin sulfate-iron complex |
0‑L | B03AB08 | ferric acetyl transferrin | WHO Anatomical Therapeutic Chemical classification | | ferric acetyl transferrin |
0‑L | B03AB09 | ferric proteinsuccinylate | WHO Anatomical Therapeutic Chemical classification | | ferric proteinsuccinylate |
0‑L | B03AB10 | ferric maltol | WHO Anatomical Therapeutic Chemical classification | | ferric maltol |
0‑L | B03AC | Iron, parenteral preparations | WHO Anatomical Therapeutic Chemical classification | | Iron, parenteral preparations |
0‑L | B03AD | Iron in combination with folic acid | WHO Anatomical Therapeutic Chemical classification | | Iron in combination with folic acid |
0‑L | B03AD01 | ferrous amino acid complex | WHO Anatomical Therapeutic Chemical classification | | ferrous amino acid complex |
0‑L | B03AD02 | ferrous fumarate | WHO Anatomical Therapeutic Chemical classification | | ferrous fumarate |
0‑L | B03AD03 | ferrous sulfate | WHO Anatomical Therapeutic Chemical classification | | ferrous sulfate |
0‑L | B03AD04 | ferric oxide polymaltose complexes | WHO Anatomical Therapeutic Chemical classification | | ferric oxide polymaltose complexes |
0‑L | B03AE | Iron in other combinations | WHO Anatomical Therapeutic Chemical classification | | Iron in other combinations |
0‑L | B03AE01 | iron, vitamin B12 and folic acid | WHO Anatomical Therapeutic Chemical classification | | iron, vitamin B12 and folic acid |
0‑L | B03AE02 | iron, multivitamins and folic acid | WHO Anatomical Therapeutic Chemical classification | | iron, multivitamins and folic acid |
0‑L | B03AE03 | iron and multivitamins | WHO Anatomical Therapeutic Chemical classification | | iron and multivitamins |
0‑L | B03AE04 | iron, multivitamins and minerals | WHO Anatomical Therapeutic Chemical classification | | iron, multivitamins and minerals |
0‑L | B03AE10 | various combinations | WHO Anatomical Therapeutic Chemical classification | | various combinations |
0‑L | B03B | VITAMIN B12 AND FOLIC ACID | WHO Anatomical Therapeutic Chemical classification | | VITAMIN B12 AND FOLIC ACID |
0‑L | B03BA | Vitamin B12 (cyanocobalamin and analogues) | WHO Anatomical Therapeutic Chemical classification | | Vitamin B12 (cyanocobalamin and analogues) |
0‑L | B03BA01 | cyanocobalamin | WHO Anatomical Therapeutic Chemical classification | | cyanocobalamin |
0‑L | B03BA02 | cyanocobalamin tannin complex | WHO Anatomical Therapeutic Chemical classification | | cyanocobalamin tannin complex |
0‑L | B03BA03 | hydroxocobalamin | WHO Anatomical Therapeutic Chemical classification | | hydroxocobalamin |
0‑L | B03BA04 | cobamamide | WHO Anatomical Therapeutic Chemical classification | | cobamamide |
0‑L | B03BA05 | mecobalamin | WHO Anatomical Therapeutic Chemical classification | | mecobalamin |
0‑L | B03BA51 | cyanocobalamin, combinations | WHO Anatomical Therapeutic Chemical classification | | cyanocobalamin, combinations |
0‑L | B03BA53 | hydroxocobalamin, combinations | WHO Anatomical Therapeutic Chemical classification | | hydroxocobalamin, combinations |
0‑L | B03BB | Folic acid and derivatives | WHO Anatomical Therapeutic Chemical classification | | Folic acid and derivatives |
0‑L | B03BB01 | folic acid | WHO Anatomical Therapeutic Chemical classification | | folic acid |
0‑L | B03BB51 | folic acid, combinations | WHO Anatomical Therapeutic Chemical classification | | folic acid, combinations |
0‑L | B03X | OTHER ANTIANEMIC PREPARATIONS | WHO Anatomical Therapeutic Chemical classification | | OTHER ANTIANEMIC PREPARATIONS |
0‑L | B03XA | Other antianemic preparations | WHO Anatomical Therapeutic Chemical classification | | Other antianemic preparations |
0‑L | B03XA01 | erythropoietin | WHO Anatomical Therapeutic Chemical classification | | erythropoietin |
0‑L | B03XA02 | darbepoetin alfa | WHO Anatomical Therapeutic Chemical classification | | darbepoetin alfa |
0‑L | B03XA03 | methoxy polyethylene glycol-epoetin beta | WHO Anatomical Therapeutic Chemical classification | | methoxy polyethylene glycol-epoetin beta |
0‑L | B03XA04 | peginesatide | WHO Anatomical Therapeutic Chemical classification | | peginesatide |
0‑L | B05 | BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS | WHO Anatomical Therapeutic Chemical classification | | BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS |
0‑L | B05A | BLOOD AND RELATED PRODUCTS | WHO Anatomical Therapeutic Chemical classification | | BLOOD AND RELATED PRODUCTS |
0‑L | B05AA | Blood substitutes and plasma protein fractions | WHO Anatomical Therapeutic Chemical classification | | Blood substitutes and plasma protein fractions |
0‑L | B05AA01 | albumin | WHO Anatomical Therapeutic Chemical classification | | albumin |
0‑L | B05AA02 | other plasma protein fractions | WHO Anatomical Therapeutic Chemical classification | | other plasma protein fractions |
0‑L | B05AA03 | fluorocarbon blood substitutes | WHO Anatomical Therapeutic Chemical classification | | fluorocarbon blood substitutes |
0‑L | B05AA05 | dextran | WHO Anatomical Therapeutic Chemical classification | | dextran |
0‑L | B05AA06 | gelatin agents | WHO Anatomical Therapeutic Chemical classification | | gelatin agents |
0‑L | B05AA07 | hydroxyethylstarch | WHO Anatomical Therapeutic Chemical classification | | hydroxyethylstarch |
0‑L | B05AA08 | hemoglobin crosfumaril | WHO Anatomical Therapeutic Chemical classification | | hemoglobin crosfumaril |
0‑L | B05AA09 | hemoglobin raffimer | WHO Anatomical Therapeutic Chemical classification | | hemoglobin raffimer |
0‑L | B05AA10 | hemoglobin glutamer (bovine) | WHO Anatomical Therapeutic Chemical classification | | hemoglobin glutamer (bovine) |
0‑L | B05AX | Other blood products | WHO Anatomical Therapeutic Chemical classification | | Other blood products |
0‑L | B05AX01 | erythrocytes | WHO Anatomical Therapeutic Chemical classification | | erythrocytes |
0‑L | B05AX02 | thrombocytes | WHO Anatomical Therapeutic Chemical classification | | thrombocytes |
0‑L | B05AX03 | blood plasma | WHO Anatomical Therapeutic Chemical classification | | blood plasma |
0‑L | B05AX04 | stem cells from umbilical cord blood | WHO Anatomical Therapeutic Chemical classification | | stem cells from umbilical cord blood |
0‑L | B05B | I.V. SOLUTIONS | WHO Anatomical Therapeutic Chemical classification | | I.V. SOLUTIONS |
0‑L | B05BA | Solutions for parenteral nutrition | WHO Anatomical Therapeutic Chemical classification | | Solutions for parenteral nutrition |
0‑L | B05BA01 | amino acids | WHO Anatomical Therapeutic Chemical classification | | amino acids |
0‑L | B05BA02 | fat emulsions | WHO Anatomical Therapeutic Chemical classification | | fat emulsions |
0‑L | B05BA03 | carbohydrates | WHO Anatomical Therapeutic Chemical classification | | carbohydrates |
0‑L | B05BA04 | protein hydrolysates | WHO Anatomical Therapeutic Chemical classification | | protein hydrolysates |
0‑L | B05BA10 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | B05BB | Solutions affecting the electrolyte balance | WHO Anatomical Therapeutic Chemical classification | | Solutions affecting the electrolyte balance |
0‑L | B05BB01 | electrolytes | WHO Anatomical Therapeutic Chemical classification | | electrolytes |
0‑L | B05BB02 | electrolytes with carbohydrates | WHO Anatomical Therapeutic Chemical classification | | electrolytes with carbohydrates |
0‑L | B05BB03 | trometamol | WHO Anatomical Therapeutic Chemical classification | | trometamol |
0‑L | B05BB04 | electrolytes in combination with other drugs | WHO Anatomical Therapeutic Chemical classification | | electrolytes in combination with other drugs |
0‑L | B05BC | Solutions producing osmotic diuresis | WHO Anatomical Therapeutic Chemical classification | | Solutions producing osmotic diuresis |
0‑L | B05BC01 | mannitol | WHO Anatomical Therapeutic Chemical classification | | mannitol |
0‑L | B05BC02 | carbamide | WHO Anatomical Therapeutic Chemical classification | | carbamide |
0‑L | B05C | IRRIGATING SOLUTIONS | WHO Anatomical Therapeutic Chemical classification | | IRRIGATING SOLUTIONS |
0‑L | B05CA | Antiinfectives | WHO Anatomical Therapeutic Chemical classification | | Antiinfectives |
0‑L | B05CA01 | cetylpyridinium | WHO Anatomical Therapeutic Chemical classification | | cetylpyridinium |
0‑L | B05CA02 | chlorhexidine | WHO Anatomical Therapeutic Chemical classification | | chlorhexidine |
0‑L | B05CA03 | nitrofural | WHO Anatomical Therapeutic Chemical classification | | nitrofural |
0‑L | B05CA04 | sulfamethizole | WHO Anatomical Therapeutic Chemical classification | | sulfamethizole |
0‑L | B05CA05 | taurolidine | WHO Anatomical Therapeutic Chemical classification | | taurolidine |
0‑L | B05CA06 | mandelic acid | WHO Anatomical Therapeutic Chemical classification | | mandelic acid |
0‑L | B05CA07 | noxytiolin | WHO Anatomical Therapeutic Chemical classification | | noxytiolin |
0‑L | B05CA08 | ethacridine lactate | WHO Anatomical Therapeutic Chemical classification | | ethacridine lactate |
0‑L | B05CA09 | neomycin | WHO Anatomical Therapeutic Chemical classification | | neomycin |
0‑L | B05CA10 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | B05CB | Salt solutions | WHO Anatomical Therapeutic Chemical classification | | Salt solutions |
0‑L | B05CB01 | sodium chloride | WHO Anatomical Therapeutic Chemical classification | | sodium chloride |
0‑L | B05CB02 | sodium citrate | WHO Anatomical Therapeutic Chemical classification | | sodium citrate |
0‑L | B05CB03 | magnesium citrate | WHO Anatomical Therapeutic Chemical classification | | magnesium citrate |
0‑L | B05CB04 | sodium bicarbonate | WHO Anatomical Therapeutic Chemical classification | | sodium bicarbonate |
0‑L | B05CB10 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | B05CX | Other irrigating solutions | WHO Anatomical Therapeutic Chemical classification | | Other irrigating solutions |
0‑L | B05CX01 | glucose | WHO Anatomical Therapeutic Chemical classification | | glucose |
0‑L | B05CX02 | sorbitol | WHO Anatomical Therapeutic Chemical classification | | sorbitol |
0‑L | B05CX03 | glycine | WHO Anatomical Therapeutic Chemical classification | | glycine |
0‑L | B05CX04 | mannitol | WHO Anatomical Therapeutic Chemical classification | | mannitol |
0‑L | B05CX10 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | B05D | PERITONEAL DIALYTICS | WHO Anatomical Therapeutic Chemical classification | | PERITONEAL DIALYTICS |
0‑L | B05DA | Isotonic solutions | WHO Anatomical Therapeutic Chemical classification | | Isotonic solutions |
0‑L | B05DB | Hypertonic solutions | WHO Anatomical Therapeutic Chemical classification | | Hypertonic solutions |
0‑L | B05X | I.V. SOLUTION ADDITIVES | WHO Anatomical Therapeutic Chemical classification | | I.V. SOLUTION ADDITIVES |
0‑L | B05XA | Electrolyte solutions | WHO Anatomical Therapeutic Chemical classification | | Electrolyte solutions |
0‑L | B05XA01 | potassium chloride | WHO Anatomical Therapeutic Chemical classification | | potassium chloride |
0‑L | B05XA02 | sodium bicarbonate | WHO Anatomical Therapeutic Chemical classification | | sodium bicarbonate |
0‑L | B05XA03 | sodium chloride | WHO Anatomical Therapeutic Chemical classification | | sodium chloride |
0‑L | B05XA04 | ammonium chloride | WHO Anatomical Therapeutic Chemical classification | | ammonium chloride |
0‑L | B05XA05 | magnesium sulfate | WHO Anatomical Therapeutic Chemical classification | | magnesium sulfate |
0‑L | B05XA06 | potassium phosphate, incl. combinations with other potassium salts | WHO Anatomical Therapeutic Chemical classification | | potassium phosphate, incl. combinations with other potassium salts |
0‑L | B05XA07 | calcium chloride | WHO Anatomical Therapeutic Chemical classification | | calcium chloride |
0‑L | B05XA08 | sodium acetate | WHO Anatomical Therapeutic Chemical classification | | sodium acetate |
0‑L | B05XA09 | sodium phosphate | WHO Anatomical Therapeutic Chemical classification | | sodium phosphate |
0‑L | B05XA10 | magnesium phosphate | WHO Anatomical Therapeutic Chemical classification | | magnesium phosphate |
0‑L | B05XA11 | magnesium chloride | WHO Anatomical Therapeutic Chemical classification | | magnesium chloride |
0‑L | B05XA12 | zinc chloride | WHO Anatomical Therapeutic Chemical classification | | zinc chloride |
0‑L | B05XA13 | hydrochloric acid | WHO Anatomical Therapeutic Chemical classification | | hydrochloric acid |
0‑L | B05XA14 | sodium glycerophosphate | WHO Anatomical Therapeutic Chemical classification | | sodium glycerophosphate |
0‑L | B05XA15 | potassium lactate | WHO Anatomical Therapeutic Chemical classification | | potassium lactate |
0‑L | B05XA16 | cardioplegia solutions | WHO Anatomical Therapeutic Chemical classification | | cardioplegia solutions |
0‑L | B05XA17 | potassium acetate | WHO Anatomical Therapeutic Chemical classification | | potassium acetate |
0‑L | B05XA30 | combinations of electrolytes | WHO Anatomical Therapeutic Chemical classification | | combinations of electrolytes |
0‑L | B05XA31 | electrolytes in combination with other drugs | WHO Anatomical Therapeutic Chemical classification | | electrolytes in combination with other drugs |
0‑L | B05XB | Amino acids | WHO Anatomical Therapeutic Chemical classification | | Amino acids |
0‑L | B05XB01 | arginine hydrochloride | WHO Anatomical Therapeutic Chemical classification | | arginine hydrochloride |
0‑L | B05XB02 | alanyl glutamine | WHO Anatomical Therapeutic Chemical classification | | alanyl glutamine |
0‑L | B05XB03 | lysine | WHO Anatomical Therapeutic Chemical classification | | lysine |
0‑L | B05XC | Vitamins | WHO Anatomical Therapeutic Chemical classification | | Vitamins |
0‑L | B05XX | Other i.v. solution additives | WHO Anatomical Therapeutic Chemical classification | | Other i.v. solution additives |
0‑L | B05XX02 | trometamol | WHO Anatomical Therapeutic Chemical classification | | trometamol |
0‑L | B05Z | HEMODIALYTICS AND HEMOFILTRATES | WHO Anatomical Therapeutic Chemical classification | | HEMODIALYTICS AND HEMOFILTRATES |
0‑L | B05ZA | Hemodialytics, concentrates | WHO Anatomical Therapeutic Chemical classification | | Hemodialytics, concentrates |
0‑L | B05ZB | Hemofiltrates | WHO Anatomical Therapeutic Chemical classification | | Hemofiltrates |
0‑L | B06 | OTHER HEMATOLOGICAL AGENTS | WHO Anatomical Therapeutic Chemical classification | | OTHER HEMATOLOGICAL AGENTS |
0‑L | B06A | OTHER HEMATOLOGICAL AGENTS | WHO Anatomical Therapeutic Chemical classification | | OTHER HEMATOLOGICAL AGENTS |
0‑L | B06AA | Enzymes | WHO Anatomical Therapeutic Chemical classification | | Enzymes |
0‑L | B06AA02 | fibrinolysin and desoxyribonuclease | WHO Anatomical Therapeutic Chemical classification | | fibrinolysin and desoxyribonuclease |
0‑L | B06AA03 | hyaluronidase | WHO Anatomical Therapeutic Chemical classification | | hyaluronidase |
0‑L | B06AA04 | chymotrypsin | WHO Anatomical Therapeutic Chemical classification | | chymotrypsin |
0‑L | B06AA07 | trypsin | WHO Anatomical Therapeutic Chemical classification | | trypsin |
0‑L | B06AA10 | desoxyribonuclease | WHO Anatomical Therapeutic Chemical classification | | desoxyribonuclease |
0‑L | B06AA55 | streptokinase, combinations | WHO Anatomical Therapeutic Chemical classification | | streptokinase, combinations |
0‑L | B06AB | Other hem products | WHO Anatomical Therapeutic Chemical classification | | Other hem products |
0‑L | B06AB01 | hematin | WHO Anatomical Therapeutic Chemical classification | | hematin |
0‑L | B06AC | Drugs used in hereditary angioedema | WHO Anatomical Therapeutic Chemical classification | | Drugs used in hereditary angioedema |
0‑L | B06AC01 | c1-inhibitor, plasma derived | WHO Anatomical Therapeutic Chemical classification | | c1-inhibitor, plasma derived |
0‑L | B06AC02 | icatibant | WHO Anatomical Therapeutic Chemical classification | | icatibant |
0‑L | B06AC03 | ecallantide | WHO Anatomical Therapeutic Chemical classification | | ecallantide |
0‑L | B06AC04 | conestat alfa | WHO Anatomical Therapeutic Chemical classification | | conestat alfa |
0‑L | C | CARDIOVASCULAR SYSTEM | WHO Anatomical Therapeutic Chemical classification | | CARDIOVASCULAR SYSTEM |
0‑L | C01 | CARDIAC THERAPY | WHO Anatomical Therapeutic Chemical classification | | CARDIAC THERAPY |
0‑L | C01A | CARDIAC GLYCOSIDES | WHO Anatomical Therapeutic Chemical classification | | CARDIAC GLYCOSIDES |
0‑L | C01AA | Digitalis glycosides | WHO Anatomical Therapeutic Chemical classification | | Digitalis glycosides |
0‑L | C01AA01 | acetyldigitoxin | WHO Anatomical Therapeutic Chemical classification | | acetyldigitoxin |
0‑L | C01AA02 | acetyldigoxin | WHO Anatomical Therapeutic Chemical classification | | acetyldigoxin |
0‑L | C01AA03 | digitalis leaves | WHO Anatomical Therapeutic Chemical classification | | digitalis leaves |
0‑L | C01AA04 | digitoxin | WHO Anatomical Therapeutic Chemical classification | | digitoxin |
0‑L | C01AA05 | digoxin | WHO Anatomical Therapeutic Chemical classification | | digoxin |
0‑L | C01AA06 | lanatoside C | WHO Anatomical Therapeutic Chemical classification | | lanatoside C |
0‑L | C01AA07 | deslanoside | WHO Anatomical Therapeutic Chemical classification | | deslanoside |
0‑L | C01AA08 | metildigoxin | WHO Anatomical Therapeutic Chemical classification | | metildigoxin |
0‑L | C01AA09 | gitoformate | WHO Anatomical Therapeutic Chemical classification | | gitoformate |
0‑L | C01AA52 | acetyldigoxin, combinations | WHO Anatomical Therapeutic Chemical classification | | acetyldigoxin, combinations |
0‑L | C01AB | Scilla glycosides | WHO Anatomical Therapeutic Chemical classification | | Scilla glycosides |
0‑L | C01AB01 | proscillaridin | WHO Anatomical Therapeutic Chemical classification | | proscillaridin |
0‑L | C01AB51 | proscillaridin, combinations | WHO Anatomical Therapeutic Chemical classification | | proscillaridin, combinations |
0‑L | C01AC | Strophanthus glycosides | WHO Anatomical Therapeutic Chemical classification | | Strophanthus glycosides |
0‑L | C01AC01 | g-strophanthin | WHO Anatomical Therapeutic Chemical classification | | g-strophanthin |
0‑L | C01AC03 | cymarin | WHO Anatomical Therapeutic Chemical classification | | cymarin |
0‑L | C01AX | Other cardiac glycosides | WHO Anatomical Therapeutic Chemical classification | | Other cardiac glycosides |
0‑L | C01AX02 | peruvoside | WHO Anatomical Therapeutic Chemical classification | | peruvoside |
0‑L | C01B | ANTIARRHYTHMICS, CLASS I AND III | WHO Anatomical Therapeutic Chemical classification | | ANTIARRHYTHMICS, CLASS I AND III |
0‑L | C01BA | Antiarrhythmics, class Ia | WHO Anatomical Therapeutic Chemical classification | | Antiarrhythmics, class Ia |
0‑L | C01BA01 | quinidine | WHO Anatomical Therapeutic Chemical classification | | quinidine |
0‑L | C01BA02 | procainamide | WHO Anatomical Therapeutic Chemical classification | | procainamide |
0‑L | C01BA03 | disopyramide | WHO Anatomical Therapeutic Chemical classification | | disopyramide |
0‑L | C01BA04 | sparteine | WHO Anatomical Therapeutic Chemical classification | | sparteine |
0‑L | C01BA05 | ajmaline | WHO Anatomical Therapeutic Chemical classification | | ajmaline |
0‑L | C01BA08 | prajmaline | WHO Anatomical Therapeutic Chemical classification | | prajmaline |
0‑L | C01BA12 | lorajmine | WHO Anatomical Therapeutic Chemical classification | | lorajmine |
0‑L | C01BA13 | hydroquinidine | WHO Anatomical Therapeutic Chemical classification | | hydroquinidine |
0‑L | C01BA51 | quinidine, combinations excl. psycholeptics | WHO Anatomical Therapeutic Chemical classification | | quinidine, combinations excl. psycholeptics |
0‑L | C01BA71 | quinidine, combinations with psycholeptics | WHO Anatomical Therapeutic Chemical classification | | quinidine, combinations with psycholeptics |
0‑L | C01BB | Antiarrhythmics, class Ib | WHO Anatomical Therapeutic Chemical classification | | Antiarrhythmics, class Ib |
0‑L | C01BB01 | lidocaine | WHO Anatomical Therapeutic Chemical classification | | lidocaine |
0‑L | C01BB02 | mexiletine | WHO Anatomical Therapeutic Chemical classification | | mexiletine |
0‑L | C01BB03 | tocainide | WHO Anatomical Therapeutic Chemical classification | | tocainide |
0‑L | C01BB04 | aprindine | WHO Anatomical Therapeutic Chemical classification | | aprindine |
0‑L | C01BC | Antiarrhythmics, class Ic | WHO Anatomical Therapeutic Chemical classification | | Antiarrhythmics, class Ic |
0‑L | C01BC03 | propafenone | WHO Anatomical Therapeutic Chemical classification | | propafenone |
0‑L | C01BC04 | flecainide | WHO Anatomical Therapeutic Chemical classification | | flecainide |
0‑L | C01BC07 | lorcainide | WHO Anatomical Therapeutic Chemical classification | | lorcainide |
0‑L | C01BC08 | encainide | WHO Anatomical Therapeutic Chemical classification | | encainide |
0‑L | C01BC09 | ethacizine | WHO Anatomical Therapeutic Chemical classification | | ethacizine |
0‑L | C01BD | Antiarrhythmics, class III | WHO Anatomical Therapeutic Chemical classification | | Antiarrhythmics, class III |
0‑L | C01BD01 | amiodarone | WHO Anatomical Therapeutic Chemical classification | | amiodarone |
0‑L | C01BD02 | bretylium tosilate | WHO Anatomical Therapeutic Chemical classification | | bretylium tosilate |
0‑L | C01BD03 | bunaftine | WHO Anatomical Therapeutic Chemical classification | | bunaftine |
0‑L | C01BD04 | dofetilide | WHO Anatomical Therapeutic Chemical classification | | dofetilide |
0‑L | C01BD05 | ibutilide | WHO Anatomical Therapeutic Chemical classification | | ibutilide |
0‑L | C01BD06 | tedisamil | WHO Anatomical Therapeutic Chemical classification | | tedisamil |
0‑L | C01BD07 | dronedarone | WHO Anatomical Therapeutic Chemical classification | | dronedarone |
0‑L | C01BG | Other antiarrhythmics, class I and III | WHO Anatomical Therapeutic Chemical classification | | Other antiarrhythmics, class I and III |
0‑L | C01BG01 | moracizine | WHO Anatomical Therapeutic Chemical classification | | moracizine |
0‑L | C01BG07 | cibenzoline | WHO Anatomical Therapeutic Chemical classification | | cibenzoline |
0‑L | C01BG11 | vernakalant | WHO Anatomical Therapeutic Chemical classification | | vernakalant |
0‑L | C01C | CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES | WHO Anatomical Therapeutic Chemical classification | | CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES |
0‑L | C01CA | Adrenergic and dopaminergic agents | WHO Anatomical Therapeutic Chemical classification | | Adrenergic and dopaminergic agents |
0‑L | C01CA01 | etilefrine | WHO Anatomical Therapeutic Chemical classification | | etilefrine |
0‑L | C01CA02 | isoprenaline | WHO Anatomical Therapeutic Chemical classification | | isoprenaline |
0‑L | C01CA03 | norepinephrine | WHO Anatomical Therapeutic Chemical classification | | norepinephrine |
0‑L | C01CA04 | dopamine | WHO Anatomical Therapeutic Chemical classification | | dopamine |
0‑L | C01CA05 | norfenefrine | WHO Anatomical Therapeutic Chemical classification | | norfenefrine |
0‑L | C01CA06 | phenylephrine | WHO Anatomical Therapeutic Chemical classification | | phenylephrine |
0‑L | C01CA07 | dobutamine | WHO Anatomical Therapeutic Chemical classification | | dobutamine |
0‑L | C01CA08 | oxedrine | WHO Anatomical Therapeutic Chemical classification | | oxedrine |
0‑L | C01CA09 | metaraminol | WHO Anatomical Therapeutic Chemical classification | | metaraminol |
0‑L | C01CA10 | methoxamine | WHO Anatomical Therapeutic Chemical classification | | methoxamine |
0‑L | C01CA11 | mephentermine | WHO Anatomical Therapeutic Chemical classification | | mephentermine |
0‑L | C01CA12 | dimetofrine | WHO Anatomical Therapeutic Chemical classification | | dimetofrine |
0‑L | C01CA13 | prenalterol | WHO Anatomical Therapeutic Chemical classification | | prenalterol |
0‑L | C01CA14 | dopexamine | WHO Anatomical Therapeutic Chemical classification | | dopexamine |
0‑L | C01CA15 | gepefrine | WHO Anatomical Therapeutic Chemical classification | | gepefrine |
0‑L | C01CA16 | ibopamine | WHO Anatomical Therapeutic Chemical classification | | ibopamine |
0‑L | C01CA17 | midodrine | WHO Anatomical Therapeutic Chemical classification | | midodrine |
0‑L | C01CA18 | octopamine | WHO Anatomical Therapeutic Chemical classification | | octopamine |
0‑L | C01CA19 | fenoldopam | WHO Anatomical Therapeutic Chemical classification | | fenoldopam |
0‑L | C01CA21 | cafedrine | WHO Anatomical Therapeutic Chemical classification | | cafedrine |
0‑L | C01CA22 | arbutamine | WHO Anatomical Therapeutic Chemical classification | | arbutamine |
0‑L | C01CA23 | theodrenaline | WHO Anatomical Therapeutic Chemical classification | | theodrenaline |
0‑L | C01CA24 | epinephrine | WHO Anatomical Therapeutic Chemical classification | | epinephrine |
0‑L | C01CA25 | amezinium metilsulfate | WHO Anatomical Therapeutic Chemical classification | | amezinium metilsulfate |
0‑L | C01CA26 | ephedrine | WHO Anatomical Therapeutic Chemical classification | | ephedrine |
0‑L | C01CA27 | droxidopa | WHO Anatomical Therapeutic Chemical classification | | droxidopa |
0‑L | C01CA30 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | C01CA51 | etilefrine, combinations | WHO Anatomical Therapeutic Chemical classification | | etilefrine, combinations |
0‑L | C01CE | Phosphodiesterase inhibitors | WHO Anatomical Therapeutic Chemical classification | | Phosphodiesterase inhibitors |
0‑L | C01CE01 | amrinone | WHO Anatomical Therapeutic Chemical classification | | amrinone |
0‑L | C01CE02 | milrinone | WHO Anatomical Therapeutic Chemical classification | | milrinone |
0‑L | C01CE03 | enoximone | WHO Anatomical Therapeutic Chemical classification | | enoximone |
0‑L | C01CE04 | bucladesine | WHO Anatomical Therapeutic Chemical classification | | bucladesine |
0‑L | C01CX | Other cardiac stimulants | WHO Anatomical Therapeutic Chemical classification | | Other cardiac stimulants |
0‑L | C01CX06 | angiotensinamide | WHO Anatomical Therapeutic Chemical classification | | angiotensinamide |
0‑L | C01CX07 | xamoterol | WHO Anatomical Therapeutic Chemical classification | | xamoterol |
0‑L | C01CX08 | levosimendan | WHO Anatomical Therapeutic Chemical classification | | levosimendan |
0‑L | C01D | VASODILATORS USED IN CARDIAC DISEASES | WHO Anatomical Therapeutic Chemical classification | | VASODILATORS USED IN CARDIAC DISEASES |
0‑L | C01DA | Organic nitrates | WHO Anatomical Therapeutic Chemical classification | | Organic nitrates |
0‑L | C01DA02 | glyceryl trinitrate | WHO Anatomical Therapeutic Chemical classification | | glyceryl trinitrate |
0‑L | C01DA04 | methylpropylpropanediol dinitrate | WHO Anatomical Therapeutic Chemical classification | | methylpropylpropanediol dinitrate |
0‑L | C01DA05 | pentaerithrityl tetranitrate | WHO Anatomical Therapeutic Chemical classification | | pentaerithrityl tetranitrate |
0‑L | C01DA07 | propatylnitrate | WHO Anatomical Therapeutic Chemical classification | | propatylnitrate |
0‑L | C01DA08 | isosorbide dinitrate | WHO Anatomical Therapeutic Chemical classification | | isosorbide dinitrate |
0‑L | C01DA09 | trolnitrate | WHO Anatomical Therapeutic Chemical classification | | trolnitrate |
0‑L | C01DA13 | eritrityl tetranitrate | WHO Anatomical Therapeutic Chemical classification | | eritrityl tetranitrate |
0‑L | C01DA14 | isosorbide mononitrate | WHO Anatomical Therapeutic Chemical classification | | isosorbide mononitrate |
0‑L | C01DA20 | organic nitrates in combination | WHO Anatomical Therapeutic Chemical classification | | organic nitrates in combination |
0‑L | C01DA38 | tenitramine | WHO Anatomical Therapeutic Chemical classification | | tenitramine |
0‑L | C01DA52 | glyceryl trinitrate, combinations | WHO Anatomical Therapeutic Chemical classification | | glyceryl trinitrate, combinations |
0‑L | C01DA54 | methylpropylpropanediol dinitrate, combinations | WHO Anatomical Therapeutic Chemical classification | | methylpropylpropanediol dinitrate, combinations |
0‑L | C01DA55 | pentaerithrityl tetranitrate, combinations | WHO Anatomical Therapeutic Chemical classification | | pentaerithrityl tetranitrate, combinations |
0‑L | C01DA57 | propatylnitrate, combinations | WHO Anatomical Therapeutic Chemical classification | | propatylnitrate, combinations |
0‑L | C01DA58 | isosorbide dinitrate, combinations | WHO Anatomical Therapeutic Chemical classification | | isosorbide dinitrate, combinations |
0‑L | C01DA59 | trolnitrate, combinations | WHO Anatomical Therapeutic Chemical classification | | trolnitrate, combinations |
0‑L | C01DA63 | eritrityl tetranitrate, combinations | WHO Anatomical Therapeutic Chemical classification | | eritrityl tetranitrate, combinations |
0‑L | C01DA70 | organic nitrates in combination with psycholeptics | WHO Anatomical Therapeutic Chemical classification | | organic nitrates in combination with psycholeptics |
0‑L | C01DB | Quinolone vasodilators | WHO Anatomical Therapeutic Chemical classification | | Quinolone vasodilators |
0‑L | C01DB01 | flosequinan | WHO Anatomical Therapeutic Chemical classification | | flosequinan |
0‑L | C01DX | Other vasodilators used in cardiac diseases | WHO Anatomical Therapeutic Chemical classification | | Other vasodilators used in cardiac diseases |
0‑L | C01DX01 | itramin tosilate | WHO Anatomical Therapeutic Chemical classification | | itramin tosilate |
0‑L | C01DX02 | prenylamine | WHO Anatomical Therapeutic Chemical classification | | prenylamine |
0‑L | C01DX03 | oxyfedrine | WHO Anatomical Therapeutic Chemical classification | | oxyfedrine |
0‑L | C01DX04 | benziodarone | WHO Anatomical Therapeutic Chemical classification | | benziodarone |
0‑L | C01DX05 | carbocromen | WHO Anatomical Therapeutic Chemical classification | | carbocromen |
0‑L | C01DX06 | hexobendine | WHO Anatomical Therapeutic Chemical classification | | hexobendine |
0‑L | C01DX07 | etafenone | WHO Anatomical Therapeutic Chemical classification | | etafenone |
0‑L | C01DX08 | heptaminol | WHO Anatomical Therapeutic Chemical classification | | heptaminol |
0‑L | C01DX09 | imolamine | WHO Anatomical Therapeutic Chemical classification | | imolamine |
0‑L | C01DX10 | dilazep | WHO Anatomical Therapeutic Chemical classification | | dilazep |
0‑L | C01DX11 | trapidil | WHO Anatomical Therapeutic Chemical classification | | trapidil |
0‑L | C01DX12 | molsidomine | WHO Anatomical Therapeutic Chemical classification | | molsidomine |
0‑L | C01DX13 | efloxate | WHO Anatomical Therapeutic Chemical classification | | efloxate |
0‑L | C01DX14 | cinepazet | WHO Anatomical Therapeutic Chemical classification | | cinepazet |
0‑L | C01DX15 | cloridarol | WHO Anatomical Therapeutic Chemical classification | | cloridarol |
0‑L | C01DX16 | nicorandil | WHO Anatomical Therapeutic Chemical classification | | nicorandil |
0‑L | C01DX18 | linsidomine | WHO Anatomical Therapeutic Chemical classification | | linsidomine |
0‑L | C01DX19 | nesiritide | WHO Anatomical Therapeutic Chemical classification | | nesiritide |
0‑L | C01DX21 | serelaxin | WHO Anatomical Therapeutic Chemical classification | | serelaxin |
0‑L | C01DX51 | itramin tosilate, combinations | WHO Anatomical Therapeutic Chemical classification | | itramin tosilate, combinations |
0‑L | C01DX52 | prenylamine, combinations | WHO Anatomical Therapeutic Chemical classification | | prenylamine, combinations |
0‑L | C01DX53 | oxyfedrine, combinations | WHO Anatomical Therapeutic Chemical classification | | oxyfedrine, combinations |
0‑L | C01DX54 | benziodarone, combinations | WHO Anatomical Therapeutic Chemical classification | | benziodarone, combinations |
0‑L | C01E | OTHER CARDIAC PREPARATIONS | WHO Anatomical Therapeutic Chemical classification | | OTHER CARDIAC PREPARATIONS |
0‑L | C01EA | Prostaglandins | WHO Anatomical Therapeutic Chemical classification | | Prostaglandins |
0‑L | C01EA01 | alprostadil | WHO Anatomical Therapeutic Chemical classification | | alprostadil |
0‑L | C01EB | Other cardiac preparations | WHO Anatomical Therapeutic Chemical classification | | Other cardiac preparations |
0‑L | C01EB02 | camphora | WHO Anatomical Therapeutic Chemical classification | | camphora |
0‑L | C01EB03 | indometacin | WHO Anatomical Therapeutic Chemical classification | | indometacin |
0‑L | C01EB04 | crataegus glycosides | WHO Anatomical Therapeutic Chemical classification | | crataegus glycosides |
0‑L | C01EB05 | creatinolfosfate | WHO Anatomical Therapeutic Chemical classification | | creatinolfosfate |
0‑L | C01EB06 | fosfocreatine | WHO Anatomical Therapeutic Chemical classification | | fosfocreatine |
0‑L | C01EB07 | fructose 1,6-diphosphate | WHO Anatomical Therapeutic Chemical classification | | fructose 1,6-diphosphate |
0‑L | C01EB09 | ubidecarenone | WHO Anatomical Therapeutic Chemical classification | | ubidecarenone |
0‑L | C01EB10 | adenosine | WHO Anatomical Therapeutic Chemical classification | | adenosine |
0‑L | C01EB11 | tiracizine | WHO Anatomical Therapeutic Chemical classification | | tiracizine |
0‑L | C01EB13 | acadesine | WHO Anatomical Therapeutic Chemical classification | | acadesine |
0‑L | C01EB15 | trimetazidine | WHO Anatomical Therapeutic Chemical classification | | trimetazidine |
0‑L | C01EB16 | ibuprofen | WHO Anatomical Therapeutic Chemical classification | | ibuprofen |
0‑L | C01EB17 | ivabradine | WHO Anatomical Therapeutic Chemical classification | | ivabradine |
0‑L | C01EB18 | ranolazine | WHO Anatomical Therapeutic Chemical classification | | ranolazine |
0‑L | C01EB21 | regadenoson | WHO Anatomical Therapeutic Chemical classification | | regadenoson |
0‑L | C01EB22 | meldonium | WHO Anatomical Therapeutic Chemical classification | | meldonium |
0‑L | C01EB23 | tiazotic acid | WHO Anatomical Therapeutic Chemical classification | | tiazotic acid |
0‑L | C01EX | Other cardiac combination products | WHO Anatomical Therapeutic Chemical classification | | Other cardiac combination products |
0‑L | C02 | ANTIHYPERTENSIVES | WHO Anatomical Therapeutic Chemical classification | | ANTIHYPERTENSIVES |
0‑L | C02A | ANTIADRENERGIC AGENTS, CENTRALLY ACTING | WHO Anatomical Therapeutic Chemical classification | | ANTIADRENERGIC AGENTS, CENTRALLY ACTING |
0‑L | C02AA | Rauwolfia alkaloids | WHO Anatomical Therapeutic Chemical classification | | Rauwolfia alkaloids |
0‑L | C02AA01 | rescinnamine | WHO Anatomical Therapeutic Chemical classification | | rescinnamine |
0‑L | C02AA02 | reserpine | WHO Anatomical Therapeutic Chemical classification | | reserpine |
0‑L | C02AA03 | combinations of rauwolfia alkaloids | WHO Anatomical Therapeutic Chemical classification | | combinations of rauwolfia alkaloids |
0‑L | C02AA04 | rauwolfia alkaloids, whole root | WHO Anatomical Therapeutic Chemical classification | | rauwolfia alkaloids, whole root |
0‑L | C02AA05 | deserpidine | WHO Anatomical Therapeutic Chemical classification | | deserpidine |
0‑L | C02AA06 | methoserpidine | WHO Anatomical Therapeutic Chemical classification | | methoserpidine |
0‑L | C02AA07 | bietaserpine | WHO Anatomical Therapeutic Chemical classification | | bietaserpine |
0‑L | C02AA52 | reserpine, combinations | WHO Anatomical Therapeutic Chemical classification | | reserpine, combinations |
0‑L | C02AA53 | combinations of rauwolfia alkoloids, combinations | WHO Anatomical Therapeutic Chemical classification | | combinations of rauwolfia alkoloids, combinations |
0‑L | C02AA57 | bietaserpine, combinations | WHO Anatomical Therapeutic Chemical classification | | bietaserpine, combinations |
0‑L | C02AB | Methyldopa | WHO Anatomical Therapeutic Chemical classification | | Methyldopa |
0‑L | C02AB01 | methyldopa (levorotatory) | WHO Anatomical Therapeutic Chemical classification | | methyldopa (levorotatory) |
0‑L | C02AB02 | methyldopa (racemic) | WHO Anatomical Therapeutic Chemical classification | | methyldopa (racemic) |
0‑L | C02AC | Imidazoline receptor agonists | WHO Anatomical Therapeutic Chemical classification | | Imidazoline receptor agonists |
0‑L | C02AC01 | clonidine | WHO Anatomical Therapeutic Chemical classification | | clonidine |
0‑L | C02AC02 | guanfacine | WHO Anatomical Therapeutic Chemical classification | | guanfacine |
0‑L | C02AC04 | tolonidine | WHO Anatomical Therapeutic Chemical classification | | tolonidine |
0‑L | C02AC05 | moxonidine | WHO Anatomical Therapeutic Chemical classification | | moxonidine |
0‑L | C02AC06 | rilmenidine | WHO Anatomical Therapeutic Chemical classification | | rilmenidine |
0‑L | C02B | ANTIADRENERGIC AGENTS, GANGLION-BLOCKING | WHO Anatomical Therapeutic Chemical classification | | ANTIADRENERGIC AGENTS, GANGLION-BLOCKING |
0‑L | C02BA | Sulfonium derivatives | WHO Anatomical Therapeutic Chemical classification | | Sulfonium derivatives |
0‑L | C02BA01 | trimetaphan | WHO Anatomical Therapeutic Chemical classification | | trimetaphan |
0‑L | C02BB | Secondary and tertiary amines | WHO Anatomical Therapeutic Chemical classification | | Secondary and tertiary amines |
0‑L | C02BB01 | mecamylamine | WHO Anatomical Therapeutic Chemical classification | | mecamylamine |
0‑L | C02BC | Bisquaternary ammonium compounds | WHO Anatomical Therapeutic Chemical classification | | Bisquaternary ammonium compounds |
0‑L | C02C | ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING | WHO Anatomical Therapeutic Chemical classification | | ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING |
0‑L | C02CA | Alpha-adrenoreceptor antagonists | WHO Anatomical Therapeutic Chemical classification | | Alpha-adrenoreceptor antagonists |
0‑L | C02CA01 | prazosin | WHO Anatomical Therapeutic Chemical classification | | prazosin |
0‑L | C02CA02 | indoramin | WHO Anatomical Therapeutic Chemical classification | | indoramin |
0‑L | C02CA03 | trimazosin | WHO Anatomical Therapeutic Chemical classification | | trimazosin |
0‑L | C02CA04 | doxazosin | WHO Anatomical Therapeutic Chemical classification | | doxazosin |
0‑L | C02CA06 | urapidil | WHO Anatomical Therapeutic Chemical classification | | urapidil |
0‑L | C02CC | Guanidine derivatives | WHO Anatomical Therapeutic Chemical classification | | Guanidine derivatives |
0‑L | C02CC01 | betanidine | WHO Anatomical Therapeutic Chemical classification | | betanidine |
0‑L | C02CC02 | guanethidine | WHO Anatomical Therapeutic Chemical classification | | guanethidine |
0‑L | C02CC03 | guanoxan | WHO Anatomical Therapeutic Chemical classification | | guanoxan |
0‑L | C02CC04 | debrisoquine | WHO Anatomical Therapeutic Chemical classification | | debrisoquine |
0‑L | C02CC05 | guanoclor | WHO Anatomical Therapeutic Chemical classification | | guanoclor |
0‑L | C02CC06 | guanazodine | WHO Anatomical Therapeutic Chemical classification | | guanazodine |
0‑L | C02CC07 | guanoxabenz | WHO Anatomical Therapeutic Chemical classification | | guanoxabenz |
0‑L | C02D | ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON | WHO Anatomical Therapeutic Chemical classification | | ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON |
0‑L | C02DA | Thiazide derivatives | WHO Anatomical Therapeutic Chemical classification | | Thiazide derivatives |
0‑L | C02DA01 | diazoxide | WHO Anatomical Therapeutic Chemical classification | | diazoxide |
0‑L | C02DB | Hydrazinophthalazine derivatives | WHO Anatomical Therapeutic Chemical classification | | Hydrazinophthalazine derivatives |
0‑L | C02DB01 | dihydralazine | WHO Anatomical Therapeutic Chemical classification | | dihydralazine |
0‑L | C02DB02 | hydralazine | WHO Anatomical Therapeutic Chemical classification | | hydralazine |
0‑L | C02DB03 | endralazine | WHO Anatomical Therapeutic Chemical classification | | endralazine |
0‑L | C02DB04 | cadralazine | WHO Anatomical Therapeutic Chemical classification | | cadralazine |
0‑L | C02DC | Pyrimidine derivatives | WHO Anatomical Therapeutic Chemical classification | | Pyrimidine derivatives |
0‑L | C02DC01 | minoxidil | WHO Anatomical Therapeutic Chemical classification | | minoxidil |
0‑L | C02DD | Nitroferricyanide derivatives | WHO Anatomical Therapeutic Chemical classification | | Nitroferricyanide derivatives |
0‑L | C02DD01 | nitroprusside | WHO Anatomical Therapeutic Chemical classification | | nitroprusside |
0‑L | C02DG | Guanidine derivatives | WHO Anatomical Therapeutic Chemical classification | | Guanidine derivatives |
0‑L | C02DG01 | pinacidil | WHO Anatomical Therapeutic Chemical classification | | pinacidil |
0‑L | C02K | OTHER ANTIHYPERTENSIVES | WHO Anatomical Therapeutic Chemical classification | | OTHER ANTIHYPERTENSIVES |
0‑L | C02KA | Alkaloids, excl. rauwolfia | WHO Anatomical Therapeutic Chemical classification | | Alkaloids, excl. rauwolfia |
0‑L | C02KA01 | veratrum | WHO Anatomical Therapeutic Chemical classification | | veratrum |
0‑L | C02KB | Tyrosine hydroxylase inhibitors | WHO Anatomical Therapeutic Chemical classification | | Tyrosine hydroxylase inhibitors |
0‑L | C02KB01 | metirosine | WHO Anatomical Therapeutic Chemical classification | | metirosine |
0‑L | C02KC | MAO inhibitors | WHO Anatomical Therapeutic Chemical classification | | MAO inhibitors |
0‑L | C02KC01 | pargyline | WHO Anatomical Therapeutic Chemical classification | | pargyline |
0‑L | C02KD | Serotonin antagonists | WHO Anatomical Therapeutic Chemical classification | | Serotonin antagonists |
0‑L | C02KD01 | ketanserin | WHO Anatomical Therapeutic Chemical classification | | ketanserin |
0‑L | C02KX | Antihypertensives for pulmonary arterial hypertension | WHO Anatomical Therapeutic Chemical classification | | Antihypertensives for pulmonary arterial hypertension |
0‑L | C02KX01 | bosentan | WHO Anatomical Therapeutic Chemical classification | | bosentan |
0‑L | C02KX02 | ambrisentan | WHO Anatomical Therapeutic Chemical classification | | ambrisentan |
0‑L | C02KX03 | sitaxentan | WHO Anatomical Therapeutic Chemical classification | | sitaxentan |
0‑L | C02KX04 | macitentan | WHO Anatomical Therapeutic Chemical classification | | macitentan |
0‑L | C02KX05 | riociguat | WHO Anatomical Therapeutic Chemical classification | | riociguat |
0‑L | C02L | ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION | WHO Anatomical Therapeutic Chemical classification | | ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION |
0‑L | C02LA | Rauwolfia alkaloids and diuretics in combination | WHO Anatomical Therapeutic Chemical classification | | Rauwolfia alkaloids and diuretics in combination |
0‑L | C02LA01 | reserpine and diuretics | WHO Anatomical Therapeutic Chemical classification | | reserpine and diuretics |
0‑L | C02LA02 | rescinnamine and diuretics | WHO Anatomical Therapeutic Chemical classification | | rescinnamine and diuretics |
0‑L | C02LA03 | deserpidine and diuretics | WHO Anatomical Therapeutic Chemical classification | | deserpidine and diuretics |
0‑L | C02LA04 | methoserpidine and diuretics | WHO Anatomical Therapeutic Chemical classification | | methoserpidine and diuretics |
0‑L | C02LA07 | bietaserpine and diuretics | WHO Anatomical Therapeutic Chemical classification | | bietaserpine and diuretics |
0‑L | C02LA08 | rauwolfia alkaloids, whole root and diuretics | WHO Anatomical Therapeutic Chemical classification | | rauwolfia alkaloids, whole root and diuretics |
0‑L | C02LA09 | syrosingopine and diuretics | WHO Anatomical Therapeutic Chemical classification | | syrosingopine and diuretics |
0‑L | C02LA50 | combination of rauwolfia alkaloids and diuretics incl. other combinations | WHO Anatomical Therapeutic Chemical classification | | combination of rauwolfia alkaloids and diuretics incl. other combinations |
0‑L | C02LA51 | reserpine and diuretics, combinations with other drugs | WHO Anatomical Therapeutic Chemical classification | | reserpine and diuretics, combinations with other drugs |
0‑L | C02LA52 | rescinnamine and diuretics, combinations with other drugs | WHO Anatomical Therapeutic Chemical classification | | rescinnamine and diuretics, combinations with other drugs |
0‑L | C02LA71 | reserpine and diuretics, combinations with psycholeptics | WHO Anatomical Therapeutic Chemical classification | | reserpine and diuretics, combinations with psycholeptics |
0‑L | C02LB | Methyldopa and diuretics in combination | WHO Anatomical Therapeutic Chemical classification | | Methyldopa and diuretics in combination |
0‑L | C02LB01 | methyldopa (levorotatory) and diuretics | WHO Anatomical Therapeutic Chemical classification | | methyldopa (levorotatory) and diuretics |
0‑L | C02LC | Imidazoline receptor agonists in combination with diuretics | WHO Anatomical Therapeutic Chemical classification | | Imidazoline receptor agonists in combination with diuretics |
0‑L | C02LC01 | clonidine and diuretics | WHO Anatomical Therapeutic Chemical classification | | clonidine and diuretics |
0‑L | C02LC05 | moxonidine and diuretics | WHO Anatomical Therapeutic Chemical classification | | moxonidine and diuretics |
0‑L | C02LC51 | clonidine and diuretics, combinations with other drugs | WHO Anatomical Therapeutic Chemical classification | | clonidine and diuretics, combinations with other drugs |
0‑L | C02LE | Alpha-adrenoreceptor antagonists and diuretics | WHO Anatomical Therapeutic Chemical classification | | Alpha-adrenoreceptor antagonists and diuretics |
0‑L | C02LE01 | prazosin and diuretics | WHO Anatomical Therapeutic Chemical classification | | prazosin and diuretics |
0‑L | C02LF | Guanidine derivatives and diuretics | WHO Anatomical Therapeutic Chemical classification | | Guanidine derivatives and diuretics |
0‑L | C02LF01 | guanethidine and diuretics | WHO Anatomical Therapeutic Chemical classification | | guanethidine and diuretics |
0‑L | C02LG | Hydrazinophthalazine derivatives and diuretics | WHO Anatomical Therapeutic Chemical classification | | Hydrazinophthalazine derivatives and diuretics |
0‑L | C02LG01 | dihydralazine and diuretics | WHO Anatomical Therapeutic Chemical classification | | dihydralazine and diuretics |
0‑L | C02LG02 | hydralazine and diuretics | WHO Anatomical Therapeutic Chemical classification | | hydralazine and diuretics |
0‑L | C02LG03 | picodralazine and diuretics | WHO Anatomical Therapeutic Chemical classification | | picodralazine and diuretics |
0‑L | C02LG51 | dihydralazine and diuretics, combinations with other drugs | WHO Anatomical Therapeutic Chemical classification | | dihydralazine and diuretics, combinations with other drugs |
0‑L | C02LG73 | picodralazine and diuretics, combinations with psycholeptics | WHO Anatomical Therapeutic Chemical classification | | picodralazine and diuretics, combinations with psycholeptics |
0‑L | C02LK | Alkaloids, excl. rauwolfia, in combination with diuretics | WHO Anatomical Therapeutic Chemical classification | | Alkaloids, excl. rauwolfia, in combination with diuretics |
0‑L | C02LK01 | veratrum and diuretics | WHO Anatomical Therapeutic Chemical classification | | veratrum and diuretics |
0‑L | C02LL | MAO inhibitors and diuretics | WHO Anatomical Therapeutic Chemical classification | | MAO inhibitors and diuretics |
0‑L | C02LL01 | pargyline and diuretics | WHO Anatomical Therapeutic Chemical classification | | pargyline and diuretics |
0‑L | C02LN | Serotonin antagonists and diuretics | WHO Anatomical Therapeutic Chemical classification | | Serotonin antagonists and diuretics |
0‑L | C02LX | Other antihypertensives and diuretics | WHO Anatomical Therapeutic Chemical classification | | Other antihypertensives and diuretics |
0‑L | C02LX01 | pinacidil and diuretics | WHO Anatomical Therapeutic Chemical classification | | pinacidil and diuretics |
0‑L | C02N | COMBINATIONS OF ANTIHYPERTENSIVES IN ATC-GR. C02 | WHO Anatomical Therapeutic Chemical classification | | COMBINATIONS OF ANTIHYPERTENSIVES IN ATC-GR. C02 |
0‑L | C03 | DIURETICS | WHO Anatomical Therapeutic Chemical classification | | DIURETICS |
0‑L | C03A | LOW-CEILING DIURETICS, THIAZIDES | WHO Anatomical Therapeutic Chemical classification | | LOW-CEILING DIURETICS, THIAZIDES |
0‑L | C03AA | Thiazides, plain | WHO Anatomical Therapeutic Chemical classification | | Thiazides, plain |
0‑L | C03AA01 | bendroflumethiazide | WHO Anatomical Therapeutic Chemical classification | | bendroflumethiazide |
0‑L | C03AA02 | hydroflumethiazide | WHO Anatomical Therapeutic Chemical classification | | hydroflumethiazide |
0‑L | C03AA03 | hydrochlorothiazide | WHO Anatomical Therapeutic Chemical classification | | hydrochlorothiazide |
0‑L | C03AA04 | chlorothiazide | WHO Anatomical Therapeutic Chemical classification | | chlorothiazide |
0‑L | C03AA05 | polythiazide | WHO Anatomical Therapeutic Chemical classification | | polythiazide |
0‑L | C03AA06 | trichlormethiazide | WHO Anatomical Therapeutic Chemical classification | | trichlormethiazide |
0‑L | C03AA07 | cyclopenthiazide | WHO Anatomical Therapeutic Chemical classification | | cyclopenthiazide |
0‑L | C03AA08 | methyclothiazide | WHO Anatomical Therapeutic Chemical classification | | methyclothiazide |
0‑L | C03AA09 | cyclothiazide | WHO Anatomical Therapeutic Chemical classification | | cyclothiazide |
0‑L | C03AA13 | mebutizide | WHO Anatomical Therapeutic Chemical classification | | mebutizide |
0‑L | C03AB | Thiazides and potassium in combination | WHO Anatomical Therapeutic Chemical classification | | Thiazides and potassium in combination |
0‑L | C03AB01 | bendroflumethiazide and potassium | WHO Anatomical Therapeutic Chemical classification | | bendroflumethiazide and potassium |
0‑L | C03AB02 | hydroflumethiazide and potassium | WHO Anatomical Therapeutic Chemical classification | | hydroflumethiazide and potassium |
0‑L | C03AB03 | hydrochlorothiazide and potassium | WHO Anatomical Therapeutic Chemical classification | | hydrochlorothiazide and potassium |
0‑L | C03AB04 | chlorothiazide and potassium | WHO Anatomical Therapeutic Chemical classification | | chlorothiazide and potassium |
0‑L | C03AB05 | polythiazide and potassium | WHO Anatomical Therapeutic Chemical classification | | polythiazide and potassium |
0‑L | C03AB06 | trichlormethiazide and potassium | WHO Anatomical Therapeutic Chemical classification | | trichlormethiazide and potassium |
0‑L | C03AB07 | cyclopenthiazide and potassium | WHO Anatomical Therapeutic Chemical classification | | cyclopenthiazide and potassium |
0‑L | C03AB08 | methyclothiazide and potassium | WHO Anatomical Therapeutic Chemical classification | | methyclothiazide and potassium |
0‑L | C03AB09 | cyclothiazide and potassium | WHO Anatomical Therapeutic Chemical classification | | cyclothiazide and potassium |
0‑L | C03AH | Thiazides, combinations with psycholeptics and/or analgesics | WHO Anatomical Therapeutic Chemical classification | | Thiazides, combinations with psycholeptics and/or analgesics |
0‑L | C03AH01 | chlorothiazide, combinations | WHO Anatomical Therapeutic Chemical classification | | chlorothiazide, combinations |
0‑L | C03AH02 | hydroflumethiazide, combinations | WHO Anatomical Therapeutic Chemical classification | | hydroflumethiazide, combinations |
0‑L | C03AX | Thiazides, combinations with other drugs | WHO Anatomical Therapeutic Chemical classification | | Thiazides, combinations with other drugs |
0‑L | C03AX01 | hydrochlorothiazide, combinations | WHO Anatomical Therapeutic Chemical classification | | hydrochlorothiazide, combinations |
0‑L | C03B | LOW-CEILING DIURETICS, EXCL. THIAZIDES | WHO Anatomical Therapeutic Chemical classification | | LOW-CEILING DIURETICS, EXCL. THIAZIDES |
0‑L | C03BA | Sulfonamides, plain | WHO Anatomical Therapeutic Chemical classification | | Sulfonamides, plain |
0‑L | C03BA02 | quinethazone | WHO Anatomical Therapeutic Chemical classification | | quinethazone |
0‑L | C03BA03 | clopamide | WHO Anatomical Therapeutic Chemical classification | | clopamide |
0‑L | C03BA04 | chlortalidone | WHO Anatomical Therapeutic Chemical classification | | chlortalidone |
0‑L | C03BA05 | mefruside | WHO Anatomical Therapeutic Chemical classification | | mefruside |
0‑L | C03BA07 | clofenamide | WHO Anatomical Therapeutic Chemical classification | | clofenamide |
0‑L | C03BA08 | metolazone | WHO Anatomical Therapeutic Chemical classification | | metolazone |
0‑L | C03BA09 | meticrane | WHO Anatomical Therapeutic Chemical classification | | meticrane |
0‑L | C03BA10 | xipamide | WHO Anatomical Therapeutic Chemical classification | | xipamide |
0‑L | C03BA11 | indapamide | WHO Anatomical Therapeutic Chemical classification | | indapamide |
0‑L | C03BA12 | clorexolone | WHO Anatomical Therapeutic Chemical classification | | clorexolone |
0‑L | C03BA13 | fenquizone | WHO Anatomical Therapeutic Chemical classification | | fenquizone |
0‑L | C03BA82 | clorexolone, combinations with psycholeptics | WHO Anatomical Therapeutic Chemical classification | | clorexolone, combinations with psycholeptics |
0‑L | C03BB | Sulfonamides and potassium in combination | WHO Anatomical Therapeutic Chemical classification | | Sulfonamides and potassium in combination |
0‑L | C03BB02 | quinethazone and potassium | WHO Anatomical Therapeutic Chemical classification | | quinethazone and potassium |
0‑L | C03BB03 | clopamide and potassium | WHO Anatomical Therapeutic Chemical classification | | clopamide and potassium |
0‑L | C03BB04 | chlortalidone and potassium | WHO Anatomical Therapeutic Chemical classification | | chlortalidone and potassium |
0‑L | C03BB05 | mefruside and potassium | WHO Anatomical Therapeutic Chemical classification | | mefruside and potassium |
0‑L | C03BB07 | clofenamide and potassium | WHO Anatomical Therapeutic Chemical classification | | clofenamide and potassium |
0‑L | C03BC | Mercurial diuretics | WHO Anatomical Therapeutic Chemical classification | | Mercurial diuretics |
0‑L | C03BC01 | mersalyl | WHO Anatomical Therapeutic Chemical classification | | mersalyl |
0‑L | C03BD | Xanthine derivatives | WHO Anatomical Therapeutic Chemical classification | | Xanthine derivatives |
0‑L | C03BD01 | theobromine | WHO Anatomical Therapeutic Chemical classification | | theobromine |
0‑L | C03BK | Sulfonamides, combinations with other drugs | WHO Anatomical Therapeutic Chemical classification | | Sulfonamides, combinations with other drugs |
0‑L | C03BX | Other low-ceiling diuretics | WHO Anatomical Therapeutic Chemical classification | | Other low-ceiling diuretics |
0‑L | C03BX03 | cicletanine | WHO Anatomical Therapeutic Chemical classification | | cicletanine |
0‑L | C03C | HIGH-CEILING DIURETICS | WHO Anatomical Therapeutic Chemical classification | | HIGH-CEILING DIURETICS |
0‑L | C03CA | Sulfonamides, plain | WHO Anatomical Therapeutic Chemical classification | | Sulfonamides, plain |
0‑L | C03CA01 | furosemide | WHO Anatomical Therapeutic Chemical classification | | furosemide |
0‑L | C03CA02 | bumetanide | WHO Anatomical Therapeutic Chemical classification | | bumetanide |
0‑L | C03CA03 | piretanide | WHO Anatomical Therapeutic Chemical classification | | piretanide |
0‑L | C03CA04 | torasemide | WHO Anatomical Therapeutic Chemical classification | | torasemide |
0‑L | C03CB | Sulfonamides and potassium in combination | WHO Anatomical Therapeutic Chemical classification | | Sulfonamides and potassium in combination |
0‑L | C03CB01 | furosemide and potassium | WHO Anatomical Therapeutic Chemical classification | | furosemide and potassium |
0‑L | C03CB02 | bumetanide and potassium | WHO Anatomical Therapeutic Chemical classification | | bumetanide and potassium |
0‑L | C03CC | Aryloxyacetic acid derivatives | WHO Anatomical Therapeutic Chemical classification | | Aryloxyacetic acid derivatives |
0‑L | C03CC01 | etacrynic acid | WHO Anatomical Therapeutic Chemical classification | | etacrynic acid |
0‑L | C03CC02 | tienilic acid | WHO Anatomical Therapeutic Chemical classification | | tienilic acid |
0‑L | C03CD | Pyrazolone derivatives | WHO Anatomical Therapeutic Chemical classification | | Pyrazolone derivatives |
0‑L | C03CD01 | muzolimine | WHO Anatomical Therapeutic Chemical classification | | muzolimine |
0‑L | C03CX | Other high-ceiling diuretics | WHO Anatomical Therapeutic Chemical classification | | Other high-ceiling diuretics |
0‑L | C03CX01 | etozolin | WHO Anatomical Therapeutic Chemical classification | | etozolin |
0‑L | C03D | POTASSIUM-SPARING AGENTS | WHO Anatomical Therapeutic Chemical classification | | POTASSIUM-SPARING AGENTS |
0‑L | C03DA | Aldosterone antagonists | WHO Anatomical Therapeutic Chemical classification | | Aldosterone antagonists |
0‑L | C03DA01 | spironolactone | WHO Anatomical Therapeutic Chemical classification | | spironolactone |
0‑L | C03DA02 | potassium canrenoate | WHO Anatomical Therapeutic Chemical classification | | potassium canrenoate |
0‑L | C03DA03 | canrenone | WHO Anatomical Therapeutic Chemical classification | | canrenone |
0‑L | C03DA04 | eplerenone | WHO Anatomical Therapeutic Chemical classification | | eplerenone |
0‑L | C03DB | Other potassium-sparing agents | WHO Anatomical Therapeutic Chemical classification | | Other potassium-sparing agents |
0‑L | C03DB01 | amiloride | WHO Anatomical Therapeutic Chemical classification | | amiloride |
0‑L | C03DB02 | triamterene | WHO Anatomical Therapeutic Chemical classification | | triamterene |
0‑L | C03E | DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION | WHO Anatomical Therapeutic Chemical classification | | DIURETICS AND POTASSIUM-SPARING AGENTS IN COMBINATION |
0‑L | C03EA | Low-ceiling diuretics and potassium-sparing agents | WHO Anatomical Therapeutic Chemical classification | | Low-ceiling diuretics and potassium-sparing agents |
0‑L | C03EA01 | hydrochlorothiazide and potassium-sparing agents | WHO Anatomical Therapeutic Chemical classification | | hydrochlorothiazide and potassium-sparing agents |
0‑L | C03EA02 | trichlormethiazide and potassium-sparing agents | WHO Anatomical Therapeutic Chemical classification | | trichlormethiazide and potassium-sparing agents |
0‑L | C03EA03 | epitizide and potassium-sparing agents | WHO Anatomical Therapeutic Chemical classification | | epitizide and potassium-sparing agents |
0‑L | C03EA04 | altizide and potassium-sparing agents | WHO Anatomical Therapeutic Chemical classification | | altizide and potassium-sparing agents |
0‑L | C03EA05 | mebutizide and potassium-sparing agents | WHO Anatomical Therapeutic Chemical classification | | mebutizide and potassium-sparing agents |
0‑L | C03EA06 | chlortalidone and potassium-sparing agents | WHO Anatomical Therapeutic Chemical classification | | chlortalidone and potassium-sparing agents |
0‑L | C03EA07 | cyclopenthiazide and potassium-sparing agents | WHO Anatomical Therapeutic Chemical classification | | cyclopenthiazide and potassium-sparing agents |
0‑L | C03EA12 | metolazone and potassium-sparing agents | WHO Anatomical Therapeutic Chemical classification | | metolazone and potassium-sparing agents |
0‑L | C03EA13 | bendroflumethiazide and potassium-sparing agents | WHO Anatomical Therapeutic Chemical classification | | bendroflumethiazide and potassium-sparing agents |
0‑L | C03EA14 | butizide and potassium-sparing agents | WHO Anatomical Therapeutic Chemical classification | | butizide and potassium-sparing agents |
0‑L | C03EB | High-ceiling diuretics and potassium-sparing agents | WHO Anatomical Therapeutic Chemical classification | | High-ceiling diuretics and potassium-sparing agents |
0‑L | C03EB01 | furosemide and potassium-sparing agents | WHO Anatomical Therapeutic Chemical classification | | furosemide and potassium-sparing agents |
0‑L | C03EB02 | bumetanide and potassium-sparing agents | WHO Anatomical Therapeutic Chemical classification | | bumetanide and potassium-sparing agents |
0‑L | C03X | OTHER DIURETICS | WHO Anatomical Therapeutic Chemical classification | | OTHER DIURETICS |
0‑L | C03XA | Vasopressin antagonists | WHO Anatomical Therapeutic Chemical classification | | Vasopressin antagonists |
0‑L | C03XA01 | tolvaptan | WHO Anatomical Therapeutic Chemical classification | | tolvaptan |
0‑L | C03XA02 | conivaptan | WHO Anatomical Therapeutic Chemical classification | | conivaptan |
0‑L | C04 | PERIPHERAL VASODILATORS | WHO Anatomical Therapeutic Chemical classification | | PERIPHERAL VASODILATORS |
0‑L | C04A | PERIPHERAL VASODILATORS | WHO Anatomical Therapeutic Chemical classification | | PERIPHERAL VASODILATORS |
0‑L | C04AA | 2-amino-1-phenylethanol derivatives | WHO Anatomical Therapeutic Chemical classification | | 2-amino-1-phenylethanol derivatives |
0‑L | C04AA01 | isoxsuprine | WHO Anatomical Therapeutic Chemical classification | | isoxsuprine |
0‑L | C04AA02 | buphenine | WHO Anatomical Therapeutic Chemical classification | | buphenine |
0‑L | C04AA31 | bamethan | WHO Anatomical Therapeutic Chemical classification | | bamethan |
0‑L | C04AB | Imidazoline derivatives | WHO Anatomical Therapeutic Chemical classification | | Imidazoline derivatives |
0‑L | C04AB01 | phentolamine | WHO Anatomical Therapeutic Chemical classification | | phentolamine |
0‑L | C04AB02 | tolazoline | WHO Anatomical Therapeutic Chemical classification | | tolazoline |
0‑L | C04AC | Nicotinic acid and derivatives | WHO Anatomical Therapeutic Chemical classification | | Nicotinic acid and derivatives |
0‑L | C04AC01 | nicotinic acid | WHO Anatomical Therapeutic Chemical classification | | nicotinic acid |
0‑L | C04AC02 | nicotinyl alcohol (pyridylcarbinol) | WHO Anatomical Therapeutic Chemical classification | | nicotinyl alcohol (pyridylcarbinol) |
0‑L | C04AC03 | inositol nicotinate | WHO Anatomical Therapeutic Chemical classification | | inositol nicotinate |
0‑L | C04AC07 | ciclonicate | WHO Anatomical Therapeutic Chemical classification | | ciclonicate |
0‑L | C04AD | Purine derivatives | WHO Anatomical Therapeutic Chemical classification | | Purine derivatives |
0‑L | C04AD01 | pentifylline | WHO Anatomical Therapeutic Chemical classification | | pentifylline |
0‑L | C04AD02 | xantinol nicotinate | WHO Anatomical Therapeutic Chemical classification | | xantinol nicotinate |
0‑L | C04AD03 | pentoxifylline | WHO Anatomical Therapeutic Chemical classification | | pentoxifylline |
0‑L | C04AD04 | etofylline nicotinate | WHO Anatomical Therapeutic Chemical classification | | etofylline nicotinate |
0‑L | C04AE | Ergot alkaloids | WHO Anatomical Therapeutic Chemical classification | | Ergot alkaloids |
0‑L | C04AE01 | ergoloid mesylates | WHO Anatomical Therapeutic Chemical classification | | ergoloid mesylates |
0‑L | C04AE02 | nicergoline | WHO Anatomical Therapeutic Chemical classification | | nicergoline |
0‑L | C04AE04 | dihydroergocristine | WHO Anatomical Therapeutic Chemical classification | | dihydroergocristine |
0‑L | C04AE51 | ergoloid mesylates, combinations | WHO Anatomical Therapeutic Chemical classification | | ergoloid mesylates, combinations |
0‑L | C04AE54 | dihydroergocristine, combinations | WHO Anatomical Therapeutic Chemical classification | | dihydroergocristine, combinations |
0‑L | C04AF | Enzymes | WHO Anatomical Therapeutic Chemical classification | | Enzymes |
0‑L | C04AF01 | kallidinogenase | WHO Anatomical Therapeutic Chemical classification | | kallidinogenase |
0‑L | C04AX | Other peripheral vasodilators | WHO Anatomical Therapeutic Chemical classification | | Other peripheral vasodilators |
0‑L | C04AX01 | cyclandelate | WHO Anatomical Therapeutic Chemical classification | | cyclandelate |
0‑L | C04AX02 | phenoxybenzamine | WHO Anatomical Therapeutic Chemical classification | | phenoxybenzamine |
0‑L | C04AX07 | vincamine | WHO Anatomical Therapeutic Chemical classification | | vincamine |
0‑L | C04AX10 | moxisylyte | WHO Anatomical Therapeutic Chemical classification | | moxisylyte |
0‑L | C04AX11 | bencyclane | WHO Anatomical Therapeutic Chemical classification | | bencyclane |
0‑L | C04AX17 | vinburnine | WHO Anatomical Therapeutic Chemical classification | | vinburnine |
0‑L | C04AX19 | suloctidil | WHO Anatomical Therapeutic Chemical classification | | suloctidil |
0‑L | C04AX20 | buflomedil | WHO Anatomical Therapeutic Chemical classification | | buflomedil |
0‑L | C04AX21 | naftidrofuryl | WHO Anatomical Therapeutic Chemical classification | | naftidrofuryl |
0‑L | C04AX23 | butalamine | WHO Anatomical Therapeutic Chemical classification | | butalamine |
0‑L | C04AX24 | visnadine | WHO Anatomical Therapeutic Chemical classification | | visnadine |
0‑L | C04AX26 | cetiedil | WHO Anatomical Therapeutic Chemical classification | | cetiedil |
0‑L | C04AX27 | cinepazide | WHO Anatomical Therapeutic Chemical classification | | cinepazide |
0‑L | C04AX28 | ifenprodil | WHO Anatomical Therapeutic Chemical classification | | ifenprodil |
0‑L | C04AX30 | azapetine | WHO Anatomical Therapeutic Chemical classification | | azapetine |
0‑L | C04AX32 | fasudil | WHO Anatomical Therapeutic Chemical classification | | fasudil |
0‑L | C05 | VASOPROTECTIVES | WHO Anatomical Therapeutic Chemical classification | | VASOPROTECTIVES |
0‑L | C05A | AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE | WHO Anatomical Therapeutic Chemical classification | | AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE |
0‑L | C05AA | Corticosteroids | WHO Anatomical Therapeutic Chemical classification | | Corticosteroids |
0‑L | C05AA01 | hydrocortisone | WHO Anatomical Therapeutic Chemical classification | | hydrocortisone |
0‑L | C05AA04 | prednisolone | WHO Anatomical Therapeutic Chemical classification | | prednisolone |
0‑L | C05AA05 | betamethasone | WHO Anatomical Therapeutic Chemical classification | | betamethasone |
0‑L | C05AA06 | fluorometholone | WHO Anatomical Therapeutic Chemical classification | | fluorometholone |
0‑L | C05AA08 | fluocortolone | WHO Anatomical Therapeutic Chemical classification | | fluocortolone |
0‑L | C05AA09 | dexamethasone | WHO Anatomical Therapeutic Chemical classification | | dexamethasone |
0‑L | C05AA10 | fluocinolone acetonide | WHO Anatomical Therapeutic Chemical classification | | fluocinolone acetonide |
0‑L | C05AA11 | fluocinonide | WHO Anatomical Therapeutic Chemical classification | | fluocinonide |
0‑L | C05AA12 | triamcinolone | WHO Anatomical Therapeutic Chemical classification | | triamcinolone |
0‑L | C05AB | Antibiotics | WHO Anatomical Therapeutic Chemical classification | | Antibiotics |
0‑L | C05AD | Local anesthetics | WHO Anatomical Therapeutic Chemical classification | | Local anesthetics |
0‑L | C05AD01 | lidocaine | WHO Anatomical Therapeutic Chemical classification | | lidocaine |
0‑L | C05AD02 | tetracaine | WHO Anatomical Therapeutic Chemical classification | | tetracaine |
0‑L | C05AD03 | benzocaine | WHO Anatomical Therapeutic Chemical classification | | benzocaine |
0‑L | C05AD04 | cinchocaine | WHO Anatomical Therapeutic Chemical classification | | cinchocaine |
0‑L | C05AD05 | procaine | WHO Anatomical Therapeutic Chemical classification | | procaine |
0‑L | C05AD06 | oxetacaine | WHO Anatomical Therapeutic Chemical classification | | oxetacaine |
0‑L | C05AD07 | pramocaine | WHO Anatomical Therapeutic Chemical classification | | pramocaine |
0‑L | C05AE | Muscle relaxants | WHO Anatomical Therapeutic Chemical classification | | Muscle relaxants |
0‑L | C05AE01 | glyceryl trinitrate | WHO Anatomical Therapeutic Chemical classification | | glyceryl trinitrate |
0‑L | C05AE02 | isosorbide dinitrate | WHO Anatomical Therapeutic Chemical classification | | isosorbide dinitrate |
0‑L | C05AE03 | diltiazem | WHO Anatomical Therapeutic Chemical classification | | diltiazem |
0‑L | C05AX | Other agents for treatment of hemorrhoids and anal fissures for topical use | WHO Anatomical Therapeutic Chemical classification | | Other agents for treatment of hemorrhoids and anal fissures for topical use |
0‑L | C05AX01 | aluminium preparations | WHO Anatomical Therapeutic Chemical classification | | aluminium preparations |
0‑L | C05AX02 | bismuth preparations, combinations | WHO Anatomical Therapeutic Chemical classification | | bismuth preparations, combinations |
0‑L | C05AX03 | other preparations, combinations | WHO Anatomical Therapeutic Chemical classification | | other preparations, combinations |
0‑L | C05AX04 | zinc preparations | WHO Anatomical Therapeutic Chemical classification | | zinc preparations |
0‑L | C05AX05 | tribenoside | WHO Anatomical Therapeutic Chemical classification | | tribenoside |
0‑L | C05B | ANTIVARICOSE THERAPY | WHO Anatomical Therapeutic Chemical classification | | ANTIVARICOSE THERAPY |
0‑L | C05BA | Heparins or heparinoids for topical use | WHO Anatomical Therapeutic Chemical classification | | Heparins or heparinoids for topical use |
0‑L | C05BA01 | organo-heparinoid | WHO Anatomical Therapeutic Chemical classification | | organo-heparinoid |
0‑L | C05BA02 | sodium apolate | WHO Anatomical Therapeutic Chemical classification | | sodium apolate |
0‑L | C05BA03 | heparin | WHO Anatomical Therapeutic Chemical classification | | heparin |
0‑L | C05BA04 | pentosan polysulfate sodium | WHO Anatomical Therapeutic Chemical classification | | pentosan polysulfate sodium |
0‑L | C05BA51 | heparinoid, combinations | WHO Anatomical Therapeutic Chemical classification | | heparinoid, combinations |
0‑L | C05BA53 | heparin, combinations | WHO Anatomical Therapeutic Chemical classification | | heparin, combinations |
0‑L | C05BB | Sclerosing agents for local injection | WHO Anatomical Therapeutic Chemical classification | | Sclerosing agents for local injection |
0‑L | C05BB01 | monoethanolamine oleate | WHO Anatomical Therapeutic Chemical classification | | monoethanolamine oleate |
0‑L | C05BB02 | polidocanol | WHO Anatomical Therapeutic Chemical classification | | polidocanol |
0‑L | C05BB03 | invert sugar | WHO Anatomical Therapeutic Chemical classification | | invert sugar |
0‑L | C05BB04 | sodium tetradecyl sulfate | WHO Anatomical Therapeutic Chemical classification | | sodium tetradecyl sulfate |
0‑L | C05BB05 | phenol | WHO Anatomical Therapeutic Chemical classification | | phenol |
0‑L | C05BB56 | glucose, combinations | WHO Anatomical Therapeutic Chemical classification | | glucose, combinations |
0‑L | C05BX | Other sclerosing agents | WHO Anatomical Therapeutic Chemical classification | | Other sclerosing agents |
0‑L | C05BX01 | calcium dobesilate | WHO Anatomical Therapeutic Chemical classification | | calcium dobesilate |
0‑L | C05BX51 | calcium dobesilate, combinations | WHO Anatomical Therapeutic Chemical classification | | calcium dobesilate, combinations |
0‑L | C05C | CAPILLARY STABILIZING AGENTS | WHO Anatomical Therapeutic Chemical classification | | CAPILLARY STABILIZING AGENTS |
0‑L | C05CA | Bioflavonoids | WHO Anatomical Therapeutic Chemical classification | | Bioflavonoids |
0‑L | C05CA01 | rutoside | WHO Anatomical Therapeutic Chemical classification | | rutoside |
0‑L | C05CA02 | monoxerutin | WHO Anatomical Therapeutic Chemical classification | | monoxerutin |
0‑L | C05CA03 | diosmin | WHO Anatomical Therapeutic Chemical classification | | diosmin |
0‑L | C05CA04 | troxerutin | WHO Anatomical Therapeutic Chemical classification | | troxerutin |
0‑L | C05CA05 | hidrosmin | WHO Anatomical Therapeutic Chemical classification | | hidrosmin |
0‑L | C05CA51 | rutoside, combinations | WHO Anatomical Therapeutic Chemical classification | | rutoside, combinations |
0‑L | C05CA53 | diosmin, combinations | WHO Anatomical Therapeutic Chemical classification | | diosmin, combinations |
0‑L | C05CA54 | troxerutin, combinations | WHO Anatomical Therapeutic Chemical classification | | troxerutin, combinations |
0‑L | C05CX | Other capillary stabilizing agents | WHO Anatomical Therapeutic Chemical classification | | Other capillary stabilizing agents |
0‑L | C05CX01 | tribenoside | WHO Anatomical Therapeutic Chemical classification | | tribenoside |
0‑L | C05CX02 | naftazone | WHO Anatomical Therapeutic Chemical classification | | naftazone |
0‑L | C05CX03 | Hippocastani semen | WHO Anatomical Therapeutic Chemical classification | | Hippocastani semen |
0‑L | C07 | BETA BLOCKING AGENTS | WHO Anatomical Therapeutic Chemical classification | | BETA BLOCKING AGENTS |
0‑L | C07A | BETA BLOCKING AGENTS | WHO Anatomical Therapeutic Chemical classification | | BETA BLOCKING AGENTS |
0‑L | C07AA | Beta blocking agents, non-selective | WHO Anatomical Therapeutic Chemical classification | | Beta blocking agents, non-selective |
0‑L | C07AA01 | alprenolol | WHO Anatomical Therapeutic Chemical classification | | alprenolol |
0‑L | C07AA02 | oxprenolol | WHO Anatomical Therapeutic Chemical classification | | oxprenolol |
0‑L | C07AA03 | pindolol | WHO Anatomical Therapeutic Chemical classification | | pindolol |
0‑L | C07AA05 | propranolol | WHO Anatomical Therapeutic Chemical classification | | propranolol |
0‑L | C07AA06 | timolol | WHO Anatomical Therapeutic Chemical classification | | timolol |
0‑L | C07AA07 | sotalol | WHO Anatomical Therapeutic Chemical classification | | sotalol |
0‑L | C07AA12 | nadolol | WHO Anatomical Therapeutic Chemical classification | | nadolol |
0‑L | C07AA14 | mepindolol | WHO Anatomical Therapeutic Chemical classification | | mepindolol |
0‑L | C07AA15 | carteolol | WHO Anatomical Therapeutic Chemical classification | | carteolol |
0‑L | C07AA16 | tertatolol | WHO Anatomical Therapeutic Chemical classification | | tertatolol |
0‑L | C07AA17 | bopindolol | WHO Anatomical Therapeutic Chemical classification | | bopindolol |
0‑L | C07AA19 | bupranolol | WHO Anatomical Therapeutic Chemical classification | | bupranolol |
0‑L | C07AA23 | penbutolol | WHO Anatomical Therapeutic Chemical classification | | penbutolol |
0‑L | C07AA27 | cloranolol | WHO Anatomical Therapeutic Chemical classification | | cloranolol |
0‑L | C07AB | Beta blocking agents, selective | WHO Anatomical Therapeutic Chemical classification | | Beta blocking agents, selective |
0‑L | C07AB01 | practolol | WHO Anatomical Therapeutic Chemical classification | | practolol |
0‑L | C07AB02 | metoprolol | WHO Anatomical Therapeutic Chemical classification | | metoprolol |
0‑L | C07AB03 | atenolol | WHO Anatomical Therapeutic Chemical classification | | atenolol |
0‑L | C07AB04 | acebutolol | WHO Anatomical Therapeutic Chemical classification | | acebutolol |
0‑L | C07AB05 | betaxolol | WHO Anatomical Therapeutic Chemical classification | | betaxolol |
0‑L | C07AB06 | bevantolol | WHO Anatomical Therapeutic Chemical classification | | bevantolol |
0‑L | C07AB07 | bisoprolol | WHO Anatomical Therapeutic Chemical classification | | bisoprolol |
0‑L | C07AB08 | celiprolol | WHO Anatomical Therapeutic Chemical classification | | celiprolol |
0‑L | C07AB09 | esmolol | WHO Anatomical Therapeutic Chemical classification | | esmolol |
0‑L | C07AB10 | epanolol | WHO Anatomical Therapeutic Chemical classification | | epanolol |
0‑L | C07AB11 | s-atenolol | WHO Anatomical Therapeutic Chemical classification | | s-atenolol |
0‑L | C07AB12 | nebivolol | WHO Anatomical Therapeutic Chemical classification | | nebivolol |
0‑L | C07AB13 | talinolol | WHO Anatomical Therapeutic Chemical classification | | talinolol |
0‑L | C07AB14 | landiolol | WHO Anatomical Therapeutic Chemical classification | | landiolol |
0‑L | C07AG | Alpha and beta blocking agents | WHO Anatomical Therapeutic Chemical classification | | Alpha and beta blocking agents |
0‑L | C07AG01 | labetalol | WHO Anatomical Therapeutic Chemical classification | | labetalol |
0‑L | C07AG02 | carvedilol | WHO Anatomical Therapeutic Chemical classification | | carvedilol |
0‑L | C07B | BETA BLOCKING AGENTS AND THIAZIDES | WHO Anatomical Therapeutic Chemical classification | | BETA BLOCKING AGENTS AND THIAZIDES |
0‑L | C07BA | Beta blocking agents, non-selective, and thiazides | WHO Anatomical Therapeutic Chemical classification | | Beta blocking agents, non-selective, and thiazides |
0‑L | C07BA02 | oxprenolol and thiazides | WHO Anatomical Therapeutic Chemical classification | | oxprenolol and thiazides |
0‑L | C07BA05 | propranolol and thiazides | WHO Anatomical Therapeutic Chemical classification | | propranolol and thiazides |
0‑L | C07BA06 | timolol and thiazides | WHO Anatomical Therapeutic Chemical classification | | timolol and thiazides |
0‑L | C07BA07 | sotalol and thiazides | WHO Anatomical Therapeutic Chemical classification | | sotalol and thiazides |
0‑L | C07BA12 | nadolol and thiazides | WHO Anatomical Therapeutic Chemical classification | | nadolol and thiazides |
0‑L | C07BA68 | metipranolol and thiazides, combinations | WHO Anatomical Therapeutic Chemical classification | | metipranolol and thiazides, combinations |
0‑L | C07BB | Beta blocking agents, selective, and thiazides | WHO Anatomical Therapeutic Chemical classification | | Beta blocking agents, selective, and thiazides |
0‑L | C07BB02 | metoprolol and thiazides | WHO Anatomical Therapeutic Chemical classification | | metoprolol and thiazides |
0‑L | C07BB03 | atenolol and thiazides | WHO Anatomical Therapeutic Chemical classification | | atenolol and thiazides |
0‑L | C07BB04 | acebutolol and thiazides | WHO Anatomical Therapeutic Chemical classification | | acebutolol and thiazides |
0‑L | C07BB06 | bevantolol and thiazides | WHO Anatomical Therapeutic Chemical classification | | bevantolol and thiazides |
0‑L | C07BB07 | bisoprolol and thiazides | WHO Anatomical Therapeutic Chemical classification | | bisoprolol and thiazides |
0‑L | C07BB12 | nebivolol and thiazides | WHO Anatomical Therapeutic Chemical classification | | nebivolol and thiazides |
0‑L | C07BB52 | metoprolol and thiazides, combinations | WHO Anatomical Therapeutic Chemical classification | | metoprolol and thiazides, combinations |
0‑L | C07BG | Alpha and beta blocking agents and thiazides | WHO Anatomical Therapeutic Chemical classification | | Alpha and beta blocking agents and thiazides |
0‑L | C07BG01 | labetalol and thiazides | WHO Anatomical Therapeutic Chemical classification | | labetalol and thiazides |
0‑L | C07C | BETA BLOCKING AGENTS AND OTHER DIURETICS | WHO Anatomical Therapeutic Chemical classification | | BETA BLOCKING AGENTS AND OTHER DIURETICS |
0‑L | C07CA | Beta blocking agents, non-selective, and other diuretics | WHO Anatomical Therapeutic Chemical classification | | Beta blocking agents, non-selective, and other diuretics |
0‑L | C07CA02 | oxprenolol and other diuretics | WHO Anatomical Therapeutic Chemical classification | | oxprenolol and other diuretics |
0‑L | C07CA03 | pindolol and other diuretics | WHO Anatomical Therapeutic Chemical classification | | pindolol and other diuretics |
0‑L | C07CA17 | bopindolol and other diuretics | WHO Anatomical Therapeutic Chemical classification | | bopindolol and other diuretics |
0‑L | C07CA23 | penbutolol and other diuretics | WHO Anatomical Therapeutic Chemical classification | | penbutolol and other diuretics |
0‑L | C07CB | Beta blocking agents, selective, and other diuretics | WHO Anatomical Therapeutic Chemical classification | | Beta blocking agents, selective, and other diuretics |
0‑L | C07CB02 | metoprolol and other diuretics | WHO Anatomical Therapeutic Chemical classification | | metoprolol and other diuretics |
0‑L | C07CB03 | atenolol and other diuretics | WHO Anatomical Therapeutic Chemical classification | | atenolol and other diuretics |
0‑L | C07CB53 | atenolol and other diuretics, combinations | WHO Anatomical Therapeutic Chemical classification | | atenolol and other diuretics, combinations |
0‑L | C07CG | Alpha and beta blocking agents and other diuretics | WHO Anatomical Therapeutic Chemical classification | | Alpha and beta blocking agents and other diuretics |
0‑L | C07CG01 | labetalol and other diuretics | WHO Anatomical Therapeutic Chemical classification | | labetalol and other diuretics |
0‑L | C07D | BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS | WHO Anatomical Therapeutic Chemical classification | | BETA BLOCKING AGENTS, THIAZIDES AND OTHER DIURETICS |
0‑L | C07DA | Beta blocking agents, non-selective, thiazides and other diuretics | WHO Anatomical Therapeutic Chemical classification | | Beta blocking agents, non-selective, thiazides and other diuretics |
0‑L | C07DA06 | timolol, thiazides and other diuretics | WHO Anatomical Therapeutic Chemical classification | | timolol, thiazides and other diuretics |
0‑L | C07DB | Beta blocking agents, selective, thiazides and other diuretics | WHO Anatomical Therapeutic Chemical classification | | Beta blocking agents, selective, thiazides and other diuretics |
0‑L | C07DB01 | atenolol, thiazides and other diuretics | WHO Anatomical Therapeutic Chemical classification | | atenolol, thiazides and other diuretics |
0‑L | C07E | BETA BLOCKING AGENTS AND VASODILATORS | WHO Anatomical Therapeutic Chemical classification | | BETA BLOCKING AGENTS AND VASODILATORS |
0‑L | C07EA | Beta blocking agents, non-selective, and vasodilators | WHO Anatomical Therapeutic Chemical classification | | Beta blocking agents, non-selective, and vasodilators |
0‑L | C07EB | Beta blocking agents, selective, and vasodilators | WHO Anatomical Therapeutic Chemical classification | | Beta blocking agents, selective, and vasodilators |
0‑L | C07F | BETA BLOCKING AGENTS, OTHER COMBINATIONS | WHO Anatomical Therapeutic Chemical classification | | BETA BLOCKING AGENTS, OTHER COMBINATIONS |
0‑L | C07FB | Beta blocking agents and calcium channel blockers | WHO Anatomical Therapeutic Chemical classification | | Beta blocking agents and calcium channel blockers |
0‑L | C07FB02 | metoprolol and felodipine | WHO Anatomical Therapeutic Chemical classification | | metoprolol and felodipine |
0‑L | C07FB03 | atenolol and nifedipine | WHO Anatomical Therapeutic Chemical classification | | atenolol and nifedipine |
0‑L | C07FB07 | bisoprolol and amlodipine | WHO Anatomical Therapeutic Chemical classification | | bisoprolol and amlodipine |
0‑L | C07FB12 | nevibolol and amlodipine | WHO Anatomical Therapeutic Chemical classification | | nevibolol and amlodipine |
0‑L | C07FB13 | metoprolol and amlodipine | WHO Anatomical Therapeutic Chemical classification | | metoprolol and amlodipine |
0‑L | C07FX | Beta blocking agents, other combinations | WHO Anatomical Therapeutic Chemical classification | | Beta blocking agents, other combinations |
0‑L | C07FX01 | propranolol and other combinations | WHO Anatomical Therapeutic Chemical classification | | propranolol and other combinations |
0‑L | C07FX02 | sotalol and acetylsalicylic acid | WHO Anatomical Therapeutic Chemical classification | | sotalol and acetylsalicylic acid |
0‑L | C07FX03 | metoprolol and acetylsalicylic acid | WHO Anatomical Therapeutic Chemical classification | | metoprolol and acetylsalicylic acid |
0‑L | C07FX04 | bisoprolol and acetylsalicylic acid | WHO Anatomical Therapeutic Chemical classification | | bisoprolol and acetylsalicylic acid |
0‑L | C07FX05 | metoprolol and ivabradine | WHO Anatomical Therapeutic Chemical classification | | metoprolol and ivabradine |
0‑L | C07FX06 | carvedilol and ivabradine | WHO Anatomical Therapeutic Chemical classification | | carvedilol and ivabradine |
0‑L | C08 | CALCIUM CHANNEL BLOCKERS | WHO Anatomical Therapeutic Chemical classification | | CALCIUM CHANNEL BLOCKERS |
0‑L | C08C | SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS | WHO Anatomical Therapeutic Chemical classification | | SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS |
0‑L | C08CA | Dihydropyridine derivatives | WHO Anatomical Therapeutic Chemical classification | | Dihydropyridine derivatives |
0‑L | C08CA01 | amlodipine | WHO Anatomical Therapeutic Chemical classification | | amlodipine |
0‑L | C08CA02 | felodipine | WHO Anatomical Therapeutic Chemical classification | | felodipine |
0‑L | C08CA03 | isradipine | WHO Anatomical Therapeutic Chemical classification | | isradipine |
0‑L | C08CA04 | nicardipine | WHO Anatomical Therapeutic Chemical classification | | nicardipine |
0‑L | C08CA05 | nifedipine | WHO Anatomical Therapeutic Chemical classification | | nifedipine |
0‑L | C08CA06 | nimodipine | WHO Anatomical Therapeutic Chemical classification | | nimodipine |
0‑L | C08CA07 | nisoldipine | WHO Anatomical Therapeutic Chemical classification | | nisoldipine |
0‑L | C08CA08 | nitrendipine | WHO Anatomical Therapeutic Chemical classification | | nitrendipine |
0‑L | C08CA09 | lacidipine | WHO Anatomical Therapeutic Chemical classification | | lacidipine |
0‑L | C08CA10 | nilvadipine | WHO Anatomical Therapeutic Chemical classification | | nilvadipine |
0‑L | C08CA11 | manidipine | WHO Anatomical Therapeutic Chemical classification | | manidipine |
0‑L | C08CA12 | barnidipine | WHO Anatomical Therapeutic Chemical classification | | barnidipine |
0‑L | C08CA13 | lercanidipine | WHO Anatomical Therapeutic Chemical classification | | lercanidipine |
0‑L | C08CA14 | cilnidipine | WHO Anatomical Therapeutic Chemical classification | | cilnidipine |
0‑L | C08CA15 | benidipine | WHO Anatomical Therapeutic Chemical classification | | benidipine |
0‑L | C08CA16 | clevidipine | WHO Anatomical Therapeutic Chemical classification | | clevidipine |
0‑L | C08CA55 | nifedipine, combinations | WHO Anatomical Therapeutic Chemical classification | | nifedipine, combinations |
0‑L | C08CX | Other selective calcium channel blockers with mainly vascular effects | WHO Anatomical Therapeutic Chemical classification | | Other selective calcium channel blockers with mainly vascular effects |
0‑L | C08CX01 | mibefradil | WHO Anatomical Therapeutic Chemical classification | | mibefradil |
0‑L | C08D | SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS | WHO Anatomical Therapeutic Chemical classification | | SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS |
0‑L | C08DA | Phenylalkylamine derivatives | WHO Anatomical Therapeutic Chemical classification | | Phenylalkylamine derivatives |
0‑L | C08DA01 | verapamil | WHO Anatomical Therapeutic Chemical classification | | verapamil |
0‑L | C08DA02 | gallopamil | WHO Anatomical Therapeutic Chemical classification | | gallopamil |
0‑L | C08DA51 | verapamil, combinations | WHO Anatomical Therapeutic Chemical classification | | verapamil, combinations |
0‑L | C08DB | Benzothiazepine derivatives | WHO Anatomical Therapeutic Chemical classification | | Benzothiazepine derivatives |
0‑L | C08DB01 | diltiazem | WHO Anatomical Therapeutic Chemical classification | | diltiazem |
0‑L | C08E | NON-SELECTIVE CALCIUM CHANNEL BLOCKERS | WHO Anatomical Therapeutic Chemical classification | | NON-SELECTIVE CALCIUM CHANNEL BLOCKERS |
0‑L | C08EA | Phenylalkylamine derivatives | WHO Anatomical Therapeutic Chemical classification | | Phenylalkylamine derivatives |
0‑L | C08EA01 | fendiline | WHO Anatomical Therapeutic Chemical classification | | fendiline |
0‑L | C08EA02 | bepridil | WHO Anatomical Therapeutic Chemical classification | | bepridil |
0‑L | C08EX | Other non-selective calcium channel blockers | WHO Anatomical Therapeutic Chemical classification | | Other non-selective calcium channel blockers |
0‑L | C08EX01 | lidoflazine | WHO Anatomical Therapeutic Chemical classification | | lidoflazine |
0‑L | C08EX02 | perhexiline | WHO Anatomical Therapeutic Chemical classification | | perhexiline |
0‑L | C08G | CALCIUM CHANNEL BLOCKERS AND DIURETICS | WHO Anatomical Therapeutic Chemical classification | | CALCIUM CHANNEL BLOCKERS AND DIURETICS |
0‑L | C08GA | Calcium channel blockers and diuretics | WHO Anatomical Therapeutic Chemical classification | | Calcium channel blockers and diuretics |
0‑L | C08GA01 | nifedipine and diuretics | WHO Anatomical Therapeutic Chemical classification | | nifedipine and diuretics |
0‑L | C08GA02 | amlodipine and diuretics | WHO Anatomical Therapeutic Chemical classification | | amlodipine and diuretics |
0‑L | C09 | AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM | WHO Anatomical Therapeutic Chemical classification | | AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM |
0‑L | C09A | ACE INHIBITORS, PLAIN | WHO Anatomical Therapeutic Chemical classification | | ACE INHIBITORS, PLAIN |
0‑L | C09AA | ACE inhibitors, plain | WHO Anatomical Therapeutic Chemical classification | | ACE inhibitors, plain |
0‑L | C09AA01 | captopril | WHO Anatomical Therapeutic Chemical classification | | captopril |
0‑L | C09AA02 | enalapril | WHO Anatomical Therapeutic Chemical classification | | enalapril |
0‑L | C09AA03 | lisinopril | WHO Anatomical Therapeutic Chemical classification | | lisinopril |
0‑L | C09AA04 | perindopril | WHO Anatomical Therapeutic Chemical classification | | perindopril |
0‑L | C09AA05 | ramipril | WHO Anatomical Therapeutic Chemical classification | | ramipril |
0‑L | C09AA06 | quinapril | WHO Anatomical Therapeutic Chemical classification | | quinapril |
0‑L | C09AA07 | benazepril | WHO Anatomical Therapeutic Chemical classification | | benazepril |
0‑L | C09AA08 | cilazapril | WHO Anatomical Therapeutic Chemical classification | | cilazapril |
0‑L | C09AA09 | fosinopril | WHO Anatomical Therapeutic Chemical classification | | fosinopril |
0‑L | C09AA10 | trandolapril | WHO Anatomical Therapeutic Chemical classification | | trandolapril |
0‑L | C09AA11 | spirapril | WHO Anatomical Therapeutic Chemical classification | | spirapril |
0‑L | C09AA12 | delapril | WHO Anatomical Therapeutic Chemical classification | | delapril |
0‑L | C09AA13 | moexipril | WHO Anatomical Therapeutic Chemical classification | | moexipril |
0‑L | C09AA14 | temocapril | WHO Anatomical Therapeutic Chemical classification | | temocapril |
0‑L | C09AA15 | zofenopril | WHO Anatomical Therapeutic Chemical classification | | zofenopril |
0‑L | C09AA16 | imidapril | WHO Anatomical Therapeutic Chemical classification | | imidapril |
0‑L | C09B | ACE INHIBITORS, COMBINATIONS | WHO Anatomical Therapeutic Chemical classification | | ACE INHIBITORS, COMBINATIONS |
0‑L | C09BA | ACE inhibitors and diuretics | WHO Anatomical Therapeutic Chemical classification | | ACE inhibitors and diuretics |
0‑L | C09BA01 | captopril and diuretics | WHO Anatomical Therapeutic Chemical classification | | captopril and diuretics |
0‑L | C09BA02 | enalapril and diuretics | WHO Anatomical Therapeutic Chemical classification | | enalapril and diuretics |
0‑L | C09BA03 | lisinopril and diuretics | WHO Anatomical Therapeutic Chemical classification | | lisinopril and diuretics |
0‑L | C09BA04 | perindopril and diuretics | WHO Anatomical Therapeutic Chemical classification | | perindopril and diuretics |
0‑L | C09BA05 | ramipril and diuretics | WHO Anatomical Therapeutic Chemical classification | | ramipril and diuretics |
0‑L | C09BA06 | quinapril and diuretics | WHO Anatomical Therapeutic Chemical classification | | quinapril and diuretics |
0‑L | C09BA07 | benazepril and diuretics | WHO Anatomical Therapeutic Chemical classification | | benazepril and diuretics |
0‑L | C09BA08 | cilazapril and diuretics | WHO Anatomical Therapeutic Chemical classification | | cilazapril and diuretics |
0‑L | C09BA09 | fosinopril and diuretics | WHO Anatomical Therapeutic Chemical classification | | fosinopril and diuretics |
0‑L | C09BA12 | delapril and diuretics | WHO Anatomical Therapeutic Chemical classification | | delapril and diuretics |
0‑L | C09BA13 | moexipril and diuretics | WHO Anatomical Therapeutic Chemical classification | | moexipril and diuretics |
0‑L | C09BA15 | zofenopril and diuretics | WHO Anatomical Therapeutic Chemical classification | | zofenopril and diuretics |
0‑L | C09BB | ACE inhibitors and calcium channel blockers | WHO Anatomical Therapeutic Chemical classification | | ACE inhibitors and calcium channel blockers |
0‑L | C09BB02 | enalapril and lercanidipine | WHO Anatomical Therapeutic Chemical classification | | enalapril and lercanidipine |
0‑L | C09BB03 | lisinopril and amlodipine | WHO Anatomical Therapeutic Chemical classification | | lisinopril and amlodipine |
0‑L | C09BB04 | perindopril and amlodipine | WHO Anatomical Therapeutic Chemical classification | | perindopril and amlodipine |
0‑L | C09BB05 | ramipril and felodipine | WHO Anatomical Therapeutic Chemical classification | | ramipril and felodipine |
0‑L | C09BB06 | enalapril and nitrendipine | WHO Anatomical Therapeutic Chemical classification | | enalapril and nitrendipine |
0‑L | C09BB07 | ramipril and amlodipine | WHO Anatomical Therapeutic Chemical classification | | ramipril and amlodipine |
0‑L | C09BB10 | trandolapril and verapamil | WHO Anatomical Therapeutic Chemical classification | | trandolapril and verapamil |
0‑L | C09BB12 | delapril and manidipine | WHO Anatomical Therapeutic Chemical classification | | delapril and manidipine |
0‑L | C09BX | ACE inhibitors, other combinations | WHO Anatomical Therapeutic Chemical classification | | ACE inhibitors, other combinations |
0‑L | C09BX01 | perindopril, amlodipine and indapamide | WHO Anatomical Therapeutic Chemical classification | | perindopril, amlodipine and indapamide |
0‑L | C09BX02 | perindopril and bisoprolol | WHO Anatomical Therapeutic Chemical classification | | perindopril and bisoprolol |
0‑L | C09C | ANGIOTENSIN II ANTAGONISTS, PLAIN | WHO Anatomical Therapeutic Chemical classification | | ANGIOTENSIN II ANTAGONISTS, PLAIN |
0‑L | C09CA | Angiotensin II antagonists, plain | WHO Anatomical Therapeutic Chemical classification | | Angiotensin II antagonists, plain |
0‑L | C09CA01 | losartan | WHO Anatomical Therapeutic Chemical classification | | losartan |
0‑L | C09CA02 | eprosartan | WHO Anatomical Therapeutic Chemical classification | | eprosartan |
0‑L | C09CA03 | valsartan | WHO Anatomical Therapeutic Chemical classification | | valsartan |
0‑L | C09CA04 | irbesartan | WHO Anatomical Therapeutic Chemical classification | | irbesartan |
0‑L | C09CA05 | tasosartan | WHO Anatomical Therapeutic Chemical classification | | tasosartan |
0‑L | C09CA06 | candesartan | WHO Anatomical Therapeutic Chemical classification | | candesartan |
0‑L | C09CA07 | telmisartan | WHO Anatomical Therapeutic Chemical classification | | telmisartan |
0‑L | C09CA08 | olmesartan medoxomil | WHO Anatomical Therapeutic Chemical classification | | olmesartan medoxomil |
0‑L | C09CA09 | azilsartan medoxomil | WHO Anatomical Therapeutic Chemical classification | | azilsartan medoxomil |
0‑L | C09CA10 | fimasartan | WHO Anatomical Therapeutic Chemical classification | | fimasartan |
0‑L | C09D | ANGIOTENSIN II ANTAGONISTS, COMBINATIONS | WHO Anatomical Therapeutic Chemical classification | | ANGIOTENSIN II ANTAGONISTS, COMBINATIONS |
0‑L | C09DA | Angiotensin II antagonists and diuretics | WHO Anatomical Therapeutic Chemical classification | | Angiotensin II antagonists and diuretics |
0‑L | C09DA01 | losartan and diuretics | WHO Anatomical Therapeutic Chemical classification | | losartan and diuretics |
0‑L | C09DA02 | eprosartan and diuretics | WHO Anatomical Therapeutic Chemical classification | | eprosartan and diuretics |
0‑L | C09DA03 | valsartan and diuretics | WHO Anatomical Therapeutic Chemical classification | | valsartan and diuretics |
0‑L | C09DA04 | irbesartan and diuretics | WHO Anatomical Therapeutic Chemical classification | | irbesartan and diuretics |
0‑L | C09DA06 | candesartan and diuretics | WHO Anatomical Therapeutic Chemical classification | | candesartan and diuretics |
0‑L | C09DA07 | telmisartan and diuretics | WHO Anatomical Therapeutic Chemical classification | | telmisartan and diuretics |
0‑L | C09DA08 | olmesartan medoxomil and diuretics | WHO Anatomical Therapeutic Chemical classification | | olmesartan medoxomil and diuretics |
0‑L | C09DA09 | azilsartan medoxomil and diuretics | WHO Anatomical Therapeutic Chemical classification | | azilsartan medoxomil and diuretics |
0‑L | C09DB | Angiotensin II antagonists and calcium channel blockers | WHO Anatomical Therapeutic Chemical classification | | Angiotensin II antagonists and calcium channel blockers |
0‑L | C09DB01 | valsartan and amlodipine | WHO Anatomical Therapeutic Chemical classification | | valsartan and amlodipine |
0‑L | C09DB02 | olmesartan medoxomil and amlodipine | WHO Anatomical Therapeutic Chemical classification | | olmesartan medoxomil and amlodipine |
0‑L | C09DB04 | telmisartan and amlodipine | WHO Anatomical Therapeutic Chemical classification | | telmisartan and amlodipine |
0‑L | C09DB05 | irbesartan and amlodipine | WHO Anatomical Therapeutic Chemical classification | | irbesartan and amlodipine |
0‑L | C09DB06 | losartan and amlodipine | WHO Anatomical Therapeutic Chemical classification | | losartan and amlodipine |
0‑L | C09DB07 | candesartan and amlodipine | WHO Anatomical Therapeutic Chemical classification | | candesartan and amlodipine |
0‑L | C09DB08 | valsartan and lercanidipine | WHO Anatomical Therapeutic Chemical classification | | valsartan and lercanidipine |
0‑L | C09DX | Angiotensin II antagonists, other combinations | WHO Anatomical Therapeutic Chemical classification | | Angiotensin II antagonists, other combinations |
0‑L | C09DX01 | valsartan, amlodipine and hydrochlorothiazide | WHO Anatomical Therapeutic Chemical classification | | valsartan, amlodipine and hydrochlorothiazide |
0‑L | C09DX02 | valsartan and aliskiren | WHO Anatomical Therapeutic Chemical classification | | valsartan and aliskiren |
0‑L | C09DX03 | olmesartan medoxomil, amlodipine and hydrochlorothiazide | WHO Anatomical Therapeutic Chemical classification | | olmesartan medoxomil, amlodipine and hydrochlorothiazide |
0‑L | C09DX04 | valsartan and sacubitril | WHO Anatomical Therapeutic Chemical classification | | valsartan and sacubitril |
0‑L | C09X | OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM | WHO Anatomical Therapeutic Chemical classification | | OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM |
0‑L | C09XA | Renin-inhibitors | WHO Anatomical Therapeutic Chemical classification | | Renin-inhibitors |
0‑L | C09XA01 | remikiren | WHO Anatomical Therapeutic Chemical classification | | remikiren |
0‑L | C09XA02 | aliskiren | WHO Anatomical Therapeutic Chemical classification | | aliskiren |
0‑L | C09XA52 | aliskiren and hydrochlorothiazide | WHO Anatomical Therapeutic Chemical classification | | aliskiren and hydrochlorothiazide |
0‑L | C09XA53 | aliskiren and amlodipine | WHO Anatomical Therapeutic Chemical classification | | aliskiren and amlodipine |
0‑L | C09XA54 | aliskiren, amlodipine and hydrochlorothiazide | WHO Anatomical Therapeutic Chemical classification | | aliskiren, amlodipine and hydrochlorothiazide |
0‑L | C10 | LIPID MODIFYING AGENTS | WHO Anatomical Therapeutic Chemical classification | | LIPID MODIFYING AGENTS |
0‑L | C10A | LIPID MODIFYING AGENTS, PLAIN | WHO Anatomical Therapeutic Chemical classification | | LIPID MODIFYING AGENTS, PLAIN |
0‑L | C10AA | HMG CoA reductase inhibitors | WHO Anatomical Therapeutic Chemical classification | | HMG CoA reductase inhibitors |
0‑L | C10AA01 | simvastatin | WHO Anatomical Therapeutic Chemical classification | | simvastatin |
0‑L | C10AA02 | lovastatin | WHO Anatomical Therapeutic Chemical classification | | lovastatin |
0‑L | C10AA03 | pravastatin | WHO Anatomical Therapeutic Chemical classification | | pravastatin |
0‑L | C10AA04 | fluvastatin | WHO Anatomical Therapeutic Chemical classification | | fluvastatin |
0‑L | C10AA05 | atorvastatin | WHO Anatomical Therapeutic Chemical classification | | atorvastatin |
0‑L | C10AA06 | cerivastatin | WHO Anatomical Therapeutic Chemical classification | | cerivastatin |
0‑L | C10AA07 | rosuvastatin | WHO Anatomical Therapeutic Chemical classification | | rosuvastatin |
0‑L | C10AA08 | pitavastatin | WHO Anatomical Therapeutic Chemical classification | | pitavastatin |
0‑L | C10AB | Fibrates | WHO Anatomical Therapeutic Chemical classification | | Fibrates |
0‑L | C10AB01 | clofibrate | WHO Anatomical Therapeutic Chemical classification | | clofibrate |
0‑L | C10AB02 | bezafibrate | WHO Anatomical Therapeutic Chemical classification | | bezafibrate |
0‑L | C10AB03 | aluminium clofibrate | WHO Anatomical Therapeutic Chemical classification | | aluminium clofibrate |
0‑L | C10AB04 | gemfibrozil | WHO Anatomical Therapeutic Chemical classification | | gemfibrozil |
0‑L | C10AB05 | fenofibrate | WHO Anatomical Therapeutic Chemical classification | | fenofibrate |
0‑L | C10AB06 | simfibrate | WHO Anatomical Therapeutic Chemical classification | | simfibrate |
0‑L | C10AB07 | ronifibrate | WHO Anatomical Therapeutic Chemical classification | | ronifibrate |
0‑L | C10AB08 | ciprofibrate | WHO Anatomical Therapeutic Chemical classification | | ciprofibrate |
0‑L | C10AB09 | etofibrate | WHO Anatomical Therapeutic Chemical classification | | etofibrate |
0‑L | C10AB10 | clofibride | WHO Anatomical Therapeutic Chemical classification | | clofibride |
0‑L | C10AB11 | choline fenofibrate | WHO Anatomical Therapeutic Chemical classification | | choline fenofibrate |
0‑L | C10AC | Bile acid sequestrants | WHO Anatomical Therapeutic Chemical classification | | Bile acid sequestrants |
0‑L | C10AC01 | colestyramine | WHO Anatomical Therapeutic Chemical classification | | colestyramine |
0‑L | C10AC02 | colestipol | WHO Anatomical Therapeutic Chemical classification | | colestipol |
0‑L | C10AC03 | colextran | WHO Anatomical Therapeutic Chemical classification | | colextran |
0‑L | C10AC04 | colesevelam | WHO Anatomical Therapeutic Chemical classification | | colesevelam |
0‑L | C10AD | Nicotinic acid and derivatives | WHO Anatomical Therapeutic Chemical classification | | Nicotinic acid and derivatives |
0‑L | C10AD01 | niceritrol | WHO Anatomical Therapeutic Chemical classification | | niceritrol |
0‑L | C10AD02 | nicotinic acid | WHO Anatomical Therapeutic Chemical classification | | nicotinic acid |
0‑L | C10AD03 | nicofuranose | WHO Anatomical Therapeutic Chemical classification | | nicofuranose |
0‑L | C10AD04 | aluminium nicotinate | WHO Anatomical Therapeutic Chemical classification | | aluminium nicotinate |
0‑L | C10AD05 | nicotinyl alcohol (pyridylcarbinol) | WHO Anatomical Therapeutic Chemical classification | | nicotinyl alcohol (pyridylcarbinol) |
0‑L | C10AD06 | acipimox | WHO Anatomical Therapeutic Chemical classification | | acipimox |
0‑L | C10AD52 | nicotinic acid, combinations | WHO Anatomical Therapeutic Chemical classification | | nicotinic acid, combinations |
0‑L | C10AX | Other lipid modifying agents | WHO Anatomical Therapeutic Chemical classification | | Other lipid modifying agents |
0‑L | C10AX01 | dextrothyroxine | WHO Anatomical Therapeutic Chemical classification | | dextrothyroxine |
0‑L | C10AX02 | probucol | WHO Anatomical Therapeutic Chemical classification | | probucol |
0‑L | C10AX03 | tiadenol | WHO Anatomical Therapeutic Chemical classification | | tiadenol |
0‑L | C10AX05 | meglutol | WHO Anatomical Therapeutic Chemical classification | | meglutol |
0‑L | C10AX06 | omega-3-triglycerides incl. other esters and acids | WHO Anatomical Therapeutic Chemical classification | | omega-3-triglycerides incl. other esters and acids |
0‑L | C10AX07 | magnesium pyridoxal 5-phosphate glutamate | WHO Anatomical Therapeutic Chemical classification | | magnesium pyridoxal 5-phosphate glutamate |
0‑L | C10AX08 | policosanol | WHO Anatomical Therapeutic Chemical classification | | policosanol |
0‑L | C10AX09 | ezetimibe | WHO Anatomical Therapeutic Chemical classification | | ezetimibe |
0‑L | C10AX10 | alipogene tiparvovec | WHO Anatomical Therapeutic Chemical classification | | alipogene tiparvovec |
0‑L | C10AX11 | mipomersen | WHO Anatomical Therapeutic Chemical classification | | mipomersen |
0‑L | C10AX12 | lomitapide | WHO Anatomical Therapeutic Chemical classification | | lomitapide |
0‑L | C10AX13 | evolocumab | WHO Anatomical Therapeutic Chemical classification | | evolocumab |
0‑L | C10AX14 | alirocumab | WHO Anatomical Therapeutic Chemical classification | | alirocumab |
0‑L | C10B | LIPID MODIFYING AGENTS, COMBINATIONS | WHO Anatomical Therapeutic Chemical classification | | LIPID MODIFYING AGENTS, COMBINATIONS |
0‑L | C10BA | HMG CoA reductase inhibitors in combination with other lipid modifying agents | WHO Anatomical Therapeutic Chemical classification | | HMG CoA reductase inhibitors in combination with other lipid modifying agents |
0‑L | C10BA01 | lovastatin and nicotinic acid | WHO Anatomical Therapeutic Chemical classification | | lovastatin and nicotinic acid |
0‑L | C10BA02 | simvastatin and ezetimibe | WHO Anatomical Therapeutic Chemical classification | | simvastatin and ezetimibe |
0‑L | C10BA03 | pravastatin and fenofibrate | WHO Anatomical Therapeutic Chemical classification | | pravastatin and fenofibrate |
0‑L | C10BA04 | simvastatin and fenofibrate | WHO Anatomical Therapeutic Chemical classification | | simvastatin and fenofibrate |
0‑L | C10BA05 | atorvastatin and ezetimibe | WHO Anatomical Therapeutic Chemical classification | | atorvastatin and ezetimibe |
0‑L | C10BA06 | rosuvastatin and ezetimibe | WHO Anatomical Therapeutic Chemical classification | | rosuvastatin and ezetimibe |
0‑L | C10BX | HMG CoA reductase inhibitors, other combinations | WHO Anatomical Therapeutic Chemical classification | | HMG CoA reductase inhibitors, other combinations |
0‑L | C10BX01 | simvastatin and acetylsalicylic acid | WHO Anatomical Therapeutic Chemical classification | | simvastatin and acetylsalicylic acid |
0‑L | C10BX02 | pravastatin and acetylsalicylic acid | WHO Anatomical Therapeutic Chemical classification | | pravastatin and acetylsalicylic acid |
0‑L | C10BX03 | atorvastatin and amlodipine | WHO Anatomical Therapeutic Chemical classification | | atorvastatin and amlodipine |
0‑L | C10BX04 | simvastatin, acetylsalicylic acid and ramipril | WHO Anatomical Therapeutic Chemical classification | | simvastatin, acetylsalicylic acid and ramipril |
0‑L | C10BX05 | rosuvastatin and acetylsalicylic acid | WHO Anatomical Therapeutic Chemical classification | | rosuvastatin and acetylsalicylic acid |
0‑L | C10BX06 | atorvastatin, acetylsalicylic acid and ramipril | WHO Anatomical Therapeutic Chemical classification | | atorvastatin, acetylsalicylic acid and ramipril |
0‑L | C10BX07 | rosuvastatin, amlodipine and lisinopril | WHO Anatomical Therapeutic Chemical classification | | rosuvastatin, amlodipine and lisinopril |
0‑L | C10BX08 | atorvastatin and acetylsalicylic acid | WHO Anatomical Therapeutic Chemical classification | | atorvastatin and acetylsalicylic acid |
0‑L | C10BX09 | rosuvastatin and amlodipine | WHO Anatomical Therapeutic Chemical classification | | rosuvastatin and amlodipine |
0‑L | C10BX10 | rosuvastatin and valsartan | WHO Anatomical Therapeutic Chemical classification | | rosuvastatin and valsartan |
0‑L | C10BX11 | atorvastatin, amlodipine and perindopril | WHO Anatomical Therapeutic Chemical classification | | atorvastatin, amlodipine and perindopril |
0‑L | C10BX12 | atorvastatin, acetylsalicylic acid and perindopril | WHO Anatomical Therapeutic Chemical classification | | atorvastatin, acetylsalicylic acid and perindopril |
0‑L | D | DERMATOLOGICALS | WHO Anatomical Therapeutic Chemical classification | | DERMATOLOGICALS |
0‑L | D01 | ANTIFUNGALS FOR DERMATOLOGICAL USE | WHO Anatomical Therapeutic Chemical classification | | ANTIFUNGALS FOR DERMATOLOGICAL USE |
0‑L | D01A | ANTIFUNGALS FOR TOPICAL USE | WHO Anatomical Therapeutic Chemical classification | | ANTIFUNGALS FOR TOPICAL USE |
0‑L | D01AA | Antibiotics | WHO Anatomical Therapeutic Chemical classification | | Antibiotics |
0‑L | D01AA01 | nystatin | WHO Anatomical Therapeutic Chemical classification | | nystatin |
0‑L | D01AA02 | natamycin | WHO Anatomical Therapeutic Chemical classification | | natamycin |
0‑L | D01AA03 | hachimycin | WHO Anatomical Therapeutic Chemical classification | | hachimycin |
0‑L | D01AA04 | pecilocin | WHO Anatomical Therapeutic Chemical classification | | pecilocin |
0‑L | D01AA06 | mepartricin | WHO Anatomical Therapeutic Chemical classification | | mepartricin |
0‑L | D01AA07 | pyrrolnitrin | WHO Anatomical Therapeutic Chemical classification | | pyrrolnitrin |
0‑L | D01AA08 | griseofulvin | WHO Anatomical Therapeutic Chemical classification | | griseofulvin |
0‑L | D01AA20 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | D01AC | Imidazole and triazole derivatives | WHO Anatomical Therapeutic Chemical classification | | Imidazole and triazole derivatives |
0‑L | D01AC01 | clotrimazole | WHO Anatomical Therapeutic Chemical classification | | clotrimazole |
0‑L | D01AC02 | miconazole | WHO Anatomical Therapeutic Chemical classification | | miconazole |
0‑L | D01AC03 | econazole | WHO Anatomical Therapeutic Chemical classification | | econazole |
0‑L | D01AC04 | chlormidazole | WHO Anatomical Therapeutic Chemical classification | | chlormidazole |
0‑L | D01AC05 | isoconazole | WHO Anatomical Therapeutic Chemical classification | | isoconazole |
0‑L | D01AC06 | tiabendazole | WHO Anatomical Therapeutic Chemical classification | | tiabendazole |
0‑L | D01AC07 | tioconazole | WHO Anatomical Therapeutic Chemical classification | | tioconazole |
0‑L | D01AC08 | ketoconazole | WHO Anatomical Therapeutic Chemical classification | | ketoconazole |
0‑L | D01AC09 | sulconazole | WHO Anatomical Therapeutic Chemical classification | | sulconazole |
0‑L | D01AC10 | bifonazole | WHO Anatomical Therapeutic Chemical classification | | bifonazole |
0‑L | D01AC11 | oxiconazole | WHO Anatomical Therapeutic Chemical classification | | oxiconazole |
0‑L | D01AC12 | fenticonazole | WHO Anatomical Therapeutic Chemical classification | | fenticonazole |
0‑L | D01AC13 | omoconazole | WHO Anatomical Therapeutic Chemical classification | | omoconazole |
0‑L | D01AC14 | sertaconazole | WHO Anatomical Therapeutic Chemical classification | | sertaconazole |
0‑L | D01AC15 | fluconazole | WHO Anatomical Therapeutic Chemical classification | | fluconazole |
0‑L | D01AC16 | flutrimazole | WHO Anatomical Therapeutic Chemical classification | | flutrimazole |
0‑L | D01AC17 | eberconazole | WHO Anatomical Therapeutic Chemical classification | | eberconazole |
0‑L | D01AC18 | luliconazole | WHO Anatomical Therapeutic Chemical classification | | luliconazole |
0‑L | D01AC19 | efinaconazole | WHO Anatomical Therapeutic Chemical classification | | efinaconazole |
0‑L | D01AC20 | imidazoles/triazoles in combination with corticosteroids | WHO Anatomical Therapeutic Chemical classification | | imidazoles/triazoles in combination with corticosteroids |
0‑L | D01AC52 | miconazole, combinations | WHO Anatomical Therapeutic Chemical classification | | miconazole, combinations |
0‑L | D01AC60 | bifonazole, combinations | WHO Anatomical Therapeutic Chemical classification | | bifonazole, combinations |
0‑L | D01AE | Other antifungals for topical use | WHO Anatomical Therapeutic Chemical classification | | Other antifungals for topical use |
0‑L | D01AE01 | bromochlorosalicylanilide | WHO Anatomical Therapeutic Chemical classification | | bromochlorosalicylanilide |
0‑L | D01AE02 | methylrosaniline | WHO Anatomical Therapeutic Chemical classification | | methylrosaniline |
0‑L | D01AE03 | tribromometacresol | WHO Anatomical Therapeutic Chemical classification | | tribromometacresol |
0‑L | D01AE04 | undecylenic acid | WHO Anatomical Therapeutic Chemical classification | | undecylenic acid |
0‑L | D01AE05 | polynoxylin | WHO Anatomical Therapeutic Chemical classification | | polynoxylin |
0‑L | D01AE06 | 2-(4-chlorphenoxy)-ethanol | WHO Anatomical Therapeutic Chemical classification | | 2-(4-chlorphenoxy)-ethanol |
0‑L | D01AE07 | chlorphenesin | WHO Anatomical Therapeutic Chemical classification | | chlorphenesin |
0‑L | D01AE08 | ticlatone | WHO Anatomical Therapeutic Chemical classification | | ticlatone |
0‑L | D01AE09 | sulbentine | WHO Anatomical Therapeutic Chemical classification | | sulbentine |
0‑L | D01AE10 | ethyl hydroxybenzoate | WHO Anatomical Therapeutic Chemical classification | | ethyl hydroxybenzoate |
0‑L | D01AE11 | haloprogin | WHO Anatomical Therapeutic Chemical classification | | haloprogin |
0‑L | D01AE12 | salicylic acid | WHO Anatomical Therapeutic Chemical classification | | salicylic acid |
0‑L | D01AE13 | selenium sulfide | WHO Anatomical Therapeutic Chemical classification | | selenium sulfide |
0‑L | D01AE14 | ciclopirox | WHO Anatomical Therapeutic Chemical classification | | ciclopirox |
0‑L | D01AE15 | terbinafine | WHO Anatomical Therapeutic Chemical classification | | terbinafine |
0‑L | D01AE16 | amorolfine | WHO Anatomical Therapeutic Chemical classification | | amorolfine |
0‑L | D01AE17 | dimazole | WHO Anatomical Therapeutic Chemical classification | | dimazole |
0‑L | D01AE18 | tolnaftate | WHO Anatomical Therapeutic Chemical classification | | tolnaftate |
0‑L | D01AE19 | tolciclate | WHO Anatomical Therapeutic Chemical classification | | tolciclate |
0‑L | D01AE20 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | D01AE21 | flucytosine | WHO Anatomical Therapeutic Chemical classification | | flucytosine |
0‑L | D01AE22 | naftifine | WHO Anatomical Therapeutic Chemical classification | | naftifine |
0‑L | D01AE23 | butenafine | WHO Anatomical Therapeutic Chemical classification | | butenafine |
0‑L | D01AE54 | undecylenic acid, combinations | WHO Anatomical Therapeutic Chemical classification | | undecylenic acid, combinations |
0‑L | D01B | ANTIFUNGALS FOR SYSTEMIC USE | WHO Anatomical Therapeutic Chemical classification | | ANTIFUNGALS FOR SYSTEMIC USE |
0‑L | D01BA | Antifungals for systemic use | WHO Anatomical Therapeutic Chemical classification | | Antifungals for systemic use |
0‑L | D01BA01 | griseofulvin | WHO Anatomical Therapeutic Chemical classification | | griseofulvin |
0‑L | D01BA02 | terbinafine | WHO Anatomical Therapeutic Chemical classification | | terbinafine |
0‑L | D02 | EMOLLIENTS AND PROTECTIVES | WHO Anatomical Therapeutic Chemical classification | | EMOLLIENTS AND PROTECTIVES |
0‑L | D02A | EMOLLIENTS AND PROTECTIVES | WHO Anatomical Therapeutic Chemical classification | | EMOLLIENTS AND PROTECTIVES |
0‑L | D02AA | Silicone products | WHO Anatomical Therapeutic Chemical classification | | Silicone products |
0‑L | D02AB | Zinc products | WHO Anatomical Therapeutic Chemical classification | | Zinc products |
0‑L | D02AC | Soft paraffin and fat products | WHO Anatomical Therapeutic Chemical classification | | Soft paraffin and fat products |
0‑L | D02AD | Liquid plasters | WHO Anatomical Therapeutic Chemical classification | | Liquid plasters |
0‑L | D02AE | Carbamide products | WHO Anatomical Therapeutic Chemical classification | | Carbamide products |
0‑L | D02AE01 | carbamide | WHO Anatomical Therapeutic Chemical classification | | carbamide |
0‑L | D02AE51 | carbamide, combinations | WHO Anatomical Therapeutic Chemical classification | | carbamide, combinations |
0‑L | D02AF | Salicylic acid preparations | WHO Anatomical Therapeutic Chemical classification | | Salicylic acid preparations |
0‑L | D02AX | Other emollients and protectives | WHO Anatomical Therapeutic Chemical classification | | Other emollients and protectives |
0‑L | D02B | PROTECTIVES AGAINST UV-RADIATION | WHO Anatomical Therapeutic Chemical classification | | PROTECTIVES AGAINST UV-RADIATION |
0‑L | D02BA | Protectives against UV-radiation for topical use | WHO Anatomical Therapeutic Chemical classification | | Protectives against UV-radiation for topical use |
0‑L | D02BA01 | aminobenzoic acid | WHO Anatomical Therapeutic Chemical classification | | aminobenzoic acid |
0‑L | D02BA02 | octinoxate | WHO Anatomical Therapeutic Chemical classification | | octinoxate |
0‑L | D02BB | Protectives against UV-radiation for systemic use | WHO Anatomical Therapeutic Chemical classification | | Protectives against UV-radiation for systemic use |
0‑L | D02BB01 | betacarotene | WHO Anatomical Therapeutic Chemical classification | | betacarotene |
0‑L | D02BB02 | afamelanotide | WHO Anatomical Therapeutic Chemical classification | | afamelanotide |
0‑L | D03 | PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS | WHO Anatomical Therapeutic Chemical classification | | PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS |
0‑L | D03A | CICATRIZANTS | WHO Anatomical Therapeutic Chemical classification | | CICATRIZANTS |
0‑L | D03AA | Cod-liver oil ointments | WHO Anatomical Therapeutic Chemical classification | | Cod-liver oil ointments |
0‑L | D03AX | Other cicatrizants | WHO Anatomical Therapeutic Chemical classification | | Other cicatrizants |
0‑L | D03AX01 | cadexomer iodine | WHO Anatomical Therapeutic Chemical classification | | cadexomer iodine |
0‑L | D03AX02 | dextranomer | WHO Anatomical Therapeutic Chemical classification | | dextranomer |
0‑L | D03AX03 | dexpanthenol | WHO Anatomical Therapeutic Chemical classification | | dexpanthenol |
0‑L | D03AX04 | calcium pantothenate | WHO Anatomical Therapeutic Chemical classification | | calcium pantothenate |
0‑L | D03AX05 | hyaluronic acid | WHO Anatomical Therapeutic Chemical classification | | hyaluronic acid |
0‑L | D03AX06 | becaplermin | WHO Anatomical Therapeutic Chemical classification | | becaplermin |
0‑L | D03AX09 | crilanomer | WHO Anatomical Therapeutic Chemical classification | | crilanomer |
0‑L | D03AX10 | enoxolone | WHO Anatomical Therapeutic Chemical classification | | enoxolone |
0‑L | D03AX11 | sodium chlorite | WHO Anatomical Therapeutic Chemical classification | | sodium chlorite |
0‑L | D03AX12 | trolamine | WHO Anatomical Therapeutic Chemical classification | | trolamine |
0‑L | D03AX13 | Betulae cortex | WHO Anatomical Therapeutic Chemical classification | | Betulae cortex |
0‑L | D03B | ENZYMES | WHO Anatomical Therapeutic Chemical classification | | ENZYMES |
0‑L | D03BA | Proteolytic enzymes | WHO Anatomical Therapeutic Chemical classification | | Proteolytic enzymes |
0‑L | D03BA01 | trypsin | WHO Anatomical Therapeutic Chemical classification | | trypsin |
0‑L | D03BA02 | collagenase | WHO Anatomical Therapeutic Chemical classification | | collagenase |
0‑L | D03BA03 | bromelains | WHO Anatomical Therapeutic Chemical classification | | bromelains |
0‑L | D03BA52 | collagenase, combinations | WHO Anatomical Therapeutic Chemical classification | | collagenase, combinations |
0‑L | D04 | ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. | WHO Anatomical Therapeutic Chemical classification | | ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. |
0‑L | D04A | ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. | WHO Anatomical Therapeutic Chemical classification | | ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. |
0‑L | D04AA | Antihistamines for topical use | WHO Anatomical Therapeutic Chemical classification | | Antihistamines for topical use |
0‑L | D04AA01 | thonzylamine | WHO Anatomical Therapeutic Chemical classification | | thonzylamine |
0‑L | D04AA02 | mepyramine | WHO Anatomical Therapeutic Chemical classification | | mepyramine |
0‑L | D04AA03 | thenalidine | WHO Anatomical Therapeutic Chemical classification | | thenalidine |
0‑L | D04AA04 | tripelennamine | WHO Anatomical Therapeutic Chemical classification | | tripelennamine |
0‑L | D04AA09 | chloropyramine | WHO Anatomical Therapeutic Chemical classification | | chloropyramine |
0‑L | D04AA10 | promethazine | WHO Anatomical Therapeutic Chemical classification | | promethazine |
0‑L | D04AA12 | tolpropamine | WHO Anatomical Therapeutic Chemical classification | | tolpropamine |
0‑L | D04AA13 | dimetindene | WHO Anatomical Therapeutic Chemical classification | | dimetindene |
0‑L | D04AA14 | clemastine | WHO Anatomical Therapeutic Chemical classification | | clemastine |
0‑L | D04AA15 | bamipine | WHO Anatomical Therapeutic Chemical classification | | bamipine |
0‑L | D04AA16 | pheniramine | WHO Anatomical Therapeutic Chemical classification | | pheniramine |
0‑L | D04AA22 | isothipendyl | WHO Anatomical Therapeutic Chemical classification | | isothipendyl |
0‑L | D04AA32 | diphenhydramine | WHO Anatomical Therapeutic Chemical classification | | diphenhydramine |
0‑L | D04AA33 | diphenhydramine methylbromide | WHO Anatomical Therapeutic Chemical classification | | diphenhydramine methylbromide |
0‑L | D04AA34 | chlorphenoxamine | WHO Anatomical Therapeutic Chemical classification | | chlorphenoxamine |
0‑L | D04AB | Anesthetics for topical use | WHO Anatomical Therapeutic Chemical classification | | Anesthetics for topical use |
0‑L | D04AB01 | lidocaine | WHO Anatomical Therapeutic Chemical classification | | lidocaine |
0‑L | D04AB02 | cinchocaine | WHO Anatomical Therapeutic Chemical classification | | cinchocaine |
0‑L | D04AB03 | oxybuprocaine | WHO Anatomical Therapeutic Chemical classification | | oxybuprocaine |
0‑L | D04AB04 | benzocaine | WHO Anatomical Therapeutic Chemical classification | | benzocaine |
0‑L | D04AB05 | quinisocaine | WHO Anatomical Therapeutic Chemical classification | | quinisocaine |
0‑L | D04AB06 | tetracaine | WHO Anatomical Therapeutic Chemical classification | | tetracaine |
0‑L | D04AB07 | pramocaine | WHO Anatomical Therapeutic Chemical classification | | pramocaine |
0‑L | D04AX | Other antipruritics | WHO Anatomical Therapeutic Chemical classification | | Other antipruritics |
0‑L | D05 | ANTIPSORIATICS | WHO Anatomical Therapeutic Chemical classification | | ANTIPSORIATICS |
0‑L | D05A | ANTIPSORIATICS FOR TOPICAL USE | WHO Anatomical Therapeutic Chemical classification | | ANTIPSORIATICS FOR TOPICAL USE |
0‑L | D05AA | Tars | WHO Anatomical Therapeutic Chemical classification | | Tars |
0‑L | D05AC | Antracen derivatives | WHO Anatomical Therapeutic Chemical classification | | Antracen derivatives |
0‑L | D05AC01 | dithranol | WHO Anatomical Therapeutic Chemical classification | | dithranol |
0‑L | D05AC51 | dithranol, combinations | WHO Anatomical Therapeutic Chemical classification | | dithranol, combinations |
0‑L | D05AD | Psoralens for topical use | WHO Anatomical Therapeutic Chemical classification | | Psoralens for topical use |
0‑L | D05AD01 | trioxysalen | WHO Anatomical Therapeutic Chemical classification | | trioxysalen |
0‑L | D05AD02 | methoxsalen | WHO Anatomical Therapeutic Chemical classification | | methoxsalen |
0‑L | D05AX | Other antipsoriatics for topical use | WHO Anatomical Therapeutic Chemical classification | | Other antipsoriatics for topical use |
0‑L | D05AX01 | fumaric acid | WHO Anatomical Therapeutic Chemical classification | | fumaric acid |
0‑L | D05AX02 | calcipotriol | WHO Anatomical Therapeutic Chemical classification | | calcipotriol |
0‑L | D05AX03 | calcitriol | WHO Anatomical Therapeutic Chemical classification | | calcitriol |
0‑L | D05AX04 | tacalcitol | WHO Anatomical Therapeutic Chemical classification | | tacalcitol |
0‑L | D05AX05 | tazarotene | WHO Anatomical Therapeutic Chemical classification | | tazarotene |
0‑L | D05AX52 | calcipotriol, combinations | WHO Anatomical Therapeutic Chemical classification | | calcipotriol, combinations |
0‑L | D05B | ANTIPSORIATICS FOR SYSTEMIC USE | WHO Anatomical Therapeutic Chemical classification | | ANTIPSORIATICS FOR SYSTEMIC USE |
0‑L | D05BA | Psoralens for systemic use | WHO Anatomical Therapeutic Chemical classification | | Psoralens for systemic use |
0‑L | D05BA01 | trioxysalen | WHO Anatomical Therapeutic Chemical classification | | trioxysalen |
0‑L | D05BA02 | methoxsalen | WHO Anatomical Therapeutic Chemical classification | | methoxsalen |
0‑L | D05BA03 | bergapten | WHO Anatomical Therapeutic Chemical classification | | bergapten |
0‑L | D05BB | Retinoids for treatment of psoriasis | WHO Anatomical Therapeutic Chemical classification | | Retinoids for treatment of psoriasis |
0‑L | D05BB01 | etretinate | WHO Anatomical Therapeutic Chemical classification | | etretinate |
0‑L | D05BB02 | acitretin | WHO Anatomical Therapeutic Chemical classification | | acitretin |
0‑L | D05BX | Other antipsoriatics for systemic use | WHO Anatomical Therapeutic Chemical classification | | Other antipsoriatics for systemic use |
0‑L | D05BX51 | fumaric acid derivatives, combinations | WHO Anatomical Therapeutic Chemical classification | | fumaric acid derivatives, combinations |
0‑L | D06 | ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE | WHO Anatomical Therapeutic Chemical classification | | ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE |
0‑L | D06A | ANTIBIOTICS FOR TOPICAL USE | WHO Anatomical Therapeutic Chemical classification | | ANTIBIOTICS FOR TOPICAL USE |
0‑L | D06AA | Tetracycline and derivatives | WHO Anatomical Therapeutic Chemical classification | | Tetracycline and derivatives |
0‑L | D06AA01 | demeclocycline | WHO Anatomical Therapeutic Chemical classification | | demeclocycline |
0‑L | D06AA02 | chlortetracycline | WHO Anatomical Therapeutic Chemical classification | | chlortetracycline |
0‑L | D06AA03 | oxytetracycline | WHO Anatomical Therapeutic Chemical classification | | oxytetracycline |
0‑L | D06AA04 | tetracycline | WHO Anatomical Therapeutic Chemical classification | | tetracycline |
0‑L | D06AX | Other antibiotics for topical use | WHO Anatomical Therapeutic Chemical classification | | Other antibiotics for topical use |
0‑L | D06AX01 | fusidic acid | WHO Anatomical Therapeutic Chemical classification | | fusidic acid |
0‑L | D06AX02 | chloramphenicol | WHO Anatomical Therapeutic Chemical classification | | chloramphenicol |
0‑L | D06AX04 | neomycin | WHO Anatomical Therapeutic Chemical classification | | neomycin |
0‑L | D06AX05 | bacitracin | WHO Anatomical Therapeutic Chemical classification | | bacitracin |
0‑L | D06AX07 | gentamicin | WHO Anatomical Therapeutic Chemical classification | | gentamicin |
0‑L | D06AX08 | tyrothricin | WHO Anatomical Therapeutic Chemical classification | | tyrothricin |
0‑L | D06AX09 | mupirocin | WHO Anatomical Therapeutic Chemical classification | | mupirocin |
0‑L | D06AX10 | virginiamycin | WHO Anatomical Therapeutic Chemical classification | | virginiamycin |
0‑L | D06AX11 | rifaximin | WHO Anatomical Therapeutic Chemical classification | | rifaximin |
0‑L | D06AX12 | amikacin | WHO Anatomical Therapeutic Chemical classification | | amikacin |
0‑L | D06AX13 | retapamulin | WHO Anatomical Therapeutic Chemical classification | | retapamulin |
0‑L | D06B | CHEMOTHERAPEUTICS FOR TOPICAL USE | WHO Anatomical Therapeutic Chemical classification | | CHEMOTHERAPEUTICS FOR TOPICAL USE |
0‑L | D06BA | Sulfonamides | WHO Anatomical Therapeutic Chemical classification | | Sulfonamides |
0‑L | D06BA01 | silver sulfadiazine | WHO Anatomical Therapeutic Chemical classification | | silver sulfadiazine |
0‑L | D06BA02 | sulfathiazole | WHO Anatomical Therapeutic Chemical classification | | sulfathiazole |
0‑L | D06BA03 | mafenide | WHO Anatomical Therapeutic Chemical classification | | mafenide |
0‑L | D06BA04 | sulfamethizole | WHO Anatomical Therapeutic Chemical classification | | sulfamethizole |
0‑L | D06BA05 | sulfanilamide | WHO Anatomical Therapeutic Chemical classification | | sulfanilamide |
0‑L | D06BA06 | sulfamerazine | WHO Anatomical Therapeutic Chemical classification | | sulfamerazine |
0‑L | D06BA51 | silver sulfadiazine, combinations | WHO Anatomical Therapeutic Chemical classification | | silver sulfadiazine, combinations |
0‑L | D06BB | Antivirals | WHO Anatomical Therapeutic Chemical classification | | Antivirals |
0‑L | D06BB01 | idoxuridine | WHO Anatomical Therapeutic Chemical classification | | idoxuridine |
0‑L | D06BB02 | tromantadine | WHO Anatomical Therapeutic Chemical classification | | tromantadine |
0‑L | D06BB03 | aciclovir | WHO Anatomical Therapeutic Chemical classification | | aciclovir |
0‑L | D06BB04 | podophyllotoxin | WHO Anatomical Therapeutic Chemical classification | | podophyllotoxin |
0‑L | D06BB05 | inosine | WHO Anatomical Therapeutic Chemical classification | | inosine |
0‑L | D06BB06 | penciclovir | WHO Anatomical Therapeutic Chemical classification | | penciclovir |
0‑L | D06BB07 | lysozyme | WHO Anatomical Therapeutic Chemical classification | | lysozyme |
0‑L | D06BB08 | ibacitabine | WHO Anatomical Therapeutic Chemical classification | | ibacitabine |
0‑L | D06BB09 | edoxudine | WHO Anatomical Therapeutic Chemical classification | | edoxudine |
0‑L | D06BB10 | imiquimod | WHO Anatomical Therapeutic Chemical classification | | imiquimod |
0‑L | D06BB11 | docosanol | WHO Anatomical Therapeutic Chemical classification | | docosanol |
0‑L | D06BB12 | sinecatechins | WHO Anatomical Therapeutic Chemical classification | | sinecatechins |
0‑L | D06BB53 | aciclovir, combinations | WHO Anatomical Therapeutic Chemical classification | | aciclovir, combinations |
0‑L | D06BX | Other chemotherapeutics | WHO Anatomical Therapeutic Chemical classification | | Other chemotherapeutics |
0‑L | D06BX01 | metronidazole | WHO Anatomical Therapeutic Chemical classification | | metronidazole |
0‑L | D06BX02 | ingenol mebutate | WHO Anatomical Therapeutic Chemical classification | | ingenol mebutate |
0‑L | D06C | ANTIBIOTICS AND CHEMOTHERAPEUTICS, COMBINATIONS | WHO Anatomical Therapeutic Chemical classification | | ANTIBIOTICS AND CHEMOTHERAPEUTICS, COMBINATIONS |
0‑L | D07 | CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS | WHO Anatomical Therapeutic Chemical classification | | CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS |
0‑L | D07A | CORTICOSTEROIDS, PLAIN | WHO Anatomical Therapeutic Chemical classification | | CORTICOSTEROIDS, PLAIN |
0‑L | D07AA | Corticosteroids, weak (group I) | WHO Anatomical Therapeutic Chemical classification | | Corticosteroids, weak (group I) |
0‑L | D07AA01 | methylprednisolone | WHO Anatomical Therapeutic Chemical classification | | methylprednisolone |
0‑L | D07AA02 | hydrocortisone | WHO Anatomical Therapeutic Chemical classification | | hydrocortisone |
0‑L | D07AA03 | prednisolone | WHO Anatomical Therapeutic Chemical classification | | prednisolone |
0‑L | D07AB | Corticosteroids, moderately potent (group II) | WHO Anatomical Therapeutic Chemical classification | | Corticosteroids, moderately potent (group II) |
0‑L | D07AB01 | clobetasone | WHO Anatomical Therapeutic Chemical classification | | clobetasone |
0‑L | D07AB02 | hydrocortisone butyrate | WHO Anatomical Therapeutic Chemical classification | | hydrocortisone butyrate |
0‑L | D07AB03 | flumetasone | WHO Anatomical Therapeutic Chemical classification | | flumetasone |
0‑L | D07AB04 | fluocortin | WHO Anatomical Therapeutic Chemical classification | | fluocortin |
0‑L | D07AB05 | fluperolone | WHO Anatomical Therapeutic Chemical classification | | fluperolone |
0‑L | D07AB06 | fluorometholone | WHO Anatomical Therapeutic Chemical classification | | fluorometholone |
0‑L | D07AB07 | fluprednidene | WHO Anatomical Therapeutic Chemical classification | | fluprednidene |
0‑L | D07AB08 | desonide | WHO Anatomical Therapeutic Chemical classification | | desonide |
0‑L | D07AB09 | triamcinolone | WHO Anatomical Therapeutic Chemical classification | | triamcinolone |
0‑L | D07AB10 | alclometasone | WHO Anatomical Therapeutic Chemical classification | | alclometasone |
0‑L | D07AB11 | hydrocortisone buteprate | WHO Anatomical Therapeutic Chemical classification | | hydrocortisone buteprate |
0‑L | D07AB19 | dexamethasone | WHO Anatomical Therapeutic Chemical classification | | dexamethasone |
0‑L | D07AB21 | clocortolone | WHO Anatomical Therapeutic Chemical classification | | clocortolone |
0‑L | D07AB30 | combinations of corticosteroids | WHO Anatomical Therapeutic Chemical classification | | combinations of corticosteroids |
0‑L | D07AC | Corticosteroids, potent (group III) | WHO Anatomical Therapeutic Chemical classification | | Corticosteroids, potent (group III) |
0‑L | D07AC01 | betamethasone | WHO Anatomical Therapeutic Chemical classification | | betamethasone |
0‑L | D07AC02 | fluclorolone | WHO Anatomical Therapeutic Chemical classification | | fluclorolone |
0‑L | D07AC03 | desoximetasone | WHO Anatomical Therapeutic Chemical classification | | desoximetasone |
0‑L | D07AC04 | fluocinolone acetonide | WHO Anatomical Therapeutic Chemical classification | | fluocinolone acetonide |
0‑L | D07AC05 | fluocortolone | WHO Anatomical Therapeutic Chemical classification | | fluocortolone |
0‑L | D07AC06 | diflucortolone | WHO Anatomical Therapeutic Chemical classification | | diflucortolone |
0‑L | D07AC07 | fludroxycortide | WHO Anatomical Therapeutic Chemical classification | | fludroxycortide |
0‑L | D07AC08 | fluocinonide | WHO Anatomical Therapeutic Chemical classification | | fluocinonide |
0‑L | D07AC09 | budesonide | WHO Anatomical Therapeutic Chemical classification | | budesonide |
0‑L | D07AC10 | diflorasone | WHO Anatomical Therapeutic Chemical classification | | diflorasone |
0‑L | D07AC11 | amcinonide | WHO Anatomical Therapeutic Chemical classification | | amcinonide |
0‑L | D07AC12 | halometasone | WHO Anatomical Therapeutic Chemical classification | | halometasone |
0‑L | D07AC13 | mometasone | WHO Anatomical Therapeutic Chemical classification | | mometasone |
0‑L | D07AC14 | methylprednisolone aceponate | WHO Anatomical Therapeutic Chemical classification | | methylprednisolone aceponate |
0‑L | D07AC15 | beclometasone | WHO Anatomical Therapeutic Chemical classification | | beclometasone |
0‑L | D07AC16 | hydrocortisone aceponate | WHO Anatomical Therapeutic Chemical classification | | hydrocortisone aceponate |
0‑L | D07AC17 | fluticasone | WHO Anatomical Therapeutic Chemical classification | | fluticasone |
0‑L | D07AC18 | prednicarbate | WHO Anatomical Therapeutic Chemical classification | | prednicarbate |
0‑L | D07AC19 | difluprednate | WHO Anatomical Therapeutic Chemical classification | | difluprednate |
0‑L | D07AC21 | ulobetasol | WHO Anatomical Therapeutic Chemical classification | | ulobetasol |
0‑L | D07AD | Corticosteroids, very potent (group IV) | WHO Anatomical Therapeutic Chemical classification | | Corticosteroids, very potent (group IV) |
0‑L | D07AD01 | clobetasol | WHO Anatomical Therapeutic Chemical classification | | clobetasol |
0‑L | D07AD02 | halcinonide | WHO Anatomical Therapeutic Chemical classification | | halcinonide |
0‑L | D07B | CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS | WHO Anatomical Therapeutic Chemical classification | | CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS |
0‑L | D07BA | Corticosteroids, weak, combinations with antiseptics | WHO Anatomical Therapeutic Chemical classification | | Corticosteroids, weak, combinations with antiseptics |
0‑L | D07BA01 | prednisolone and antiseptics | WHO Anatomical Therapeutic Chemical classification | | prednisolone and antiseptics |
0‑L | D07BA04 | hydrocortisone and antiseptics | WHO Anatomical Therapeutic Chemical classification | | hydrocortisone and antiseptics |
0‑L | D07BB | Corticosteroids, moderately potent, combinations with antiseptics | WHO Anatomical Therapeutic Chemical classification | | Corticosteroids, moderately potent, combinations with antiseptics |
0‑L | D07BB01 | flumetasone and antiseptics | WHO Anatomical Therapeutic Chemical classification | | flumetasone and antiseptics |
0‑L | D07BB02 | desonide and antiseptics | WHO Anatomical Therapeutic Chemical classification | | desonide and antiseptics |
0‑L | D07BB03 | triamcinolone and antiseptics | WHO Anatomical Therapeutic Chemical classification | | triamcinolone and antiseptics |
0‑L | D07BB04 | hydrocortisone butyrate and antiseptics | WHO Anatomical Therapeutic Chemical classification | | hydrocortisone butyrate and antiseptics |
0‑L | D07BC | Corticosteroids, potent, combinations with antiseptics | WHO Anatomical Therapeutic Chemical classification | | Corticosteroids, potent, combinations with antiseptics |
0‑L | D07BC01 | betamethasone and antiseptics | WHO Anatomical Therapeutic Chemical classification | | betamethasone and antiseptics |
0‑L | D07BC02 | fluocinolone acetonide and antiseptics | WHO Anatomical Therapeutic Chemical classification | | fluocinolone acetonide and antiseptics |
0‑L | D07BC03 | fluocortolone and antiseptics | WHO Anatomical Therapeutic Chemical classification | | fluocortolone and antiseptics |
0‑L | D07BC04 | diflucortolone and antiseptics | WHO Anatomical Therapeutic Chemical classification | | diflucortolone and antiseptics |
0‑L | D07BD | Corticosteroids, very potent, combinations with antiseptics | WHO Anatomical Therapeutic Chemical classification | | Corticosteroids, very potent, combinations with antiseptics |
0‑L | D07C | CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS | WHO Anatomical Therapeutic Chemical classification | | CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS |
0‑L | D07CA | Corticosteroids, weak, combinations with antibiotics | WHO Anatomical Therapeutic Chemical classification | | Corticosteroids, weak, combinations with antibiotics |
0‑L | D07CA01 | hydrocortisone and antibiotics | WHO Anatomical Therapeutic Chemical classification | | hydrocortisone and antibiotics |
0‑L | D07CA02 | methylprednisolone and antibiotics | WHO Anatomical Therapeutic Chemical classification | | methylprednisolone and antibiotics |
0‑L | D07CA03 | prednisolone and antibiotics | WHO Anatomical Therapeutic Chemical classification | | prednisolone and antibiotics |
0‑L | D07CB | Corticosteroids, moderately potent, combinations with antibiotics | WHO Anatomical Therapeutic Chemical classification | | Corticosteroids, moderately potent, combinations with antibiotics |
0‑L | D07CB01 | triamcinolone and antibiotics | WHO Anatomical Therapeutic Chemical classification | | triamcinolone and antibiotics |
0‑L | D07CB02 | fluprednidene and antibiotics | WHO Anatomical Therapeutic Chemical classification | | fluprednidene and antibiotics |
0‑L | D07CB03 | fluorometholone and antibiotics | WHO Anatomical Therapeutic Chemical classification | | fluorometholone and antibiotics |
0‑L | D07CB04 | dexamethasone and antibiotics | WHO Anatomical Therapeutic Chemical classification | | dexamethasone and antibiotics |
0‑L | D07CB05 | flumetasone and antibiotics | WHO Anatomical Therapeutic Chemical classification | | flumetasone and antibiotics |
0‑L | D07CC | Corticosteroids, potent, combinations with antibiotics | WHO Anatomical Therapeutic Chemical classification | | Corticosteroids, potent, combinations with antibiotics |
0‑L | D07CC01 | betamethasone and antibiotics | WHO Anatomical Therapeutic Chemical classification | | betamethasone and antibiotics |
0‑L | D07CC02 | fluocinolone acetonide and antibiotics | WHO Anatomical Therapeutic Chemical classification | | fluocinolone acetonide and antibiotics |
0‑L | D07CC03 | fludroxycortide and antibiotics | WHO Anatomical Therapeutic Chemical classification | | fludroxycortide and antibiotics |
0‑L | D07CC04 | beclometasone and antibiotics | WHO Anatomical Therapeutic Chemical classification | | beclometasone and antibiotics |
0‑L | D07CC05 | fluocinonide and antibiotics | WHO Anatomical Therapeutic Chemical classification | | fluocinonide and antibiotics |
0‑L | D07CC06 | fluocortolone and antibiotics | WHO Anatomical Therapeutic Chemical classification | | fluocortolone and antibiotics |
0‑L | D07CD | Corticosteroids, very potent, combinations with antibiotics | WHO Anatomical Therapeutic Chemical classification | | Corticosteroids, very potent, combinations with antibiotics |
0‑L | D07CD01 | clobetasol and antibiotics | WHO Anatomical Therapeutic Chemical classification | | clobetasol and antibiotics |
0‑L | D07X | CORTICOSTEROIDS, OTHER COMBINATIONS | WHO Anatomical Therapeutic Chemical classification | | CORTICOSTEROIDS, OTHER COMBINATIONS |
0‑L | D07XA | Corticosteroids, weak, other combinations | WHO Anatomical Therapeutic Chemical classification | | Corticosteroids, weak, other combinations |
0‑L | D07XA01 | hydrocortisone | WHO Anatomical Therapeutic Chemical classification | | hydrocortisone |
0‑L | D07XA02 | prednisolone | WHO Anatomical Therapeutic Chemical classification | | prednisolone |
0‑L | D07XB | Corticosteroids, moderately potent, other combinations | WHO Anatomical Therapeutic Chemical classification | | Corticosteroids, moderately potent, other combinations |
0‑L | D07XB01 | flumetasone | WHO Anatomical Therapeutic Chemical classification | | flumetasone |
0‑L | D07XB02 | triamcinolone | WHO Anatomical Therapeutic Chemical classification | | triamcinolone |
0‑L | D07XB03 | fluprednidene | WHO Anatomical Therapeutic Chemical classification | | fluprednidene |
0‑L | D07XB04 | fluorometholone | WHO Anatomical Therapeutic Chemical classification | | fluorometholone |
0‑L | D07XB05 | dexamethasone | WHO Anatomical Therapeutic Chemical classification | | dexamethasone |
0‑L | D07XB30 | combinations of corticosteroids | WHO Anatomical Therapeutic Chemical classification | | combinations of corticosteroids |
0‑L | D07XC | Corticosteroids, potent, other combinations | WHO Anatomical Therapeutic Chemical classification | | Corticosteroids, potent, other combinations |
0‑L | D07XC01 | betamethasone | WHO Anatomical Therapeutic Chemical classification | | betamethasone |
0‑L | D07XC02 | desoximetasone | WHO Anatomical Therapeutic Chemical classification | | desoximetasone |
0‑L | D07XC03 | mometasone | WHO Anatomical Therapeutic Chemical classification | | mometasone |
0‑L | D07XC04 | diflucortolone | WHO Anatomical Therapeutic Chemical classification | | diflucortolone |
0‑L | D07XC05 | fluocortolone | WHO Anatomical Therapeutic Chemical classification | | fluocortolone |
0‑L | D07XD | Corticosteroids, very potent, other combinations | WHO Anatomical Therapeutic Chemical classification | | Corticosteroids, very potent, other combinations |
0‑L | D08 | ANTISEPTICS AND DISINFECTANTS | WHO Anatomical Therapeutic Chemical classification | | ANTISEPTICS AND DISINFECTANTS |
0‑L | D08A | ANTISEPTICS AND DISINFECTANTS | WHO Anatomical Therapeutic Chemical classification | | ANTISEPTICS AND DISINFECTANTS |
0‑L | D08AA | Acridine derivatives | WHO Anatomical Therapeutic Chemical classification | | Acridine derivatives |
0‑L | D08AA01 | ethacridine lactate | WHO Anatomical Therapeutic Chemical classification | | ethacridine lactate |
0‑L | D08AA02 | aminoacridine | WHO Anatomical Therapeutic Chemical classification | | aminoacridine |
0‑L | D08AA03 | euflavine | WHO Anatomical Therapeutic Chemical classification | | euflavine |
0‑L | D08AB | Aluminium agents | WHO Anatomical Therapeutic Chemical classification | | Aluminium agents |
0‑L | D08AC | Biguanides and amidines | WHO Anatomical Therapeutic Chemical classification | | Biguanides and amidines |
0‑L | D08AC01 | dibrompropamidine | WHO Anatomical Therapeutic Chemical classification | | dibrompropamidine |
0‑L | D08AC02 | chlorhexidine | WHO Anatomical Therapeutic Chemical classification | | chlorhexidine |
0‑L | D08AC03 | propamidine | WHO Anatomical Therapeutic Chemical classification | | propamidine |
0‑L | D08AC04 | hexamidine | WHO Anatomical Therapeutic Chemical classification | | hexamidine |
0‑L | D08AC05 | polihexanide | WHO Anatomical Therapeutic Chemical classification | | polihexanide |
0‑L | D08AC52 | chlorhexidine, combinations | WHO Anatomical Therapeutic Chemical classification | | chlorhexidine, combinations |
0‑L | D08AD | Boric acid products | WHO Anatomical Therapeutic Chemical classification | | Boric acid products |
0‑L | D08AE | Phenol and derivatives | WHO Anatomical Therapeutic Chemical classification | | Phenol and derivatives |
0‑L | D08AE01 | hexachlorophene | WHO Anatomical Therapeutic Chemical classification | | hexachlorophene |
0‑L | D08AE02 | policresulen | WHO Anatomical Therapeutic Chemical classification | | policresulen |
0‑L | D08AE03 | phenol | WHO Anatomical Therapeutic Chemical classification | | phenol |
0‑L | D08AE04 | triclosan | WHO Anatomical Therapeutic Chemical classification | | triclosan |
0‑L | D08AE05 | chloroxylenol | WHO Anatomical Therapeutic Chemical classification | | chloroxylenol |
0‑L | D08AE06 | biphenylol | WHO Anatomical Therapeutic Chemical classification | | biphenylol |
0‑L | D08AF | Nitrofuran derivatives | WHO Anatomical Therapeutic Chemical classification | | Nitrofuran derivatives |
0‑L | D08AF01 | nitrofural | WHO Anatomical Therapeutic Chemical classification | | nitrofural |
0‑L | D08AG | Iodine products | WHO Anatomical Therapeutic Chemical classification | | Iodine products |
0‑L | D08AG01 | iodine/octylphenoxypolyglycolether | WHO Anatomical Therapeutic Chemical classification | | iodine/octylphenoxypolyglycolether |
0‑L | D08AG02 | povidone-iodine | WHO Anatomical Therapeutic Chemical classification | | povidone-iodine |
0‑L | D08AG03 | iodine | WHO Anatomical Therapeutic Chemical classification | | iodine |
0‑L | D08AG04 | diiodohydroxypropane | WHO Anatomical Therapeutic Chemical classification | | diiodohydroxypropane |
0‑L | D08AH | Quinoline derivatives | WHO Anatomical Therapeutic Chemical classification | | Quinoline derivatives |
0‑L | D08AH01 | dequalinium | WHO Anatomical Therapeutic Chemical classification | | dequalinium |
0‑L | D08AH02 | chlorquinaldol | WHO Anatomical Therapeutic Chemical classification | | chlorquinaldol |
0‑L | D08AH03 | oxyquinoline | WHO Anatomical Therapeutic Chemical classification | | oxyquinoline |
0‑L | D08AH30 | clioquinol | WHO Anatomical Therapeutic Chemical classification | | clioquinol |
0‑L | D08AJ | Quaternary ammonium compounds | WHO Anatomical Therapeutic Chemical classification | | Quaternary ammonium compounds |
0‑L | D08AJ01 | benzalkonium | WHO Anatomical Therapeutic Chemical classification | | benzalkonium |
0‑L | D08AJ02 | cetrimonium | WHO Anatomical Therapeutic Chemical classification | | cetrimonium |
0‑L | D08AJ03 | cetylpyridinium | WHO Anatomical Therapeutic Chemical classification | | cetylpyridinium |
0‑L | D08AJ04 | cetrimide | WHO Anatomical Therapeutic Chemical classification | | cetrimide |
0‑L | D08AJ05 | benzoxonium chloride | WHO Anatomical Therapeutic Chemical classification | | benzoxonium chloride |
0‑L | D08AJ06 | didecyldimethylammonium chloride | WHO Anatomical Therapeutic Chemical classification | | didecyldimethylammonium chloride |
0‑L | D08AJ08 | benzethonium chloride | WHO Anatomical Therapeutic Chemical classification | | benzethonium chloride |
0‑L | D08AJ10 | decamethoxine | WHO Anatomical Therapeutic Chemical classification | | decamethoxine |
0‑L | D08AJ57 | octenidine, combinations | WHO Anatomical Therapeutic Chemical classification | | octenidine, combinations |
0‑L | D08AJ58 | benzethonium chloride, combinations | WHO Anatomical Therapeutic Chemical classification | | benzethonium chloride, combinations |
0‑L | D08AJ59 | dodeclonium bromide, combinations | WHO Anatomical Therapeutic Chemical classification | | dodeclonium bromide, combinations |
0‑L | D08AK | Mercurial products | WHO Anatomical Therapeutic Chemical classification | | Mercurial products |
0‑L | D08AK01 | mercuric amidochloride | WHO Anatomical Therapeutic Chemical classification | | mercuric amidochloride |
0‑L | D08AK02 | phenylmercuric borate | WHO Anatomical Therapeutic Chemical classification | | phenylmercuric borate |
0‑L | D08AK03 | mercuric chloride | WHO Anatomical Therapeutic Chemical classification | | mercuric chloride |
0‑L | D08AK04 | mercurochrome | WHO Anatomical Therapeutic Chemical classification | | mercurochrome |
0‑L | D08AK05 | mercury, metallic | WHO Anatomical Therapeutic Chemical classification | | mercury, metallic |
0‑L | D08AK06 | thiomersal | WHO Anatomical Therapeutic Chemical classification | | thiomersal |
0‑L | D08AK30 | mercuric iodide | WHO Anatomical Therapeutic Chemical classification | | mercuric iodide |
0‑L | D08AL | Silver compounds | WHO Anatomical Therapeutic Chemical classification | | Silver compounds |
0‑L | D08AL01 | silver nitrate | WHO Anatomical Therapeutic Chemical classification | | silver nitrate |
0‑L | D08AL30 | silver | WHO Anatomical Therapeutic Chemical classification | | silver |
0‑L | D08AX | Other antiseptics and disinfectants | WHO Anatomical Therapeutic Chemical classification | | Other antiseptics and disinfectants |
0‑L | D08AX01 | hydrogen peroxide | WHO Anatomical Therapeutic Chemical classification | | hydrogen peroxide |
0‑L | D08AX02 | eosin | WHO Anatomical Therapeutic Chemical classification | | eosin |
0‑L | D08AX03 | propanol | WHO Anatomical Therapeutic Chemical classification | | propanol |
0‑L | D08AX04 | tosylchloramide sodium | WHO Anatomical Therapeutic Chemical classification | | tosylchloramide sodium |
0‑L | D08AX05 | isopropanol | WHO Anatomical Therapeutic Chemical classification | | isopropanol |
0‑L | D08AX06 | potassium permanganate | WHO Anatomical Therapeutic Chemical classification | | potassium permanganate |
0‑L | D08AX07 | sodium hypochlorite | WHO Anatomical Therapeutic Chemical classification | | sodium hypochlorite |
0‑L | D08AX08 | ethanol | WHO Anatomical Therapeutic Chemical classification | | ethanol |
0‑L | D08AX53 | propanol, combinations | WHO Anatomical Therapeutic Chemical classification | | propanol, combinations |
0‑L | D09 | MEDICATED DRESSINGS | WHO Anatomical Therapeutic Chemical classification | | MEDICATED DRESSINGS |
0‑L | D09A | MEDICATED DRESSINGS | WHO Anatomical Therapeutic Chemical classification | | MEDICATED DRESSINGS |
0‑L | D09AA | Medicated dressings with antiinfectives | WHO Anatomical Therapeutic Chemical classification | | Medicated dressings with antiinfectives |
0‑L | D09AA01 | framycetin | WHO Anatomical Therapeutic Chemical classification | | framycetin |
0‑L | D09AA02 | fusidic acid | WHO Anatomical Therapeutic Chemical classification | | fusidic acid |
0‑L | D09AA03 | nitrofural | WHO Anatomical Therapeutic Chemical classification | | nitrofural |
0‑L | D09AA04 | phenylmercuric nitrate | WHO Anatomical Therapeutic Chemical classification | | phenylmercuric nitrate |
0‑L | D09AA05 | benzododecinium | WHO Anatomical Therapeutic Chemical classification | | benzododecinium |
0‑L | D09AA06 | triclosan | WHO Anatomical Therapeutic Chemical classification | | triclosan |
0‑L | D09AA07 | cetylpyridinium | WHO Anatomical Therapeutic Chemical classification | | cetylpyridinium |
0‑L | D09AA08 | aluminium chlorohydrate | WHO Anatomical Therapeutic Chemical classification | | aluminium chlorohydrate |
0‑L | D09AA09 | povidone-iodine | WHO Anatomical Therapeutic Chemical classification | | povidone-iodine |
0‑L | D09AA10 | clioquinol | WHO Anatomical Therapeutic Chemical classification | | clioquinol |
0‑L | D09AA11 | benzalkonium | WHO Anatomical Therapeutic Chemical classification | | benzalkonium |
0‑L | D09AA12 | chlorhexidine | WHO Anatomical Therapeutic Chemical classification | | chlorhexidine |
0‑L | D09AA13 | iodoform | WHO Anatomical Therapeutic Chemical classification | | iodoform |
0‑L | D09AB | Zinc bandages | WHO Anatomical Therapeutic Chemical classification | | Zinc bandages |
0‑L | D09AB01 | zinc bandage without supplements | WHO Anatomical Therapeutic Chemical classification | | zinc bandage without supplements |
0‑L | D09AB02 | zinc bandage with supplements | WHO Anatomical Therapeutic Chemical classification | | zinc bandage with supplements |
0‑L | D09AX | Soft paraffin dressings | WHO Anatomical Therapeutic Chemical classification | | Soft paraffin dressings |
0‑L | D10 | ANTI-ACNE PREPARATIONS | WHO Anatomical Therapeutic Chemical classification | | ANTI-ACNE PREPARATIONS |
0‑L | D10A | ANTI-ACNE PREPARATIONS FOR TOPICAL USE | WHO Anatomical Therapeutic Chemical classification | | ANTI-ACNE PREPARATIONS FOR TOPICAL USE |
0‑L | D10AA | Corticosteroids, combinations for treatment of acne | WHO Anatomical Therapeutic Chemical classification | | Corticosteroids, combinations for treatment of acne |
0‑L | D10AA01 | fluorometholone | WHO Anatomical Therapeutic Chemical classification | | fluorometholone |
0‑L | D10AA02 | methylprednisolone | WHO Anatomical Therapeutic Chemical classification | | methylprednisolone |
0‑L | D10AA03 | dexamethasone | WHO Anatomical Therapeutic Chemical classification | | dexamethasone |
0‑L | D10AB | Preparations containing sulfur | WHO Anatomical Therapeutic Chemical classification | | Preparations containing sulfur |
0‑L | D10AB01 | bithionol | WHO Anatomical Therapeutic Chemical classification | | bithionol |
0‑L | D10AB02 | sulfur | WHO Anatomical Therapeutic Chemical classification | | sulfur |
0‑L | D10AB03 | tioxolone | WHO Anatomical Therapeutic Chemical classification | | tioxolone |
0‑L | D10AB05 | mesulfen | WHO Anatomical Therapeutic Chemical classification | | mesulfen |
0‑L | D10AD | Retinoids for topical use in acne | WHO Anatomical Therapeutic Chemical classification | | Retinoids for topical use in acne |
0‑L | D10AD01 | tretinoin | WHO Anatomical Therapeutic Chemical classification | | tretinoin |
0‑L | D10AD02 | retinol | WHO Anatomical Therapeutic Chemical classification | | retinol |
0‑L | D10AD03 | adapalene | WHO Anatomical Therapeutic Chemical classification | | adapalene |
0‑L | D10AD04 | isotretinoin | WHO Anatomical Therapeutic Chemical classification | | isotretinoin |
0‑L | D10AD05 | motretinide | WHO Anatomical Therapeutic Chemical classification | | motretinide |
0‑L | D10AD51 | tretinoin, combinations | WHO Anatomical Therapeutic Chemical classification | | tretinoin, combinations |
0‑L | D10AD53 | adapalene, combinations | WHO Anatomical Therapeutic Chemical classification | | adapalene, combinations |
0‑L | D10AD54 | isotretinoin, combinations | WHO Anatomical Therapeutic Chemical classification | | isotretinoin, combinations |
0‑L | D10AE | Peroxides | WHO Anatomical Therapeutic Chemical classification | | Peroxides |
0‑L | D10AE01 | benzoyl peroxide | WHO Anatomical Therapeutic Chemical classification | | benzoyl peroxide |
0‑L | D10AE51 | benzoyl peroxide, combinations | WHO Anatomical Therapeutic Chemical classification | | benzoyl peroxide, combinations |
0‑L | D10AF | Antiinfectives for treatment of acne | WHO Anatomical Therapeutic Chemical classification | | Antiinfectives for treatment of acne |
0‑L | D10AF01 | clindamycin | WHO Anatomical Therapeutic Chemical classification | | clindamycin |
0‑L | D10AF02 | erythromycin | WHO Anatomical Therapeutic Chemical classification | | erythromycin |
0‑L | D10AF03 | chloramphenicol | WHO Anatomical Therapeutic Chemical classification | | chloramphenicol |
0‑L | D10AF04 | meclocycline | WHO Anatomical Therapeutic Chemical classification | | meclocycline |
0‑L | D10AF05 | nadifloxacin | WHO Anatomical Therapeutic Chemical classification | | nadifloxacin |
0‑L | D10AF06 | sulfacetamide | WHO Anatomical Therapeutic Chemical classification | | sulfacetamide |
0‑L | D10AF51 | clindamycin, combinations | WHO Anatomical Therapeutic Chemical classification | | clindamycin, combinations |
0‑L | D10AF52 | erythromycin, combinations | WHO Anatomical Therapeutic Chemical classification | | erythromycin, combinations |
0‑L | D10AX | Other anti-acne preparations for topical use | WHO Anatomical Therapeutic Chemical classification | | Other anti-acne preparations for topical use |
0‑L | D10AX01 | aluminium chloride | WHO Anatomical Therapeutic Chemical classification | | aluminium chloride |
0‑L | D10AX02 | resorcinol | WHO Anatomical Therapeutic Chemical classification | | resorcinol |
0‑L | D10AX03 | azelaic acid | WHO Anatomical Therapeutic Chemical classification | | azelaic acid |
0‑L | D10AX04 | aluminium oxide | WHO Anatomical Therapeutic Chemical classification | | aluminium oxide |
0‑L | D10AX05 | dapsone | WHO Anatomical Therapeutic Chemical classification | | dapsone |
0‑L | D10AX30 | various combinations | WHO Anatomical Therapeutic Chemical classification | | various combinations |
0‑L | D10B | ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE | WHO Anatomical Therapeutic Chemical classification | | ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE |
0‑L | D10BA | Retinoids for treatment of acne | WHO Anatomical Therapeutic Chemical classification | | Retinoids for treatment of acne |
0‑L | D10BA01 | isotretinoin | WHO Anatomical Therapeutic Chemical classification | | isotretinoin |
0‑L | D10BX | Other anti-acne preparations for systemic use | WHO Anatomical Therapeutic Chemical classification | | Other anti-acne preparations for systemic use |
0‑L | D10BX01 | ichtasol | WHO Anatomical Therapeutic Chemical classification | | ichtasol |
0‑L | D11 | OTHER DERMATOLOGICAL PREPARATIONS | WHO Anatomical Therapeutic Chemical classification | | OTHER DERMATOLOGICAL PREPARATIONS |
0‑L | D11A | OTHER DERMATOLOGICAL PREPARATIONS | WHO Anatomical Therapeutic Chemical classification | | OTHER DERMATOLOGICAL PREPARATIONS |
0‑L | D11AA | Antihidrotics | WHO Anatomical Therapeutic Chemical classification | | Antihidrotics |
0‑L | D11AC | Medicated shampoos | WHO Anatomical Therapeutic Chemical classification | | Medicated shampoos |
0‑L | D11AC01 | cetrimide | WHO Anatomical Therapeutic Chemical classification | | cetrimide |
0‑L | D11AC02 | cadmium compounds | WHO Anatomical Therapeutic Chemical classification | | cadmium compounds |
0‑L | D11AC03 | selenium compounds | WHO Anatomical Therapeutic Chemical classification | | selenium compounds |
0‑L | D11AC06 | povidone-iodine | WHO Anatomical Therapeutic Chemical classification | | povidone-iodine |
0‑L | D11AC08 | sulfur compounds | WHO Anatomical Therapeutic Chemical classification | | sulfur compounds |
0‑L | D11AC09 | xenysalate | WHO Anatomical Therapeutic Chemical classification | | xenysalate |
0‑L | D11AC30 | others | WHO Anatomical Therapeutic Chemical classification | | others |
0‑L | D11AE | Androgens for topical use | WHO Anatomical Therapeutic Chemical classification | | Androgens for topical use |
0‑L | D11AE01 | metandienone | WHO Anatomical Therapeutic Chemical classification | | metandienone |
0‑L | D11AF | Wart and anti-corn preparations | WHO Anatomical Therapeutic Chemical classification | | Wart and anti-corn preparations |
0‑L | D11AH | Agents for dermatitis, excluding corticosteroids | WHO Anatomical Therapeutic Chemical classification | | Agents for dermatitis, excluding corticosteroids |
0‑L | D11AH01 | tacrolimus | WHO Anatomical Therapeutic Chemical classification | | tacrolimus |
0‑L | D11AH02 | pimecrolimus | WHO Anatomical Therapeutic Chemical classification | | pimecrolimus |
0‑L | D11AH03 | cromoglicic acid | WHO Anatomical Therapeutic Chemical classification | | cromoglicic acid |
0‑L | D11AH04 | alitretinoin | WHO Anatomical Therapeutic Chemical classification | | alitretinoin |
0‑L | D11AX | Other dermatologicals | WHO Anatomical Therapeutic Chemical classification | | Other dermatologicals |
0‑L | D11AX01 | minoxidil | WHO Anatomical Therapeutic Chemical classification | | minoxidil |
0‑L | D11AX02 | gamolenic acid | WHO Anatomical Therapeutic Chemical classification | | gamolenic acid |
0‑L | D11AX03 | calcium gluconate | WHO Anatomical Therapeutic Chemical classification | | calcium gluconate |
0‑L | D11AX04 | lithium succinate | WHO Anatomical Therapeutic Chemical classification | | lithium succinate |
0‑L | D11AX05 | magnesium sulfate | WHO Anatomical Therapeutic Chemical classification | | magnesium sulfate |
0‑L | D11AX06 | mequinol | WHO Anatomical Therapeutic Chemical classification | | mequinol |
0‑L | D11AX08 | tiratricol | WHO Anatomical Therapeutic Chemical classification | | tiratricol |
0‑L | D11AX09 | oxaceprol | WHO Anatomical Therapeutic Chemical classification | | oxaceprol |
0‑L | D11AX10 | finasteride | WHO Anatomical Therapeutic Chemical classification | | finasteride |
0‑L | D11AX11 | hydroquinone | WHO Anatomical Therapeutic Chemical classification | | hydroquinone |
0‑L | D11AX12 | pyrithione zinc | WHO Anatomical Therapeutic Chemical classification | | pyrithione zinc |
0‑L | D11AX13 | monobenzone | WHO Anatomical Therapeutic Chemical classification | | monobenzone |
0‑L | D11AX16 | eflornithine | WHO Anatomical Therapeutic Chemical classification | | eflornithine |
0‑L | D11AX18 | diclofenac | WHO Anatomical Therapeutic Chemical classification | | diclofenac |
0‑L | D11AX21 | brimonidine | WHO Anatomical Therapeutic Chemical classification | | brimonidine |
0‑L | D11AX22 | ivermectin | WHO Anatomical Therapeutic Chemical classification | | ivermectin |
0‑L | D11AX23 | aminobenzoate potassium | WHO Anatomical Therapeutic Chemical classification | | aminobenzoate potassium |
0‑L | D11AX24 | deoxycholic acid | WHO Anatomical Therapeutic Chemical classification | | deoxycholic acid |
0‑L | D11AX52 | gamolenic acid, combinations | WHO Anatomical Therapeutic Chemical classification | | gamolenic acid, combinations |
0‑L | D11AX57 | collagen, combinations | WHO Anatomical Therapeutic Chemical classification | | collagen, combinations |
0‑L | G | GENITO URINARY SYSTEM AND SEX HORMONES | WHO Anatomical Therapeutic Chemical classification | | GENITO URINARY SYSTEM AND SEX HORMONES |
0‑L | G01 | GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS | WHO Anatomical Therapeutic Chemical classification | | GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS |
0‑L | G01A | ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS | WHO Anatomical Therapeutic Chemical classification | | ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS |
0‑L | G01AA | Antibiotics | WHO Anatomical Therapeutic Chemical classification | | Antibiotics |
0‑L | G01AA01 | nystatin | WHO Anatomical Therapeutic Chemical classification | | nystatin |
0‑L | G01AA02 | natamycin | WHO Anatomical Therapeutic Chemical classification | | natamycin |
0‑L | G01AA03 | amphotericin B | WHO Anatomical Therapeutic Chemical classification | | amphotericin B |
0‑L | G01AA04 | candicidin | WHO Anatomical Therapeutic Chemical classification | | candicidin |
0‑L | G01AA05 | chloramphenicol | WHO Anatomical Therapeutic Chemical classification | | chloramphenicol |
0‑L | G01AA06 | hachimycin | WHO Anatomical Therapeutic Chemical classification | | hachimycin |
0‑L | G01AA07 | oxytetracycline | WHO Anatomical Therapeutic Chemical classification | | oxytetracycline |
0‑L | G01AA08 | carfecillin | WHO Anatomical Therapeutic Chemical classification | | carfecillin |
0‑L | G01AA09 | mepartricin | WHO Anatomical Therapeutic Chemical classification | | mepartricin |
0‑L | G01AA10 | clindamycin | WHO Anatomical Therapeutic Chemical classification | | clindamycin |
0‑L | G01AA11 | pentamycin | WHO Anatomical Therapeutic Chemical classification | | pentamycin |
0‑L | G01AA51 | nystatin, combinations | WHO Anatomical Therapeutic Chemical classification | | nystatin, combinations |
0‑L | G01AB | Arsenic compounds | WHO Anatomical Therapeutic Chemical classification | | Arsenic compounds |
0‑L | G01AB01 | acetarsol | WHO Anatomical Therapeutic Chemical classification | | acetarsol |
0‑L | G01AC | Quinoline derivatives | WHO Anatomical Therapeutic Chemical classification | | Quinoline derivatives |
0‑L | G01AC01 | diiodohydroxyquinoline | WHO Anatomical Therapeutic Chemical classification | | diiodohydroxyquinoline |
0‑L | G01AC02 | clioquinol | WHO Anatomical Therapeutic Chemical classification | | clioquinol |
0‑L | G01AC03 | chlorquinaldol | WHO Anatomical Therapeutic Chemical classification | | chlorquinaldol |
0‑L | G01AC05 | dequalinium | WHO Anatomical Therapeutic Chemical classification | | dequalinium |
0‑L | G01AC06 | broxyquinoline | WHO Anatomical Therapeutic Chemical classification | | broxyquinoline |
0‑L | G01AC30 | oxyquinoline | WHO Anatomical Therapeutic Chemical classification | | oxyquinoline |
0‑L | G01AD | Organic acids | WHO Anatomical Therapeutic Chemical classification | | Organic acids |
0‑L | G01AD01 | lactic acid | WHO Anatomical Therapeutic Chemical classification | | lactic acid |
0‑L | G01AD02 | acetic acid | WHO Anatomical Therapeutic Chemical classification | | acetic acid |
0‑L | G01AD03 | ascorbic acid | WHO Anatomical Therapeutic Chemical classification | | ascorbic acid |
0‑L | G01AE | Sulfonamides | WHO Anatomical Therapeutic Chemical classification | | Sulfonamides |
0‑L | G01AE01 | sulfatolamide | WHO Anatomical Therapeutic Chemical classification | | sulfatolamide |
0‑L | G01AE10 | combinations of sulfonamides | WHO Anatomical Therapeutic Chemical classification | | combinations of sulfonamides |
0‑L | G01AF | Imidazole derivatives | WHO Anatomical Therapeutic Chemical classification | | Imidazole derivatives |
0‑L | G01AF01 | metronidazole | WHO Anatomical Therapeutic Chemical classification | | metronidazole |
0‑L | G01AF02 | clotrimazole | WHO Anatomical Therapeutic Chemical classification | | clotrimazole |
0‑L | G01AF04 | miconazole | WHO Anatomical Therapeutic Chemical classification | | miconazole |
0‑L | G01AF05 | econazole | WHO Anatomical Therapeutic Chemical classification | | econazole |
0‑L | G01AF06 | ornidazole | WHO Anatomical Therapeutic Chemical classification | | ornidazole |
0‑L | G01AF07 | isoconazole | WHO Anatomical Therapeutic Chemical classification | | isoconazole |
0‑L | G01AF08 | tioconazole | WHO Anatomical Therapeutic Chemical classification | | tioconazole |
0‑L | G01AF11 | ketoconazole | WHO Anatomical Therapeutic Chemical classification | | ketoconazole |
0‑L | G01AF12 | fenticonazole | WHO Anatomical Therapeutic Chemical classification | | fenticonazole |
0‑L | G01AF13 | azanidazole | WHO Anatomical Therapeutic Chemical classification | | azanidazole |
0‑L | G01AF14 | propenidazole | WHO Anatomical Therapeutic Chemical classification | | propenidazole |
0‑L | G01AF15 | butoconazole | WHO Anatomical Therapeutic Chemical classification | | butoconazole |
0‑L | G01AF16 | omoconazole | WHO Anatomical Therapeutic Chemical classification | | omoconazole |
0‑L | G01AF17 | oxiconazole | WHO Anatomical Therapeutic Chemical classification | | oxiconazole |
0‑L | G01AF18 | flutrimazole | WHO Anatomical Therapeutic Chemical classification | | flutrimazole |
0‑L | G01AF19 | sertaconazole | WHO Anatomical Therapeutic Chemical classification | | sertaconazole |
0‑L | G01AF20 | combinations of imidazole derivatives | WHO Anatomical Therapeutic Chemical classification | | combinations of imidazole derivatives |
0‑L | G01AG | Triazole derivatives | WHO Anatomical Therapeutic Chemical classification | | Triazole derivatives |
0‑L | G01AG02 | terconazole | WHO Anatomical Therapeutic Chemical classification | | terconazole |
0‑L | G01AX | Other antiinfectives and antiseptics | WHO Anatomical Therapeutic Chemical classification | | Other antiinfectives and antiseptics |
0‑L | G01AX01 | clodantoin | WHO Anatomical Therapeutic Chemical classification | | clodantoin |
0‑L | G01AX02 | inosine | WHO Anatomical Therapeutic Chemical classification | | inosine |
0‑L | G01AX03 | policresulen | WHO Anatomical Therapeutic Chemical classification | | policresulen |
0‑L | G01AX05 | nifuratel | WHO Anatomical Therapeutic Chemical classification | | nifuratel |
0‑L | G01AX06 | furazolidone | WHO Anatomical Therapeutic Chemical classification | | furazolidone |
0‑L | G01AX09 | methylrosaniline | WHO Anatomical Therapeutic Chemical classification | | methylrosaniline |
0‑L | G01AX11 | povidone-iodine | WHO Anatomical Therapeutic Chemical classification | | povidone-iodine |
0‑L | G01AX12 | ciclopirox | WHO Anatomical Therapeutic Chemical classification | | ciclopirox |
0‑L | G01AX13 | protiofate | WHO Anatomical Therapeutic Chemical classification | | protiofate |
0‑L | G01AX14 | lactobacillus fermentum | WHO Anatomical Therapeutic Chemical classification | | lactobacillus fermentum |
0‑L | G01AX15 | copper usnate | WHO Anatomical Therapeutic Chemical classification | | copper usnate |
0‑L | G01AX16 | hexetidine | WHO Anatomical Therapeutic Chemical classification | | hexetidine |
0‑L | G01AX66 | octenidine, combinations | WHO Anatomical Therapeutic Chemical classification | | octenidine, combinations |
0‑L | G01B | ANTIINFECTIVES/ANTISEPTICS IN COMBINATION WITH CORTICOSTEROIDS | WHO Anatomical Therapeutic Chemical classification | | ANTIINFECTIVES/ANTISEPTICS IN COMBINATION WITH CORTICOSTEROIDS |
0‑L | G01BA | Antibiotics and corticosteroids | WHO Anatomical Therapeutic Chemical classification | | Antibiotics and corticosteroids |
0‑L | G01BC | Quinoline derivatives and corticosteroids | WHO Anatomical Therapeutic Chemical classification | | Quinoline derivatives and corticosteroids |
0‑L | G01BD | Antiseptics and corticosteroids | WHO Anatomical Therapeutic Chemical classification | | Antiseptics and corticosteroids |
0‑L | G01BE | Sulfonamides and corticosteroids | WHO Anatomical Therapeutic Chemical classification | | Sulfonamides and corticosteroids |
0‑L | G01BF | Imidazole derivatives and corticosteroids | WHO Anatomical Therapeutic Chemical classification | | Imidazole derivatives and corticosteroids |
0‑L | G02 | OTHER GYNECOLOGICALS | WHO Anatomical Therapeutic Chemical classification | | OTHER GYNECOLOGICALS |
0‑L | G02A | UTEROTONICS | WHO Anatomical Therapeutic Chemical classification | | UTEROTONICS |
0‑L | G02AB | Ergot alkaloids | WHO Anatomical Therapeutic Chemical classification | | Ergot alkaloids |
0‑L | G02AB01 | methylergometrine | WHO Anatomical Therapeutic Chemical classification | | methylergometrine |
0‑L | G02AB02 | ergot alkaloids | WHO Anatomical Therapeutic Chemical classification | | ergot alkaloids |
0‑L | G02AB03 | ergometrine | WHO Anatomical Therapeutic Chemical classification | | ergometrine |
0‑L | G02AC | Ergot alkaloids and oxytocin incl. analogues, in combination | WHO Anatomical Therapeutic Chemical classification | | Ergot alkaloids and oxytocin incl. analogues, in combination |
0‑L | G02AC01 | methylergometrine and oxytocin | WHO Anatomical Therapeutic Chemical classification | | methylergometrine and oxytocin |
0‑L | G02AD | Prostaglandins | WHO Anatomical Therapeutic Chemical classification | | Prostaglandins |
0‑L | G02AD01 | dinoprost | WHO Anatomical Therapeutic Chemical classification | | dinoprost |
0‑L | G02AD02 | dinoprostone | WHO Anatomical Therapeutic Chemical classification | | dinoprostone |
0‑L | G02AD03 | gemeprost | WHO Anatomical Therapeutic Chemical classification | | gemeprost |
0‑L | G02AD04 | carboprost | WHO Anatomical Therapeutic Chemical classification | | carboprost |
0‑L | G02AD05 | sulprostone | WHO Anatomical Therapeutic Chemical classification | | sulprostone |
0‑L | G02AD06 | misoprostol | WHO Anatomical Therapeutic Chemical classification | | misoprostol |
0‑L | G02AX | Other uterotonics | WHO Anatomical Therapeutic Chemical classification | | Other uterotonics |
0‑L | G02B | CONTRACEPTIVES FOR TOPICAL USE | WHO Anatomical Therapeutic Chemical classification | | CONTRACEPTIVES FOR TOPICAL USE |
0‑L | G02BA | Intrauterine contraceptives | WHO Anatomical Therapeutic Chemical classification | | Intrauterine contraceptives |
0‑L | G02BA01 | plastic IUD | WHO Anatomical Therapeutic Chemical classification | | plastic IUD |
0‑L | G02BA02 | plastic IUD with copper | WHO Anatomical Therapeutic Chemical classification | | plastic IUD with copper |
0‑L | G02BA03 | plastic IUD with progestogen | WHO Anatomical Therapeutic Chemical classification | | plastic IUD with progestogen |
0‑L | G02BB | Intravaginal contraceptives | WHO Anatomical Therapeutic Chemical classification | | Intravaginal contraceptives |
0‑L | G02BB01 | vaginal ring with progestogen and estrogen | WHO Anatomical Therapeutic Chemical classification | | vaginal ring with progestogen and estrogen |
0‑L | G02C | OTHER GYNECOLOGICALS | WHO Anatomical Therapeutic Chemical classification | | OTHER GYNECOLOGICALS |
0‑L | G02CA | Sympathomimetics, labour repressants | WHO Anatomical Therapeutic Chemical classification | | Sympathomimetics, labour repressants |
0‑L | G02CA01 | ritodrine | WHO Anatomical Therapeutic Chemical classification | | ritodrine |
0‑L | G02CA02 | buphenine | WHO Anatomical Therapeutic Chemical classification | | buphenine |
0‑L | G02CA03 | fenoterol | WHO Anatomical Therapeutic Chemical classification | | fenoterol |
0‑L | G02CB | Prolactine inhibitors | WHO Anatomical Therapeutic Chemical classification | | Prolactine inhibitors |
0‑L | G02CB01 | bromocriptine | WHO Anatomical Therapeutic Chemical classification | | bromocriptine |
0‑L | G02CB02 | lisuride | WHO Anatomical Therapeutic Chemical classification | | lisuride |
0‑L | G02CB03 | cabergoline | WHO Anatomical Therapeutic Chemical classification | | cabergoline |
0‑L | G02CB04 | quinagolide | WHO Anatomical Therapeutic Chemical classification | | quinagolide |
0‑L | G02CB05 | metergoline | WHO Anatomical Therapeutic Chemical classification | | metergoline |
0‑L | G02CB06 | terguride | WHO Anatomical Therapeutic Chemical classification | | terguride |
0‑L | G02CC | Antiinflammatory products for vaginal administration | WHO Anatomical Therapeutic Chemical classification | | Antiinflammatory products for vaginal administration |
0‑L | G02CC01 | ibuprofen | WHO Anatomical Therapeutic Chemical classification | | ibuprofen |
0‑L | G02CC02 | naproxen | WHO Anatomical Therapeutic Chemical classification | | naproxen |
0‑L | G02CC03 | benzydamine | WHO Anatomical Therapeutic Chemical classification | | benzydamine |
0‑L | G02CC04 | flunoxaprofen | WHO Anatomical Therapeutic Chemical classification | | flunoxaprofen |
0‑L | G02CX | Other gynecologicals | WHO Anatomical Therapeutic Chemical classification | | Other gynecologicals |
0‑L | G02CX01 | atosiban | WHO Anatomical Therapeutic Chemical classification | | atosiban |
0‑L | G02CX02 | flibanserin | WHO Anatomical Therapeutic Chemical classification | | flibanserin |
0‑L | G02CX03 | Agni casti fructus | WHO Anatomical Therapeutic Chemical classification | | Agni casti fructus |
0‑L | G02CX04 | Cimicifugae rhizoma | WHO Anatomical Therapeutic Chemical classification | | Cimicifugae rhizoma |
0‑L | G03 | SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM | WHO Anatomical Therapeutic Chemical classification | | SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM |
0‑L | G03A | HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE | WHO Anatomical Therapeutic Chemical classification | | HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE |
0‑L | G03AA | Progestogens and estrogens, fixed combinations | WHO Anatomical Therapeutic Chemical classification | | Progestogens and estrogens, fixed combinations |
0‑L | G03AA01 | etynodiol and ethinylestradiol | WHO Anatomical Therapeutic Chemical classification | | etynodiol and ethinylestradiol |
0‑L | G03AA02 | quingestanol and ethinylestradiol | WHO Anatomical Therapeutic Chemical classification | | quingestanol and ethinylestradiol |
0‑L | G03AA03 | lynestrenol and ethinylestradiol | WHO Anatomical Therapeutic Chemical classification | | lynestrenol and ethinylestradiol |
0‑L | G03AA04 | megestrol and ethinylestradiol | WHO Anatomical Therapeutic Chemical classification | | megestrol and ethinylestradiol |
0‑L | G03AA05 | norethisterone and ethinylestradiol | WHO Anatomical Therapeutic Chemical classification | | norethisterone and ethinylestradiol |
0‑L | G03AA06 | norgestrel and ethinylestradiol | WHO Anatomical Therapeutic Chemical classification | | norgestrel and ethinylestradiol |
0‑L | G03AA07 | levonorgestrel and ethinylestradiol | WHO Anatomical Therapeutic Chemical classification | | levonorgestrel and ethinylestradiol |
0‑L | G03AA08 | medroxyprogesterone and ethinylestradiol | WHO Anatomical Therapeutic Chemical classification | | medroxyprogesterone and ethinylestradiol |
0‑L | G03AA09 | desogestrel and ethinylestradiol | WHO Anatomical Therapeutic Chemical classification | | desogestrel and ethinylestradiol |
0‑L | G03AA10 | gestodene and ethinylestradiol | WHO Anatomical Therapeutic Chemical classification | | gestodene and ethinylestradiol |
0‑L | G03AA11 | norgestimate and ethinylestradiol | WHO Anatomical Therapeutic Chemical classification | | norgestimate and ethinylestradiol |
0‑L | G03AA12 | drospirenone and ethinylestradiol | WHO Anatomical Therapeutic Chemical classification | | drospirenone and ethinylestradiol |
0‑L | G03AA13 | norelgestromin and ethinylestradiol | WHO Anatomical Therapeutic Chemical classification | | norelgestromin and ethinylestradiol |
0‑L | G03AA14 | nomegestrol and estradiol | WHO Anatomical Therapeutic Chemical classification | | nomegestrol and estradiol |
0‑L | G03AA15 | chlormadinone and ethinylestradiol | WHO Anatomical Therapeutic Chemical classification | | chlormadinone and ethinylestradiol |
0‑L | G03AA16 | dienogest and ethinylestradiol | WHO Anatomical Therapeutic Chemical classification | | dienogest and ethinylestradiol |
0‑L | G03AB | Progestogens and estrogens, sequential preparations | WHO Anatomical Therapeutic Chemical classification | | Progestogens and estrogens, sequential preparations |
0‑L | G03AB01 | megestrol and ethinylestradiol | WHO Anatomical Therapeutic Chemical classification | | megestrol and ethinylestradiol |
0‑L | G03AB02 | lynestrenol and ethinylestradiol | WHO Anatomical Therapeutic Chemical classification | | lynestrenol and ethinylestradiol |
0‑L | G03AB03 | levonorgestrel and ethinylestradiol | WHO Anatomical Therapeutic Chemical classification | | levonorgestrel and ethinylestradiol |
0‑L | G03AB04 | norethisterone and ethinylestradiol | WHO Anatomical Therapeutic Chemical classification | | norethisterone and ethinylestradiol |
0‑L | G03AB05 | desogestrel and ethinylestradiol | WHO Anatomical Therapeutic Chemical classification | | desogestrel and ethinylestradiol |
0‑L | G03AB06 | gestodene and ethinylestradiol | WHO Anatomical Therapeutic Chemical classification | | gestodene and ethinylestradiol |
0‑L | G03AB07 | chlormadinone and ethinylestradiol | WHO Anatomical Therapeutic Chemical classification | | chlormadinone and ethinylestradiol |
0‑L | G03AB08 | dienogest and estradiol | WHO Anatomical Therapeutic Chemical classification | | dienogest and estradiol |
0‑L | G03AC | Progestogens | WHO Anatomical Therapeutic Chemical classification | | Progestogens |
0‑L | G03AC01 | norethisterone | WHO Anatomical Therapeutic Chemical classification | | norethisterone |
0‑L | G03AC02 | lynestrenol | WHO Anatomical Therapeutic Chemical classification | | lynestrenol |
0‑L | G03AC03 | levonorgestrel | WHO Anatomical Therapeutic Chemical classification | | levonorgestrel |
0‑L | G03AC04 | quingestanol | WHO Anatomical Therapeutic Chemical classification | | quingestanol |
0‑L | G03AC05 | megestrol | WHO Anatomical Therapeutic Chemical classification | | megestrol |
0‑L | G03AC06 | medroxyprogesterone | WHO Anatomical Therapeutic Chemical classification | | medroxyprogesterone |
0‑L | G03AC07 | norgestrienone | WHO Anatomical Therapeutic Chemical classification | | norgestrienone |
0‑L | G03AC08 | etonogestrel | WHO Anatomical Therapeutic Chemical classification | | etonogestrel |
0‑L | G03AC09 | desogestrel | WHO Anatomical Therapeutic Chemical classification | | desogestrel |
0‑L | G03AC10 | drospirenone | WHO Anatomical Therapeutic Chemical classification | | drospirenone |
0‑L | G03AD | Emergency contraceptives | WHO Anatomical Therapeutic Chemical classification | | Emergency contraceptives |
0‑L | G03AD01 | levonorgestrel | WHO Anatomical Therapeutic Chemical classification | | levonorgestrel |
0‑L | G03AD02 | ulipristal | WHO Anatomical Therapeutic Chemical classification | | ulipristal |
0‑L | G03B | ANDROGENS | WHO Anatomical Therapeutic Chemical classification | | ANDROGENS |
0‑L | G03BA | 3-oxoandrosten (4) derivatives | WHO Anatomical Therapeutic Chemical classification | | 3-oxoandrosten (4) derivatives |
0‑L | G03BA01 | fluoxymesterone | WHO Anatomical Therapeutic Chemical classification | | fluoxymesterone |
0‑L | G03BA02 | methyltestosterone | WHO Anatomical Therapeutic Chemical classification | | methyltestosterone |
0‑L | G03BA03 | testosterone | WHO Anatomical Therapeutic Chemical classification | | testosterone |
0‑L | G03BB | 5-androstanon (3) derivatives | WHO Anatomical Therapeutic Chemical classification | | 5-androstanon (3) derivatives |
0‑L | G03BB01 | mesterolone | WHO Anatomical Therapeutic Chemical classification | | mesterolone |
0‑L | G03BB02 | androstanolone | WHO Anatomical Therapeutic Chemical classification | | androstanolone |
0‑L | G03C | ESTROGENS | WHO Anatomical Therapeutic Chemical classification | | ESTROGENS |
0‑L | G03CA | Natural and semisynthetic estrogens, plain | WHO Anatomical Therapeutic Chemical classification | | Natural and semisynthetic estrogens, plain |
0‑L | G03CA01 | ethinylestradiol | WHO Anatomical Therapeutic Chemical classification | | ethinylestradiol |
0‑L | G03CA03 | estradiol | WHO Anatomical Therapeutic Chemical classification | | estradiol |
0‑L | G03CA04 | estriol | WHO Anatomical Therapeutic Chemical classification | | estriol |
0‑L | G03CA06 | chlorotrianisene | WHO Anatomical Therapeutic Chemical classification | | chlorotrianisene |
0‑L | G03CA07 | estrone | WHO Anatomical Therapeutic Chemical classification | | estrone |
0‑L | G03CA09 | promestriene | WHO Anatomical Therapeutic Chemical classification | | promestriene |
0‑L | G03CA53 | estradiol, combinations | WHO Anatomical Therapeutic Chemical classification | | estradiol, combinations |
0‑L | G03CA57 | conjugated estrogens | WHO Anatomical Therapeutic Chemical classification | | conjugated estrogens |
0‑L | G03CB | Synthetic estrogens, plain | WHO Anatomical Therapeutic Chemical classification | | Synthetic estrogens, plain |
0‑L | G03CB01 | dienestrol | WHO Anatomical Therapeutic Chemical classification | | dienestrol |
0‑L | G03CB02 | diethylstilbestrol | WHO Anatomical Therapeutic Chemical classification | | diethylstilbestrol |
0‑L | G03CB03 | methallenestril | WHO Anatomical Therapeutic Chemical classification | | methallenestril |
0‑L | G03CB04 | moxestrol | WHO Anatomical Therapeutic Chemical classification | | moxestrol |
0‑L | G03CC | Estrogens, combinations with other drugs | WHO Anatomical Therapeutic Chemical classification | | Estrogens, combinations with other drugs |
0‑L | G03CC02 | dienestrol | WHO Anatomical Therapeutic Chemical classification | | dienestrol |
0‑L | G03CC03 | methallenestril | WHO Anatomical Therapeutic Chemical classification | | methallenestril |
0‑L | G03CC04 | estrone | WHO Anatomical Therapeutic Chemical classification | | estrone |
0‑L | G03CC05 | diethylstilbestrol | WHO Anatomical Therapeutic Chemical classification | | diethylstilbestrol |
0‑L | G03CC06 | estriol | WHO Anatomical Therapeutic Chemical classification | | estriol |
0‑L | G03CC07 | conjugated estrogens and bazedoxifene | WHO Anatomical Therapeutic Chemical classification | | conjugated estrogens and bazedoxifene |
0‑L | G03CX | Other estrogens | WHO Anatomical Therapeutic Chemical classification | | Other estrogens |
0‑L | G03CX01 | tibolone | WHO Anatomical Therapeutic Chemical classification | | tibolone |
0‑L | G03D | PROGESTOGENS | WHO Anatomical Therapeutic Chemical classification | | PROGESTOGENS |
0‑L | G03DA | Pregnen (4) derivatives | WHO Anatomical Therapeutic Chemical classification | | Pregnen (4) derivatives |
0‑L | G03DA01 | gestonorone | WHO Anatomical Therapeutic Chemical classification | | gestonorone |
0‑L | G03DA02 | medroxyprogesterone | WHO Anatomical Therapeutic Chemical classification | | medroxyprogesterone |
0‑L | G03DA03 | hydroxyprogesterone | WHO Anatomical Therapeutic Chemical classification | | hydroxyprogesterone |
0‑L | G03DA04 | progesterone | WHO Anatomical Therapeutic Chemical classification | | progesterone |
0‑L | G03DB | Pregnadien derivatives | WHO Anatomical Therapeutic Chemical classification | | Pregnadien derivatives |
0‑L | G03DB01 | dydrogesterone | WHO Anatomical Therapeutic Chemical classification | | dydrogesterone |
0‑L | G03DB02 | megestrol | WHO Anatomical Therapeutic Chemical classification | | megestrol |
0‑L | G03DB03 | medrogestone | WHO Anatomical Therapeutic Chemical classification | | medrogestone |
0‑L | G03DB04 | nomegestrol | WHO Anatomical Therapeutic Chemical classification | | nomegestrol |
0‑L | G03DB05 | demegestone | WHO Anatomical Therapeutic Chemical classification | | demegestone |
0‑L | G03DB06 | chlormadinone | WHO Anatomical Therapeutic Chemical classification | | chlormadinone |
0‑L | G03DB07 | promegestone | WHO Anatomical Therapeutic Chemical classification | | promegestone |
0‑L | G03DB08 | dienogest | WHO Anatomical Therapeutic Chemical classification | | dienogest |
0‑L | G03DC | Estren derivatives | WHO Anatomical Therapeutic Chemical classification | | Estren derivatives |
0‑L | G03DC01 | allylestrenol | WHO Anatomical Therapeutic Chemical classification | | allylestrenol |
0‑L | G03DC02 | norethisterone | WHO Anatomical Therapeutic Chemical classification | | norethisterone |
0‑L | G03DC03 | lynestrenol | WHO Anatomical Therapeutic Chemical classification | | lynestrenol |
0‑L | G03DC04 | ethisterone | WHO Anatomical Therapeutic Chemical classification | | ethisterone |
0‑L | G03DC06 | etynodiol | WHO Anatomical Therapeutic Chemical classification | | etynodiol |
0‑L | G03DC31 | methylestrenolone | WHO Anatomical Therapeutic Chemical classification | | methylestrenolone |
0‑L | G03E | ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION | WHO Anatomical Therapeutic Chemical classification | | ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION |
0‑L | G03EA | Androgens and estrogens | WHO Anatomical Therapeutic Chemical classification | | Androgens and estrogens |
0‑L | G03EA01 | methyltestosterone and estrogen | WHO Anatomical Therapeutic Chemical classification | | methyltestosterone and estrogen |
0‑L | G03EA02 | testosterone and estrogen | WHO Anatomical Therapeutic Chemical classification | | testosterone and estrogen |
0‑L | G03EA03 | prasterone and estrogen | WHO Anatomical Therapeutic Chemical classification | | prasterone and estrogen |
0‑L | G03EB | Androgen, progestogen and estrogen in combination | WHO Anatomical Therapeutic Chemical classification | | Androgen, progestogen and estrogen in combination |
0‑L | G03EK | Androgens and female sex hormones in combination with other drugs | WHO Anatomical Therapeutic Chemical classification | | Androgens and female sex hormones in combination with other drugs |
0‑L | G03EK01 | methyltestosterone | WHO Anatomical Therapeutic Chemical classification | | methyltestosterone |
0‑L | G03F | PROGESTOGENS AND ESTROGENS IN COMBINATION | WHO Anatomical Therapeutic Chemical classification | | PROGESTOGENS AND ESTROGENS IN COMBINATION |
0‑L | G03FA | Progestogens and estrogens, fixed combinations | WHO Anatomical Therapeutic Chemical classification | | Progestogens and estrogens, fixed combinations |
0‑L | G03FA01 | norethisterone and estrogen | WHO Anatomical Therapeutic Chemical classification | | norethisterone and estrogen |
0‑L | G03FA02 | hydroxyprogesterone and estrogen | WHO Anatomical Therapeutic Chemical classification | | hydroxyprogesterone and estrogen |
0‑L | G03FA03 | ethisterone and estrogen | WHO Anatomical Therapeutic Chemical classification | | ethisterone and estrogen |
0‑L | G03FA04 | progesterone and estrogen | WHO Anatomical Therapeutic Chemical classification | | progesterone and estrogen |
0‑L | G03FA05 | methylnortestosterone and estrogen | WHO Anatomical Therapeutic Chemical classification | | methylnortestosterone and estrogen |
0‑L | G03FA06 | etynodiol and estrogen | WHO Anatomical Therapeutic Chemical classification | | etynodiol and estrogen |
0‑L | G03FA07 | lynestrenol and estrogen | WHO Anatomical Therapeutic Chemical classification | | lynestrenol and estrogen |
0‑L | G03FA08 | megestrol and estrogen | WHO Anatomical Therapeutic Chemical classification | | megestrol and estrogen |
0‑L | G03FA09 | noretynodrel and estrogen | WHO Anatomical Therapeutic Chemical classification | | noretynodrel and estrogen |
0‑L | G03FA10 | norgestrel and estrogen | WHO Anatomical Therapeutic Chemical classification | | norgestrel and estrogen |
0‑L | G03FA11 | levonorgestrel and estrogen | WHO Anatomical Therapeutic Chemical classification | | levonorgestrel and estrogen |
0‑L | G03FA12 | medroxyprogesterone and estrogen | WHO Anatomical Therapeutic Chemical classification | | medroxyprogesterone and estrogen |
0‑L | G03FA13 | norgestimate and estrogen | WHO Anatomical Therapeutic Chemical classification | | norgestimate and estrogen |
0‑L | G03FA14 | dydrogesterone and estrogen | WHO Anatomical Therapeutic Chemical classification | | dydrogesterone and estrogen |
0‑L | G03FA15 | dienogest and estrogen | WHO Anatomical Therapeutic Chemical classification | | dienogest and estrogen |
0‑L | G03FA16 | trimegestone and estrogen | WHO Anatomical Therapeutic Chemical classification | | trimegestone and estrogen |
0‑L | G03FA17 | drospirenone and estrogen | WHO Anatomical Therapeutic Chemical classification | | drospirenone and estrogen |
0‑L | G03FB | Progestogens and estrogens, sequential preparations | WHO Anatomical Therapeutic Chemical classification | | Progestogens and estrogens, sequential preparations |
0‑L | G03FB01 | norgestrel and estrogen | WHO Anatomical Therapeutic Chemical classification | | norgestrel and estrogen |
0‑L | G03FB02 | lynestrenol and estrogen | WHO Anatomical Therapeutic Chemical classification | | lynestrenol and estrogen |
0‑L | G03FB03 | chlormadinone and estrogen | WHO Anatomical Therapeutic Chemical classification | | chlormadinone and estrogen |
0‑L | G03FB04 | megestrol and estrogen | WHO Anatomical Therapeutic Chemical classification | | megestrol and estrogen |
0‑L | G03FB05 | norethisterone and estrogen | WHO Anatomical Therapeutic Chemical classification | | norethisterone and estrogen |
0‑L | G03FB06 | medroxyprogesterone and estrogen | WHO Anatomical Therapeutic Chemical classification | | medroxyprogesterone and estrogen |
0‑L | G03FB07 | medrogestone and estrogen | WHO Anatomical Therapeutic Chemical classification | | medrogestone and estrogen |
0‑L | G03FB08 | dydrogesterone and estrogen | WHO Anatomical Therapeutic Chemical classification | | dydrogesterone and estrogen |
0‑L | G03FB09 | levonorgestrel and estrogen | WHO Anatomical Therapeutic Chemical classification | | levonorgestrel and estrogen |
0‑L | G03FB10 | desogestrel and estrogen | WHO Anatomical Therapeutic Chemical classification | | desogestrel and estrogen |
0‑L | G03FB11 | trimegestone and estrogen | WHO Anatomical Therapeutic Chemical classification | | trimegestone and estrogen |
0‑L | G03FB12 | nomegestrol and estrogen | WHO Anatomical Therapeutic Chemical classification | | nomegestrol and estrogen |
0‑L | G03G | GONADOTROPINS AND OTHER OVULATION STIMULANTS | WHO Anatomical Therapeutic Chemical classification | | GONADOTROPINS AND OTHER OVULATION STIMULANTS |
0‑L | G03GA | Gonadotropins | WHO Anatomical Therapeutic Chemical classification | | Gonadotropins |
0‑L | G03GA01 | chorionic gonadotrophin | WHO Anatomical Therapeutic Chemical classification | | chorionic gonadotrophin |
0‑L | G03GA02 | human menopausal gonadotrophin | WHO Anatomical Therapeutic Chemical classification | | human menopausal gonadotrophin |
0‑L | G03GA03 | serum gonadotrophin | WHO Anatomical Therapeutic Chemical classification | | serum gonadotrophin |
0‑L | G03GA04 | urofollitropin | WHO Anatomical Therapeutic Chemical classification | | urofollitropin |
0‑L | G03GA05 | follitropin alfa | WHO Anatomical Therapeutic Chemical classification | | follitropin alfa |
0‑L | G03GA06 | follitropin beta | WHO Anatomical Therapeutic Chemical classification | | follitropin beta |
0‑L | G03GA07 | lutropin alfa | WHO Anatomical Therapeutic Chemical classification | | lutropin alfa |
0‑L | G03GA08 | choriogonadotropin alfa | WHO Anatomical Therapeutic Chemical classification | | choriogonadotropin alfa |
0‑L | G03GA09 | corifollitropin alfa | WHO Anatomical Therapeutic Chemical classification | | corifollitropin alfa |
0‑L | G03GA10 | follitropin delta | WHO Anatomical Therapeutic Chemical classification | | follitropin delta |
0‑L | G03GA30 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | G03GB | Ovulation stimulants, synthetic | WHO Anatomical Therapeutic Chemical classification | | Ovulation stimulants, synthetic |
0‑L | G03GB01 | cyclofenil | WHO Anatomical Therapeutic Chemical classification | | cyclofenil |
0‑L | G03GB02 | clomifene | WHO Anatomical Therapeutic Chemical classification | | clomifene |
0‑L | G03GB03 | epimestrol | WHO Anatomical Therapeutic Chemical classification | | epimestrol |
0‑L | G03H | ANTIANDROGENS | WHO Anatomical Therapeutic Chemical classification | | ANTIANDROGENS |
0‑L | G03HA | Antiandrogens, plain | WHO Anatomical Therapeutic Chemical classification | | Antiandrogens, plain |
0‑L | G03HA01 | cyproterone | WHO Anatomical Therapeutic Chemical classification | | cyproterone |
0‑L | G03HB | Antiandrogens and estrogens | WHO Anatomical Therapeutic Chemical classification | | Antiandrogens and estrogens |
0‑L | G03HB01 | cyproterone and estrogen | WHO Anatomical Therapeutic Chemical classification | | cyproterone and estrogen |
0‑L | G03X | OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM | WHO Anatomical Therapeutic Chemical classification | | OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM |
0‑L | G03XA | Antigonadotropins and similar agents | WHO Anatomical Therapeutic Chemical classification | | Antigonadotropins and similar agents |
0‑L | G03XA01 | danazol | WHO Anatomical Therapeutic Chemical classification | | danazol |
0‑L | G03XA02 | gestrinone | WHO Anatomical Therapeutic Chemical classification | | gestrinone |
0‑L | G03XB | Progesterone receptor modulators | WHO Anatomical Therapeutic Chemical classification | | Progesterone receptor modulators |
0‑L | G03XB01 | mifepristone | WHO Anatomical Therapeutic Chemical classification | | mifepristone |
0‑L | G03XB02 | ulipristal | WHO Anatomical Therapeutic Chemical classification | | ulipristal |
0‑L | G03XB51 | mifepristone, combinations | WHO Anatomical Therapeutic Chemical classification | | mifepristone, combinations |
0‑L | G03XC | Selective estrogen receptor modulators | WHO Anatomical Therapeutic Chemical classification | | Selective estrogen receptor modulators |
0‑L | G03XC01 | raloxifene | WHO Anatomical Therapeutic Chemical classification | | raloxifene |
0‑L | G03XC02 | bazedoxifene | WHO Anatomical Therapeutic Chemical classification | | bazedoxifene |
0‑L | G03XC03 | lasofoxifene | WHO Anatomical Therapeutic Chemical classification | | lasofoxifene |
0‑L | G03XC04 | ormeloxifene | WHO Anatomical Therapeutic Chemical classification | | ormeloxifene |
0‑L | G03XC05 | ospemifene | WHO Anatomical Therapeutic Chemical classification | | ospemifene |
0‑L | G04 | UROLOGICALS | WHO Anatomical Therapeutic Chemical classification | | UROLOGICALS |
0‑L | G04B | UROLOGICALS | WHO Anatomical Therapeutic Chemical classification | | UROLOGICALS |
0‑L | G04BA | Acidifiers | WHO Anatomical Therapeutic Chemical classification | | Acidifiers |
0‑L | G04BA01 | ammonium chloride | WHO Anatomical Therapeutic Chemical classification | | ammonium chloride |
0‑L | G04BA03 | calcium chloride | WHO Anatomical Therapeutic Chemical classification | | calcium chloride |
0‑L | G04BC | Urinary concrement solvents | WHO Anatomical Therapeutic Chemical classification | | Urinary concrement solvents |
0‑L | G04BD | Drugs for urinary frequency and incontinence | WHO Anatomical Therapeutic Chemical classification | | Drugs for urinary frequency and incontinence |
0‑L | G04BD01 | emepronium | WHO Anatomical Therapeutic Chemical classification | | emepronium |
0‑L | G04BD02 | flavoxate | WHO Anatomical Therapeutic Chemical classification | | flavoxate |
0‑L | G04BD03 | meladrazine | WHO Anatomical Therapeutic Chemical classification | | meladrazine |
0‑L | G04BD04 | oxybutynin | WHO Anatomical Therapeutic Chemical classification | | oxybutynin |
0‑L | G04BD05 | terodiline | WHO Anatomical Therapeutic Chemical classification | | terodiline |
0‑L | G04BD06 | propiverine | WHO Anatomical Therapeutic Chemical classification | | propiverine |
0‑L | G04BD07 | tolterodine | WHO Anatomical Therapeutic Chemical classification | | tolterodine |
0‑L | G04BD08 | solifenacin | WHO Anatomical Therapeutic Chemical classification | | solifenacin |
0‑L | G04BD09 | trospium | WHO Anatomical Therapeutic Chemical classification | | trospium |
0‑L | G04BD10 | darifenacin | WHO Anatomical Therapeutic Chemical classification | | darifenacin |
0‑L | G04BD11 | fesoterodine | WHO Anatomical Therapeutic Chemical classification | | fesoterodine |
0‑L | G04BD12 | mirabegron | WHO Anatomical Therapeutic Chemical classification | | mirabegron |
0‑L | G04BD13 | desfesoterodine | WHO Anatomical Therapeutic Chemical classification | | desfesoterodine |
0‑L | G04BE | Drugs used in erectile dysfunction | WHO Anatomical Therapeutic Chemical classification | | Drugs used in erectile dysfunction |
0‑L | G04BE01 | alprostadil | WHO Anatomical Therapeutic Chemical classification | | alprostadil |
0‑L | G04BE02 | papaverine | WHO Anatomical Therapeutic Chemical classification | | papaverine |
0‑L | G04BE03 | sildenafil | WHO Anatomical Therapeutic Chemical classification | | sildenafil |
0‑L | G04BE04 | yohimbine | WHO Anatomical Therapeutic Chemical classification | | yohimbine |
0‑L | G04BE06 | moxisylyte | WHO Anatomical Therapeutic Chemical classification | | moxisylyte |
0‑L | G04BE07 | apomorphine | WHO Anatomical Therapeutic Chemical classification | | apomorphine |
0‑L | G04BE08 | tadalafil | WHO Anatomical Therapeutic Chemical classification | | tadalafil |
0‑L | G04BE09 | vardenafil | WHO Anatomical Therapeutic Chemical classification | | vardenafil |
0‑L | G04BE10 | avanafil | WHO Anatomical Therapeutic Chemical classification | | avanafil |
0‑L | G04BE11 | udenafil | WHO Anatomical Therapeutic Chemical classification | | udenafil |
0‑L | G04BE30 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | G04BE52 | papaverine, combinations | WHO Anatomical Therapeutic Chemical classification | | papaverine, combinations |
0‑L | G04BX | Other urologicals | WHO Anatomical Therapeutic Chemical classification | | Other urologicals |
0‑L | G04BX01 | magnesium hydroxide | WHO Anatomical Therapeutic Chemical classification | | magnesium hydroxide |
0‑L | G04BX03 | acetohydroxamic acid | WHO Anatomical Therapeutic Chemical classification | | acetohydroxamic acid |
0‑L | G04BX06 | phenazopyridine | WHO Anatomical Therapeutic Chemical classification | | phenazopyridine |
0‑L | G04BX10 | succinimide | WHO Anatomical Therapeutic Chemical classification | | succinimide |
0‑L | G04BX11 | collagen | WHO Anatomical Therapeutic Chemical classification | | collagen |
0‑L | G04BX12 | phenyl salicylate | WHO Anatomical Therapeutic Chemical classification | | phenyl salicylate |
0‑L | G04BX13 | dimethyl sulfoxide | WHO Anatomical Therapeutic Chemical classification | | dimethyl sulfoxide |
0‑L | G04BX14 | dapoxetine | WHO Anatomical Therapeutic Chemical classification | | dapoxetine |
0‑L | G04BX15 | pentosan polysulfate sodium | WHO Anatomical Therapeutic Chemical classification | | pentosan polysulfate sodium |
0‑L | G04BX16 | tiopronin | WHO Anatomical Therapeutic Chemical classification | | tiopronin |
0‑L | G04C | DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY | WHO Anatomical Therapeutic Chemical classification | | DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY |
0‑L | G04CA | Alpha-adrenoreceptor antagonists | WHO Anatomical Therapeutic Chemical classification | | Alpha-adrenoreceptor antagonists |
0‑L | G04CA01 | alfuzosin | WHO Anatomical Therapeutic Chemical classification | | alfuzosin |
0‑L | G04CA02 | tamsulosin | WHO Anatomical Therapeutic Chemical classification | | tamsulosin |
0‑L | G04CA03 | terazosin | WHO Anatomical Therapeutic Chemical classification | | terazosin |
0‑L | G04CA04 | silodosin | WHO Anatomical Therapeutic Chemical classification | | silodosin |
0‑L | G04CA51 | alfuzosin and finasteride | WHO Anatomical Therapeutic Chemical classification | | alfuzosin and finasteride |
0‑L | G04CA52 | tamsulosin and dutasteride | WHO Anatomical Therapeutic Chemical classification | | tamsulosin and dutasteride |
0‑L | G04CA53 | tamsulosin and solifenacin | WHO Anatomical Therapeutic Chemical classification | | tamsulosin and solifenacin |
0‑L | G04CB | Testosterone-5-alpha reductase inhibitors | WHO Anatomical Therapeutic Chemical classification | | Testosterone-5-alpha reductase inhibitors |
0‑L | G04CB01 | finasteride | WHO Anatomical Therapeutic Chemical classification | | finasteride |
0‑L | G04CB02 | dutasteride | WHO Anatomical Therapeutic Chemical classification | | dutasteride |
0‑L | G04CX | Other drugs used in benign prostatic hypertrophy | WHO Anatomical Therapeutic Chemical classification | | Other drugs used in benign prostatic hypertrophy |
0‑L | G04CX01 | Prunus africanae cortex | WHO Anatomical Therapeutic Chemical classification | | Prunus africanae cortex |
0‑L | G04CX02 | Sabalis serrulatae fructus | WHO Anatomical Therapeutic Chemical classification | | Sabalis serrulatae fructus |
0‑L | G04CX03 | mepartricin | WHO Anatomical Therapeutic Chemical classification | | mepartricin |
0‑L | H | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS | WHO Anatomical Therapeutic Chemical classification | | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS |
0‑L | H01 | PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES | WHO Anatomical Therapeutic Chemical classification | | PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES |
0‑L | H01A | ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES | WHO Anatomical Therapeutic Chemical classification | | ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES |
0‑L | H01AA | ACTH | WHO Anatomical Therapeutic Chemical classification | | ACTH |
0‑L | H01AA01 | corticotropin | WHO Anatomical Therapeutic Chemical classification | | corticotropin |
0‑L | H01AA02 | tetracosactide | WHO Anatomical Therapeutic Chemical classification | | tetracosactide |
0‑L | H01AB | Thyrotropin | WHO Anatomical Therapeutic Chemical classification | | Thyrotropin |
0‑L | H01AB01 | thyrotropin alfa | WHO Anatomical Therapeutic Chemical classification | | thyrotropin alfa |
0‑L | H01AC | Somatropin and somatropin agonists | WHO Anatomical Therapeutic Chemical classification | | Somatropin and somatropin agonists |
0‑L | H01AC01 | somatropin | WHO Anatomical Therapeutic Chemical classification | | somatropin |
0‑L | H01AC02 | somatrem | WHO Anatomical Therapeutic Chemical classification | | somatrem |
0‑L | H01AC03 | mecasermin | WHO Anatomical Therapeutic Chemical classification | | mecasermin |
0‑L | H01AC04 | sermorelin | WHO Anatomical Therapeutic Chemical classification | | sermorelin |
0‑L | H01AC05 | mecasermin rinfabate | WHO Anatomical Therapeutic Chemical classification | | mecasermin rinfabate |
0‑L | H01AC06 | tesamorelin | WHO Anatomical Therapeutic Chemical classification | | tesamorelin |
0‑L | H01AX | Other anterior pituitary lobe hormones and analogues | WHO Anatomical Therapeutic Chemical classification | | Other anterior pituitary lobe hormones and analogues |
0‑L | H01AX01 | pegvisomant | WHO Anatomical Therapeutic Chemical classification | | pegvisomant |
0‑L | H01B | POSTERIOR PITUITARY LOBE HORMONES | WHO Anatomical Therapeutic Chemical classification | | POSTERIOR PITUITARY LOBE HORMONES |
0‑L | H01BA | Vasopressin and analogues | WHO Anatomical Therapeutic Chemical classification | | Vasopressin and analogues |
0‑L | H01BA01 | vasopressin | WHO Anatomical Therapeutic Chemical classification | | vasopressin |
0‑L | H01BA02 | desmopressin | WHO Anatomical Therapeutic Chemical classification | | desmopressin |
0‑L | H01BA03 | lypressin | WHO Anatomical Therapeutic Chemical classification | | lypressin |
0‑L | H01BA04 | terlipressin | WHO Anatomical Therapeutic Chemical classification | | terlipressin |
0‑L | H01BA05 | ornipressin | WHO Anatomical Therapeutic Chemical classification | | ornipressin |
0‑L | H01BA06 | argipressin | WHO Anatomical Therapeutic Chemical classification | | argipressin |
0‑L | H01BB | Oxytocin and analogues | WHO Anatomical Therapeutic Chemical classification | | Oxytocin and analogues |
0‑L | H01BB01 | demoxytocin | WHO Anatomical Therapeutic Chemical classification | | demoxytocin |
0‑L | H01BB02 | oxytocin | WHO Anatomical Therapeutic Chemical classification | | oxytocin |
0‑L | H01BB03 | carbetocin | WHO Anatomical Therapeutic Chemical classification | | carbetocin |
0‑L | H01C | HYPOTHALAMIC HORMONES | WHO Anatomical Therapeutic Chemical classification | | HYPOTHALAMIC HORMONES |
0‑L | H01CA | Gonadotropin-releasing hormones | WHO Anatomical Therapeutic Chemical classification | | Gonadotropin-releasing hormones |
0‑L | H01CA01 | gonadorelin | WHO Anatomical Therapeutic Chemical classification | | gonadorelin |
0‑L | H01CA02 | nafarelin | WHO Anatomical Therapeutic Chemical classification | | nafarelin |
0‑L | H01CB | Somatostatin and analogues | WHO Anatomical Therapeutic Chemical classification | | Somatostatin and analogues |
0‑L | H01CB01 | somatostatin | WHO Anatomical Therapeutic Chemical classification | | somatostatin |
0‑L | H01CB02 | octreotide | WHO Anatomical Therapeutic Chemical classification | | octreotide |
0‑L | H01CB03 | lanreotide | WHO Anatomical Therapeutic Chemical classification | | lanreotide |
0‑L | H01CB04 | vapreotide | WHO Anatomical Therapeutic Chemical classification | | vapreotide |
0‑L | H01CB05 | pasireotide | WHO Anatomical Therapeutic Chemical classification | | pasireotide |
0‑L | H01CC | Anti-gonadotropin-releasing hormones | WHO Anatomical Therapeutic Chemical classification | | Anti-gonadotropin-releasing hormones |
0‑L | H01CC01 | ganirelix | WHO Anatomical Therapeutic Chemical classification | | ganirelix |
0‑L | H01CC02 | cetrorelix | WHO Anatomical Therapeutic Chemical classification | | cetrorelix |
0‑L | H02 | CORTICOSTEROIDS FOR SYSTEMIC USE | WHO Anatomical Therapeutic Chemical classification | | CORTICOSTEROIDS FOR SYSTEMIC USE |
0‑L | H02A | CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN | WHO Anatomical Therapeutic Chemical classification | | CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN |
0‑L | H02AA | Mineralocorticoids | WHO Anatomical Therapeutic Chemical classification | | Mineralocorticoids |
0‑L | H02AA01 | aldosterone | WHO Anatomical Therapeutic Chemical classification | | aldosterone |
0‑L | H02AA02 | fludrocortisone | WHO Anatomical Therapeutic Chemical classification | | fludrocortisone |
0‑L | H02AA03 | desoxycortone | WHO Anatomical Therapeutic Chemical classification | | desoxycortone |
0‑L | H02AB | Glucocorticoids | WHO Anatomical Therapeutic Chemical classification | | Glucocorticoids |
0‑L | H02AB01 | betamethasone | WHO Anatomical Therapeutic Chemical classification | | betamethasone |
0‑L | H02AB02 | dexamethasone | WHO Anatomical Therapeutic Chemical classification | | dexamethasone |
0‑L | H02AB03 | fluocortolone | WHO Anatomical Therapeutic Chemical classification | | fluocortolone |
0‑L | H02AB04 | methylprednisolone | WHO Anatomical Therapeutic Chemical classification | | methylprednisolone |
0‑L | H02AB05 | paramethasone | WHO Anatomical Therapeutic Chemical classification | | paramethasone |
0‑L | H02AB06 | prednisolone | WHO Anatomical Therapeutic Chemical classification | | prednisolone |
0‑L | H02AB07 | prednisone | WHO Anatomical Therapeutic Chemical classification | | prednisone |
0‑L | H02AB08 | triamcinolone | WHO Anatomical Therapeutic Chemical classification | | triamcinolone |
0‑L | H02AB09 | hydrocortisone | WHO Anatomical Therapeutic Chemical classification | | hydrocortisone |
0‑L | H02AB10 | cortisone | WHO Anatomical Therapeutic Chemical classification | | cortisone |
0‑L | H02AB11 | prednylidene | WHO Anatomical Therapeutic Chemical classification | | prednylidene |
0‑L | H02AB12 | rimexolone | WHO Anatomical Therapeutic Chemical classification | | rimexolone |
0‑L | H02AB13 | deflazacort | WHO Anatomical Therapeutic Chemical classification | | deflazacort |
0‑L | H02AB14 | cloprednol | WHO Anatomical Therapeutic Chemical classification | | cloprednol |
0‑L | H02AB15 | meprednisone | WHO Anatomical Therapeutic Chemical classification | | meprednisone |
0‑L | H02AB17 | cortivazol | WHO Anatomical Therapeutic Chemical classification | | cortivazol |
0‑L | H02B | CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS | WHO Anatomical Therapeutic Chemical classification | | CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS |
0‑L | H02BX | Corticosteroids for systemic use, combinations | WHO Anatomical Therapeutic Chemical classification | | Corticosteroids for systemic use, combinations |
0‑L | H02BX01 | methylprednisolone, combinations | WHO Anatomical Therapeutic Chemical classification | | methylprednisolone, combinations |
0‑L | H02C | ANTIADRENAL PREPARATIONS | WHO Anatomical Therapeutic Chemical classification | | ANTIADRENAL PREPARATIONS |
0‑L | H02CA | Anticorticosteroids | WHO Anatomical Therapeutic Chemical classification | | Anticorticosteroids |
0‑L | H02CA01 | trilostane | WHO Anatomical Therapeutic Chemical classification | | trilostane |
0‑L | H03 | THYROID THERAPY | WHO Anatomical Therapeutic Chemical classification | | THYROID THERAPY |
0‑L | H03A | THYROID PREPARATIONS | WHO Anatomical Therapeutic Chemical classification | | THYROID PREPARATIONS |
0‑L | H03AA | Thyroid hormones | WHO Anatomical Therapeutic Chemical classification | | Thyroid hormones |
0‑L | H03AA01 | levothyroxine sodium | WHO Anatomical Therapeutic Chemical classification | | levothyroxine sodium |
0‑L | H03AA02 | liothyronine sodium | WHO Anatomical Therapeutic Chemical classification | | liothyronine sodium |
0‑L | H03AA03 | combinations of levothyroxine and liothyronine | WHO Anatomical Therapeutic Chemical classification | | combinations of levothyroxine and liothyronine |
0‑L | H03AA04 | tiratricol | WHO Anatomical Therapeutic Chemical classification | | tiratricol |
0‑L | H03AA05 | thyroid gland preparations | WHO Anatomical Therapeutic Chemical classification | | thyroid gland preparations |
0‑L | H03B | ANTITHYROID PREPARATIONS | WHO Anatomical Therapeutic Chemical classification | | ANTITHYROID PREPARATIONS |
0‑L | H03BA | Thiouracils | WHO Anatomical Therapeutic Chemical classification | | Thiouracils |
0‑L | H03BA01 | methylthiouracil | WHO Anatomical Therapeutic Chemical classification | | methylthiouracil |
0‑L | H03BA02 | propylthiouracil | WHO Anatomical Therapeutic Chemical classification | | propylthiouracil |
0‑L | H03BA03 | benzylthiouracil | WHO Anatomical Therapeutic Chemical classification | | benzylthiouracil |
0‑L | H03BB | Sulfur-containing imidazole derivatives | WHO Anatomical Therapeutic Chemical classification | | Sulfur-containing imidazole derivatives |
0‑L | H03BB01 | carbimazole | WHO Anatomical Therapeutic Chemical classification | | carbimazole |
0‑L | H03BB02 | thiamazole | WHO Anatomical Therapeutic Chemical classification | | thiamazole |
0‑L | H03BB52 | thiamazole, combinations | WHO Anatomical Therapeutic Chemical classification | | thiamazole, combinations |
0‑L | H03BC | Perchlorates | WHO Anatomical Therapeutic Chemical classification | | Perchlorates |
0‑L | H03BC01 | potassium perchlorate | WHO Anatomical Therapeutic Chemical classification | | potassium perchlorate |
0‑L | H03BX | Other antithyroid preparations | WHO Anatomical Therapeutic Chemical classification | | Other antithyroid preparations |
0‑L | H03BX01 | diiodotyrosine | WHO Anatomical Therapeutic Chemical classification | | diiodotyrosine |
0‑L | H03BX02 | dibromotyrosine | WHO Anatomical Therapeutic Chemical classification | | dibromotyrosine |
0‑L | H03C | IODINE THERAPY | WHO Anatomical Therapeutic Chemical classification | | IODINE THERAPY |
0‑L | H03CA | Iodine therapy | WHO Anatomical Therapeutic Chemical classification | | Iodine therapy |
0‑L | H04 | PANCREATIC HORMONES | WHO Anatomical Therapeutic Chemical classification | | PANCREATIC HORMONES |
0‑L | H04A | GLYCOGENOLYTIC HORMONES | WHO Anatomical Therapeutic Chemical classification | | GLYCOGENOLYTIC HORMONES |
0‑L | H04AA | Glycogenolytic hormones | WHO Anatomical Therapeutic Chemical classification | | Glycogenolytic hormones |
0‑L | H04AA01 | glucagon | WHO Anatomical Therapeutic Chemical classification | | glucagon |
0‑L | H05 | CALCIUM HOMEOSTASIS | WHO Anatomical Therapeutic Chemical classification | | CALCIUM HOMEOSTASIS |
0‑L | H05A | PARATHYROID HORMONES AND ANALOGUES | WHO Anatomical Therapeutic Chemical classification | | PARATHYROID HORMONES AND ANALOGUES |
0‑L | H05AA | Parathyroid hormones and analogues | WHO Anatomical Therapeutic Chemical classification | | Parathyroid hormones and analogues |
0‑L | H05AA01 | parathyroid gland extract | WHO Anatomical Therapeutic Chemical classification | | parathyroid gland extract |
0‑L | H05AA02 | teriparatide | WHO Anatomical Therapeutic Chemical classification | | teriparatide |
0‑L | H05AA03 | parathyroid hormone | WHO Anatomical Therapeutic Chemical classification | | parathyroid hormone |
0‑L | H05B | ANTI-PARATHYROID AGENTS | WHO Anatomical Therapeutic Chemical classification | | ANTI-PARATHYROID AGENTS |
0‑L | H05BA | Calcitonin preparations | WHO Anatomical Therapeutic Chemical classification | | Calcitonin preparations |
0‑L | H05BA01 | calcitonin (salmon synthetic) | WHO Anatomical Therapeutic Chemical classification | | calcitonin (salmon synthetic) |
0‑L | H05BA02 | calcitonin (pork natural) | WHO Anatomical Therapeutic Chemical classification | | calcitonin (pork natural) |
0‑L | H05BA03 | calcitonin (human synthetic) | WHO Anatomical Therapeutic Chemical classification | | calcitonin (human synthetic) |
0‑L | H05BA04 | elcatonin | WHO Anatomical Therapeutic Chemical classification | | elcatonin |
0‑L | H05BX | Other anti-parathyroid agents | WHO Anatomical Therapeutic Chemical classification | | Other anti-parathyroid agents |
0‑L | H05BX01 | cinacalcet | WHO Anatomical Therapeutic Chemical classification | | cinacalcet |
0‑L | H05BX02 | paricalcitol | WHO Anatomical Therapeutic Chemical classification | | paricalcitol |
0‑L | H05BX03 | doxercalciferol | WHO Anatomical Therapeutic Chemical classification | | doxercalciferol |
0‑L | H05BX04 | etelcalcetide | WHO Anatomical Therapeutic Chemical classification | | etelcalcetide |
0‑L | J | ANTIINFECTIVES FOR SYSTEMIC USE | WHO Anatomical Therapeutic Chemical classification | | ANTIINFECTIVES FOR SYSTEMIC USE |
0‑L | J01 | ANTIBACTERIALS FOR SYSTEMIC USE | WHO Anatomical Therapeutic Chemical classification | | ANTIBACTERIALS FOR SYSTEMIC USE |
0‑L | J01A | TETRACYCLINES | WHO Anatomical Therapeutic Chemical classification | | TETRACYCLINES |
0‑L | J01AA | Tetracyclines | WHO Anatomical Therapeutic Chemical classification | | Tetracyclines |
0‑L | J01AA01 | demeclocycline | WHO Anatomical Therapeutic Chemical classification | | demeclocycline |
0‑L | J01AA02 | doxycycline | WHO Anatomical Therapeutic Chemical classification | | doxycycline |
0‑L | J01AA03 | chlortetracycline | WHO Anatomical Therapeutic Chemical classification | | chlortetracycline |
0‑L | J01AA04 | lymecycline | WHO Anatomical Therapeutic Chemical classification | | lymecycline |
0‑L | J01AA05 | metacycline | WHO Anatomical Therapeutic Chemical classification | | metacycline |
0‑L | J01AA06 | oxytetracycline | WHO Anatomical Therapeutic Chemical classification | | oxytetracycline |
0‑L | J01AA07 | tetracycline | WHO Anatomical Therapeutic Chemical classification | | tetracycline |
0‑L | J01AA08 | minocycline | WHO Anatomical Therapeutic Chemical classification | | minocycline |
0‑L | J01AA09 | rolitetracycline | WHO Anatomical Therapeutic Chemical classification | | rolitetracycline |
0‑L | J01AA10 | penimepicycline | WHO Anatomical Therapeutic Chemical classification | | penimepicycline |
0‑L | J01AA11 | clomocycline | WHO Anatomical Therapeutic Chemical classification | | clomocycline |
0‑L | J01AA12 | tigecycline | WHO Anatomical Therapeutic Chemical classification | | tigecycline |
0‑L | J01AA20 | combinations of tetracyclines | WHO Anatomical Therapeutic Chemical classification | | combinations of tetracyclines |
0‑L | J01AA56 | oxytetracycline, combinations | WHO Anatomical Therapeutic Chemical classification | | oxytetracycline, combinations |
0‑L | J01B | AMPHENICOLS | WHO Anatomical Therapeutic Chemical classification | | AMPHENICOLS |
0‑L | J01BA | Amphenicols | WHO Anatomical Therapeutic Chemical classification | | Amphenicols |
0‑L | J01BA01 | chloramphenicol | WHO Anatomical Therapeutic Chemical classification | | chloramphenicol |
0‑L | J01BA02 | thiamphenicol | WHO Anatomical Therapeutic Chemical classification | | thiamphenicol |
0‑L | J01BA52 | thiamphenicol, combinations | WHO Anatomical Therapeutic Chemical classification | | thiamphenicol, combinations |
0‑L | J01C | BETA-LACTAM ANTIBACTERIALS, PENICILLINS | WHO Anatomical Therapeutic Chemical classification | | BETA-LACTAM ANTIBACTERIALS, PENICILLINS |
0‑L | J01CA | Penicillins with extended spectrum | WHO Anatomical Therapeutic Chemical classification | | Penicillins with extended spectrum |
0‑L | J01CA01 | ampicillin | WHO Anatomical Therapeutic Chemical classification | | ampicillin |
0‑L | J01CA02 | pivampicillin | WHO Anatomical Therapeutic Chemical classification | | pivampicillin |
0‑L | J01CA03 | carbenicillin | WHO Anatomical Therapeutic Chemical classification | | carbenicillin |
0‑L | J01CA04 | amoxicillin | WHO Anatomical Therapeutic Chemical classification | | amoxicillin |
0‑L | J01CA05 | carindacillin | WHO Anatomical Therapeutic Chemical classification | | carindacillin |
0‑L | J01CA06 | bacampicillin | WHO Anatomical Therapeutic Chemical classification | | bacampicillin |
0‑L | J01CA07 | epicillin | WHO Anatomical Therapeutic Chemical classification | | epicillin |
0‑L | J01CA08 | pivmecillinam | WHO Anatomical Therapeutic Chemical classification | | pivmecillinam |
0‑L | J01CA09 | azlocillin | WHO Anatomical Therapeutic Chemical classification | | azlocillin |
0‑L | J01CA10 | mezlocillin | WHO Anatomical Therapeutic Chemical classification | | mezlocillin |
0‑L | J01CA11 | mecillinam | WHO Anatomical Therapeutic Chemical classification | | mecillinam |
0‑L | J01CA12 | piperacillin | WHO Anatomical Therapeutic Chemical classification | | piperacillin |
0‑L | J01CA13 | ticarcillin | WHO Anatomical Therapeutic Chemical classification | | ticarcillin |
0‑L | J01CA14 | metampicillin | WHO Anatomical Therapeutic Chemical classification | | metampicillin |
0‑L | J01CA15 | talampicillin | WHO Anatomical Therapeutic Chemical classification | | talampicillin |
0‑L | J01CA16 | sulbenicillin | WHO Anatomical Therapeutic Chemical classification | | sulbenicillin |
0‑L | J01CA17 | temocillin | WHO Anatomical Therapeutic Chemical classification | | temocillin |
0‑L | J01CA18 | hetacillin | WHO Anatomical Therapeutic Chemical classification | | hetacillin |
0‑L | J01CA19 | aspoxicillin | WHO Anatomical Therapeutic Chemical classification | | aspoxicillin |
0‑L | J01CA20 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | J01CA51 | ampicillin, combinations | WHO Anatomical Therapeutic Chemical classification | | ampicillin, combinations |
0‑L | J01CE | Beta-lactamase sensitive penicillins | WHO Anatomical Therapeutic Chemical classification | | Beta-lactamase sensitive penicillins |
0‑L | J01CE01 | benzylpenicillin | WHO Anatomical Therapeutic Chemical classification | | benzylpenicillin |
0‑L | J01CE02 | phenoxymethylpenicillin | WHO Anatomical Therapeutic Chemical classification | | phenoxymethylpenicillin |
0‑L | J01CE03 | propicillin | WHO Anatomical Therapeutic Chemical classification | | propicillin |
0‑L | J01CE04 | azidocillin | WHO Anatomical Therapeutic Chemical classification | | azidocillin |
0‑L | J01CE05 | pheneticillin | WHO Anatomical Therapeutic Chemical classification | | pheneticillin |
0‑L | J01CE06 | penamecillin | WHO Anatomical Therapeutic Chemical classification | | penamecillin |
0‑L | J01CE07 | clometocillin | WHO Anatomical Therapeutic Chemical classification | | clometocillin |
0‑L | J01CE08 | benzathine benzylpenicillin | WHO Anatomical Therapeutic Chemical classification | | benzathine benzylpenicillin |
0‑L | J01CE09 | procaine benzylpenicillin | WHO Anatomical Therapeutic Chemical classification | | procaine benzylpenicillin |
0‑L | J01CE10 | benzathine phenoxymethylpenicillin | WHO Anatomical Therapeutic Chemical classification | | benzathine phenoxymethylpenicillin |
0‑L | J01CE30 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | J01CF | Beta-lactamase resistant penicillins | WHO Anatomical Therapeutic Chemical classification | | Beta-lactamase resistant penicillins |
0‑L | J01CF01 | dicloxacillin | WHO Anatomical Therapeutic Chemical classification | | dicloxacillin |
0‑L | J01CF02 | cloxacillin | WHO Anatomical Therapeutic Chemical classification | | cloxacillin |
0‑L | J01CF03 | meticillin | WHO Anatomical Therapeutic Chemical classification | | meticillin |
0‑L | J01CF04 | oxacillin | WHO Anatomical Therapeutic Chemical classification | | oxacillin |
0‑L | J01CF05 | flucloxacillin | WHO Anatomical Therapeutic Chemical classification | | flucloxacillin |
0‑L | J01CF06 | nafcillin | WHO Anatomical Therapeutic Chemical classification | | nafcillin |
0‑L | J01CG | Beta-lactamase inhibitors | WHO Anatomical Therapeutic Chemical classification | | Beta-lactamase inhibitors |
0‑L | J01CG01 | sulbactam | WHO Anatomical Therapeutic Chemical classification | | sulbactam |
0‑L | J01CG02 | tazobactam | WHO Anatomical Therapeutic Chemical classification | | tazobactam |
0‑L | J01CR | Combinations of penicillins, incl. beta-lactamase inhibitors | WHO Anatomical Therapeutic Chemical classification | | Combinations of penicillins, incl. beta-lactamase inhibitors |
0‑L | J01CR01 | ampicillin and enzyme inhibitor | WHO Anatomical Therapeutic Chemical classification | | ampicillin and enzyme inhibitor |
0‑L | J01CR02 | amoxicillin and enzyme inhibitor | WHO Anatomical Therapeutic Chemical classification | | amoxicillin and enzyme inhibitor |
0‑L | J01CR03 | ticarcillin and enzyme inhibitor | WHO Anatomical Therapeutic Chemical classification | | ticarcillin and enzyme inhibitor |
0‑L | J01CR04 | sultamicillin | WHO Anatomical Therapeutic Chemical classification | | sultamicillin |
0‑L | J01CR05 | piperacillin and enzyme inhibitor | WHO Anatomical Therapeutic Chemical classification | | piperacillin and enzyme inhibitor |
0‑L | J01CR50 | combinations of penicillins | WHO Anatomical Therapeutic Chemical classification | | combinations of penicillins |
0‑L | J01D | OTHER BETA-LACTAM ANTIBACTERIALS | WHO Anatomical Therapeutic Chemical classification | | OTHER BETA-LACTAM ANTIBACTERIALS |
0‑L | J01DB | First-generation cephalosporins | WHO Anatomical Therapeutic Chemical classification | | First-generation cephalosporins |
0‑L | J01DB01 | cefalexin | WHO Anatomical Therapeutic Chemical classification | | cefalexin |
0‑L | J01DB02 | cefaloridine | WHO Anatomical Therapeutic Chemical classification | | cefaloridine |
0‑L | J01DB03 | cefalotin | WHO Anatomical Therapeutic Chemical classification | | cefalotin |
0‑L | J01DB04 | cefazolin | WHO Anatomical Therapeutic Chemical classification | | cefazolin |
0‑L | J01DB05 | cefadroxil | WHO Anatomical Therapeutic Chemical classification | | cefadroxil |
0‑L | J01DB06 | cefazedone | WHO Anatomical Therapeutic Chemical classification | | cefazedone |
0‑L | J01DB07 | cefatrizine | WHO Anatomical Therapeutic Chemical classification | | cefatrizine |
0‑L | J01DB08 | cefapirin | WHO Anatomical Therapeutic Chemical classification | | cefapirin |
0‑L | J01DB09 | cefradine | WHO Anatomical Therapeutic Chemical classification | | cefradine |
0‑L | J01DB10 | cefacetrile | WHO Anatomical Therapeutic Chemical classification | | cefacetrile |
0‑L | J01DB11 | cefroxadine | WHO Anatomical Therapeutic Chemical classification | | cefroxadine |
0‑L | J01DB12 | ceftezole | WHO Anatomical Therapeutic Chemical classification | | ceftezole |
0‑L | J01DC | Second-generation cephalosporins | WHO Anatomical Therapeutic Chemical classification | | Second-generation cephalosporins |
0‑L | J01DC01 | cefoxitin | WHO Anatomical Therapeutic Chemical classification | | cefoxitin |
0‑L | J01DC02 | cefuroxime | WHO Anatomical Therapeutic Chemical classification | | cefuroxime |
0‑L | J01DC03 | cefamandole | WHO Anatomical Therapeutic Chemical classification | | cefamandole |
0‑L | J01DC04 | cefaclor | WHO Anatomical Therapeutic Chemical classification | | cefaclor |
0‑L | J01DC05 | cefotetan | WHO Anatomical Therapeutic Chemical classification | | cefotetan |
0‑L | J01DC06 | cefonicid | WHO Anatomical Therapeutic Chemical classification | | cefonicid |
0‑L | J01DC07 | cefotiam | WHO Anatomical Therapeutic Chemical classification | | cefotiam |
0‑L | J01DC08 | loracarbef | WHO Anatomical Therapeutic Chemical classification | | loracarbef |
0‑L | J01DC09 | cefmetazole | WHO Anatomical Therapeutic Chemical classification | | cefmetazole |
0‑L | J01DC10 | cefprozil | WHO Anatomical Therapeutic Chemical classification | | cefprozil |
0‑L | J01DC11 | ceforanide | WHO Anatomical Therapeutic Chemical classification | | ceforanide |
0‑L | J01DC12 | cefminox | WHO Anatomical Therapeutic Chemical classification | | cefminox |
0‑L | J01DC13 | cefbuperazone | WHO Anatomical Therapeutic Chemical classification | | cefbuperazone |
0‑L | J01DC14 | flomoxef | WHO Anatomical Therapeutic Chemical classification | | flomoxef |
0‑L | J01DD | Third-generation cephalosporins | WHO Anatomical Therapeutic Chemical classification | | Third-generation cephalosporins |
0‑L | J01DD01 | cefotaxime | WHO Anatomical Therapeutic Chemical classification | | cefotaxime |
0‑L | J01DD02 | ceftazidime | WHO Anatomical Therapeutic Chemical classification | | ceftazidime |
0‑L | J01DD03 | cefsulodin | WHO Anatomical Therapeutic Chemical classification | | cefsulodin |
0‑L | J01DD04 | ceftriaxone | WHO Anatomical Therapeutic Chemical classification | | ceftriaxone |
0‑L | J01DD05 | cefmenoxime | WHO Anatomical Therapeutic Chemical classification | | cefmenoxime |
0‑L | J01DD06 | latamoxef | WHO Anatomical Therapeutic Chemical classification | | latamoxef |
0‑L | J01DD07 | ceftizoxime | WHO Anatomical Therapeutic Chemical classification | | ceftizoxime |
0‑L | J01DD08 | cefixime | WHO Anatomical Therapeutic Chemical classification | | cefixime |
0‑L | J01DD09 | cefodizime | WHO Anatomical Therapeutic Chemical classification | | cefodizime |
0‑L | J01DD10 | cefetamet | WHO Anatomical Therapeutic Chemical classification | | cefetamet |
0‑L | J01DD11 | cefpiramide | WHO Anatomical Therapeutic Chemical classification | | cefpiramide |
0‑L | J01DD12 | cefoperazone | WHO Anatomical Therapeutic Chemical classification | | cefoperazone |
0‑L | J01DD13 | cefpodoxime | WHO Anatomical Therapeutic Chemical classification | | cefpodoxime |
0‑L | J01DD14 | ceftibuten | WHO Anatomical Therapeutic Chemical classification | | ceftibuten |
0‑L | J01DD15 | cefdinir | WHO Anatomical Therapeutic Chemical classification | | cefdinir |
0‑L | J01DD16 | cefditoren | WHO Anatomical Therapeutic Chemical classification | | cefditoren |
0‑L | J01DD17 | cefcapene | WHO Anatomical Therapeutic Chemical classification | | cefcapene |
0‑L | J01DD51 | cefotaxime, combinations | WHO Anatomical Therapeutic Chemical classification | | cefotaxime, combinations |
0‑L | J01DD52 | ceftazidime, combinations | WHO Anatomical Therapeutic Chemical classification | | ceftazidime, combinations |
0‑L | J01DD54 | ceftriaxone, combinations | WHO Anatomical Therapeutic Chemical classification | | ceftriaxone, combinations |
0‑L | J01DD62 | cefoperazone, combinations | WHO Anatomical Therapeutic Chemical classification | | cefoperazone, combinations |
0‑L | J01DE | Fourth-generation cephalosporins | WHO Anatomical Therapeutic Chemical classification | | Fourth-generation cephalosporins |
0‑L | J01DE01 | cefepime | WHO Anatomical Therapeutic Chemical classification | | cefepime |
0‑L | J01DE02 | cefpirome | WHO Anatomical Therapeutic Chemical classification | | cefpirome |
0‑L | J01DE03 | cefozopran | WHO Anatomical Therapeutic Chemical classification | | cefozopran |
0‑L | J01DF | Monobactams | WHO Anatomical Therapeutic Chemical classification | | Monobactams |
0‑L | J01DF01 | aztreonam | WHO Anatomical Therapeutic Chemical classification | | aztreonam |
0‑L | J01DF02 | carumonam | WHO Anatomical Therapeutic Chemical classification | | carumonam |
0‑L | J01DH | Carbapenems | WHO Anatomical Therapeutic Chemical classification | | Carbapenems |
0‑L | J01DH02 | meropenem | WHO Anatomical Therapeutic Chemical classification | | meropenem |
0‑L | J01DH03 | ertapenem | WHO Anatomical Therapeutic Chemical classification | | ertapenem |
0‑L | J01DH04 | doripenem | WHO Anatomical Therapeutic Chemical classification | | doripenem |
0‑L | J01DH05 | biapenem | WHO Anatomical Therapeutic Chemical classification | | biapenem |
0‑L | J01DH51 | imipenem and enzyme inhibitor | WHO Anatomical Therapeutic Chemical classification | | imipenem and enzyme inhibitor |
0‑L | J01DH55 | panipenem and betamipron | WHO Anatomical Therapeutic Chemical classification | | panipenem and betamipron |
0‑L | J01DI | Other cephalosporins and penems | WHO Anatomical Therapeutic Chemical classification | | Other cephalosporins and penems |
0‑L | J01DI01 | ceftobiprole medocaril | WHO Anatomical Therapeutic Chemical classification | | ceftobiprole medocaril |
0‑L | J01DI02 | ceftaroline fosamil | WHO Anatomical Therapeutic Chemical classification | | ceftaroline fosamil |
0‑L | J01DI03 | faropenem | WHO Anatomical Therapeutic Chemical classification | | faropenem |
0‑L | J01DI54 | ceftolozane and enzyme inhibitor | WHO Anatomical Therapeutic Chemical classification | | ceftolozane and enzyme inhibitor |
0‑L | J01E | SULFONAMIDES AND TRIMETHOPRIM | WHO Anatomical Therapeutic Chemical classification | | SULFONAMIDES AND TRIMETHOPRIM |
0‑L | J01EA | Trimethoprim and derivatives | WHO Anatomical Therapeutic Chemical classification | | Trimethoprim and derivatives |
0‑L | J01EA01 | trimethoprim | WHO Anatomical Therapeutic Chemical classification | | trimethoprim |
0‑L | J01EA02 | brodimoprim | WHO Anatomical Therapeutic Chemical classification | | brodimoprim |
0‑L | J01EA03 | iclaprim | WHO Anatomical Therapeutic Chemical classification | | iclaprim |
0‑L | J01EB | Short-acting sulfonamides | WHO Anatomical Therapeutic Chemical classification | | Short-acting sulfonamides |
0‑L | J01EB01 | sulfaisodimidine | WHO Anatomical Therapeutic Chemical classification | | sulfaisodimidine |
0‑L | J01EB02 | sulfamethizole | WHO Anatomical Therapeutic Chemical classification | | sulfamethizole |
0‑L | J01EB03 | sulfadimidine | WHO Anatomical Therapeutic Chemical classification | | sulfadimidine |
0‑L | J01EB04 | sulfapyridine | WHO Anatomical Therapeutic Chemical classification | | sulfapyridine |
0‑L | J01EB05 | sulfafurazole | WHO Anatomical Therapeutic Chemical classification | | sulfafurazole |
0‑L | J01EB06 | sulfanilamide | WHO Anatomical Therapeutic Chemical classification | | sulfanilamide |
0‑L | J01EB07 | sulfathiazole | WHO Anatomical Therapeutic Chemical classification | | sulfathiazole |
0‑L | J01EB08 | sulfathiourea | WHO Anatomical Therapeutic Chemical classification | | sulfathiourea |
0‑L | J01EB20 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | J01EC | Intermediate-acting sulfonamides | WHO Anatomical Therapeutic Chemical classification | | Intermediate-acting sulfonamides |
0‑L | J01EC01 | sulfamethoxazole | WHO Anatomical Therapeutic Chemical classification | | sulfamethoxazole |
0‑L | J01EC02 | sulfadiazine | WHO Anatomical Therapeutic Chemical classification | | sulfadiazine |
0‑L | J01EC03 | sulfamoxole | WHO Anatomical Therapeutic Chemical classification | | sulfamoxole |
0‑L | J01EC20 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | J01ED | Long-acting sulfonamides | WHO Anatomical Therapeutic Chemical classification | | Long-acting sulfonamides |
0‑L | J01ED01 | sulfadimethoxine | WHO Anatomical Therapeutic Chemical classification | | sulfadimethoxine |
0‑L | J01ED02 | sulfalene | WHO Anatomical Therapeutic Chemical classification | | sulfalene |
0‑L | J01ED03 | sulfametomidine | WHO Anatomical Therapeutic Chemical classification | | sulfametomidine |
0‑L | J01ED04 | sulfametoxydiazine | WHO Anatomical Therapeutic Chemical classification | | sulfametoxydiazine |
0‑L | J01ED05 | sulfamethoxypyridazine | WHO Anatomical Therapeutic Chemical classification | | sulfamethoxypyridazine |
0‑L | J01ED06 | sulfaperin | WHO Anatomical Therapeutic Chemical classification | | sulfaperin |
0‑L | J01ED07 | sulfamerazine | WHO Anatomical Therapeutic Chemical classification | | sulfamerazine |
0‑L | J01ED08 | sulfaphenazole | WHO Anatomical Therapeutic Chemical classification | | sulfaphenazole |
0‑L | J01ED09 | sulfamazone | WHO Anatomical Therapeutic Chemical classification | | sulfamazone |
0‑L | J01ED20 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | J01EE | Combinations of sulfonamides and trimethoprim, incl. derivatives | WHO Anatomical Therapeutic Chemical classification | | Combinations of sulfonamides and trimethoprim, incl. derivatives |
0‑L | J01EE01 | sulfamethoxazole and trimethoprim | WHO Anatomical Therapeutic Chemical classification | | sulfamethoxazole and trimethoprim |
0‑L | J01EE02 | sulfadiazine and trimethoprim | WHO Anatomical Therapeutic Chemical classification | | sulfadiazine and trimethoprim |
0‑L | J01EE03 | sulfametrole and trimethoprim | WHO Anatomical Therapeutic Chemical classification | | sulfametrole and trimethoprim |
0‑L | J01EE04 | sulfamoxole and trimethoprim | WHO Anatomical Therapeutic Chemical classification | | sulfamoxole and trimethoprim |
0‑L | J01EE05 | sulfadimidine and trimethoprim | WHO Anatomical Therapeutic Chemical classification | | sulfadimidine and trimethoprim |
0‑L | J01EE06 | sulfadiazine and tetroxoprim | WHO Anatomical Therapeutic Chemical classification | | sulfadiazine and tetroxoprim |
0‑L | J01EE07 | sulfamerazine and trimethoprim | WHO Anatomical Therapeutic Chemical classification | | sulfamerazine and trimethoprim |
0‑L | J01F | MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS | WHO Anatomical Therapeutic Chemical classification | | MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS |
0‑L | J01FA | Macrolides | WHO Anatomical Therapeutic Chemical classification | | Macrolides |
0‑L | J01FA01 | erythromycin | WHO Anatomical Therapeutic Chemical classification | | erythromycin |
0‑L | J01FA02 | spiramycin | WHO Anatomical Therapeutic Chemical classification | | spiramycin |
0‑L | J01FA03 | midecamycin | WHO Anatomical Therapeutic Chemical classification | | midecamycin |
0‑L | J01FA05 | oleandomycin | WHO Anatomical Therapeutic Chemical classification | | oleandomycin |
0‑L | J01FA06 | roxithromycin | WHO Anatomical Therapeutic Chemical classification | | roxithromycin |
0‑L | J01FA07 | josamycin | WHO Anatomical Therapeutic Chemical classification | | josamycin |
0‑L | J01FA08 | troleandomycin | WHO Anatomical Therapeutic Chemical classification | | troleandomycin |
0‑L | J01FA09 | clarithromycin | WHO Anatomical Therapeutic Chemical classification | | clarithromycin |
0‑L | J01FA10 | azithromycin | WHO Anatomical Therapeutic Chemical classification | | azithromycin |
0‑L | J01FA11 | miocamycin | WHO Anatomical Therapeutic Chemical classification | | miocamycin |
0‑L | J01FA12 | rokitamycin | WHO Anatomical Therapeutic Chemical classification | | rokitamycin |
0‑L | J01FA13 | dirithromycin | WHO Anatomical Therapeutic Chemical classification | | dirithromycin |
0‑L | J01FA14 | flurithromycin | WHO Anatomical Therapeutic Chemical classification | | flurithromycin |
0‑L | J01FA15 | telithromycin | WHO Anatomical Therapeutic Chemical classification | | telithromycin |
0‑L | J01FA16 | solithromycin | WHO Anatomical Therapeutic Chemical classification | | solithromycin |
0‑L | J01FF | Lincosamides | WHO Anatomical Therapeutic Chemical classification | | Lincosamides |
0‑L | J01FF01 | clindamycin | WHO Anatomical Therapeutic Chemical classification | | clindamycin |
0‑L | J01FF02 | lincomycin | WHO Anatomical Therapeutic Chemical classification | | lincomycin |
0‑L | J01FG | Streptogramins | WHO Anatomical Therapeutic Chemical classification | | Streptogramins |
0‑L | J01FG01 | pristinamycin | WHO Anatomical Therapeutic Chemical classification | | pristinamycin |
0‑L | J01FG02 | quinupristin/dalfopristin | WHO Anatomical Therapeutic Chemical classification | | quinupristin/dalfopristin |
0‑L | J01G | AMINOGLYCOSIDE ANTIBACTERIALS | WHO Anatomical Therapeutic Chemical classification | | AMINOGLYCOSIDE ANTIBACTERIALS |
0‑L | J01GA | Streptomycins | WHO Anatomical Therapeutic Chemical classification | | Streptomycins |
0‑L | J01GA01 | streptomycin | WHO Anatomical Therapeutic Chemical classification | | streptomycin |
0‑L | J01GA02 | streptoduocin | WHO Anatomical Therapeutic Chemical classification | | streptoduocin |
0‑L | J01GB | Other aminoglycosides | WHO Anatomical Therapeutic Chemical classification | | Other aminoglycosides |
0‑L | J01GB01 | tobramycin | WHO Anatomical Therapeutic Chemical classification | | tobramycin |
0‑L | J01GB03 | gentamicin | WHO Anatomical Therapeutic Chemical classification | | gentamicin |
0‑L | J01GB04 | kanamycin | WHO Anatomical Therapeutic Chemical classification | | kanamycin |
0‑L | J01GB05 | neomycin | WHO Anatomical Therapeutic Chemical classification | | neomycin |
0‑L | J01GB06 | amikacin | WHO Anatomical Therapeutic Chemical classification | | amikacin |
0‑L | J01GB07 | netilmicin | WHO Anatomical Therapeutic Chemical classification | | netilmicin |
0‑L | J01GB08 | sisomicin | WHO Anatomical Therapeutic Chemical classification | | sisomicin |
0‑L | J01GB09 | dibekacin | WHO Anatomical Therapeutic Chemical classification | | dibekacin |
0‑L | J01GB10 | ribostamycin | WHO Anatomical Therapeutic Chemical classification | | ribostamycin |
0‑L | J01GB11 | isepamicin | WHO Anatomical Therapeutic Chemical classification | | isepamicin |
0‑L | J01GB12 | arbekacin | WHO Anatomical Therapeutic Chemical classification | | arbekacin |
0‑L | J01GB13 | bekanamycin | WHO Anatomical Therapeutic Chemical classification | | bekanamycin |
0‑L | J01M | QUINOLONE ANTIBACTERIALS | WHO Anatomical Therapeutic Chemical classification | | QUINOLONE ANTIBACTERIALS |
0‑L | J01MA | Fluoroquinolones | WHO Anatomical Therapeutic Chemical classification | | Fluoroquinolones |
0‑L | J01MA01 | ofloxacin | WHO Anatomical Therapeutic Chemical classification | | ofloxacin |
0‑L | J01MA02 | ciprofloxacin | WHO Anatomical Therapeutic Chemical classification | | ciprofloxacin |
0‑L | J01MA03 | pefloxacin | WHO Anatomical Therapeutic Chemical classification | | pefloxacin |
0‑L | J01MA04 | enoxacin | WHO Anatomical Therapeutic Chemical classification | | enoxacin |
0‑L | J01MA05 | temafloxacin | WHO Anatomical Therapeutic Chemical classification | | temafloxacin |
0‑L | J01MA06 | norfloxacin | WHO Anatomical Therapeutic Chemical classification | | norfloxacin |
0‑L | J01MA07 | lomefloxacin | WHO Anatomical Therapeutic Chemical classification | | lomefloxacin |
0‑L | J01MA08 | fleroxacin | WHO Anatomical Therapeutic Chemical classification | | fleroxacin |
0‑L | J01MA09 | sparfloxacin | WHO Anatomical Therapeutic Chemical classification | | sparfloxacin |
0‑L | J01MA10 | rufloxacin | WHO Anatomical Therapeutic Chemical classification | | rufloxacin |
0‑L | J01MA11 | grepafloxacin | WHO Anatomical Therapeutic Chemical classification | | grepafloxacin |
0‑L | J01MA12 | levofloxacin | WHO Anatomical Therapeutic Chemical classification | | levofloxacin |
0‑L | J01MA13 | trovafloxacin | WHO Anatomical Therapeutic Chemical classification | | trovafloxacin |
0‑L | J01MA14 | moxifloxacin | WHO Anatomical Therapeutic Chemical classification | | moxifloxacin |
0‑L | J01MA15 | gemifloxacin | WHO Anatomical Therapeutic Chemical classification | | gemifloxacin |
0‑L | J01MA16 | gatifloxacin | WHO Anatomical Therapeutic Chemical classification | | gatifloxacin |
0‑L | J01MA17 | prulifloxacin | WHO Anatomical Therapeutic Chemical classification | | prulifloxacin |
0‑L | J01MA18 | pazufloxacin | WHO Anatomical Therapeutic Chemical classification | | pazufloxacin |
0‑L | J01MA19 | garenoxacin | WHO Anatomical Therapeutic Chemical classification | | garenoxacin |
0‑L | J01MA21 | sitafloxacin | WHO Anatomical Therapeutic Chemical classification | | sitafloxacin |
0‑L | J01MB | Other quinolones | WHO Anatomical Therapeutic Chemical classification | | Other quinolones |
0‑L | J01MB01 | rosoxacin | WHO Anatomical Therapeutic Chemical classification | | rosoxacin |
0‑L | J01MB02 | nalidixic acid | WHO Anatomical Therapeutic Chemical classification | | nalidixic acid |
0‑L | J01MB03 | piromidic acid | WHO Anatomical Therapeutic Chemical classification | | piromidic acid |
0‑L | J01MB04 | pipemidic acid | WHO Anatomical Therapeutic Chemical classification | | pipemidic acid |
0‑L | J01MB05 | oxolinic acid | WHO Anatomical Therapeutic Chemical classification | | oxolinic acid |
0‑L | J01MB06 | cinoxacin | WHO Anatomical Therapeutic Chemical classification | | cinoxacin |
0‑L | J01MB07 | flumequine | WHO Anatomical Therapeutic Chemical classification | | flumequine |
0‑L | J01MB08 | nemonoxacin | WHO Anatomical Therapeutic Chemical classification | | nemonoxacin |
0‑L | J01R | COMBINATIONS OF ANTIBACTERIALS | WHO Anatomical Therapeutic Chemical classification | | COMBINATIONS OF ANTIBACTERIALS |
0‑L | J01RA | Combinations of antibacterials | WHO Anatomical Therapeutic Chemical classification | | Combinations of antibacterials |
0‑L | J01RA01 | penicillins, combinations with other antibacterials | WHO Anatomical Therapeutic Chemical classification | | penicillins, combinations with other antibacterials |
0‑L | J01RA02 | sulfonamides, combinations with other antibacterials (excl. trimethoprim) | WHO Anatomical Therapeutic Chemical classification | | sulfonamides, combinations with other antibacterials (excl. trimethoprim) |
0‑L | J01RA03 | cefuroxime and metronidazole | WHO Anatomical Therapeutic Chemical classification | | cefuroxime and metronidazole |
0‑L | J01RA04 | spiramycin and metronidazole | WHO Anatomical Therapeutic Chemical classification | | spiramycin and metronidazole |
0‑L | J01RA05 | levofloxacin and ornidazole | WHO Anatomical Therapeutic Chemical classification | | levofloxacin and ornidazole |
0‑L | J01RA06 | cefepime and amikacin | WHO Anatomical Therapeutic Chemical classification | | cefepime and amikacin |
0‑L | J01RA07 | azithromycin, fluconazole and secnidazole | WHO Anatomical Therapeutic Chemical classification | | azithromycin, fluconazole and secnidazole |
0‑L | J01RA08 | tetracycline and oleandomycin | WHO Anatomical Therapeutic Chemical classification | | tetracycline and oleandomycin |
0‑L | J01RA09 | ofloxacin and ornidazole | WHO Anatomical Therapeutic Chemical classification | | ofloxacin and ornidazole |
0‑L | J01RA10 | ciprofloxacin and metronidazole | WHO Anatomical Therapeutic Chemical classification | | ciprofloxacin and metronidazole |
0‑L | J01RA11 | ciprofloxacin and tinidazole | WHO Anatomical Therapeutic Chemical classification | | ciprofloxacin and tinidazole |
0‑L | J01RA12 | ciprofloxacin and ornidazole | WHO Anatomical Therapeutic Chemical classification | | ciprofloxacin and ornidazole |
0‑L | J01RA13 | norfloxacin and tinidazole | WHO Anatomical Therapeutic Chemical classification | | norfloxacin and tinidazole |
0‑L | J01X | OTHER ANTIBACTERIALS | WHO Anatomical Therapeutic Chemical classification | | OTHER ANTIBACTERIALS |
0‑L | J01XA | Glycopeptide antibacterials | WHO Anatomical Therapeutic Chemical classification | | Glycopeptide antibacterials |
0‑L | J01XA01 | vancomycin | WHO Anatomical Therapeutic Chemical classification | | vancomycin |
0‑L | J01XA02 | teicoplanin | WHO Anatomical Therapeutic Chemical classification | | teicoplanin |
0‑L | J01XA03 | telavancin | WHO Anatomical Therapeutic Chemical classification | | telavancin |
0‑L | J01XA04 | dalbavancin | WHO Anatomical Therapeutic Chemical classification | | dalbavancin |
0‑L | J01XA05 | oritavancin | WHO Anatomical Therapeutic Chemical classification | | oritavancin |
0‑L | J01XB | Polymyxins | WHO Anatomical Therapeutic Chemical classification | | Polymyxins |
0‑L | J01XB01 | colistin | WHO Anatomical Therapeutic Chemical classification | | colistin |
0‑L | J01XB02 | polymyxin B | WHO Anatomical Therapeutic Chemical classification | | polymyxin B |
0‑L | J01XC | Steroid antibacterials | WHO Anatomical Therapeutic Chemical classification | | Steroid antibacterials |
0‑L | J01XC01 | fusidic acid | WHO Anatomical Therapeutic Chemical classification | | fusidic acid |
0‑L | J01XD | Imidazole derivatives | WHO Anatomical Therapeutic Chemical classification | | Imidazole derivatives |
0‑L | J01XD01 | metronidazole | WHO Anatomical Therapeutic Chemical classification | | metronidazole |
0‑L | J01XD02 | tinidazole | WHO Anatomical Therapeutic Chemical classification | | tinidazole |
0‑L | J01XD03 | ornidazole | WHO Anatomical Therapeutic Chemical classification | | ornidazole |
0‑L | J01XE | Nitrofuran derivatives | WHO Anatomical Therapeutic Chemical classification | | Nitrofuran derivatives |
0‑L | J01XE01 | nitrofurantoin | WHO Anatomical Therapeutic Chemical classification | | nitrofurantoin |
0‑L | J01XE02 | nifurtoinol | WHO Anatomical Therapeutic Chemical classification | | nifurtoinol |
0‑L | J01XE03 | furazidin | WHO Anatomical Therapeutic Chemical classification | | furazidin |
0‑L | J01XE51 | nitrofurantoin, combinations | WHO Anatomical Therapeutic Chemical classification | | nitrofurantoin, combinations |
0‑L | J01XX | Other antibacterials | WHO Anatomical Therapeutic Chemical classification | | Other antibacterials |
0‑L | J01XX01 | fosfomycin | WHO Anatomical Therapeutic Chemical classification | | fosfomycin |
0‑L | J01XX02 | xibornol | WHO Anatomical Therapeutic Chemical classification | | xibornol |
0‑L | J01XX03 | clofoctol | WHO Anatomical Therapeutic Chemical classification | | clofoctol |
0‑L | J01XX04 | spectinomycin | WHO Anatomical Therapeutic Chemical classification | | spectinomycin |
0‑L | J01XX05 | methenamine | WHO Anatomical Therapeutic Chemical classification | | methenamine |
0‑L | J01XX06 | mandelic acid | WHO Anatomical Therapeutic Chemical classification | | mandelic acid |
0‑L | J01XX07 | nitroxoline | WHO Anatomical Therapeutic Chemical classification | | nitroxoline |
0‑L | J01XX08 | linezolid | WHO Anatomical Therapeutic Chemical classification | | linezolid |
0‑L | J01XX09 | daptomycin | WHO Anatomical Therapeutic Chemical classification | | daptomycin |
0‑L | J01XX10 | bacitracin | WHO Anatomical Therapeutic Chemical classification | | bacitracin |
0‑L | J01XX11 | tedizolid | WHO Anatomical Therapeutic Chemical classification | | tedizolid |
0‑L | J02 | ANTIMYCOTICS FOR SYSTEMIC USE | WHO Anatomical Therapeutic Chemical classification | | ANTIMYCOTICS FOR SYSTEMIC USE |
0‑L | J02A | ANTIMYCOTICS FOR SYSTEMIC USE | WHO Anatomical Therapeutic Chemical classification | | ANTIMYCOTICS FOR SYSTEMIC USE |
0‑L | J02AA | Antibiotics | WHO Anatomical Therapeutic Chemical classification | | Antibiotics |
0‑L | J02AA01 | amphotericin B | WHO Anatomical Therapeutic Chemical classification | | amphotericin B |
0‑L | J02AA02 | hachimycin | WHO Anatomical Therapeutic Chemical classification | | hachimycin |
0‑L | J02AB | Imidazole derivatives | WHO Anatomical Therapeutic Chemical classification | | Imidazole derivatives |
0‑L | J02AB01 | miconazole | WHO Anatomical Therapeutic Chemical classification | | miconazole |
0‑L | J02AB02 | ketoconazole | WHO Anatomical Therapeutic Chemical classification | | ketoconazole |
0‑L | J02AC | Triazole derivatives | WHO Anatomical Therapeutic Chemical classification | | Triazole derivatives |
0‑L | J02AC01 | fluconazole | WHO Anatomical Therapeutic Chemical classification | | fluconazole |
0‑L | J02AC02 | itraconazole | WHO Anatomical Therapeutic Chemical classification | | itraconazole |
0‑L | J02AC03 | voriconazole | WHO Anatomical Therapeutic Chemical classification | | voriconazole |
0‑L | J02AC04 | posaconazole | WHO Anatomical Therapeutic Chemical classification | | posaconazole |
0‑L | J02AC05 | isavuconazole | WHO Anatomical Therapeutic Chemical classification | | isavuconazole |
0‑L | J02AX | Other antimycotics for systemic use | WHO Anatomical Therapeutic Chemical classification | | Other antimycotics for systemic use |
0‑L | J02AX01 | flucytosine | WHO Anatomical Therapeutic Chemical classification | | flucytosine |
0‑L | J02AX04 | caspofungin | WHO Anatomical Therapeutic Chemical classification | | caspofungin |
0‑L | J02AX05 | micafungin | WHO Anatomical Therapeutic Chemical classification | | micafungin |
0‑L | J02AX06 | anidulafungin | WHO Anatomical Therapeutic Chemical classification | | anidulafungin |
0‑L | J04 | ANTIMYCOBACTERIALS | WHO Anatomical Therapeutic Chemical classification | | ANTIMYCOBACTERIALS |
0‑L | J04A | DRUGS FOR TREATMENT OF TUBERCULOSIS | WHO Anatomical Therapeutic Chemical classification | | DRUGS FOR TREATMENT OF TUBERCULOSIS |
0‑L | J04AA | Aminosalicylic acid and derivatives | WHO Anatomical Therapeutic Chemical classification | | Aminosalicylic acid and derivatives |
0‑L | J04AA01 | 4-aminosalicylic acid | WHO Anatomical Therapeutic Chemical classification | | 4-aminosalicylic acid |
0‑L | J04AA02 | sodium aminosalicylate | WHO Anatomical Therapeutic Chemical classification | | sodium aminosalicylate |
0‑L | J04AA03 | calcium aminosalicylate | WHO Anatomical Therapeutic Chemical classification | | calcium aminosalicylate |
0‑L | J04AB | Antibiotics | WHO Anatomical Therapeutic Chemical classification | | Antibiotics |
0‑L | J04AB01 | cycloserine | WHO Anatomical Therapeutic Chemical classification | | cycloserine |
0‑L | J04AB02 | rifampicin | WHO Anatomical Therapeutic Chemical classification | | rifampicin |
0‑L | J04AB03 | rifamycin | WHO Anatomical Therapeutic Chemical classification | | rifamycin |
0‑L | J04AB04 | rifabutin | WHO Anatomical Therapeutic Chemical classification | | rifabutin |
0‑L | J04AB05 | rifapentine | WHO Anatomical Therapeutic Chemical classification | | rifapentine |
0‑L | J04AB30 | capreomycin | WHO Anatomical Therapeutic Chemical classification | | capreomycin |
0‑L | J04AC | Hydrazides | WHO Anatomical Therapeutic Chemical classification | | Hydrazides |
0‑L | J04AC01 | isoniazid | WHO Anatomical Therapeutic Chemical classification | | isoniazid |
0‑L | J04AC51 | isoniazid, combinations | WHO Anatomical Therapeutic Chemical classification | | isoniazid, combinations |
0‑L | J04AD | Thiocarbamide derivatives | WHO Anatomical Therapeutic Chemical classification | | Thiocarbamide derivatives |
0‑L | J04AD01 | protionamide | WHO Anatomical Therapeutic Chemical classification | | protionamide |
0‑L | J04AD02 | tiocarlide | WHO Anatomical Therapeutic Chemical classification | | tiocarlide |
0‑L | J04AD03 | ethionamide | WHO Anatomical Therapeutic Chemical classification | | ethionamide |
0‑L | J04AK | Other drugs for treatment of tuberculosis | WHO Anatomical Therapeutic Chemical classification | | Other drugs for treatment of tuberculosis |
0‑L | J04AK01 | pyrazinamide | WHO Anatomical Therapeutic Chemical classification | | pyrazinamide |
0‑L | J04AK02 | ethambutol | WHO Anatomical Therapeutic Chemical classification | | ethambutol |
0‑L | J04AK03 | terizidone | WHO Anatomical Therapeutic Chemical classification | | terizidone |
0‑L | J04AK04 | morinamide | WHO Anatomical Therapeutic Chemical classification | | morinamide |
0‑L | J04AK05 | bedaquiline | WHO Anatomical Therapeutic Chemical classification | | bedaquiline |
0‑L | J04AK06 | delamanid | WHO Anatomical Therapeutic Chemical classification | | delamanid |
0‑L | J04AK07 | thioacetazone | WHO Anatomical Therapeutic Chemical classification | | thioacetazone |
0‑L | J04AM | Combinations of drugs for treatment of tuberculosis | WHO Anatomical Therapeutic Chemical classification | | Combinations of drugs for treatment of tuberculosis |
0‑L | J04AM01 | streptomycin and isoniazid | WHO Anatomical Therapeutic Chemical classification | | streptomycin and isoniazid |
0‑L | J04AM02 | rifampicin and isoniazid | WHO Anatomical Therapeutic Chemical classification | | rifampicin and isoniazid |
0‑L | J04AM03 | ethambutol and isoniazid | WHO Anatomical Therapeutic Chemical classification | | ethambutol and isoniazid |
0‑L | J04AM04 | thioacetazone and isoniazid | WHO Anatomical Therapeutic Chemical classification | | thioacetazone and isoniazid |
0‑L | J04AM05 | rifampicin, pyrazinamide and isoniazid | WHO Anatomical Therapeutic Chemical classification | | rifampicin, pyrazinamide and isoniazid |
0‑L | J04AM06 | rifampicin, pyrazinamide, ethambutol and isoniazid | WHO Anatomical Therapeutic Chemical classification | | rifampicin, pyrazinamide, ethambutol and isoniazid |
0‑L | J04B | DRUGS FOR TREATMENT OF LEPRA | WHO Anatomical Therapeutic Chemical classification | | DRUGS FOR TREATMENT OF LEPRA |
0‑L | J04BA | Drugs for treatment of lepra | WHO Anatomical Therapeutic Chemical classification | | Drugs for treatment of lepra |
0‑L | J04BA01 | clofazimine | WHO Anatomical Therapeutic Chemical classification | | clofazimine |
0‑L | J04BA02 | dapsone | WHO Anatomical Therapeutic Chemical classification | | dapsone |
0‑L | J04BA03 | aldesulfone sodium | WHO Anatomical Therapeutic Chemical classification | | aldesulfone sodium |
0‑L | J05 | ANTIVIRALS FOR SYSTEMIC USE | WHO Anatomical Therapeutic Chemical classification | | ANTIVIRALS FOR SYSTEMIC USE |
0‑L | J05A | DIRECT ACTING ANTIVIRALS | WHO Anatomical Therapeutic Chemical classification | | DIRECT ACTING ANTIVIRALS |
0‑L | J05AA | Thiosemicarbazones | WHO Anatomical Therapeutic Chemical classification | | Thiosemicarbazones |
0‑L | J05AA01 | metisazone | WHO Anatomical Therapeutic Chemical classification | | metisazone |
0‑L | J05AB | Nucleosides and nucleotides excl. reverse transcriptase inhibitors | WHO Anatomical Therapeutic Chemical classification | | Nucleosides and nucleotides excl. reverse transcriptase inhibitors |
0‑L | J05AB01 | aciclovir | WHO Anatomical Therapeutic Chemical classification | | aciclovir |
0‑L | J05AB02 | idoxuridine | WHO Anatomical Therapeutic Chemical classification | | idoxuridine |
0‑L | J05AB03 | vidarabine | WHO Anatomical Therapeutic Chemical classification | | vidarabine |
0‑L | J05AB04 | ribavirin | WHO Anatomical Therapeutic Chemical classification | | ribavirin |
0‑L | J05AB06 | ganciclovir | WHO Anatomical Therapeutic Chemical classification | | ganciclovir |
0‑L | J05AB09 | famciclovir | WHO Anatomical Therapeutic Chemical classification | | famciclovir |
0‑L | J05AB11 | valaciclovir | WHO Anatomical Therapeutic Chemical classification | | valaciclovir |
0‑L | J05AB12 | cidofovir | WHO Anatomical Therapeutic Chemical classification | | cidofovir |
0‑L | J05AB13 | penciclovir | WHO Anatomical Therapeutic Chemical classification | | penciclovir |
0‑L | J05AB14 | valganciclovir | WHO Anatomical Therapeutic Chemical classification | | valganciclovir |
0‑L | J05AB15 | brivudine | WHO Anatomical Therapeutic Chemical classification | | brivudine |
0‑L | J05AC | Cyclic amines | WHO Anatomical Therapeutic Chemical classification | | Cyclic amines |
0‑L | J05AC02 | rimantadine | WHO Anatomical Therapeutic Chemical classification | | rimantadine |
0‑L | J05AC03 | tromantadine | WHO Anatomical Therapeutic Chemical classification | | tromantadine |
0‑L | J05AD | Phosphonic acid derivatives | WHO Anatomical Therapeutic Chemical classification | | Phosphonic acid derivatives |
0‑L | J05AD01 | foscarnet | WHO Anatomical Therapeutic Chemical classification | | foscarnet |
0‑L | J05AD02 | fosfonet | WHO Anatomical Therapeutic Chemical classification | | fosfonet |
0‑L | J05AE | Protease inhibitors | WHO Anatomical Therapeutic Chemical classification | | Protease inhibitors |
0‑L | J05AE01 | saquinavir | WHO Anatomical Therapeutic Chemical classification | | saquinavir |
0‑L | J05AE02 | indinavir | WHO Anatomical Therapeutic Chemical classification | | indinavir |
0‑L | J05AE03 | ritonavir | WHO Anatomical Therapeutic Chemical classification | | ritonavir |
0‑L | J05AE04 | nelfinavir | WHO Anatomical Therapeutic Chemical classification | | nelfinavir |
0‑L | J05AE05 | amprenavir | WHO Anatomical Therapeutic Chemical classification | | amprenavir |
0‑L | J05AE07 | fosamprenavir | WHO Anatomical Therapeutic Chemical classification | | fosamprenavir |
0‑L | J05AE08 | atazanavir | WHO Anatomical Therapeutic Chemical classification | | atazanavir |
0‑L | J05AE09 | tipranavir | WHO Anatomical Therapeutic Chemical classification | | tipranavir |
0‑L | J05AE10 | darunavir | WHO Anatomical Therapeutic Chemical classification | | darunavir |
0‑L | J05AE11 | telaprevir | WHO Anatomical Therapeutic Chemical classification | | telaprevir |
0‑L | J05AE12 | boceprevir | WHO Anatomical Therapeutic Chemical classification | | boceprevir |
0‑L | J05AE13 | faldaprevir | WHO Anatomical Therapeutic Chemical classification | | faldaprevir |
0‑L | J05AE14 | simeprevir | WHO Anatomical Therapeutic Chemical classification | | simeprevir |
0‑L | J05AE15 | asunaprevir | WHO Anatomical Therapeutic Chemical classification | | asunaprevir |
0‑L | J05AF | Nucleoside and nucleotide reverse transcriptase inhibitors | WHO Anatomical Therapeutic Chemical classification | | Nucleoside and nucleotide reverse transcriptase inhibitors |
0‑L | J05AF01 | zidovudine | WHO Anatomical Therapeutic Chemical classification | | zidovudine |
0‑L | J05AF02 | didanosine | WHO Anatomical Therapeutic Chemical classification | | didanosine |
0‑L | J05AF03 | zalcitabine | WHO Anatomical Therapeutic Chemical classification | | zalcitabine |
0‑L | J05AF04 | stavudine | WHO Anatomical Therapeutic Chemical classification | | stavudine |
0‑L | J05AF05 | lamivudine | WHO Anatomical Therapeutic Chemical classification | | lamivudine |
0‑L | J05AF06 | abacavir | WHO Anatomical Therapeutic Chemical classification | | abacavir |
0‑L | J05AF07 | tenofovir disoproxil | WHO Anatomical Therapeutic Chemical classification | | tenofovir disoproxil |
0‑L | J05AF08 | adefovir dipivoxil | WHO Anatomical Therapeutic Chemical classification | | adefovir dipivoxil |
0‑L | J05AF09 | emtricitabine | WHO Anatomical Therapeutic Chemical classification | | emtricitabine |
0‑L | J05AF10 | entecavir | WHO Anatomical Therapeutic Chemical classification | | entecavir |
0‑L | J05AF11 | telbivudine | WHO Anatomical Therapeutic Chemical classification | | telbivudine |
0‑L | J05AF12 | clevudine | WHO Anatomical Therapeutic Chemical classification | | clevudine |
0‑L | J05AF13 | tenofovir alafenamide | WHO Anatomical Therapeutic Chemical classification | | tenofovir alafenamide |
0‑L | J05AG | Non-nucleoside reverse transcriptase inhibitors | WHO Anatomical Therapeutic Chemical classification | | Non-nucleoside reverse transcriptase inhibitors |
0‑L | J05AG01 | nevirapine | WHO Anatomical Therapeutic Chemical classification | | nevirapine |
0‑L | J05AG02 | delavirdine | WHO Anatomical Therapeutic Chemical classification | | delavirdine |
0‑L | J05AG03 | efavirenz | WHO Anatomical Therapeutic Chemical classification | | efavirenz |
0‑L | J05AG04 | etravirine | WHO Anatomical Therapeutic Chemical classification | | etravirine |
0‑L | J05AG05 | rilpivirine | WHO Anatomical Therapeutic Chemical classification | | rilpivirine |
0‑L | J05AH | Neuraminidase inhibitors | WHO Anatomical Therapeutic Chemical classification | | Neuraminidase inhibitors |
0‑L | J05AH01 | zanamivir | WHO Anatomical Therapeutic Chemical classification | | zanamivir |
0‑L | J05AH02 | oseltamivir | WHO Anatomical Therapeutic Chemical classification | | oseltamivir |
0‑L | J05AR | Antivirals for treatment of HIV infections, combinations | WHO Anatomical Therapeutic Chemical classification | | Antivirals for treatment of HIV infections, combinations |
0‑L | J05AR01 | zidovudine and lamivudine | WHO Anatomical Therapeutic Chemical classification | | zidovudine and lamivudine |
0‑L | J05AR02 | lamivudine and abacavir | WHO Anatomical Therapeutic Chemical classification | | lamivudine and abacavir |
0‑L | J05AR03 | tenofovir disoproxil and emtricitabine | WHO Anatomical Therapeutic Chemical classification | | tenofovir disoproxil and emtricitabine |
0‑L | J05AR04 | zidovudine, lamivudine and abacavir | WHO Anatomical Therapeutic Chemical classification | | zidovudine, lamivudine and abacavir |
0‑L | J05AR05 | zidovudine, lamivudine and nevirapine | WHO Anatomical Therapeutic Chemical classification | | zidovudine, lamivudine and nevirapine |
0‑L | J05AR06 | emtricitabine, tenofovir disoproxil and efavirenz | WHO Anatomical Therapeutic Chemical classification | | emtricitabine, tenofovir disoproxil and efavirenz |
0‑L | J05AR07 | stavudine, lamivudine and nevirapine | WHO Anatomical Therapeutic Chemical classification | | stavudine, lamivudine and nevirapine |
0‑L | J05AR08 | emtricitabine, tenofovir disoproxil and rilpivirine | WHO Anatomical Therapeutic Chemical classification | | emtricitabine, tenofovir disoproxil and rilpivirine |
0‑L | J05AR09 | emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat | WHO Anatomical Therapeutic Chemical classification | | emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat |
0‑L | J05AR10 | lopinavir and ritonavir | WHO Anatomical Therapeutic Chemical classification | | lopinavir and ritonavir |
0‑L | J05AR11 | lamivudine, tenofovir disoproxil and efavirenz | WHO Anatomical Therapeutic Chemical classification | | lamivudine, tenofovir disoproxil and efavirenz |
0‑L | J05AR12 | lamivudine and tenofovir disoproxil | WHO Anatomical Therapeutic Chemical classification | | lamivudine and tenofovir disoproxil |
0‑L | J05AR13 | lamivudine, abacavir and dolutegravir | WHO Anatomical Therapeutic Chemical classification | | lamivudine, abacavir and dolutegravir |
0‑L | J05AR14 | darunavir and cobicistat | WHO Anatomical Therapeutic Chemical classification | | darunavir and cobicistat |
0‑L | J05AR15 | atazanavir and cobicistat | WHO Anatomical Therapeutic Chemical classification | | atazanavir and cobicistat |
0‑L | J05AR16 | lamivudine and raltegravir | WHO Anatomical Therapeutic Chemical classification | | lamivudine and raltegravir |
0‑L | J05AR17 | emtricitabine and tenofovir alafenamide | WHO Anatomical Therapeutic Chemical classification | | emtricitabine and tenofovir alafenamide |
0‑L | J05AR18 | emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat | WHO Anatomical Therapeutic Chemical classification | | emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat |
0‑L | J05AR19 | emtricitabine, tenofovir alafenamide and rilpivirine | WHO Anatomical Therapeutic Chemical classification | | emtricitabine, tenofovir alafenamide and rilpivirine |
0‑L | J05AX | Other antivirals | WHO Anatomical Therapeutic Chemical classification | | Other antivirals |
0‑L | J05AX01 | moroxydine | WHO Anatomical Therapeutic Chemical classification | | moroxydine |
0‑L | J05AX02 | lysozyme | WHO Anatomical Therapeutic Chemical classification | | lysozyme |
0‑L | J05AX05 | inosine pranobex | WHO Anatomical Therapeutic Chemical classification | | inosine pranobex |
0‑L | J05AX06 | pleconaril | WHO Anatomical Therapeutic Chemical classification | | pleconaril |
0‑L | J05AX07 | enfuvirtide | WHO Anatomical Therapeutic Chemical classification | | enfuvirtide |
0‑L | J05AX08 | raltegravir | WHO Anatomical Therapeutic Chemical classification | | raltegravir |
0‑L | J05AX09 | maraviroc | WHO Anatomical Therapeutic Chemical classification | | maraviroc |
0‑L | J05AX10 | maribavir | WHO Anatomical Therapeutic Chemical classification | | maribavir |
0‑L | J05AX11 | elvitegravir | WHO Anatomical Therapeutic Chemical classification | | elvitegravir |
0‑L | J05AX12 | dolutegravir | WHO Anatomical Therapeutic Chemical classification | | dolutegravir |
0‑L | J05AX13 | umifenovir | WHO Anatomical Therapeutic Chemical classification | | umifenovir |
0‑L | J05AX14 | daclatasvir | WHO Anatomical Therapeutic Chemical classification | | daclatasvir |
0‑L | J05AX15 | sofosbuvir | WHO Anatomical Therapeutic Chemical classification | | sofosbuvir |
0‑L | J05AX16 | dasabuvir | WHO Anatomical Therapeutic Chemical classification | | dasabuvir |
0‑L | J05AX65 | sofosbuvir and ledipasvir | WHO Anatomical Therapeutic Chemical classification | | sofosbuvir and ledipasvir |
0‑L | J05AX66 | dasabuvir, ombitasvir, paritaprevir and ritonavir | WHO Anatomical Therapeutic Chemical classification | | dasabuvir, ombitasvir, paritaprevir and ritonavir |
0‑L | J05AX67 | ombitasvir, paritaprevir and ritonavir | WHO Anatomical Therapeutic Chemical classification | | ombitasvir, paritaprevir and ritonavir |
0‑L | J05AX68 | elbasvir and grazoprevir | WHO Anatomical Therapeutic Chemical classification | | elbasvir and grazoprevir |
0‑L | J06 | IMMUNE SERA AND IMMUNOGLOBULINS | WHO Anatomical Therapeutic Chemical classification | | IMMUNE SERA AND IMMUNOGLOBULINS |
0‑L | J06A | IMMUNE SERA | WHO Anatomical Therapeutic Chemical classification | | IMMUNE SERA |
0‑L | J06AA | Immune sera | WHO Anatomical Therapeutic Chemical classification | | Immune sera |
0‑L | J06AA01 | diphtheria antitoxin | WHO Anatomical Therapeutic Chemical classification | | diphtheria antitoxin |
0‑L | J06AA02 | tetanus antitoxin | WHO Anatomical Therapeutic Chemical classification | | tetanus antitoxin |
0‑L | J06AA03 | snake venom antiserum | WHO Anatomical Therapeutic Chemical classification | | snake venom antiserum |
0‑L | J06AA04 | botulinum antitoxin | WHO Anatomical Therapeutic Chemical classification | | botulinum antitoxin |
0‑L | J06AA05 | gas-gangrene sera | WHO Anatomical Therapeutic Chemical classification | | gas-gangrene sera |
0‑L | J06AA06 | rabies serum | WHO Anatomical Therapeutic Chemical classification | | rabies serum |
0‑L | J06B | IMMUNOGLOBULINS | WHO Anatomical Therapeutic Chemical classification | | IMMUNOGLOBULINS |
0‑L | J06BA | Immunoglobulins, normal human | WHO Anatomical Therapeutic Chemical classification | | Immunoglobulins, normal human |
0‑L | J06BA01 | immunoglobulins, normal human, for extravascular adm. | WHO Anatomical Therapeutic Chemical classification | | immunoglobulins, normal human, for extravascular adm. |
0‑L | J06BA02 | immunoglobulins, normal human, for intravascular adm. | WHO Anatomical Therapeutic Chemical classification | | immunoglobulins, normal human, for intravascular adm. |
0‑L | J06BB | Specific immunoglobulins | WHO Anatomical Therapeutic Chemical classification | | Specific immunoglobulins |
0‑L | J06BB01 | anti-D (rh) immunoglobulin | WHO Anatomical Therapeutic Chemical classification | | anti-D (rh) immunoglobulin |
0‑L | J06BB02 | tetanus immunoglobulin | WHO Anatomical Therapeutic Chemical classification | | tetanus immunoglobulin |
0‑L | J06BB03 | varicella/zoster immunoglobulin | WHO Anatomical Therapeutic Chemical classification | | varicella/zoster immunoglobulin |
0‑L | J06BB04 | hepatitis B immunoglobulin | WHO Anatomical Therapeutic Chemical classification | | hepatitis B immunoglobulin |
0‑L | J06BB05 | rabies immunoglobulin | WHO Anatomical Therapeutic Chemical classification | | rabies immunoglobulin |
0‑L | J06BB06 | rubella immunoglobulin | WHO Anatomical Therapeutic Chemical classification | | rubella immunoglobulin |
0‑L | J06BB07 | vaccinia immunoglobulin | WHO Anatomical Therapeutic Chemical classification | | vaccinia immunoglobulin |
0‑L | J06BB08 | staphylococcus immunoglobulin | WHO Anatomical Therapeutic Chemical classification | | staphylococcus immunoglobulin |
0‑L | J06BB09 | cytomegalovirus immunoglobulin | WHO Anatomical Therapeutic Chemical classification | | cytomegalovirus immunoglobulin |
0‑L | J06BB10 | diphtheria immunoglobulin | WHO Anatomical Therapeutic Chemical classification | | diphtheria immunoglobulin |
0‑L | J06BB11 | hepatitis A immunoglobulin | WHO Anatomical Therapeutic Chemical classification | | hepatitis A immunoglobulin |
0‑L | J06BB12 | encephalitis, tick borne immunoglobulin | WHO Anatomical Therapeutic Chemical classification | | encephalitis, tick borne immunoglobulin |
0‑L | J06BB13 | pertussis immunoglobulin | WHO Anatomical Therapeutic Chemical classification | | pertussis immunoglobulin |
0‑L | J06BB14 | measles immunoglobulin | WHO Anatomical Therapeutic Chemical classification | | measles immunoglobulin |
0‑L | J06BB15 | mumps immunoglobulin | WHO Anatomical Therapeutic Chemical classification | | mumps immunoglobulin |
0‑L | J06BB16 | palivizumab | WHO Anatomical Therapeutic Chemical classification | | palivizumab |
0‑L | J06BB17 | motavizumab | WHO Anatomical Therapeutic Chemical classification | | motavizumab |
0‑L | J06BB18 | raxibacumab | WHO Anatomical Therapeutic Chemical classification | | raxibacumab |
0‑L | J06BB19 | anthrax immunoglobulin | WHO Anatomical Therapeutic Chemical classification | | anthrax immunoglobulin |
0‑L | J06BB21 | bezlotoxumab | WHO Anatomical Therapeutic Chemical classification | | bezlotoxumab |
0‑L | J06BB30 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | J06BC | Other immunoglobulins | WHO Anatomical Therapeutic Chemical classification | | Other immunoglobulins |
0‑L | J06BC01 | nebacumab | WHO Anatomical Therapeutic Chemical classification | | nebacumab |
0‑L | J07 | VACCINES | WHO Anatomical Therapeutic Chemical classification | | VACCINES |
0‑L | J07A | BACTERIAL VACCINES | WHO Anatomical Therapeutic Chemical classification | | BACTERIAL VACCINES |
0‑L | J07AC | Anthrax vaccines | WHO Anatomical Therapeutic Chemical classification | | Anthrax vaccines |
0‑L | J07AC01 | anthrax antigen | WHO Anatomical Therapeutic Chemical classification | | anthrax antigen |
0‑L | J07AD | Brucellosis vaccines | WHO Anatomical Therapeutic Chemical classification | | Brucellosis vaccines |
0‑L | J07AD01 | brucella antigen | WHO Anatomical Therapeutic Chemical classification | | brucella antigen |
0‑L | J07AE | Cholera vaccines | WHO Anatomical Therapeutic Chemical classification | | Cholera vaccines |
0‑L | J07AE01 | cholera, inactivated, whole cell | WHO Anatomical Therapeutic Chemical classification | | cholera, inactivated, whole cell |
0‑L | J07AE02 | cholera, live attenuated | WHO Anatomical Therapeutic Chemical classification | | cholera, live attenuated |
0‑L | J07AE51 | cholera, combinations with typhoid vaccine, inactivated, whole cell | WHO Anatomical Therapeutic Chemical classification | | cholera, combinations with typhoid vaccine, inactivated, whole cell |
0‑L | J07AF | Diphtheria vaccines | WHO Anatomical Therapeutic Chemical classification | | Diphtheria vaccines |
0‑L | J07AF01 | diphtheria toxoid | WHO Anatomical Therapeutic Chemical classification | | diphtheria toxoid |
0‑L | J07AG | Hemophilus influenzae B vaccines | WHO Anatomical Therapeutic Chemical classification | | Hemophilus influenzae B vaccines |
0‑L | J07AG01 | hemophilus influenzae B, purified antigen conjugated | WHO Anatomical Therapeutic Chemical classification | | hemophilus influenzae B, purified antigen conjugated |
0‑L | J07AG51 | hemophilus influenzae B, combinations with toxoids | WHO Anatomical Therapeutic Chemical classification | | hemophilus influenzae B, combinations with toxoids |
0‑L | J07AG52 | hemophilus influenzae B, combinations with pertussis and toxoids | WHO Anatomical Therapeutic Chemical classification | | hemophilus influenzae B, combinations with pertussis and toxoids |
0‑L | J07AG53 | hemophilus influenzae B, combinations with meningococcus C, conjugated | WHO Anatomical Therapeutic Chemical classification | | hemophilus influenzae B, combinations with meningococcus C, conjugated |
0‑L | J07AH | Meningococcal vaccines | WHO Anatomical Therapeutic Chemical classification | | Meningococcal vaccines |
0‑L | J07AH01 | meningococcus A, purified polysaccharides antigen | WHO Anatomical Therapeutic Chemical classification | | meningococcus A, purified polysaccharides antigen |
0‑L | J07AH02 | other meningococcal monovalent purified polysaccharides antigen | WHO Anatomical Therapeutic Chemical classification | | other meningococcal monovalent purified polysaccharides antigen |
0‑L | J07AH03 | meningococcus A,C, bivalent purified polysaccharides antigen | WHO Anatomical Therapeutic Chemical classification | | meningococcus A,C, bivalent purified polysaccharides antigen |
0‑L | J07AH04 | meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen | WHO Anatomical Therapeutic Chemical classification | | meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen |
0‑L | J07AH05 | other meningococcal polyvalent purified polysaccharides antigen | WHO Anatomical Therapeutic Chemical classification | | other meningococcal polyvalent purified polysaccharides antigen |
0‑L | J07AH06 | meningococcus B, outer membrane vesicle vaccine | WHO Anatomical Therapeutic Chemical classification | | meningococcus B, outer membrane vesicle vaccine |
0‑L | J07AH07 | meningococcus C, purified polysaccharides antigen conjugated | WHO Anatomical Therapeutic Chemical classification | | meningococcus C, purified polysaccharides antigen conjugated |
0‑L | J07AH08 | meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugated | WHO Anatomical Therapeutic Chemical classification | | meningococcus A,C,Y,W-135, tetravalent purified polysaccharides antigen conjugated |
0‑L | J07AH09 | meningococcus B, multicomponent vaccine | WHO Anatomical Therapeutic Chemical classification | | meningococcus B, multicomponent vaccine |
0‑L | J07AH10 | meningococcus A, purified polysaccharides antigen conjugated | WHO Anatomical Therapeutic Chemical classification | | meningococcus A, purified polysaccharides antigen conjugated |
0‑L | J07AJ | Pertussis vaccines | WHO Anatomical Therapeutic Chemical classification | | Pertussis vaccines |
0‑L | J07AJ01 | pertussis, inactivated, whole cell | WHO Anatomical Therapeutic Chemical classification | | pertussis, inactivated, whole cell |
0‑L | J07AJ02 | pertussis, purified antigen | WHO Anatomical Therapeutic Chemical classification | | pertussis, purified antigen |
0‑L | J07AJ51 | pertussis, inactivated, whole cell, combinations with toxoids | WHO Anatomical Therapeutic Chemical classification | | pertussis, inactivated, whole cell, combinations with toxoids |
0‑L | J07AJ52 | pertussis, purified antigen, combinations with toxoids | WHO Anatomical Therapeutic Chemical classification | | pertussis, purified antigen, combinations with toxoids |
0‑L | J07AK | Plague vaccines | WHO Anatomical Therapeutic Chemical classification | | Plague vaccines |
0‑L | J07AK01 | plague, inactivated, whole cell | WHO Anatomical Therapeutic Chemical classification | | plague, inactivated, whole cell |
0‑L | J07AL | Pneumococcal vaccines | WHO Anatomical Therapeutic Chemical classification | | Pneumococcal vaccines |
0‑L | J07AL01 | pneumococcus, purified polysaccharides antigen | WHO Anatomical Therapeutic Chemical classification | | pneumococcus, purified polysaccharides antigen |
0‑L | J07AL02 | pneumococcus, purified polysaccharides antigen conjugated | WHO Anatomical Therapeutic Chemical classification | | pneumococcus, purified polysaccharides antigen conjugated |
0‑L | J07AL52 | pneumococcus purified polysaccharides antigen and haemophilus influenzae, conjugated | WHO Anatomical Therapeutic Chemical classification | | pneumococcus purified polysaccharides antigen and haemophilus influenzae, conjugated |
0‑L | J07AM | Tetanus vaccines | WHO Anatomical Therapeutic Chemical classification | | Tetanus vaccines |
0‑L | J07AM01 | tetanus toxoid | WHO Anatomical Therapeutic Chemical classification | | tetanus toxoid |
0‑L | J07AM51 | tetanus toxoid, combinations with diphtheria toxoid | WHO Anatomical Therapeutic Chemical classification | | tetanus toxoid, combinations with diphtheria toxoid |
0‑L | J07AM52 | tetanus toxoid, combinations with tetanus immunoglobulin | WHO Anatomical Therapeutic Chemical classification | | tetanus toxoid, combinations with tetanus immunoglobulin |
0‑L | J07AN | Tuberculosis vaccines | WHO Anatomical Therapeutic Chemical classification | | Tuberculosis vaccines |
0‑L | J07AN01 | tuberculosis, live attenuated | WHO Anatomical Therapeutic Chemical classification | | tuberculosis, live attenuated |
0‑L | J07AP | Typhoid vaccines | WHO Anatomical Therapeutic Chemical classification | | Typhoid vaccines |
0‑L | J07AP01 | typhoid, oral, live attenuated | WHO Anatomical Therapeutic Chemical classification | | typhoid, oral, live attenuated |
0‑L | J07AP02 | typhoid, inactivated, whole cell | WHO Anatomical Therapeutic Chemical classification | | typhoid, inactivated, whole cell |
0‑L | J07AP03 | typhoid, purified polysaccharide antigen | WHO Anatomical Therapeutic Chemical classification | | typhoid, purified polysaccharide antigen |
0‑L | J07AP10 | typhoid, combinations with paratyphi types | WHO Anatomical Therapeutic Chemical classification | | typhoid, combinations with paratyphi types |
0‑L | J07AR | Typhus (exanthematicus) vaccines | WHO Anatomical Therapeutic Chemical classification | | Typhus (exanthematicus) vaccines |
0‑L | J07AR01 | typhus exanthematicus, inactivated, whole cell | WHO Anatomical Therapeutic Chemical classification | | typhus exanthematicus, inactivated, whole cell |
0‑L | J07AX | Other bacterial vaccines | WHO Anatomical Therapeutic Chemical classification | | Other bacterial vaccines |
0‑L | J07B | VIRAL VACCINES | WHO Anatomical Therapeutic Chemical classification | | VIRAL VACCINES |
0‑L | J07BA | Encephalitis vaccines | WHO Anatomical Therapeutic Chemical classification | | Encephalitis vaccines |
0‑L | J07BA01 | encephalitis, tick borne, inactivated, whole virus | WHO Anatomical Therapeutic Chemical classification | | encephalitis, tick borne, inactivated, whole virus |
0‑L | J07BA02 | encephalitis, Japanese, inactivated, whole virus | WHO Anatomical Therapeutic Chemical classification | | encephalitis, Japanese, inactivated, whole virus |
0‑L | J07BA03 | encephalitis, Japanese, live attenuated | WHO Anatomical Therapeutic Chemical classification | | encephalitis, Japanese, live attenuated |
0‑L | J07BB | Influenza vaccines | WHO Anatomical Therapeutic Chemical classification | | Influenza vaccines |
0‑L | J07BB01 | influenza, inactivated, whole virus | WHO Anatomical Therapeutic Chemical classification | | influenza, inactivated, whole virus |
0‑L | J07BB02 | influenza, inactivated, split virus or surface antigen | WHO Anatomical Therapeutic Chemical classification | | influenza, inactivated, split virus or surface antigen |
0‑L | J07BB03 | influenza, live attenuated | WHO Anatomical Therapeutic Chemical classification | | influenza, live attenuated |
0‑L | J07BC | Hepatitis vaccines | WHO Anatomical Therapeutic Chemical classification | | Hepatitis vaccines |
0‑L | J07BC01 | hepatitis B, purified antigen | WHO Anatomical Therapeutic Chemical classification | | hepatitis B, purified antigen |
0‑L | J07BC02 | hepatitis A, inactivated, whole virus | WHO Anatomical Therapeutic Chemical classification | | hepatitis A, inactivated, whole virus |
0‑L | J07BC20 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | J07BD | Measles vaccines | WHO Anatomical Therapeutic Chemical classification | | Measles vaccines |
0‑L | J07BD01 | measles, live attenuated | WHO Anatomical Therapeutic Chemical classification | | measles, live attenuated |
0‑L | J07BD51 | measles, combinations with mumps, live attenuated | WHO Anatomical Therapeutic Chemical classification | | measles, combinations with mumps, live attenuated |
0‑L | J07BD52 | measles, combinations with mumps and rubella, live attenuated | WHO Anatomical Therapeutic Chemical classification | | measles, combinations with mumps and rubella, live attenuated |
0‑L | J07BD53 | measles, combinations with rubella, live attenuated | WHO Anatomical Therapeutic Chemical classification | | measles, combinations with rubella, live attenuated |
0‑L | J07BD54 | measles, combinations with mumps, rubella and varicella, live attenuated | WHO Anatomical Therapeutic Chemical classification | | measles, combinations with mumps, rubella and varicella, live attenuated |
0‑L | J07BE | Mumps vaccines | WHO Anatomical Therapeutic Chemical classification | | Mumps vaccines |
0‑L | J07BE01 | mumps, live attenuated | WHO Anatomical Therapeutic Chemical classification | | mumps, live attenuated |
0‑L | J07BF | Poliomyelitis vaccines | WHO Anatomical Therapeutic Chemical classification | | Poliomyelitis vaccines |
0‑L | J07BF01 | poliomyelitis oral, monovalent, live attenuated | WHO Anatomical Therapeutic Chemical classification | | poliomyelitis oral, monovalent, live attenuated |
0‑L | J07BF02 | poliomyelitis oral, trivalent, live attenuated | WHO Anatomical Therapeutic Chemical classification | | poliomyelitis oral, trivalent, live attenuated |
0‑L | J07BF03 | poliomyelitis, trivalent, inactivated, whole virus | WHO Anatomical Therapeutic Chemical classification | | poliomyelitis, trivalent, inactivated, whole virus |
0‑L | J07BF04 | poliomyelitis oral, bivalent, live attenuated | WHO Anatomical Therapeutic Chemical classification | | poliomyelitis oral, bivalent, live attenuated |
0‑L | J07BG | Rabies vaccines | WHO Anatomical Therapeutic Chemical classification | | Rabies vaccines |
0‑L | J07BG01 | rabies, inactivated, whole virus | WHO Anatomical Therapeutic Chemical classification | | rabies, inactivated, whole virus |
0‑L | J07BH | Rota virus diarrhea vaccines | WHO Anatomical Therapeutic Chemical classification | | Rota virus diarrhea vaccines |
0‑L | J07BH01 | rota virus, live attenuated | WHO Anatomical Therapeutic Chemical classification | | rota virus, live attenuated |
0‑L | J07BH02 | rota virus, pentavalent, live, reassorted | WHO Anatomical Therapeutic Chemical classification | | rota virus, pentavalent, live, reassorted |
0‑L | J07BJ | Rubella vaccines | WHO Anatomical Therapeutic Chemical classification | | Rubella vaccines |
0‑L | J07BJ01 | rubella, live attenuated | WHO Anatomical Therapeutic Chemical classification | | rubella, live attenuated |
0‑L | J07BJ51 | rubella, combinations with mumps, live attenuated | WHO Anatomical Therapeutic Chemical classification | | rubella, combinations with mumps, live attenuated |
0‑L | J07BK | Varicella zoster vaccines | WHO Anatomical Therapeutic Chemical classification | | Varicella zoster vaccines |
0‑L | J07BK01 | varicella, live attenuated | WHO Anatomical Therapeutic Chemical classification | | varicella, live attenuated |
0‑L | J07BK02 | zoster, live attenuated | WHO Anatomical Therapeutic Chemical classification | | zoster, live attenuated |
0‑L | J07BL | Yellow fever vaccines | WHO Anatomical Therapeutic Chemical classification | | Yellow fever vaccines |
0‑L | J07BL01 | yellow fever, live attenuated | WHO Anatomical Therapeutic Chemical classification | | yellow fever, live attenuated |
0‑L | J07BM | Papillomavirus vaccines | WHO Anatomical Therapeutic Chemical classification | | Papillomavirus vaccines |
0‑L | J07BM01 | papillomavirus (human types 6, 11, 16, 18) | WHO Anatomical Therapeutic Chemical classification | | papillomavirus (human types 6, 11, 16, 18) |
0‑L | J07BM02 | papillomavirus (human types 16, 18) | WHO Anatomical Therapeutic Chemical classification | | papillomavirus (human types 16, 18) |
0‑L | J07BM03 | papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58) | WHO Anatomical Therapeutic Chemical classification | | papillomavirus (human types 6, 11, 16, 18, 31, 33, 45, 52, 58) |
0‑L | J07BX | Other viral vaccines | WHO Anatomical Therapeutic Chemical classification | | Other viral vaccines |
0‑L | J07BX01 | smallpox, live attenuated | WHO Anatomical Therapeutic Chemical classification | | smallpox, live attenuated |
0‑L | J07C | BACTERIAL AND VIRAL VACCINES, COMBINED | WHO Anatomical Therapeutic Chemical classification | | BACTERIAL AND VIRAL VACCINES, COMBINED |
0‑L | J07CA | Bacterial and viral vaccines, combined | WHO Anatomical Therapeutic Chemical classification | | Bacterial and viral vaccines, combined |
0‑L | J07CA01 | diphtheria-poliomyelitis-tetanus | WHO Anatomical Therapeutic Chemical classification | | diphtheria-poliomyelitis-tetanus |
0‑L | J07CA02 | diphtheria-pertussis-poliomyelitis-tetanus | WHO Anatomical Therapeutic Chemical classification | | diphtheria-pertussis-poliomyelitis-tetanus |
0‑L | J07CA03 | diphtheria-rubella-tetanus | WHO Anatomical Therapeutic Chemical classification | | diphtheria-rubella-tetanus |
0‑L | J07CA04 | hemophilus influenzae B and poliomyelitis | WHO Anatomical Therapeutic Chemical classification | | hemophilus influenzae B and poliomyelitis |
0‑L | J07CA05 | diphtheria-hepatitis B-pertussis-tetanus | WHO Anatomical Therapeutic Chemical classification | | diphtheria-hepatitis B-pertussis-tetanus |
0‑L | J07CA06 | diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus | WHO Anatomical Therapeutic Chemical classification | | diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus |
0‑L | J07CA07 | diphtheria-hepatitis B-tetanus | WHO Anatomical Therapeutic Chemical classification | | diphtheria-hepatitis B-tetanus |
0‑L | J07CA08 | hemophilus influenzae B and hepatitis B | WHO Anatomical Therapeutic Chemical classification | | hemophilus influenzae B and hepatitis B |
0‑L | J07CA09 | diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B | WHO Anatomical Therapeutic Chemical classification | | diphtheria-hemophilus influenzae B-pertussis-poliomyelitis-tetanus-hepatitis B |
0‑L | J07CA10 | typhoid-hepatitis A | WHO Anatomical Therapeutic Chemical classification | | typhoid-hepatitis A |
0‑L | J07CA11 | diphtheria-hemophilus influenzae B-pertussis-tetanus-hepatitis B | WHO Anatomical Therapeutic Chemical classification | | diphtheria-hemophilus influenzae B-pertussis-tetanus-hepatitis B |
0‑L | J07CA12 | diphtheria-pertussis-poliomyelitis-tetanus-hepatitis B | WHO Anatomical Therapeutic Chemical classification | | diphtheria-pertussis-poliomyelitis-tetanus-hepatitis B |
0‑L | J07CA13 | diphtheria-hemophilus influenzae B-pertussis-tetanus-hepatitis B-meningococcus A + C | WHO Anatomical Therapeutic Chemical classification | | diphtheria-hemophilus influenzae B-pertussis-tetanus-hepatitis B-meningococcus A + C |
0‑L | J07X | OTHER VACCINES | WHO Anatomical Therapeutic Chemical classification | | OTHER VACCINES |
0‑L | L | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS | WHO Anatomical Therapeutic Chemical classification | | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS |
0‑L | L01 | ANTINEOPLASTIC AGENTS | WHO Anatomical Therapeutic Chemical classification | | ANTINEOPLASTIC AGENTS |
0‑L | L01A | ALKYLATING AGENTS | WHO Anatomical Therapeutic Chemical classification | | ALKYLATING AGENTS |
0‑L | L01AA | Nitrogen mustard analogues | WHO Anatomical Therapeutic Chemical classification | | Nitrogen mustard analogues |
0‑L | L01AA01 | cyclophosphamide | WHO Anatomical Therapeutic Chemical classification | | cyclophosphamide |
0‑L | L01AA02 | chlorambucil | WHO Anatomical Therapeutic Chemical classification | | chlorambucil |
0‑L | L01AA03 | melphalan | WHO Anatomical Therapeutic Chemical classification | | melphalan |
0‑L | L01AA05 | chlormethine | WHO Anatomical Therapeutic Chemical classification | | chlormethine |
0‑L | L01AA06 | ifosfamide | WHO Anatomical Therapeutic Chemical classification | | ifosfamide |
0‑L | L01AA07 | trofosfamide | WHO Anatomical Therapeutic Chemical classification | | trofosfamide |
0‑L | L01AA08 | prednimustine | WHO Anatomical Therapeutic Chemical classification | | prednimustine |
0‑L | L01AA09 | bendamustine | WHO Anatomical Therapeutic Chemical classification | | bendamustine |
0‑L | L01AB | Alkyl sulfonates | WHO Anatomical Therapeutic Chemical classification | | Alkyl sulfonates |
0‑L | L01AB01 | busulfan | WHO Anatomical Therapeutic Chemical classification | | busulfan |
0‑L | L01AB02 | treosulfan | WHO Anatomical Therapeutic Chemical classification | | treosulfan |
0‑L | L01AB03 | mannosulfan | WHO Anatomical Therapeutic Chemical classification | | mannosulfan |
0‑L | L01AC | Ethylene imines | WHO Anatomical Therapeutic Chemical classification | | Ethylene imines |
0‑L | L01AC01 | thiotepa | WHO Anatomical Therapeutic Chemical classification | | thiotepa |
0‑L | L01AC02 | triaziquone | WHO Anatomical Therapeutic Chemical classification | | triaziquone |
0‑L | L01AC03 | carboquone | WHO Anatomical Therapeutic Chemical classification | | carboquone |
0‑L | L01AD | Nitrosoureas | WHO Anatomical Therapeutic Chemical classification | | Nitrosoureas |
0‑L | L01AD01 | carmustine | WHO Anatomical Therapeutic Chemical classification | | carmustine |
0‑L | L01AD02 | lomustine | WHO Anatomical Therapeutic Chemical classification | | lomustine |
0‑L | L01AD03 | semustine | WHO Anatomical Therapeutic Chemical classification | | semustine |
0‑L | L01AD04 | streptozocin | WHO Anatomical Therapeutic Chemical classification | | streptozocin |
0‑L | L01AD05 | fotemustine | WHO Anatomical Therapeutic Chemical classification | | fotemustine |
0‑L | L01AD06 | nimustine | WHO Anatomical Therapeutic Chemical classification | | nimustine |
0‑L | L01AD07 | ranimustine | WHO Anatomical Therapeutic Chemical classification | | ranimustine |
0‑L | L01AG | Epoxides | WHO Anatomical Therapeutic Chemical classification | | Epoxides |
0‑L | L01AG01 | etoglucid | WHO Anatomical Therapeutic Chemical classification | | etoglucid |
0‑L | L01AX | Other alkylating agents | WHO Anatomical Therapeutic Chemical classification | | Other alkylating agents |
0‑L | L01AX01 | mitobronitol | WHO Anatomical Therapeutic Chemical classification | | mitobronitol |
0‑L | L01AX02 | pipobroman | WHO Anatomical Therapeutic Chemical classification | | pipobroman |
0‑L | L01AX03 | temozolomide | WHO Anatomical Therapeutic Chemical classification | | temozolomide |
0‑L | L01AX04 | dacarbazine | WHO Anatomical Therapeutic Chemical classification | | dacarbazine |
0‑L | L01B | ANTIMETABOLITES | WHO Anatomical Therapeutic Chemical classification | | ANTIMETABOLITES |
0‑L | L01BA | Folic acid analogues | WHO Anatomical Therapeutic Chemical classification | | Folic acid analogues |
0‑L | L01BA01 | methotrexate | WHO Anatomical Therapeutic Chemical classification | | methotrexate |
0‑L | L01BA03 | raltitrexed | WHO Anatomical Therapeutic Chemical classification | | raltitrexed |
0‑L | L01BA04 | pemetrexed | WHO Anatomical Therapeutic Chemical classification | | pemetrexed |
0‑L | L01BA05 | pralatrexate | WHO Anatomical Therapeutic Chemical classification | | pralatrexate |
0‑L | L01BB | Purine analogues | WHO Anatomical Therapeutic Chemical classification | | Purine analogues |
0‑L | L01BB02 | mercaptopurine | WHO Anatomical Therapeutic Chemical classification | | mercaptopurine |
0‑L | L01BB03 | tioguanine | WHO Anatomical Therapeutic Chemical classification | | tioguanine |
0‑L | L01BB04 | cladribine | WHO Anatomical Therapeutic Chemical classification | | cladribine |
0‑L | L01BB05 | fludarabine | WHO Anatomical Therapeutic Chemical classification | | fludarabine |
0‑L | L01BB06 | clofarabine | WHO Anatomical Therapeutic Chemical classification | | clofarabine |
0‑L | L01BB07 | nelarabine | WHO Anatomical Therapeutic Chemical classification | | nelarabine |
0‑L | L01BC | Pyrimidine analogues | WHO Anatomical Therapeutic Chemical classification | | Pyrimidine analogues |
0‑L | L01BC01 | cytarabine | WHO Anatomical Therapeutic Chemical classification | | cytarabine |
0‑L | L01BC02 | fluorouracil | WHO Anatomical Therapeutic Chemical classification | | fluorouracil |
0‑L | L01BC03 | tegafur | WHO Anatomical Therapeutic Chemical classification | | tegafur |
0‑L | L01BC04 | carmofur | WHO Anatomical Therapeutic Chemical classification | | carmofur |
0‑L | L01BC05 | gemcitabine | WHO Anatomical Therapeutic Chemical classification | | gemcitabine |
0‑L | L01BC06 | capecitabine | WHO Anatomical Therapeutic Chemical classification | | capecitabine |
0‑L | L01BC07 | azacitidine | WHO Anatomical Therapeutic Chemical classification | | azacitidine |
0‑L | L01BC08 | decitabine | WHO Anatomical Therapeutic Chemical classification | | decitabine |
0‑L | L01BC52 | fluorouracil, combinations | WHO Anatomical Therapeutic Chemical classification | | fluorouracil, combinations |
0‑L | L01BC53 | tegafur, combinations | WHO Anatomical Therapeutic Chemical classification | | tegafur, combinations |
0‑L | L01BC59 | trifluridine, combinations | WHO Anatomical Therapeutic Chemical classification | | trifluridine, combinations |
0‑L | L01C | PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS | WHO Anatomical Therapeutic Chemical classification | | PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS |
0‑L | L01CA | Vinca alkaloids and analogues | WHO Anatomical Therapeutic Chemical classification | | Vinca alkaloids and analogues |
0‑L | L01CA01 | vinblastine | WHO Anatomical Therapeutic Chemical classification | | vinblastine |
0‑L | L01CA02 | vincristine | WHO Anatomical Therapeutic Chemical classification | | vincristine |
0‑L | L01CA03 | vindesine | WHO Anatomical Therapeutic Chemical classification | | vindesine |
0‑L | L01CA04 | vinorelbine | WHO Anatomical Therapeutic Chemical classification | | vinorelbine |
0‑L | L01CA05 | vinflunine | WHO Anatomical Therapeutic Chemical classification | | vinflunine |
0‑L | L01CA06 | vintafolide | WHO Anatomical Therapeutic Chemical classification | | vintafolide |
0‑L | L01CB | Podophyllotoxin derivatives | WHO Anatomical Therapeutic Chemical classification | | Podophyllotoxin derivatives |
0‑L | L01CB01 | etoposide | WHO Anatomical Therapeutic Chemical classification | | etoposide |
0‑L | L01CB02 | teniposide | WHO Anatomical Therapeutic Chemical classification | | teniposide |
0‑L | L01CC | Colchicine derivatives | WHO Anatomical Therapeutic Chemical classification | | Colchicine derivatives |
0‑L | L01CC01 | demecolcine | WHO Anatomical Therapeutic Chemical classification | | demecolcine |
0‑L | L01CD | Taxanes | WHO Anatomical Therapeutic Chemical classification | | Taxanes |
0‑L | L01CD01 | paclitaxel | WHO Anatomical Therapeutic Chemical classification | | paclitaxel |
0‑L | L01CD02 | docetaxel | WHO Anatomical Therapeutic Chemical classification | | docetaxel |
0‑L | L01CD03 | paclitaxel poliglumex | WHO Anatomical Therapeutic Chemical classification | | paclitaxel poliglumex |
0‑L | L01CD04 | cabazitaxel | WHO Anatomical Therapeutic Chemical classification | | cabazitaxel |
0‑L | L01CX | Other plant alkaloids and natural products | WHO Anatomical Therapeutic Chemical classification | | Other plant alkaloids and natural products |
0‑L | L01CX01 | trabectedin | WHO Anatomical Therapeutic Chemical classification | | trabectedin |
0‑L | L01D | CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES | WHO Anatomical Therapeutic Chemical classification | | CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES |
0‑L | L01DA | Actinomycines | WHO Anatomical Therapeutic Chemical classification | | Actinomycines |
0‑L | L01DA01 | dactinomycin | WHO Anatomical Therapeutic Chemical classification | | dactinomycin |
0‑L | L01DB | Anthracyclines and related substances | WHO Anatomical Therapeutic Chemical classification | | Anthracyclines and related substances |
0‑L | L01DB01 | doxorubicin | WHO Anatomical Therapeutic Chemical classification | | doxorubicin |
0‑L | L01DB02 | daunorubicin | WHO Anatomical Therapeutic Chemical classification | | daunorubicin |
0‑L | L01DB03 | epirubicin | WHO Anatomical Therapeutic Chemical classification | | epirubicin |
0‑L | L01DB04 | aclarubicin | WHO Anatomical Therapeutic Chemical classification | | aclarubicin |
0‑L | L01DB05 | zorubicin | WHO Anatomical Therapeutic Chemical classification | | zorubicin |
0‑L | L01DB06 | idarubicin | WHO Anatomical Therapeutic Chemical classification | | idarubicin |
0‑L | L01DB07 | mitoxantrone | WHO Anatomical Therapeutic Chemical classification | | mitoxantrone |
0‑L | L01DB08 | pirarubicin | WHO Anatomical Therapeutic Chemical classification | | pirarubicin |
0‑L | L01DB09 | valrubicin | WHO Anatomical Therapeutic Chemical classification | | valrubicin |
0‑L | L01DB10 | amrubicin | WHO Anatomical Therapeutic Chemical classification | | amrubicin |
0‑L | L01DB11 | pixantrone | WHO Anatomical Therapeutic Chemical classification | | pixantrone |
0‑L | L01DC | Other cytotoxic antibiotics | WHO Anatomical Therapeutic Chemical classification | | Other cytotoxic antibiotics |
0‑L | L01DC01 | bleomycin | WHO Anatomical Therapeutic Chemical classification | | bleomycin |
0‑L | L01DC02 | plicamycin | WHO Anatomical Therapeutic Chemical classification | | plicamycin |
0‑L | L01DC03 | mitomycin | WHO Anatomical Therapeutic Chemical classification | | mitomycin |
0‑L | L01DC04 | ixabepilone | WHO Anatomical Therapeutic Chemical classification | | ixabepilone |
0‑L | L01X | OTHER ANTINEOPLASTIC AGENTS | WHO Anatomical Therapeutic Chemical classification | | OTHER ANTINEOPLASTIC AGENTS |
0‑L | L01XA | Platinum compounds | WHO Anatomical Therapeutic Chemical classification | | Platinum compounds |
0‑L | L01XA01 | cisplatin | WHO Anatomical Therapeutic Chemical classification | | cisplatin |
0‑L | L01XA02 | carboplatin | WHO Anatomical Therapeutic Chemical classification | | carboplatin |
0‑L | L01XA03 | oxaliplatin | WHO Anatomical Therapeutic Chemical classification | | oxaliplatin |
0‑L | L01XA04 | satraplatin | WHO Anatomical Therapeutic Chemical classification | | satraplatin |
0‑L | L01XA05 | polyplatillen | WHO Anatomical Therapeutic Chemical classification | | polyplatillen |
0‑L | L01XB | Methylhydrazines | WHO Anatomical Therapeutic Chemical classification | | Methylhydrazines |
0‑L | L01XB01 | procarbazine | WHO Anatomical Therapeutic Chemical classification | | procarbazine |
0‑L | L01XC | Monoclonal antibodies | WHO Anatomical Therapeutic Chemical classification | | Monoclonal antibodies |
0‑L | L01XC01 | edrecolomab | WHO Anatomical Therapeutic Chemical classification | | edrecolomab |
0‑L | L01XC02 | rituximab | WHO Anatomical Therapeutic Chemical classification | | rituximab |
0‑L | L01XC03 | trastuzumab | WHO Anatomical Therapeutic Chemical classification | | trastuzumab |
0‑L | L01XC05 | gemtuzumab | WHO Anatomical Therapeutic Chemical classification | | gemtuzumab |
0‑L | L01XC06 | cetuximab | WHO Anatomical Therapeutic Chemical classification | | cetuximab |
0‑L | L01XC07 | bevacizumab | WHO Anatomical Therapeutic Chemical classification | | bevacizumab |
0‑L | L01XC08 | panitumumab | WHO Anatomical Therapeutic Chemical classification | | panitumumab |
0‑L | L01XC09 | catumaxomab | WHO Anatomical Therapeutic Chemical classification | | catumaxomab |
0‑L | L01XC10 | ofatumumab | WHO Anatomical Therapeutic Chemical classification | | ofatumumab |
0‑L | L01XC11 | ipilimumab | WHO Anatomical Therapeutic Chemical classification | | ipilimumab |
0‑L | L01XC12 | brentuximab vedotin | WHO Anatomical Therapeutic Chemical classification | | brentuximab vedotin |
0‑L | L01XC13 | pertuzumab | WHO Anatomical Therapeutic Chemical classification | | pertuzumab |
0‑L | L01XC14 | trastuzumab emtansine | WHO Anatomical Therapeutic Chemical classification | | trastuzumab emtansine |
0‑L | L01XC15 | obinutuzumab | WHO Anatomical Therapeutic Chemical classification | | obinutuzumab |
0‑L | L01XC16 | dinutuximab | WHO Anatomical Therapeutic Chemical classification | | dinutuximab |
0‑L | L01XC17 | nivolumab | WHO Anatomical Therapeutic Chemical classification | | nivolumab |
0‑L | L01XC18 | pembrolizumab | WHO Anatomical Therapeutic Chemical classification | | pembrolizumab |
0‑L | L01XC19 | blinatumomab | WHO Anatomical Therapeutic Chemical classification | | blinatumomab |
0‑L | L01XC21 | ramucirumab | WHO Anatomical Therapeutic Chemical classification | | ramucirumab |
0‑L | L01XC22 | necitumumab | WHO Anatomical Therapeutic Chemical classification | | necitumumab |
0‑L | L01XC23 | elotuzumab | WHO Anatomical Therapeutic Chemical classification | | elotuzumab |
0‑L | L01XC24 | daratumumab | WHO Anatomical Therapeutic Chemical classification | | daratumumab |
0‑L | L01XC25 | mogamulizumab | WHO Anatomical Therapeutic Chemical classification | | mogamulizumab |
0‑L | L01XC26 | inotuzumab ozogamicin | WHO Anatomical Therapeutic Chemical classification | | inotuzumab ozogamicin |
0‑L | L01XD | Sensitizers used in photodynamic/radiation therapy | WHO Anatomical Therapeutic Chemical classification | | Sensitizers used in photodynamic/radiation therapy |
0‑L | L01XD01 | porfimer sodium | WHO Anatomical Therapeutic Chemical classification | | porfimer sodium |
0‑L | L01XD03 | methyl aminolevulinate | WHO Anatomical Therapeutic Chemical classification | | methyl aminolevulinate |
0‑L | L01XD04 | aminolevulinic acid | WHO Anatomical Therapeutic Chemical classification | | aminolevulinic acid |
0‑L | L01XD05 | temoporfin | WHO Anatomical Therapeutic Chemical classification | | temoporfin |
0‑L | L01XD06 | efaproxiral | WHO Anatomical Therapeutic Chemical classification | | efaproxiral |
0‑L | L01XE | Protein kinase inhibitors | WHO Anatomical Therapeutic Chemical classification | | Protein kinase inhibitors |
0‑L | L01XE01 | imatinib | WHO Anatomical Therapeutic Chemical classification | | imatinib |
0‑L | L01XE02 | gefitinib | WHO Anatomical Therapeutic Chemical classification | | gefitinib |
0‑L | L01XE03 | erlotinib | WHO Anatomical Therapeutic Chemical classification | | erlotinib |
0‑L | L01XE04 | sunitinib | WHO Anatomical Therapeutic Chemical classification | | sunitinib |
0‑L | L01XE05 | sorafenib | WHO Anatomical Therapeutic Chemical classification | | sorafenib |
0‑L | L01XE06 | dasatinib | WHO Anatomical Therapeutic Chemical classification | | dasatinib |
0‑L | L01XE07 | lapatinib | WHO Anatomical Therapeutic Chemical classification | | lapatinib |
0‑L | L01XE08 | nilotinib | WHO Anatomical Therapeutic Chemical classification | | nilotinib |
0‑L | L01XE09 | temsirolimus | WHO Anatomical Therapeutic Chemical classification | | temsirolimus |
0‑L | L01XE10 | everolimus | WHO Anatomical Therapeutic Chemical classification | | everolimus |
0‑L | L01XE11 | pazopanib | WHO Anatomical Therapeutic Chemical classification | | pazopanib |
0‑L | L01XE12 | vandetanib | WHO Anatomical Therapeutic Chemical classification | | vandetanib |
0‑L | L01XE13 | afatinib | WHO Anatomical Therapeutic Chemical classification | | afatinib |
0‑L | L01XE14 | bosutinib | WHO Anatomical Therapeutic Chemical classification | | bosutinib |
0‑L | L01XE15 | vemurafenib | WHO Anatomical Therapeutic Chemical classification | | vemurafenib |
0‑L | L01XE16 | crizotinib | WHO Anatomical Therapeutic Chemical classification | | crizotinib |
0‑L | L01XE17 | axitinib | WHO Anatomical Therapeutic Chemical classification | | axitinib |
0‑L | L01XE18 | ruxolitinib | WHO Anatomical Therapeutic Chemical classification | | ruxolitinib |
0‑L | L01XE19 | ridaforolimus | WHO Anatomical Therapeutic Chemical classification | | ridaforolimus |
0‑L | L01XE21 | regorafenib | WHO Anatomical Therapeutic Chemical classification | | regorafenib |
0‑L | L01XE22 | masitinib | WHO Anatomical Therapeutic Chemical classification | | masitinib |
0‑L | L01XE23 | dabrafenib | WHO Anatomical Therapeutic Chemical classification | | dabrafenib |
0‑L | L01XE24 | ponatinib | WHO Anatomical Therapeutic Chemical classification | | ponatinib |
0‑L | L01XE25 | trametinib | WHO Anatomical Therapeutic Chemical classification | | trametinib |
0‑L | L01XE26 | cabozantinib | WHO Anatomical Therapeutic Chemical classification | | cabozantinib |
0‑L | L01XE27 | ibrutinib | WHO Anatomical Therapeutic Chemical classification | | ibrutinib |
0‑L | L01XE28 | ceritinib | WHO Anatomical Therapeutic Chemical classification | | ceritinib |
0‑L | L01XE29 | lenvatinib | WHO Anatomical Therapeutic Chemical classification | | lenvatinib |
0‑L | L01XE31 | nintedanib | WHO Anatomical Therapeutic Chemical classification | | nintedanib |
0‑L | L01XE32 | cediranib | WHO Anatomical Therapeutic Chemical classification | | cediranib |
0‑L | L01XE33 | palbociclib | WHO Anatomical Therapeutic Chemical classification | | palbociclib |
0‑L | L01XE34 | tivozanib | WHO Anatomical Therapeutic Chemical classification | | tivozanib |
0‑L | L01XE35 | osimertinib | WHO Anatomical Therapeutic Chemical classification | | osimertinib |
0‑L | L01XE36 | alectinib | WHO Anatomical Therapeutic Chemical classification | | alectinib |
0‑L | L01XE37 | rociletinib | WHO Anatomical Therapeutic Chemical classification | | rociletinib |
0‑L | L01XE38 | cobimetinib | WHO Anatomical Therapeutic Chemical classification | | cobimetinib |
0‑L | L01XE39 | midostaurin | WHO Anatomical Therapeutic Chemical classification | | midostaurin |
0‑L | L01XE40 | olmutinib | WHO Anatomical Therapeutic Chemical classification | | olmutinib |
0‑L | L01XX | Other antineoplastic agents | WHO Anatomical Therapeutic Chemical classification | | Other antineoplastic agents |
0‑L | L01XX01 | amsacrine | WHO Anatomical Therapeutic Chemical classification | | amsacrine |
0‑L | L01XX02 | asparaginase | WHO Anatomical Therapeutic Chemical classification | | asparaginase |
0‑L | L01XX03 | altretamine | WHO Anatomical Therapeutic Chemical classification | | altretamine |
0‑L | L01XX05 | hydroxycarbamide | WHO Anatomical Therapeutic Chemical classification | | hydroxycarbamide |
0‑L | L01XX07 | lonidamine | WHO Anatomical Therapeutic Chemical classification | | lonidamine |
0‑L | L01XX08 | pentostatin | WHO Anatomical Therapeutic Chemical classification | | pentostatin |
0‑L | L01XX09 | miltefosine | WHO Anatomical Therapeutic Chemical classification | | miltefosine |
0‑L | L01XX10 | masoprocol | WHO Anatomical Therapeutic Chemical classification | | masoprocol |
0‑L | L01XX11 | estramustine | WHO Anatomical Therapeutic Chemical classification | | estramustine |
0‑L | L01XX14 | tretinoin | WHO Anatomical Therapeutic Chemical classification | | tretinoin |
0‑L | L01XX16 | mitoguazone | WHO Anatomical Therapeutic Chemical classification | | mitoguazone |
0‑L | L01XX17 | topotecan | WHO Anatomical Therapeutic Chemical classification | | topotecan |
0‑L | L01XX18 | tiazofurine | WHO Anatomical Therapeutic Chemical classification | | tiazofurine |
0‑L | L01XX19 | irinotecan | WHO Anatomical Therapeutic Chemical classification | | irinotecan |
0‑L | L01XX22 | alitretinoin | WHO Anatomical Therapeutic Chemical classification | | alitretinoin |
0‑L | L01XX23 | mitotane | WHO Anatomical Therapeutic Chemical classification | | mitotane |
0‑L | L01XX24 | pegaspargase | WHO Anatomical Therapeutic Chemical classification | | pegaspargase |
0‑L | L01XX25 | bexarotene | WHO Anatomical Therapeutic Chemical classification | | bexarotene |
0‑L | L01XX27 | arsenic trioxide | WHO Anatomical Therapeutic Chemical classification | | arsenic trioxide |
0‑L | L01XX29 | denileukin diftitox | WHO Anatomical Therapeutic Chemical classification | | denileukin diftitox |
0‑L | L01XX32 | bortezomib | WHO Anatomical Therapeutic Chemical classification | | bortezomib |
0‑L | L01XX33 | celecoxib | WHO Anatomical Therapeutic Chemical classification | | celecoxib |
0‑L | L01XX35 | anagrelide | WHO Anatomical Therapeutic Chemical classification | | anagrelide |
0‑L | L01XX36 | oblimersen | WHO Anatomical Therapeutic Chemical classification | | oblimersen |
0‑L | L01XX37 | sitimagene ceradenovec | WHO Anatomical Therapeutic Chemical classification | | sitimagene ceradenovec |
0‑L | L01XX38 | vorinostat | WHO Anatomical Therapeutic Chemical classification | | vorinostat |
0‑L | L01XX39 | romidepsin | WHO Anatomical Therapeutic Chemical classification | | romidepsin |
0‑L | L01XX40 | omacetaxine mepesuccinate | WHO Anatomical Therapeutic Chemical classification | | omacetaxine mepesuccinate |
0‑L | L01XX41 | eribulin | WHO Anatomical Therapeutic Chemical classification | | eribulin |
0‑L | L01XX42 | panobinostat | WHO Anatomical Therapeutic Chemical classification | | panobinostat |
0‑L | L01XX43 | vismodegib | WHO Anatomical Therapeutic Chemical classification | | vismodegib |
0‑L | L01XX44 | aflibercept | WHO Anatomical Therapeutic Chemical classification | | aflibercept |
0‑L | L01XX45 | carfilzomib | WHO Anatomical Therapeutic Chemical classification | | carfilzomib |
0‑L | L01XX46 | olaparib | WHO Anatomical Therapeutic Chemical classification | | olaparib |
0‑L | L01XX47 | idelalisib | WHO Anatomical Therapeutic Chemical classification | | idelalisib |
0‑L | L01XX48 | sonidegib | WHO Anatomical Therapeutic Chemical classification | | sonidegib |
0‑L | L01XX49 | belinostat | WHO Anatomical Therapeutic Chemical classification | | belinostat |
0‑L | L01XX50 | ixazomib | WHO Anatomical Therapeutic Chemical classification | | ixazomib |
0‑L | L01XX51 | talimogene laherparepvec | WHO Anatomical Therapeutic Chemical classification | | talimogene laherparepvec |
0‑L | L01XX52 | venetoclax | WHO Anatomical Therapeutic Chemical classification | | venetoclax |
0‑L | L01XX53 | vosaroxin | WHO Anatomical Therapeutic Chemical classification | | vosaroxin |
0‑L | L01XY | Combinations of antineoplastic agents | WHO Anatomical Therapeutic Chemical classification | | Combinations of antineoplastic agents |
0‑L | L02 | ENDOCRINE THERAPY | WHO Anatomical Therapeutic Chemical classification | | ENDOCRINE THERAPY |
0‑L | L02A | HORMONES AND RELATED AGENTS | WHO Anatomical Therapeutic Chemical classification | | HORMONES AND RELATED AGENTS |
0‑L | L02AA | Estrogens | WHO Anatomical Therapeutic Chemical classification | | Estrogens |
0‑L | L02AA01 | diethylstilbestrol | WHO Anatomical Therapeutic Chemical classification | | diethylstilbestrol |
0‑L | L02AA02 | polyestradiol phosphate | WHO Anatomical Therapeutic Chemical classification | | polyestradiol phosphate |
0‑L | L02AA03 | ethinylestradiol | WHO Anatomical Therapeutic Chemical classification | | ethinylestradiol |
0‑L | L02AA04 | fosfestrol | WHO Anatomical Therapeutic Chemical classification | | fosfestrol |
0‑L | L02AB | Progestogens | WHO Anatomical Therapeutic Chemical classification | | Progestogens |
0‑L | L02AB01 | megestrol | WHO Anatomical Therapeutic Chemical classification | | megestrol |
0‑L | L02AB02 | medroxyprogesterone | WHO Anatomical Therapeutic Chemical classification | | medroxyprogesterone |
0‑L | L02AB03 | gestonorone | WHO Anatomical Therapeutic Chemical classification | | gestonorone |
0‑L | L02AE | Gonadotropin releasing hormone analogues | WHO Anatomical Therapeutic Chemical classification | | Gonadotropin releasing hormone analogues |
0‑L | L02AE01 | buserelin | WHO Anatomical Therapeutic Chemical classification | | buserelin |
0‑L | L02AE02 | leuprorelin | WHO Anatomical Therapeutic Chemical classification | | leuprorelin |
0‑L | L02AE03 | goserelin | WHO Anatomical Therapeutic Chemical classification | | goserelin |
0‑L | L02AE04 | triptorelin | WHO Anatomical Therapeutic Chemical classification | | triptorelin |
0‑L | L02AE05 | histrelin | WHO Anatomical Therapeutic Chemical classification | | histrelin |
0‑L | L02AX | Other hormones | WHO Anatomical Therapeutic Chemical classification | | Other hormones |
0‑L | L02B | HORMONE ANTAGONISTS AND RELATED AGENTS | WHO Anatomical Therapeutic Chemical classification | | HORMONE ANTAGONISTS AND RELATED AGENTS |
0‑L | L02BA | Anti-estrogens | WHO Anatomical Therapeutic Chemical classification | | Anti-estrogens |
0‑L | L02BA01 | tamoxifen | WHO Anatomical Therapeutic Chemical classification | | tamoxifen |
0‑L | L02BA02 | toremifene | WHO Anatomical Therapeutic Chemical classification | | toremifene |
0‑L | L02BA03 | fulvestrant | WHO Anatomical Therapeutic Chemical classification | | fulvestrant |
0‑L | L02BB | Anti-androgens | WHO Anatomical Therapeutic Chemical classification | | Anti-androgens |
0‑L | L02BB01 | flutamide | WHO Anatomical Therapeutic Chemical classification | | flutamide |
0‑L | L02BB02 | nilutamide | WHO Anatomical Therapeutic Chemical classification | | nilutamide |
0‑L | L02BB03 | bicalutamide | WHO Anatomical Therapeutic Chemical classification | | bicalutamide |
0‑L | L02BB04 | enzalutamide | WHO Anatomical Therapeutic Chemical classification | | enzalutamide |
0‑L | L02BG | Aromatase inhibitors | WHO Anatomical Therapeutic Chemical classification | | Aromatase inhibitors |
0‑L | L02BG01 | aminoglutethimide | WHO Anatomical Therapeutic Chemical classification | | aminoglutethimide |
0‑L | L02BG02 | formestane | WHO Anatomical Therapeutic Chemical classification | | formestane |
0‑L | L02BG03 | anastrozole | WHO Anatomical Therapeutic Chemical classification | | anastrozole |
0‑L | L02BG04 | letrozole | WHO Anatomical Therapeutic Chemical classification | | letrozole |
0‑L | L02BG05 | vorozole | WHO Anatomical Therapeutic Chemical classification | | vorozole |
0‑L | L02BG06 | exemestane | WHO Anatomical Therapeutic Chemical classification | | exemestane |
0‑L | L02BX | Other hormone antagonists and related agents | WHO Anatomical Therapeutic Chemical classification | | Other hormone antagonists and related agents |
0‑L | L02BX01 | abarelix | WHO Anatomical Therapeutic Chemical classification | | abarelix |
0‑L | L02BX02 | degarelix | WHO Anatomical Therapeutic Chemical classification | | degarelix |
0‑L | L02BX03 | abiraterone | WHO Anatomical Therapeutic Chemical classification | | abiraterone |
0‑L | L03 | IMMUNOSTIMULANTS | WHO Anatomical Therapeutic Chemical classification | | IMMUNOSTIMULANTS |
0‑L | L03A | IMMUNOSTIMULANTS | WHO Anatomical Therapeutic Chemical classification | | IMMUNOSTIMULANTS |
0‑L | L03AA | Colony stimulating factors | WHO Anatomical Therapeutic Chemical classification | | Colony stimulating factors |
0‑L | L03AA02 | filgrastim | WHO Anatomical Therapeutic Chemical classification | | filgrastim |
0‑L | L03AA03 | molgramostim | WHO Anatomical Therapeutic Chemical classification | | molgramostim |
0‑L | L03AA09 | sargramostim | WHO Anatomical Therapeutic Chemical classification | | sargramostim |
0‑L | L03AA10 | lenograstim | WHO Anatomical Therapeutic Chemical classification | | lenograstim |
0‑L | L03AA12 | ancestim | WHO Anatomical Therapeutic Chemical classification | | ancestim |
0‑L | L03AA13 | pegfilgrastim | WHO Anatomical Therapeutic Chemical classification | | pegfilgrastim |
0‑L | L03AA14 | lipegfilgrastim | WHO Anatomical Therapeutic Chemical classification | | lipegfilgrastim |
0‑L | L03AA15 | balugrastim | WHO Anatomical Therapeutic Chemical classification | | balugrastim |
0‑L | L03AA16 | empegfilgrastim | WHO Anatomical Therapeutic Chemical classification | | empegfilgrastim |
0‑L | L03AB | Interferons | WHO Anatomical Therapeutic Chemical classification | | Interferons |
0‑L | L03AB01 | interferon alfa natural | WHO Anatomical Therapeutic Chemical classification | | interferon alfa natural |
0‑L | L03AB02 | interferon beta natural | WHO Anatomical Therapeutic Chemical classification | | interferon beta natural |
0‑L | L03AB03 | interferon gamma | WHO Anatomical Therapeutic Chemical classification | | interferon gamma |
0‑L | L03AB04 | interferon alfa-2a | WHO Anatomical Therapeutic Chemical classification | | interferon alfa-2a |
0‑L | L03AB05 | interferon alfa-2b | WHO Anatomical Therapeutic Chemical classification | | interferon alfa-2b |
0‑L | L03AB06 | interferon alfa-n1 | WHO Anatomical Therapeutic Chemical classification | | interferon alfa-n1 |
0‑L | L03AB07 | interferon beta-1a | WHO Anatomical Therapeutic Chemical classification | | interferon beta-1a |
0‑L | L03AB08 | interferon beta-1b | WHO Anatomical Therapeutic Chemical classification | | interferon beta-1b |
0‑L | L03AB09 | interferon alfacon-1 | WHO Anatomical Therapeutic Chemical classification | | interferon alfacon-1 |
0‑L | L03AB10 | peginterferon alfa-2b | WHO Anatomical Therapeutic Chemical classification | | peginterferon alfa-2b |
0‑L | L03AB11 | peginterferon alfa-2a | WHO Anatomical Therapeutic Chemical classification | | peginterferon alfa-2a |
0‑L | L03AB12 | albinterferon alfa-2b | WHO Anatomical Therapeutic Chemical classification | | albinterferon alfa-2b |
0‑L | L03AB13 | peginterferon beta-1a | WHO Anatomical Therapeutic Chemical classification | | peginterferon beta-1a |
0‑L | L03AB14 | cepeginterferon alfa-2b | WHO Anatomical Therapeutic Chemical classification | | cepeginterferon alfa-2b |
0‑L | L03AB60 | peginterferon alfa-2b, combinations | WHO Anatomical Therapeutic Chemical classification | | peginterferon alfa-2b, combinations |
0‑L | L03AB61 | peginterferon alfa-2a, combinations | WHO Anatomical Therapeutic Chemical classification | | peginterferon alfa-2a, combinations |
0‑L | L03AC | Interleukins | WHO Anatomical Therapeutic Chemical classification | | Interleukins |
0‑L | L03AC01 | aldesleukin | WHO Anatomical Therapeutic Chemical classification | | aldesleukin |
0‑L | L03AC02 | oprelvekin | WHO Anatomical Therapeutic Chemical classification | | oprelvekin |
0‑L | L03AX | Other immunostimulants | WHO Anatomical Therapeutic Chemical classification | | Other immunostimulants |
0‑L | L03AX01 | lentinan | WHO Anatomical Therapeutic Chemical classification | | lentinan |
0‑L | L03AX02 | roquinimex | WHO Anatomical Therapeutic Chemical classification | | roquinimex |
0‑L | L03AX03 | BCG vaccine | WHO Anatomical Therapeutic Chemical classification | | BCG vaccine |
0‑L | L03AX04 | pegademase | WHO Anatomical Therapeutic Chemical classification | | pegademase |
0‑L | L03AX05 | pidotimod | WHO Anatomical Therapeutic Chemical classification | | pidotimod |
0‑L | L03AX07 | poly I:C | WHO Anatomical Therapeutic Chemical classification | | poly I:C |
0‑L | L03AX08 | poly ICLC | WHO Anatomical Therapeutic Chemical classification | | poly ICLC |
0‑L | L03AX09 | thymopentin | WHO Anatomical Therapeutic Chemical classification | | thymopentin |
0‑L | L03AX10 | immunocyanin | WHO Anatomical Therapeutic Chemical classification | | immunocyanin |
0‑L | L03AX11 | tasonermin | WHO Anatomical Therapeutic Chemical classification | | tasonermin |
0‑L | L03AX12 | melanoma vaccine | WHO Anatomical Therapeutic Chemical classification | | melanoma vaccine |
0‑L | L03AX13 | glatiramer acetate | WHO Anatomical Therapeutic Chemical classification | | glatiramer acetate |
0‑L | L03AX14 | histamine dihydrochloride | WHO Anatomical Therapeutic Chemical classification | | histamine dihydrochloride |
0‑L | L03AX15 | mifamurtide | WHO Anatomical Therapeutic Chemical classification | | mifamurtide |
0‑L | L03AX16 | plerixafor | WHO Anatomical Therapeutic Chemical classification | | plerixafor |
0‑L | L03AX17 | sipuleucel-T | WHO Anatomical Therapeutic Chemical classification | | sipuleucel-T |
0‑L | L03AX18 | cridanimod | WHO Anatomical Therapeutic Chemical classification | | cridanimod |
0‑L | L03AX19 | dasiprotimut-T | WHO Anatomical Therapeutic Chemical classification | | dasiprotimut-T |
0‑L | L04 | IMMUNOSUPPRESSANTS | WHO Anatomical Therapeutic Chemical classification | | IMMUNOSUPPRESSANTS |
0‑L | L04A | IMMUNOSUPPRESSANTS | WHO Anatomical Therapeutic Chemical classification | | IMMUNOSUPPRESSANTS |
0‑L | L04AA | Selective immunosuppressants | WHO Anatomical Therapeutic Chemical classification | | Selective immunosuppressants |
0‑L | L04AA02 | muromonab-CD3 | WHO Anatomical Therapeutic Chemical classification | | muromonab-CD3 |
0‑L | L04AA03 | antilymphocyte immunoglobulin (horse) | WHO Anatomical Therapeutic Chemical classification | | antilymphocyte immunoglobulin (horse) |
0‑L | L04AA04 | antithymocyte immunoglobulin (rabbit) | WHO Anatomical Therapeutic Chemical classification | | antithymocyte immunoglobulin (rabbit) |
0‑L | L04AA06 | mycophenolic acid | WHO Anatomical Therapeutic Chemical classification | | mycophenolic acid |
0‑L | L04AA10 | sirolimus | WHO Anatomical Therapeutic Chemical classification | | sirolimus |
0‑L | L04AA13 | leflunomide | WHO Anatomical Therapeutic Chemical classification | | leflunomide |
0‑L | L04AA15 | alefacept | WHO Anatomical Therapeutic Chemical classification | | alefacept |
0‑L | L04AA18 | everolimus | WHO Anatomical Therapeutic Chemical classification | | everolimus |
0‑L | L04AA19 | gusperimus | WHO Anatomical Therapeutic Chemical classification | | gusperimus |
0‑L | L04AA21 | efalizumab | WHO Anatomical Therapeutic Chemical classification | | efalizumab |
0‑L | L04AA22 | abetimus | WHO Anatomical Therapeutic Chemical classification | | abetimus |
0‑L | L04AA23 | natalizumab | WHO Anatomical Therapeutic Chemical classification | | natalizumab |
0‑L | L04AA24 | abatacept | WHO Anatomical Therapeutic Chemical classification | | abatacept |
0‑L | L04AA25 | eculizumab | WHO Anatomical Therapeutic Chemical classification | | eculizumab |
0‑L | L04AA26 | belimumab | WHO Anatomical Therapeutic Chemical classification | | belimumab |
0‑L | L04AA27 | fingolimod | WHO Anatomical Therapeutic Chemical classification | | fingolimod |
0‑L | L04AA28 | belatacept | WHO Anatomical Therapeutic Chemical classification | | belatacept |
0‑L | L04AA29 | tofacitinib | WHO Anatomical Therapeutic Chemical classification | | tofacitinib |
0‑L | L04AA31 | teriflunomide | WHO Anatomical Therapeutic Chemical classification | | teriflunomide |
0‑L | L04AA32 | apremilast | WHO Anatomical Therapeutic Chemical classification | | apremilast |
0‑L | L04AA33 | vedolizumab | WHO Anatomical Therapeutic Chemical classification | | vedolizumab |
0‑L | L04AA34 | alemtuzumab | WHO Anatomical Therapeutic Chemical classification | | alemtuzumab |
0‑L | L04AA35 | begelomab | WHO Anatomical Therapeutic Chemical classification | | begelomab |
0‑L | L04AA36 | ocrelizumab | WHO Anatomical Therapeutic Chemical classification | | ocrelizumab |
0‑L | L04AA37 | baricitinib | WHO Anatomical Therapeutic Chemical classification | | baricitinib |
0‑L | L04AB | Tumor necrosis factor alpha (TNF-) inhibitors | WHO Anatomical Therapeutic Chemical classification | | Tumor necrosis factor alpha (TNF-) inhibitors |
0‑L | L04AB01 | etanercept | WHO Anatomical Therapeutic Chemical classification | | etanercept |
0‑L | L04AB02 | infliximab | WHO Anatomical Therapeutic Chemical classification | | infliximab |
0‑L | L04AB03 | afelimomab | WHO Anatomical Therapeutic Chemical classification | | afelimomab |
0‑L | L04AB04 | adalimumab | WHO Anatomical Therapeutic Chemical classification | | adalimumab |
0‑L | L04AB05 | certolizumab pegol | WHO Anatomical Therapeutic Chemical classification | | certolizumab pegol |
0‑L | L04AB06 | golimumab | WHO Anatomical Therapeutic Chemical classification | | golimumab |
0‑L | L04AC | Interleukin inhibitors | WHO Anatomical Therapeutic Chemical classification | | Interleukin inhibitors |
0‑L | L04AC01 | daclizumab | WHO Anatomical Therapeutic Chemical classification | | daclizumab |
0‑L | L04AC02 | basiliximab | WHO Anatomical Therapeutic Chemical classification | | basiliximab |
0‑L | L04AC03 | anakinra | WHO Anatomical Therapeutic Chemical classification | | anakinra |
0‑L | L04AC04 | rilonacept | WHO Anatomical Therapeutic Chemical classification | | rilonacept |
0‑L | L04AC05 | ustekinumab | WHO Anatomical Therapeutic Chemical classification | | ustekinumab |
0‑L | L04AC07 | tocilizumab | WHO Anatomical Therapeutic Chemical classification | | tocilizumab |
0‑L | L04AC08 | canakinumab | WHO Anatomical Therapeutic Chemical classification | | canakinumab |
0‑L | L04AC09 | briakinumab | WHO Anatomical Therapeutic Chemical classification | | briakinumab |
0‑L | L04AC10 | secukinumab | WHO Anatomical Therapeutic Chemical classification | | secukinumab |
0‑L | L04AC11 | siltuximab | WHO Anatomical Therapeutic Chemical classification | | siltuximab |
0‑L | L04AC12 | brodalumab | WHO Anatomical Therapeutic Chemical classification | | brodalumab |
0‑L | L04AC13 | ixekizumab | WHO Anatomical Therapeutic Chemical classification | | ixekizumab |
0‑L | L04AC14 | sarilumab | WHO Anatomical Therapeutic Chemical classification | | sarilumab |
0‑L | L04AD | Calcineurin inhibitors | WHO Anatomical Therapeutic Chemical classification | | Calcineurin inhibitors |
0‑L | L04AD01 | ciclosporin | WHO Anatomical Therapeutic Chemical classification | | ciclosporin |
0‑L | L04AD02 | tacrolimus | WHO Anatomical Therapeutic Chemical classification | | tacrolimus |
0‑L | L04AD03 | voclosporin | WHO Anatomical Therapeutic Chemical classification | | voclosporin |
0‑L | L04AX | Other immunosuppressants | WHO Anatomical Therapeutic Chemical classification | | Other immunosuppressants |
0‑L | L04AX01 | azathioprine | WHO Anatomical Therapeutic Chemical classification | | azathioprine |
0‑L | L04AX02 | thalidomide | WHO Anatomical Therapeutic Chemical classification | | thalidomide |
0‑L | L04AX03 | methotrexate | WHO Anatomical Therapeutic Chemical classification | | methotrexate |
0‑L | L04AX04 | lenalidomide | WHO Anatomical Therapeutic Chemical classification | | lenalidomide |
0‑L | L04AX05 | pirfenidone | WHO Anatomical Therapeutic Chemical classification | | pirfenidone |
0‑L | L04AX06 | pomalidomide | WHO Anatomical Therapeutic Chemical classification | | pomalidomide |
0‑L | M | MUSCULO-SKELETAL SYSTEM | WHO Anatomical Therapeutic Chemical classification | | MUSCULO-SKELETAL SYSTEM |
0‑L | M01 | ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS | WHO Anatomical Therapeutic Chemical classification | | ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS |
0‑L | M01A | ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS | WHO Anatomical Therapeutic Chemical classification | | ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS |
0‑L | M01AA | Butylpyrazolidines | WHO Anatomical Therapeutic Chemical classification | | Butylpyrazolidines |
0‑L | M01AA01 | phenylbutazone | WHO Anatomical Therapeutic Chemical classification | | phenylbutazone |
0‑L | M01AA02 | mofebutazone | WHO Anatomical Therapeutic Chemical classification | | mofebutazone |
0‑L | M01AA03 | oxyphenbutazone | WHO Anatomical Therapeutic Chemical classification | | oxyphenbutazone |
0‑L | M01AA05 | clofezone | WHO Anatomical Therapeutic Chemical classification | | clofezone |
0‑L | M01AA06 | kebuzone | WHO Anatomical Therapeutic Chemical classification | | kebuzone |
0‑L | M01AB | Acetic acid derivatives and related substances | WHO Anatomical Therapeutic Chemical classification | | Acetic acid derivatives and related substances |
0‑L | M01AB01 | indometacin | WHO Anatomical Therapeutic Chemical classification | | indometacin |
0‑L | M01AB02 | sulindac | WHO Anatomical Therapeutic Chemical classification | | sulindac |
0‑L | M01AB03 | tolmetin | WHO Anatomical Therapeutic Chemical classification | | tolmetin |
0‑L | M01AB04 | zomepirac | WHO Anatomical Therapeutic Chemical classification | | zomepirac |
0‑L | M01AB05 | diclofenac | WHO Anatomical Therapeutic Chemical classification | | diclofenac |
0‑L | M01AB06 | alclofenac | WHO Anatomical Therapeutic Chemical classification | | alclofenac |
0‑L | M01AB07 | bumadizone | WHO Anatomical Therapeutic Chemical classification | | bumadizone |
0‑L | M01AB08 | etodolac | WHO Anatomical Therapeutic Chemical classification | | etodolac |
0‑L | M01AB09 | lonazolac | WHO Anatomical Therapeutic Chemical classification | | lonazolac |
0‑L | M01AB10 | fentiazac | WHO Anatomical Therapeutic Chemical classification | | fentiazac |
0‑L | M01AB11 | acemetacin | WHO Anatomical Therapeutic Chemical classification | | acemetacin |
0‑L | M01AB12 | difenpiramide | WHO Anatomical Therapeutic Chemical classification | | difenpiramide |
0‑L | M01AB13 | oxametacin | WHO Anatomical Therapeutic Chemical classification | | oxametacin |
0‑L | M01AB14 | proglumetacin | WHO Anatomical Therapeutic Chemical classification | | proglumetacin |
0‑L | M01AB15 | ketorolac | WHO Anatomical Therapeutic Chemical classification | | ketorolac |
0‑L | M01AB16 | aceclofenac | WHO Anatomical Therapeutic Chemical classification | | aceclofenac |
0‑L | M01AB17 | bufexamac | WHO Anatomical Therapeutic Chemical classification | | bufexamac |
0‑L | M01AB51 | indometacin, combinations | WHO Anatomical Therapeutic Chemical classification | | indometacin, combinations |
0‑L | M01AB55 | diclofenac, combinations | WHO Anatomical Therapeutic Chemical classification | | diclofenac, combinations |
0‑L | M01AC | Oxicams | WHO Anatomical Therapeutic Chemical classification | | Oxicams |
0‑L | M01AC01 | piroxicam | WHO Anatomical Therapeutic Chemical classification | | piroxicam |
0‑L | M01AC02 | tenoxicam | WHO Anatomical Therapeutic Chemical classification | | tenoxicam |
0‑L | M01AC04 | droxicam | WHO Anatomical Therapeutic Chemical classification | | droxicam |
0‑L | M01AC05 | lornoxicam | WHO Anatomical Therapeutic Chemical classification | | lornoxicam |
0‑L | M01AC06 | meloxicam | WHO Anatomical Therapeutic Chemical classification | | meloxicam |
0‑L | M01AC56 | meloxicam, combinations | WHO Anatomical Therapeutic Chemical classification | | meloxicam, combinations |
0‑L | M01AE | Propionic acid derivatives | WHO Anatomical Therapeutic Chemical classification | | Propionic acid derivatives |
0‑L | M01AE01 | ibuprofen | WHO Anatomical Therapeutic Chemical classification | | ibuprofen |
0‑L | M01AE02 | naproxen | WHO Anatomical Therapeutic Chemical classification | | naproxen |
0‑L | M01AE03 | ketoprofen | WHO Anatomical Therapeutic Chemical classification | | ketoprofen |
0‑L | M01AE04 | fenoprofen | WHO Anatomical Therapeutic Chemical classification | | fenoprofen |
0‑L | M01AE05 | fenbufen | WHO Anatomical Therapeutic Chemical classification | | fenbufen |
0‑L | M01AE06 | benoxaprofen | WHO Anatomical Therapeutic Chemical classification | | benoxaprofen |
0‑L | M01AE07 | suprofen | WHO Anatomical Therapeutic Chemical classification | | suprofen |
0‑L | M01AE08 | pirprofen | WHO Anatomical Therapeutic Chemical classification | | pirprofen |
0‑L | M01AE09 | flurbiprofen | WHO Anatomical Therapeutic Chemical classification | | flurbiprofen |
0‑L | M01AE10 | indoprofen | WHO Anatomical Therapeutic Chemical classification | | indoprofen |
0‑L | M01AE11 | tiaprofenic acid | WHO Anatomical Therapeutic Chemical classification | | tiaprofenic acid |
0‑L | M01AE12 | oxaprozin | WHO Anatomical Therapeutic Chemical classification | | oxaprozin |
0‑L | M01AE13 | ibuproxam | WHO Anatomical Therapeutic Chemical classification | | ibuproxam |
0‑L | M01AE14 | dexibuprofen | WHO Anatomical Therapeutic Chemical classification | | dexibuprofen |
0‑L | M01AE15 | flunoxaprofen | WHO Anatomical Therapeutic Chemical classification | | flunoxaprofen |
0‑L | M01AE16 | alminoprofen | WHO Anatomical Therapeutic Chemical classification | | alminoprofen |
0‑L | M01AE17 | dexketoprofen | WHO Anatomical Therapeutic Chemical classification | | dexketoprofen |
0‑L | M01AE18 | naproxcinod | WHO Anatomical Therapeutic Chemical classification | | naproxcinod |
0‑L | M01AE51 | ibuprofen, combinations | WHO Anatomical Therapeutic Chemical classification | | ibuprofen, combinations |
0‑L | M01AE52 | naproxen and esomeprazole | WHO Anatomical Therapeutic Chemical classification | | naproxen and esomeprazole |
0‑L | M01AE53 | ketoprofen, combinations | WHO Anatomical Therapeutic Chemical classification | | ketoprofen, combinations |
0‑L | M01AE56 | naproxen and misoprostol | WHO Anatomical Therapeutic Chemical classification | | naproxen and misoprostol |
0‑L | M01AG | Fenamates | WHO Anatomical Therapeutic Chemical classification | | Fenamates |
0‑L | M01AG01 | mefenamic acid | WHO Anatomical Therapeutic Chemical classification | | mefenamic acid |
0‑L | M01AG02 | tolfenamic acid | WHO Anatomical Therapeutic Chemical classification | | tolfenamic acid |
0‑L | M01AG03 | flufenamic acid | WHO Anatomical Therapeutic Chemical classification | | flufenamic acid |
0‑L | M01AG04 | meclofenamic acid | WHO Anatomical Therapeutic Chemical classification | | meclofenamic acid |
0‑L | M01AH | Coxibs | WHO Anatomical Therapeutic Chemical classification | | Coxibs |
0‑L | M01AH01 | celecoxib | WHO Anatomical Therapeutic Chemical classification | | celecoxib |
0‑L | M01AH02 | rofecoxib | WHO Anatomical Therapeutic Chemical classification | | rofecoxib |
0‑L | M01AH03 | valdecoxib | WHO Anatomical Therapeutic Chemical classification | | valdecoxib |
0‑L | M01AH04 | parecoxib | WHO Anatomical Therapeutic Chemical classification | | parecoxib |
0‑L | M01AH05 | etoricoxib | WHO Anatomical Therapeutic Chemical classification | | etoricoxib |
0‑L | M01AH06 | lumiracoxib | WHO Anatomical Therapeutic Chemical classification | | lumiracoxib |
0‑L | M01AX | Other antiinflammatory and antirheumatic agents, non-steroids | WHO Anatomical Therapeutic Chemical classification | | Other antiinflammatory and antirheumatic agents, non-steroids |
0‑L | M01AX01 | nabumetone | WHO Anatomical Therapeutic Chemical classification | | nabumetone |
0‑L | M01AX02 | niflumic acid | WHO Anatomical Therapeutic Chemical classification | | niflumic acid |
0‑L | M01AX04 | azapropazone | WHO Anatomical Therapeutic Chemical classification | | azapropazone |
0‑L | M01AX05 | glucosamine | WHO Anatomical Therapeutic Chemical classification | | glucosamine |
0‑L | M01AX07 | benzydamine | WHO Anatomical Therapeutic Chemical classification | | benzydamine |
0‑L | M01AX12 | glucosaminoglycan polysulfate | WHO Anatomical Therapeutic Chemical classification | | glucosaminoglycan polysulfate |
0‑L | M01AX13 | proquazone | WHO Anatomical Therapeutic Chemical classification | | proquazone |
0‑L | M01AX14 | orgotein | WHO Anatomical Therapeutic Chemical classification | | orgotein |
0‑L | M01AX17 | nimesulide | WHO Anatomical Therapeutic Chemical classification | | nimesulide |
0‑L | M01AX18 | feprazone | WHO Anatomical Therapeutic Chemical classification | | feprazone |
0‑L | M01AX21 | diacerein | WHO Anatomical Therapeutic Chemical classification | | diacerein |
0‑L | M01AX22 | morniflumate | WHO Anatomical Therapeutic Chemical classification | | morniflumate |
0‑L | M01AX23 | tenidap | WHO Anatomical Therapeutic Chemical classification | | tenidap |
0‑L | M01AX24 | oxaceprol | WHO Anatomical Therapeutic Chemical classification | | oxaceprol |
0‑L | M01AX25 | chondroitin sulfate | WHO Anatomical Therapeutic Chemical classification | | chondroitin sulfate |
0‑L | M01AX26 | avocado and soyabean oil, unsaponifiables | WHO Anatomical Therapeutic Chemical classification | | avocado and soyabean oil, unsaponifiables |
0‑L | M01AX68 | feprazone, combinations | WHO Anatomical Therapeutic Chemical classification | | feprazone, combinations |
0‑L | M01B | ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION | WHO Anatomical Therapeutic Chemical classification | | ANTIINFLAMMATORY/ANTIRHEUMATIC AGENTS IN COMBINATION |
0‑L | M01BA | Antiinflammatory/antirheumatic agents in combination with corticosteroids | WHO Anatomical Therapeutic Chemical classification | | Antiinflammatory/antirheumatic agents in combination with corticosteroids |
0‑L | M01BA01 | phenylbutazone and corticosteroids | WHO Anatomical Therapeutic Chemical classification | | phenylbutazone and corticosteroids |
0‑L | M01BA02 | dipyrocetyl and corticosteroids | WHO Anatomical Therapeutic Chemical classification | | dipyrocetyl and corticosteroids |
0‑L | M01BA03 | acetylsalicylic acid and corticosteroids | WHO Anatomical Therapeutic Chemical classification | | acetylsalicylic acid and corticosteroids |
0‑L | M01BX | Other antiinflammatory/antirheumatic agents in combination with other drugs | WHO Anatomical Therapeutic Chemical classification | | Other antiinflammatory/antirheumatic agents in combination with other drugs |
0‑L | M01C | SPECIFIC ANTIRHEUMATIC AGENTS | WHO Anatomical Therapeutic Chemical classification | | SPECIFIC ANTIRHEUMATIC AGENTS |
0‑L | M01CA | Quinolines | WHO Anatomical Therapeutic Chemical classification | | Quinolines |
0‑L | M01CA03 | oxycinchophen | WHO Anatomical Therapeutic Chemical classification | | oxycinchophen |
0‑L | M01CB | Gold preparations | WHO Anatomical Therapeutic Chemical classification | | Gold preparations |
0‑L | M01CB01 | sodium aurothiomalate | WHO Anatomical Therapeutic Chemical classification | | sodium aurothiomalate |
0‑L | M01CB02 | sodium aurotiosulfate | WHO Anatomical Therapeutic Chemical classification | | sodium aurotiosulfate |
0‑L | M01CB03 | auranofin | WHO Anatomical Therapeutic Chemical classification | | auranofin |
0‑L | M01CB04 | aurothioglucose | WHO Anatomical Therapeutic Chemical classification | | aurothioglucose |
0‑L | M01CB05 | aurotioprol | WHO Anatomical Therapeutic Chemical classification | | aurotioprol |
0‑L | M01CC | Penicillamine and similar agents | WHO Anatomical Therapeutic Chemical classification | | Penicillamine and similar agents |
0‑L | M01CC01 | penicillamine | WHO Anatomical Therapeutic Chemical classification | | penicillamine |
0‑L | M01CC02 | bucillamine | WHO Anatomical Therapeutic Chemical classification | | bucillamine |
0‑L | M01CX | Other specific antirheumatic agents | WHO Anatomical Therapeutic Chemical classification | | Other specific antirheumatic agents |
0‑L | M02 | TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN | WHO Anatomical Therapeutic Chemical classification | | TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN |
0‑L | M02A | TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN | WHO Anatomical Therapeutic Chemical classification | | TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN |
0‑L | M02AA | Antiinflammatory preparations, non-steroids for topical use | WHO Anatomical Therapeutic Chemical classification | | Antiinflammatory preparations, non-steroids for topical use |
0‑L | M02AA01 | phenylbutazone | WHO Anatomical Therapeutic Chemical classification | | phenylbutazone |
0‑L | M02AA02 | mofebutazone | WHO Anatomical Therapeutic Chemical classification | | mofebutazone |
0‑L | M02AA03 | clofezone | WHO Anatomical Therapeutic Chemical classification | | clofezone |
0‑L | M02AA04 | oxyphenbutazone | WHO Anatomical Therapeutic Chemical classification | | oxyphenbutazone |
0‑L | M02AA05 | benzydamine | WHO Anatomical Therapeutic Chemical classification | | benzydamine |
0‑L | M02AA06 | etofenamate | WHO Anatomical Therapeutic Chemical classification | | etofenamate |
0‑L | M02AA07 | piroxicam | WHO Anatomical Therapeutic Chemical classification | | piroxicam |
0‑L | M02AA08 | felbinac | WHO Anatomical Therapeutic Chemical classification | | felbinac |
0‑L | M02AA09 | bufexamac | WHO Anatomical Therapeutic Chemical classification | | bufexamac |
0‑L | M02AA10 | ketoprofen | WHO Anatomical Therapeutic Chemical classification | | ketoprofen |
0‑L | M02AA11 | bendazac | WHO Anatomical Therapeutic Chemical classification | | bendazac |
0‑L | M02AA12 | naproxen | WHO Anatomical Therapeutic Chemical classification | | naproxen |
0‑L | M02AA13 | ibuprofen | WHO Anatomical Therapeutic Chemical classification | | ibuprofen |
0‑L | M02AA14 | fentiazac | WHO Anatomical Therapeutic Chemical classification | | fentiazac |
0‑L | M02AA15 | diclofenac | WHO Anatomical Therapeutic Chemical classification | | diclofenac |
0‑L | M02AA16 | feprazone | WHO Anatomical Therapeutic Chemical classification | | feprazone |
0‑L | M02AA17 | niflumic acid | WHO Anatomical Therapeutic Chemical classification | | niflumic acid |
0‑L | M02AA18 | meclofenamic acid | WHO Anatomical Therapeutic Chemical classification | | meclofenamic acid |
0‑L | M02AA19 | flurbiprofen | WHO Anatomical Therapeutic Chemical classification | | flurbiprofen |
0‑L | M02AA21 | tolmetin | WHO Anatomical Therapeutic Chemical classification | | tolmetin |
0‑L | M02AA22 | suxibuzone | WHO Anatomical Therapeutic Chemical classification | | suxibuzone |
0‑L | M02AA23 | indometacin | WHO Anatomical Therapeutic Chemical classification | | indometacin |
0‑L | M02AA24 | nifenazone | WHO Anatomical Therapeutic Chemical classification | | nifenazone |
0‑L | M02AA25 | aceclofenac | WHO Anatomical Therapeutic Chemical classification | | aceclofenac |
0‑L | M02AA26 | nimesulide | WHO Anatomical Therapeutic Chemical classification | | nimesulide |
0‑L | M02AA27 | dexketoprofen | WHO Anatomical Therapeutic Chemical classification | | dexketoprofen |
0‑L | M02AA28 | piketoprofen | WHO Anatomical Therapeutic Chemical classification | | piketoprofen |
0‑L | M02AB | Capsaicin and similar agents | WHO Anatomical Therapeutic Chemical classification | | Capsaicin and similar agents |
0‑L | M02AB01 | capsaicin | WHO Anatomical Therapeutic Chemical classification | | capsaicin |
0‑L | M02AB02 | zucapsaicin | WHO Anatomical Therapeutic Chemical classification | | zucapsaicin |
0‑L | M02AC | Preparations with salicylic acid derivatives | WHO Anatomical Therapeutic Chemical classification | | Preparations with salicylic acid derivatives |
0‑L | M02AX | Other topical products for joint and muscular pain | WHO Anatomical Therapeutic Chemical classification | | Other topical products for joint and muscular pain |
0‑L | M02AX02 | tolazoline | WHO Anatomical Therapeutic Chemical classification | | tolazoline |
0‑L | M02AX03 | dimethyl sulfoxide | WHO Anatomical Therapeutic Chemical classification | | dimethyl sulfoxide |
0‑L | M02AX05 | idrocilamide | WHO Anatomical Therapeutic Chemical classification | | idrocilamide |
0‑L | M02AX06 | tolperisone | WHO Anatomical Therapeutic Chemical classification | | tolperisone |
0‑L | M02AX10 | various | WHO Anatomical Therapeutic Chemical classification | | various |
0‑L | M03 | MUSCLE RELAXANTS | WHO Anatomical Therapeutic Chemical classification | | MUSCLE RELAXANTS |
0‑L | M03A | MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS | WHO Anatomical Therapeutic Chemical classification | | MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS |
0‑L | M03AA | Curare alkaloids | WHO Anatomical Therapeutic Chemical classification | | Curare alkaloids |
0‑L | M03AA01 | alcuronium | WHO Anatomical Therapeutic Chemical classification | | alcuronium |
0‑L | M03AA02 | tubocurarine | WHO Anatomical Therapeutic Chemical classification | | tubocurarine |
0‑L | M03AA04 | dimethyltubocurarine | WHO Anatomical Therapeutic Chemical classification | | dimethyltubocurarine |
0‑L | M03AB | Choline derivatives | WHO Anatomical Therapeutic Chemical classification | | Choline derivatives |
0‑L | M03AB01 | suxamethonium | WHO Anatomical Therapeutic Chemical classification | | suxamethonium |
0‑L | M03AC | Other quaternary ammonium compounds | WHO Anatomical Therapeutic Chemical classification | | Other quaternary ammonium compounds |
0‑L | M03AC01 | pancuronium | WHO Anatomical Therapeutic Chemical classification | | pancuronium |
0‑L | M03AC02 | gallamine | WHO Anatomical Therapeutic Chemical classification | | gallamine |
0‑L | M03AC03 | vecuronium | WHO Anatomical Therapeutic Chemical classification | | vecuronium |
0‑L | M03AC04 | atracurium | WHO Anatomical Therapeutic Chemical classification | | atracurium |
0‑L | M03AC05 | hexafluronium | WHO Anatomical Therapeutic Chemical classification | | hexafluronium |
0‑L | M03AC06 | pipecuronium bromide | WHO Anatomical Therapeutic Chemical classification | | pipecuronium bromide |
0‑L | M03AC07 | doxacurium chloride | WHO Anatomical Therapeutic Chemical classification | | doxacurium chloride |
0‑L | M03AC08 | fazadinium bromide | WHO Anatomical Therapeutic Chemical classification | | fazadinium bromide |
0‑L | M03AC09 | rocuronium bromide | WHO Anatomical Therapeutic Chemical classification | | rocuronium bromide |
0‑L | M03AC10 | mivacurium chloride | WHO Anatomical Therapeutic Chemical classification | | mivacurium chloride |
0‑L | M03AC11 | cisatracurium | WHO Anatomical Therapeutic Chemical classification | | cisatracurium |
0‑L | M03AX | Other muscle relaxants, peripherally acting agents | WHO Anatomical Therapeutic Chemical classification | | Other muscle relaxants, peripherally acting agents |
0‑L | M03AX01 | botulinum toxin | WHO Anatomical Therapeutic Chemical classification | | botulinum toxin |
0‑L | M03B | MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS | WHO Anatomical Therapeutic Chemical classification | | MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS |
0‑L | M03BA | Carbamic acid esters | WHO Anatomical Therapeutic Chemical classification | | Carbamic acid esters |
0‑L | M03BA01 | phenprobamate | WHO Anatomical Therapeutic Chemical classification | | phenprobamate |
0‑L | M03BA02 | carisoprodol | WHO Anatomical Therapeutic Chemical classification | | carisoprodol |
0‑L | M03BA03 | methocarbamol | WHO Anatomical Therapeutic Chemical classification | | methocarbamol |
0‑L | M03BA04 | styramate | WHO Anatomical Therapeutic Chemical classification | | styramate |
0‑L | M03BA05 | febarbamate | WHO Anatomical Therapeutic Chemical classification | | febarbamate |
0‑L | M03BA51 | phenprobamate, combinations excl. psycholeptics | WHO Anatomical Therapeutic Chemical classification | | phenprobamate, combinations excl. psycholeptics |
0‑L | M03BA52 | carisoprodol, combinations excl. psycholeptics | WHO Anatomical Therapeutic Chemical classification | | carisoprodol, combinations excl. psycholeptics |
0‑L | M03BA53 | methocarbamol, combinations excl. psycholeptics | WHO Anatomical Therapeutic Chemical classification | | methocarbamol, combinations excl. psycholeptics |
0‑L | M03BA71 | phenprobamate, combinations with psycholeptics | WHO Anatomical Therapeutic Chemical classification | | phenprobamate, combinations with psycholeptics |
0‑L | M03BA72 | carisoprodol, combinations with psycholeptics | WHO Anatomical Therapeutic Chemical classification | | carisoprodol, combinations with psycholeptics |
0‑L | M03BA73 | methocarbamol, combinations with psycholeptics | WHO Anatomical Therapeutic Chemical classification | | methocarbamol, combinations with psycholeptics |
0‑L | M03BB | Oxazol, thiazine, and triazine derivatives | WHO Anatomical Therapeutic Chemical classification | | Oxazol, thiazine, and triazine derivatives |
0‑L | M03BB02 | chlormezanone | WHO Anatomical Therapeutic Chemical classification | | chlormezanone |
0‑L | M03BB03 | chlorzoxazone | WHO Anatomical Therapeutic Chemical classification | | chlorzoxazone |
0‑L | M03BB52 | chlormezanone, combinations excl. psycholeptics | WHO Anatomical Therapeutic Chemical classification | | chlormezanone, combinations excl. psycholeptics |
0‑L | M03BB53 | chlorzoxazone, combinations excl. psycholeptics | WHO Anatomical Therapeutic Chemical classification | | chlorzoxazone, combinations excl. psycholeptics |
0‑L | M03BB72 | chlormezanone, combinations with psycholeptics | WHO Anatomical Therapeutic Chemical classification | | chlormezanone, combinations with psycholeptics |
0‑L | M03BB73 | chlorzoxazone, combinations with psycholeptics | WHO Anatomical Therapeutic Chemical classification | | chlorzoxazone, combinations with psycholeptics |
0‑L | M03BC | Ethers, chemically close to antihistamines | WHO Anatomical Therapeutic Chemical classification | | Ethers, chemically close to antihistamines |
0‑L | M03BC01 | orphenadrine (citrate) | WHO Anatomical Therapeutic Chemical classification | | orphenadrine (citrate) |
0‑L | M03BC51 | orphenadrine, combinations | WHO Anatomical Therapeutic Chemical classification | | orphenadrine, combinations |
0‑L | M03BX | Other centrally acting agents | WHO Anatomical Therapeutic Chemical classification | | Other centrally acting agents |
0‑L | M03BX01 | baclofen | WHO Anatomical Therapeutic Chemical classification | | baclofen |
0‑L | M03BX02 | tizanidine | WHO Anatomical Therapeutic Chemical classification | | tizanidine |
0‑L | M03BX03 | pridinol | WHO Anatomical Therapeutic Chemical classification | | pridinol |
0‑L | M03BX04 | tolperisone | WHO Anatomical Therapeutic Chemical classification | | tolperisone |
0‑L | M03BX05 | thiocolchicoside | WHO Anatomical Therapeutic Chemical classification | | thiocolchicoside |
0‑L | M03BX06 | mephenesin | WHO Anatomical Therapeutic Chemical classification | | mephenesin |
0‑L | M03BX07 | tetrazepam | WHO Anatomical Therapeutic Chemical classification | | tetrazepam |
0‑L | M03BX08 | cyclobenzaprine | WHO Anatomical Therapeutic Chemical classification | | cyclobenzaprine |
0‑L | M03BX09 | eperisone | WHO Anatomical Therapeutic Chemical classification | | eperisone |
0‑L | M03BX30 | fenyramidol | WHO Anatomical Therapeutic Chemical classification | | fenyramidol |
0‑L | M03BX55 | thiocolchicoside, combinations | WHO Anatomical Therapeutic Chemical classification | | thiocolchicoside, combinations |
0‑L | M03C | MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS | WHO Anatomical Therapeutic Chemical classification | | MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS |
0‑L | M03CA | Dantrolene and derivatives | WHO Anatomical Therapeutic Chemical classification | | Dantrolene and derivatives |
0‑L | M03CA01 | dantrolene | WHO Anatomical Therapeutic Chemical classification | | dantrolene |
0‑L | M04 | ANTIGOUT PREPARATIONS | WHO Anatomical Therapeutic Chemical classification | | ANTIGOUT PREPARATIONS |
0‑L | M04A | ANTIGOUT PREPARATIONS | WHO Anatomical Therapeutic Chemical classification | | ANTIGOUT PREPARATIONS |
0‑L | M04AA | Preparations inhibiting uric acid production | WHO Anatomical Therapeutic Chemical classification | | Preparations inhibiting uric acid production |
0‑L | M04AA01 | allopurinol | WHO Anatomical Therapeutic Chemical classification | | allopurinol |
0‑L | M04AA02 | tisopurine | WHO Anatomical Therapeutic Chemical classification | | tisopurine |
0‑L | M04AA03 | febuxostat | WHO Anatomical Therapeutic Chemical classification | | febuxostat |
0‑L | M04AA51 | allopurinol, combinations | WHO Anatomical Therapeutic Chemical classification | | allopurinol, combinations |
0‑L | M04AB | Preparations increasing uric acid excretion | WHO Anatomical Therapeutic Chemical classification | | Preparations increasing uric acid excretion |
0‑L | M04AB01 | probenecid | WHO Anatomical Therapeutic Chemical classification | | probenecid |
0‑L | M04AB02 | sulfinpyrazone | WHO Anatomical Therapeutic Chemical classification | | sulfinpyrazone |
0‑L | M04AB03 | benzbromarone | WHO Anatomical Therapeutic Chemical classification | | benzbromarone |
0‑L | M04AB04 | isobromindione | WHO Anatomical Therapeutic Chemical classification | | isobromindione |
0‑L | M04AB05 | lesinurad | WHO Anatomical Therapeutic Chemical classification | | lesinurad |
0‑L | M04AC | Preparations with no effect on uric acid metabolism | WHO Anatomical Therapeutic Chemical classification | | Preparations with no effect on uric acid metabolism |
0‑L | M04AC01 | colchicine | WHO Anatomical Therapeutic Chemical classification | | colchicine |
0‑L | M04AC02 | cinchophen | WHO Anatomical Therapeutic Chemical classification | | cinchophen |
0‑L | M04AX | Other antigout preparations | WHO Anatomical Therapeutic Chemical classification | | Other antigout preparations |
0‑L | M04AX01 | urate oxidase | WHO Anatomical Therapeutic Chemical classification | | urate oxidase |
0‑L | M04AX02 | pegloticase | WHO Anatomical Therapeutic Chemical classification | | pegloticase |
0‑L | M05 | DRUGS FOR TREATMENT OF BONE DISEASES | WHO Anatomical Therapeutic Chemical classification | | DRUGS FOR TREATMENT OF BONE DISEASES |
0‑L | M05B | DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION | WHO Anatomical Therapeutic Chemical classification | | DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION |
0‑L | M05BA | Bisphosphonates | WHO Anatomical Therapeutic Chemical classification | | Bisphosphonates |
0‑L | M05BA01 | etidronic acid | WHO Anatomical Therapeutic Chemical classification | | etidronic acid |
0‑L | M05BA02 | clodronic acid | WHO Anatomical Therapeutic Chemical classification | | clodronic acid |
0‑L | M05BA03 | pamidronic acid | WHO Anatomical Therapeutic Chemical classification | | pamidronic acid |
0‑L | M05BA04 | alendronic acid | WHO Anatomical Therapeutic Chemical classification | | alendronic acid |
0‑L | M05BA05 | tiludronic acid | WHO Anatomical Therapeutic Chemical classification | | tiludronic acid |
0‑L | M05BA06 | ibandronic acid | WHO Anatomical Therapeutic Chemical classification | | ibandronic acid |
0‑L | M05BA07 | risedronic acid | WHO Anatomical Therapeutic Chemical classification | | risedronic acid |
0‑L | M05BA08 | zoledronic acid | WHO Anatomical Therapeutic Chemical classification | | zoledronic acid |
0‑L | M05BB | Bisphosphonates, combinations | WHO Anatomical Therapeutic Chemical classification | | Bisphosphonates, combinations |
0‑L | M05BB01 | etidronic acid and calcium, sequential | WHO Anatomical Therapeutic Chemical classification | | etidronic acid and calcium, sequential |
0‑L | M05BB02 | risedronic acid and calcium, sequential | WHO Anatomical Therapeutic Chemical classification | | risedronic acid and calcium, sequential |
0‑L | M05BB03 | alendronic acid and colecalciferol | WHO Anatomical Therapeutic Chemical classification | | alendronic acid and colecalciferol |
0‑L | M05BB04 | risedronic acid, calcium and colecalciferol, sequential | WHO Anatomical Therapeutic Chemical classification | | risedronic acid, calcium and colecalciferol, sequential |
0‑L | M05BB05 | alendronic acid, calcium and colecalciferol, sequential | WHO Anatomical Therapeutic Chemical classification | | alendronic acid, calcium and colecalciferol, sequential |
0‑L | M05BB06 | alendronic acid and alfacalcidol, sequential | WHO Anatomical Therapeutic Chemical classification | | alendronic acid and alfacalcidol, sequential |
0‑L | M05BB07 | risedronic acid and colecalciferol | WHO Anatomical Therapeutic Chemical classification | | risedronic acid and colecalciferol |
0‑L | M05BB08 | zoledronic acid, calcium and colecalciferol, sequential | WHO Anatomical Therapeutic Chemical classification | | zoledronic acid, calcium and colecalciferol, sequential |
0‑L | M05BC | Bone morphogenetic proteins | WHO Anatomical Therapeutic Chemical classification | | Bone morphogenetic proteins |
0‑L | M05BC01 | dibotermin alfa | WHO Anatomical Therapeutic Chemical classification | | dibotermin alfa |
0‑L | M05BC02 | eptotermin alfa | WHO Anatomical Therapeutic Chemical classification | | eptotermin alfa |
0‑L | M05BX | Other drugs affecting bone structure and mineralization | WHO Anatomical Therapeutic Chemical classification | | Other drugs affecting bone structure and mineralization |
0‑L | M05BX01 | ipriflavone | WHO Anatomical Therapeutic Chemical classification | | ipriflavone |
0‑L | M05BX02 | aluminium chlorohydrate | WHO Anatomical Therapeutic Chemical classification | | aluminium chlorohydrate |
0‑L | M05BX03 | strontium ranelate | WHO Anatomical Therapeutic Chemical classification | | strontium ranelate |
0‑L | M05BX04 | denosumab | WHO Anatomical Therapeutic Chemical classification | | denosumab |
0‑L | M05BX05 | burosumab | WHO Anatomical Therapeutic Chemical classification | | burosumab |
0‑L | M05BX53 | strontium ranelate and colecalciferol | WHO Anatomical Therapeutic Chemical classification | | strontium ranelate and colecalciferol |
0‑L | M09 | OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM | WHO Anatomical Therapeutic Chemical classification | | OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM |
0‑L | M09A | OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM | WHO Anatomical Therapeutic Chemical classification | | OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM |
0‑L | M09AA | Quinine and derivatives | WHO Anatomical Therapeutic Chemical classification | | Quinine and derivatives |
0‑L | M09AA01 | hydroquinine | WHO Anatomical Therapeutic Chemical classification | | hydroquinine |
0‑L | M09AA72 | quinine, combinations with psycholeptics | WHO Anatomical Therapeutic Chemical classification | | quinine, combinations with psycholeptics |
0‑L | M09AB | Enzymes | WHO Anatomical Therapeutic Chemical classification | | Enzymes |
0‑L | M09AB01 | chymopapain | WHO Anatomical Therapeutic Chemical classification | | chymopapain |
0‑L | M09AB02 | collagenase clostridium histolyticum | WHO Anatomical Therapeutic Chemical classification | | collagenase clostridium histolyticum |
0‑L | M09AB03 | bromelains | WHO Anatomical Therapeutic Chemical classification | | bromelains |
0‑L | M09AB52 | trypsin, combinations | WHO Anatomical Therapeutic Chemical classification | | trypsin, combinations |
0‑L | M09AX | Other drugs for disorders of the musculo-skeletal system | WHO Anatomical Therapeutic Chemical classification | | Other drugs for disorders of the musculo-skeletal system |
0‑L | M09AX01 | hyaluronic acid | WHO Anatomical Therapeutic Chemical classification | | hyaluronic acid |
0‑L | M09AX02 | chondrocytes, autologous | WHO Anatomical Therapeutic Chemical classification | | chondrocytes, autologous |
0‑L | M09AX03 | ataluren | WHO Anatomical Therapeutic Chemical classification | | ataluren |
0‑L | M09AX04 | drisapersen | WHO Anatomical Therapeutic Chemical classification | | drisapersen |
0‑L | M09AX05 | aceneuramic acid | WHO Anatomical Therapeutic Chemical classification | | aceneuramic acid |
0‑L | N | NERVOUS SYSTEM | WHO Anatomical Therapeutic Chemical classification | | NERVOUS SYSTEM |
0‑L | N01 | ANESTHETICS | WHO Anatomical Therapeutic Chemical classification | | ANESTHETICS |
0‑L | N01A | ANESTHETICS, GENERAL | WHO Anatomical Therapeutic Chemical classification | | ANESTHETICS, GENERAL |
0‑L | N01AA | Ethers | WHO Anatomical Therapeutic Chemical classification | | Ethers |
0‑L | N01AA01 | diethyl ether | WHO Anatomical Therapeutic Chemical classification | | diethyl ether |
0‑L | N01AA02 | vinyl ether | WHO Anatomical Therapeutic Chemical classification | | vinyl ether |
0‑L | N01AB | Halogenated hydrocarbons | WHO Anatomical Therapeutic Chemical classification | | Halogenated hydrocarbons |
0‑L | N01AB01 | halothane | WHO Anatomical Therapeutic Chemical classification | | halothane |
0‑L | N01AB02 | chloroform | WHO Anatomical Therapeutic Chemical classification | | chloroform |
0‑L | N01AB04 | enflurane | WHO Anatomical Therapeutic Chemical classification | | enflurane |
0‑L | N01AB05 | trichloroethylene | WHO Anatomical Therapeutic Chemical classification | | trichloroethylene |
0‑L | N01AB06 | isoflurane | WHO Anatomical Therapeutic Chemical classification | | isoflurane |
0‑L | N01AB07 | desflurane | WHO Anatomical Therapeutic Chemical classification | | desflurane |
0‑L | N01AB08 | sevoflurane | WHO Anatomical Therapeutic Chemical classification | | sevoflurane |
0‑L | N01AF | Barbiturates, plain | WHO Anatomical Therapeutic Chemical classification | | Barbiturates, plain |
0‑L | N01AF01 | methohexital | WHO Anatomical Therapeutic Chemical classification | | methohexital |
0‑L | N01AF02 | hexobarbital | WHO Anatomical Therapeutic Chemical classification | | hexobarbital |
0‑L | N01AF03 | thiopental | WHO Anatomical Therapeutic Chemical classification | | thiopental |
0‑L | N01AG | Barbiturates in combination with other drugs | WHO Anatomical Therapeutic Chemical classification | | Barbiturates in combination with other drugs |
0‑L | N01AG01 | narcobarbital | WHO Anatomical Therapeutic Chemical classification | | narcobarbital |
0‑L | N01AH | Opioid anesthetics | WHO Anatomical Therapeutic Chemical classification | | Opioid anesthetics |
0‑L | N01AH01 | fentanyl | WHO Anatomical Therapeutic Chemical classification | | fentanyl |
0‑L | N01AH02 | alfentanil | WHO Anatomical Therapeutic Chemical classification | | alfentanil |
0‑L | N01AH03 | sufentanil | WHO Anatomical Therapeutic Chemical classification | | sufentanil |
0‑L | N01AH04 | phenoperidine | WHO Anatomical Therapeutic Chemical classification | | phenoperidine |
0‑L | N01AH05 | anileridine | WHO Anatomical Therapeutic Chemical classification | | anileridine |
0‑L | N01AH06 | remifentanil | WHO Anatomical Therapeutic Chemical classification | | remifentanil |
0‑L | N01AH51 | fentanyl, combinations | WHO Anatomical Therapeutic Chemical classification | | fentanyl, combinations |
0‑L | N01AX | Other general anesthetics | WHO Anatomical Therapeutic Chemical classification | | Other general anesthetics |
0‑L | N01AX03 | ketamine | WHO Anatomical Therapeutic Chemical classification | | ketamine |
0‑L | N01AX04 | propanidid | WHO Anatomical Therapeutic Chemical classification | | propanidid |
0‑L | N01AX05 | alfaxalone | WHO Anatomical Therapeutic Chemical classification | | alfaxalone |
0‑L | N01AX07 | etomidate | WHO Anatomical Therapeutic Chemical classification | | etomidate |
0‑L | N01AX10 | propofol | WHO Anatomical Therapeutic Chemical classification | | propofol |
0‑L | N01AX11 | sodium oxybate | WHO Anatomical Therapeutic Chemical classification | | sodium oxybate |
0‑L | N01AX13 | nitrous oxide | WHO Anatomical Therapeutic Chemical classification | | nitrous oxide |
0‑L | N01AX14 | esketamine | WHO Anatomical Therapeutic Chemical classification | | esketamine |
0‑L | N01AX15 | xenon | WHO Anatomical Therapeutic Chemical classification | | xenon |
0‑L | N01AX63 | nitrous oxide, combinations | WHO Anatomical Therapeutic Chemical classification | | nitrous oxide, combinations |
0‑L | N01B | ANESTHETICS, LOCAL | WHO Anatomical Therapeutic Chemical classification | | ANESTHETICS, LOCAL |
0‑L | N01BA | Esters of aminobenzoic acid | WHO Anatomical Therapeutic Chemical classification | | Esters of aminobenzoic acid |
0‑L | N01BA01 | metabutethamine | WHO Anatomical Therapeutic Chemical classification | | metabutethamine |
0‑L | N01BA02 | procaine | WHO Anatomical Therapeutic Chemical classification | | procaine |
0‑L | N01BA03 | tetracaine | WHO Anatomical Therapeutic Chemical classification | | tetracaine |
0‑L | N01BA04 | chloroprocaine | WHO Anatomical Therapeutic Chemical classification | | chloroprocaine |
0‑L | N01BA05 | benzocaine | WHO Anatomical Therapeutic Chemical classification | | benzocaine |
0‑L | N01BA52 | procaine, combinations | WHO Anatomical Therapeutic Chemical classification | | procaine, combinations |
0‑L | N01BB | Amides | WHO Anatomical Therapeutic Chemical classification | | Amides |
0‑L | N01BB01 | bupivacaine | WHO Anatomical Therapeutic Chemical classification | | bupivacaine |
0‑L | N01BB02 | lidocaine | WHO Anatomical Therapeutic Chemical classification | | lidocaine |
0‑L | N01BB03 | mepivacaine | WHO Anatomical Therapeutic Chemical classification | | mepivacaine |
0‑L | N01BB04 | prilocaine | WHO Anatomical Therapeutic Chemical classification | | prilocaine |
0‑L | N01BB05 | butanilicaine | WHO Anatomical Therapeutic Chemical classification | | butanilicaine |
0‑L | N01BB06 | cinchocaine | WHO Anatomical Therapeutic Chemical classification | | cinchocaine |
0‑L | N01BB07 | etidocaine | WHO Anatomical Therapeutic Chemical classification | | etidocaine |
0‑L | N01BB08 | articaine | WHO Anatomical Therapeutic Chemical classification | | articaine |
0‑L | N01BB09 | ropivacaine | WHO Anatomical Therapeutic Chemical classification | | ropivacaine |
0‑L | N01BB10 | levobupivacaine | WHO Anatomical Therapeutic Chemical classification | | levobupivacaine |
0‑L | N01BB20 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | N01BB51 | bupivacaine, combinations | WHO Anatomical Therapeutic Chemical classification | | bupivacaine, combinations |
0‑L | N01BB52 | lidocaine, combinations | WHO Anatomical Therapeutic Chemical classification | | lidocaine, combinations |
0‑L | N01BB53 | mepivacaine, combinations | WHO Anatomical Therapeutic Chemical classification | | mepivacaine, combinations |
0‑L | N01BB54 | prilocaine, combinations | WHO Anatomical Therapeutic Chemical classification | | prilocaine, combinations |
0‑L | N01BB57 | etidocaine, combinations | WHO Anatomical Therapeutic Chemical classification | | etidocaine, combinations |
0‑L | N01BB58 | articaine, combinations | WHO Anatomical Therapeutic Chemical classification | | articaine, combinations |
0‑L | N01BC | Esters of benzoic acid | WHO Anatomical Therapeutic Chemical classification | | Esters of benzoic acid |
0‑L | N01BC01 | cocaine | WHO Anatomical Therapeutic Chemical classification | | cocaine |
0‑L | N01BX | Other local anesthetics | WHO Anatomical Therapeutic Chemical classification | | Other local anesthetics |
0‑L | N01BX01 | ethyl chloride | WHO Anatomical Therapeutic Chemical classification | | ethyl chloride |
0‑L | N01BX02 | dyclonine | WHO Anatomical Therapeutic Chemical classification | | dyclonine |
0‑L | N01BX03 | phenol | WHO Anatomical Therapeutic Chemical classification | | phenol |
0‑L | N01BX04 | capsaicin | WHO Anatomical Therapeutic Chemical classification | | capsaicin |
0‑L | N02 | ANALGESICS | WHO Anatomical Therapeutic Chemical classification | | ANALGESICS |
0‑L | N02A | OPIOIDS | WHO Anatomical Therapeutic Chemical classification | | OPIOIDS |
0‑L | N02AA | Natural opium alkaloids | WHO Anatomical Therapeutic Chemical classification | | Natural opium alkaloids |
0‑L | N02AA01 | morphine | WHO Anatomical Therapeutic Chemical classification | | morphine |
0‑L | N02AA02 | opium | WHO Anatomical Therapeutic Chemical classification | | opium |
0‑L | N02AA03 | hydromorphone | WHO Anatomical Therapeutic Chemical classification | | hydromorphone |
0‑L | N02AA04 | nicomorphine | WHO Anatomical Therapeutic Chemical classification | | nicomorphine |
0‑L | N02AA05 | oxycodone | WHO Anatomical Therapeutic Chemical classification | | oxycodone |
0‑L | N02AA08 | dihydrocodeine | WHO Anatomical Therapeutic Chemical classification | | dihydrocodeine |
0‑L | N02AA10 | papaveretum | WHO Anatomical Therapeutic Chemical classification | | papaveretum |
0‑L | N02AA51 | morphine, combinations | WHO Anatomical Therapeutic Chemical classification | | morphine, combinations |
0‑L | N02AA55 | oxycodone and naloxone | WHO Anatomical Therapeutic Chemical classification | | oxycodone and naloxone |
0‑L | N02AA58 | dihydrocodeine, combinations | WHO Anatomical Therapeutic Chemical classification | | dihydrocodeine, combinations |
0‑L | N02AA59 | codeine, combinations excl. psycholeptics | WHO Anatomical Therapeutic Chemical classification | | codeine, combinations excl. psycholeptics |
0‑L | N02AA79 | codeine, combinations with psycholeptics | WHO Anatomical Therapeutic Chemical classification | | codeine, combinations with psycholeptics |
0‑L | N02AB | Phenylpiperidine derivatives | WHO Anatomical Therapeutic Chemical classification | | Phenylpiperidine derivatives |
0‑L | N02AB01 | ketobemidone | WHO Anatomical Therapeutic Chemical classification | | ketobemidone |
0‑L | N02AB02 | pethidine | WHO Anatomical Therapeutic Chemical classification | | pethidine |
0‑L | N02AB03 | fentanyl | WHO Anatomical Therapeutic Chemical classification | | fentanyl |
0‑L | N02AB52 | pethidine, combinations excl. psycholeptics | WHO Anatomical Therapeutic Chemical classification | | pethidine, combinations excl. psycholeptics |
0‑L | N02AB72 | pethidine, combinations with psycholeptics | WHO Anatomical Therapeutic Chemical classification | | pethidine, combinations with psycholeptics |
0‑L | N02AC | Diphenylpropylamine derivatives | WHO Anatomical Therapeutic Chemical classification | | Diphenylpropylamine derivatives |
0‑L | N02AC01 | dextromoramide | WHO Anatomical Therapeutic Chemical classification | | dextromoramide |
0‑L | N02AC03 | piritramide | WHO Anatomical Therapeutic Chemical classification | | piritramide |
0‑L | N02AC04 | dextropropoxyphene | WHO Anatomical Therapeutic Chemical classification | | dextropropoxyphene |
0‑L | N02AC05 | bezitramide | WHO Anatomical Therapeutic Chemical classification | | bezitramide |
0‑L | N02AC52 | methadone, combinations excl. psycholeptics | WHO Anatomical Therapeutic Chemical classification | | methadone, combinations excl. psycholeptics |
0‑L | N02AC54 | dextropropoxyphene, combinations excl. psycholeptics | WHO Anatomical Therapeutic Chemical classification | | dextropropoxyphene, combinations excl. psycholeptics |
0‑L | N02AC74 | dextropropoxyphene, combinations with psycholeptics | WHO Anatomical Therapeutic Chemical classification | | dextropropoxyphene, combinations with psycholeptics |
0‑L | N02AD | Benzomorphan derivatives | WHO Anatomical Therapeutic Chemical classification | | Benzomorphan derivatives |
0‑L | N02AD01 | pentazocine | WHO Anatomical Therapeutic Chemical classification | | pentazocine |
0‑L | N02AD02 | phenazocine | WHO Anatomical Therapeutic Chemical classification | | phenazocine |
0‑L | N02AE | Oripavine derivatives | WHO Anatomical Therapeutic Chemical classification | | Oripavine derivatives |
0‑L | N02AE01 | buprenorphine | WHO Anatomical Therapeutic Chemical classification | | buprenorphine |
0‑L | N02AF | Morphinan derivatives | WHO Anatomical Therapeutic Chemical classification | | Morphinan derivatives |
0‑L | N02AF01 | butorphanol | WHO Anatomical Therapeutic Chemical classification | | butorphanol |
0‑L | N02AF02 | nalbuphine | WHO Anatomical Therapeutic Chemical classification | | nalbuphine |
0‑L | N02AG | Opioids in combination with antispasmodics | WHO Anatomical Therapeutic Chemical classification | | Opioids in combination with antispasmodics |
0‑L | N02AG01 | morphine and antispasmodics | WHO Anatomical Therapeutic Chemical classification | | morphine and antispasmodics |
0‑L | N02AG02 | ketobemidone and antispasmodics | WHO Anatomical Therapeutic Chemical classification | | ketobemidone and antispasmodics |
0‑L | N02AG03 | pethidine and antispasmodics | WHO Anatomical Therapeutic Chemical classification | | pethidine and antispasmodics |
0‑L | N02AG04 | hydromorphone and antispasmodics | WHO Anatomical Therapeutic Chemical classification | | hydromorphone and antispasmodics |
0‑L | N02AJ | Opioids in combination with non-opioid analgesics | WHO Anatomical Therapeutic Chemical classification | | Opioids in combination with non-opioid analgesics |
0‑L | N02AJ01 | dihydrocodeine and paracetamol | WHO Anatomical Therapeutic Chemical classification | | dihydrocodeine and paracetamol |
0‑L | N02AJ02 | dihydrocodeine and acetylsalicylic acid | WHO Anatomical Therapeutic Chemical classification | | dihydrocodeine and acetylsalicylic acid |
0‑L | N02AJ03 | dihydrocodeine and other non-opioid analgesics | WHO Anatomical Therapeutic Chemical classification | | dihydrocodeine and other non-opioid analgesics |
0‑L | N02AJ06 | codeine and paracetamol | WHO Anatomical Therapeutic Chemical classification | | codeine and paracetamol |
0‑L | N02AJ07 | codeine and acetylsalicylic acid | WHO Anatomical Therapeutic Chemical classification | | codeine and acetylsalicylic acid |
0‑L | N02AJ08 | codeine and ibuprofen | WHO Anatomical Therapeutic Chemical classification | | codeine and ibuprofen |
0‑L | N02AJ09 | codeine and other non-opioid analgesics | WHO Anatomical Therapeutic Chemical classification | | codeine and other non-opioid analgesics |
0‑L | N02AJ13 | tramadol and paracetamol | WHO Anatomical Therapeutic Chemical classification | | tramadol and paracetamol |
0‑L | N02AJ14 | tramadol and dexketoprofen | WHO Anatomical Therapeutic Chemical classification | | tramadol and dexketoprofen |
0‑L | N02AJ15 | tramadol and other non-opioid analgesics | WHO Anatomical Therapeutic Chemical classification | | tramadol and other non-opioid analgesics |
0‑L | N02AJ17 | oxycodone and paracetamol | WHO Anatomical Therapeutic Chemical classification | | oxycodone and paracetamol |
0‑L | N02AJ18 | oxycodone and acetylsalicylic acid | WHO Anatomical Therapeutic Chemical classification | | oxycodone and acetylsalicylic acid |
0‑L | N02AJ19 | oxycodone and ibuprofen | WHO Anatomical Therapeutic Chemical classification | | oxycodone and ibuprofen |
0‑L | N02AX | Other opioids | WHO Anatomical Therapeutic Chemical classification | | Other opioids |
0‑L | N02AX01 | tilidine | WHO Anatomical Therapeutic Chemical classification | | tilidine |
0‑L | N02AX02 | tramadol | WHO Anatomical Therapeutic Chemical classification | | tramadol |
0‑L | N02AX03 | dezocine | WHO Anatomical Therapeutic Chemical classification | | dezocine |
0‑L | N02AX05 | meptazinol | WHO Anatomical Therapeutic Chemical classification | | meptazinol |
0‑L | N02AX06 | tapentadol | WHO Anatomical Therapeutic Chemical classification | | tapentadol |
0‑L | N02B | OTHER ANALGESICS AND ANTIPYRETICS | WHO Anatomical Therapeutic Chemical classification | | OTHER ANALGESICS AND ANTIPYRETICS |
0‑L | N02BA | Salicylic acid and derivatives | WHO Anatomical Therapeutic Chemical classification | | Salicylic acid and derivatives |
0‑L | N02BA01 | acetylsalicylic acid | WHO Anatomical Therapeutic Chemical classification | | acetylsalicylic acid |
0‑L | N02BA02 | aloxiprin | WHO Anatomical Therapeutic Chemical classification | | aloxiprin |
0‑L | N02BA03 | choline salicylate | WHO Anatomical Therapeutic Chemical classification | | choline salicylate |
0‑L | N02BA04 | sodium salicylate | WHO Anatomical Therapeutic Chemical classification | | sodium salicylate |
0‑L | N02BA05 | salicylamide | WHO Anatomical Therapeutic Chemical classification | | salicylamide |
0‑L | N02BA06 | salsalate | WHO Anatomical Therapeutic Chemical classification | | salsalate |
0‑L | N02BA07 | ethenzamide | WHO Anatomical Therapeutic Chemical classification | | ethenzamide |
0‑L | N02BA08 | morpholine salicylate | WHO Anatomical Therapeutic Chemical classification | | morpholine salicylate |
0‑L | N02BA09 | dipyrocetyl | WHO Anatomical Therapeutic Chemical classification | | dipyrocetyl |
0‑L | N02BA10 | benorilate | WHO Anatomical Therapeutic Chemical classification | | benorilate |
0‑L | N02BA11 | diflunisal | WHO Anatomical Therapeutic Chemical classification | | diflunisal |
0‑L | N02BA12 | potassium salicylate | WHO Anatomical Therapeutic Chemical classification | | potassium salicylate |
0‑L | N02BA14 | guacetisal | WHO Anatomical Therapeutic Chemical classification | | guacetisal |
0‑L | N02BA15 | carbasalate calcium | WHO Anatomical Therapeutic Chemical classification | | carbasalate calcium |
0‑L | N02BA16 | imidazole salicylate | WHO Anatomical Therapeutic Chemical classification | | imidazole salicylate |
0‑L | N02BA51 | acetylsalicylic acid, combinations excl. psycholeptics | WHO Anatomical Therapeutic Chemical classification | | acetylsalicylic acid, combinations excl. psycholeptics |
0‑L | N02BA55 | salicylamide, combinations excl. psycholeptics | WHO Anatomical Therapeutic Chemical classification | | salicylamide, combinations excl. psycholeptics |
0‑L | N02BA57 | ethenzamide, combinations excl. psycholeptics | WHO Anatomical Therapeutic Chemical classification | | ethenzamide, combinations excl. psycholeptics |
0‑L | N02BA59 | dipyrocetyl, combinations excl. psycholeptics | WHO Anatomical Therapeutic Chemical classification | | dipyrocetyl, combinations excl. psycholeptics |
0‑L | N02BA65 | carbasalate calcium combinations excl. psycholeptics | WHO Anatomical Therapeutic Chemical classification | | carbasalate calcium combinations excl. psycholeptics |
0‑L | N02BA71 | acetylsalicylic acid, combinations with psycholeptics | WHO Anatomical Therapeutic Chemical classification | | acetylsalicylic acid, combinations with psycholeptics |
0‑L | N02BA75 | salicylamide, combinations with psycholeptics | WHO Anatomical Therapeutic Chemical classification | | salicylamide, combinations with psycholeptics |
0‑L | N02BA77 | ethenzamide, combinations with psycholeptics | WHO Anatomical Therapeutic Chemical classification | | ethenzamide, combinations with psycholeptics |
0‑L | N02BA79 | dipyrocetyl, combinations with psycholeptics | WHO Anatomical Therapeutic Chemical classification | | dipyrocetyl, combinations with psycholeptics |
0‑L | N02BB | Pyrazolones | WHO Anatomical Therapeutic Chemical classification | | Pyrazolones |
0‑L | N02BB01 | phenazone | WHO Anatomical Therapeutic Chemical classification | | phenazone |
0‑L | N02BB02 | metamizole sodium | WHO Anatomical Therapeutic Chemical classification | | metamizole sodium |
0‑L | N02BB03 | aminophenazone | WHO Anatomical Therapeutic Chemical classification | | aminophenazone |
0‑L | N02BB04 | propyphenazone | WHO Anatomical Therapeutic Chemical classification | | propyphenazone |
0‑L | N02BB05 | nifenazone | WHO Anatomical Therapeutic Chemical classification | | nifenazone |
0‑L | N02BB51 | phenazone, combinations excl. psycholeptics | WHO Anatomical Therapeutic Chemical classification | | phenazone, combinations excl. psycholeptics |
0‑L | N02BB52 | metamizole sodium, combinations excl. psycholeptics | WHO Anatomical Therapeutic Chemical classification | | metamizole sodium, combinations excl. psycholeptics |
0‑L | N02BB53 | aminophenazone, combinations excl. psycholeptics | WHO Anatomical Therapeutic Chemical classification | | aminophenazone, combinations excl. psycholeptics |
0‑L | N02BB54 | propyphenazone, combinations excl. psycholeptics | WHO Anatomical Therapeutic Chemical classification | | propyphenazone, combinations excl. psycholeptics |
0‑L | N02BB71 | phenazone, combinations with psycholeptics | WHO Anatomical Therapeutic Chemical classification | | phenazone, combinations with psycholeptics |
0‑L | N02BB72 | metamizole sodium, combinations with psycholeptics | WHO Anatomical Therapeutic Chemical classification | | metamizole sodium, combinations with psycholeptics |
0‑L | N02BB73 | aminophenazone, combinations with psycholeptics | WHO Anatomical Therapeutic Chemical classification | | aminophenazone, combinations with psycholeptics |
0‑L | N02BB74 | propyphenazone, combinations with psycholeptics | WHO Anatomical Therapeutic Chemical classification | | propyphenazone, combinations with psycholeptics |
0‑L | N02BE | Anilides | WHO Anatomical Therapeutic Chemical classification | | Anilides |
0‑L | N02BE01 | paracetamol | WHO Anatomical Therapeutic Chemical classification | | paracetamol |
0‑L | N02BE03 | phenacetin | WHO Anatomical Therapeutic Chemical classification | | phenacetin |
0‑L | N02BE04 | bucetin | WHO Anatomical Therapeutic Chemical classification | | bucetin |
0‑L | N02BE05 | propacetamol | WHO Anatomical Therapeutic Chemical classification | | propacetamol |
0‑L | N02BE51 | paracetamol, combinations excl. psycholeptics | WHO Anatomical Therapeutic Chemical classification | | paracetamol, combinations excl. psycholeptics |
0‑L | N02BE53 | phenacetin, combinations excl. psycholeptics | WHO Anatomical Therapeutic Chemical classification | | phenacetin, combinations excl. psycholeptics |
0‑L | N02BE54 | bucetin, combinations excl. psycholeptics | WHO Anatomical Therapeutic Chemical classification | | bucetin, combinations excl. psycholeptics |
0‑L | N02BE71 | paracetamol, combinations with psycholeptics | WHO Anatomical Therapeutic Chemical classification | | paracetamol, combinations with psycholeptics |
0‑L | N02BE73 | phenacetin, combinations with psycholeptics | WHO Anatomical Therapeutic Chemical classification | | phenacetin, combinations with psycholeptics |
0‑L | N02BE74 | bucetin, combinations with psycholeptics | WHO Anatomical Therapeutic Chemical classification | | bucetin, combinations with psycholeptics |
0‑L | N02BG | Other analgesics and antipyretics | WHO Anatomical Therapeutic Chemical classification | | Other analgesics and antipyretics |
0‑L | N02BG02 | rimazolium | WHO Anatomical Therapeutic Chemical classification | | rimazolium |
0‑L | N02BG03 | glafenine | WHO Anatomical Therapeutic Chemical classification | | glafenine |
0‑L | N02BG04 | floctafenine | WHO Anatomical Therapeutic Chemical classification | | floctafenine |
0‑L | N02BG05 | viminol | WHO Anatomical Therapeutic Chemical classification | | viminol |
0‑L | N02BG06 | nefopam | WHO Anatomical Therapeutic Chemical classification | | nefopam |
0‑L | N02BG07 | flupirtine | WHO Anatomical Therapeutic Chemical classification | | flupirtine |
0‑L | N02BG08 | ziconotide | WHO Anatomical Therapeutic Chemical classification | | ziconotide |
0‑L | N02BG09 | methoxyflurane | WHO Anatomical Therapeutic Chemical classification | | methoxyflurane |
0‑L | N02BG10 | cannabinoids | WHO Anatomical Therapeutic Chemical classification | | cannabinoids |
0‑L | N02C | ANTIMIGRAINE PREPARATIONS | WHO Anatomical Therapeutic Chemical classification | | ANTIMIGRAINE PREPARATIONS |
0‑L | N02CA | Ergot alkaloids | WHO Anatomical Therapeutic Chemical classification | | Ergot alkaloids |
0‑L | N02CA01 | dihydroergotamine | WHO Anatomical Therapeutic Chemical classification | | dihydroergotamine |
0‑L | N02CA02 | ergotamine | WHO Anatomical Therapeutic Chemical classification | | ergotamine |
0‑L | N02CA04 | methysergide | WHO Anatomical Therapeutic Chemical classification | | methysergide |
0‑L | N02CA07 | lisuride | WHO Anatomical Therapeutic Chemical classification | | lisuride |
0‑L | N02CA51 | dihydroergotamine, combinations | WHO Anatomical Therapeutic Chemical classification | | dihydroergotamine, combinations |
0‑L | N02CA52 | ergotamine, combinations excl. psycholeptics | WHO Anatomical Therapeutic Chemical classification | | ergotamine, combinations excl. psycholeptics |
0‑L | N02CA72 | ergotamine, combinations with psycholeptics | WHO Anatomical Therapeutic Chemical classification | | ergotamine, combinations with psycholeptics |
0‑L | N02CB | Corticosteroid derivatives | WHO Anatomical Therapeutic Chemical classification | | Corticosteroid derivatives |
0‑L | N02CB01 | flumedroxone | WHO Anatomical Therapeutic Chemical classification | | flumedroxone |
0‑L | N02CC | Selective serotonin (5HT1) agonists | WHO Anatomical Therapeutic Chemical classification | | Selective serotonin (5HT1) agonists |
0‑L | N02CC01 | sumatriptan | WHO Anatomical Therapeutic Chemical classification | | sumatriptan |
0‑L | N02CC02 | naratriptan | WHO Anatomical Therapeutic Chemical classification | | naratriptan |
0‑L | N02CC03 | zolmitriptan | WHO Anatomical Therapeutic Chemical classification | | zolmitriptan |
0‑L | N02CC04 | rizatriptan | WHO Anatomical Therapeutic Chemical classification | | rizatriptan |
0‑L | N02CC05 | almotriptan | WHO Anatomical Therapeutic Chemical classification | | almotriptan |
0‑L | N02CC06 | eletriptan | WHO Anatomical Therapeutic Chemical classification | | eletriptan |
0‑L | N02CC07 | frovatriptan | WHO Anatomical Therapeutic Chemical classification | | frovatriptan |
0‑L | N02CX | Other antimigraine preparations | WHO Anatomical Therapeutic Chemical classification | | Other antimigraine preparations |
0‑L | N02CX01 | pizotifen | WHO Anatomical Therapeutic Chemical classification | | pizotifen |
0‑L | N02CX02 | clonidine | WHO Anatomical Therapeutic Chemical classification | | clonidine |
0‑L | N02CX03 | iprazochrome | WHO Anatomical Therapeutic Chemical classification | | iprazochrome |
0‑L | N02CX05 | dimetotiazine | WHO Anatomical Therapeutic Chemical classification | | dimetotiazine |
0‑L | N02CX06 | oxetorone | WHO Anatomical Therapeutic Chemical classification | | oxetorone |
0‑L | N03 | ANTIEPILEPTICS | WHO Anatomical Therapeutic Chemical classification | | ANTIEPILEPTICS |
0‑L | N03A | ANTIEPILEPTICS | WHO Anatomical Therapeutic Chemical classification | | ANTIEPILEPTICS |
0‑L | N03AA | Barbiturates and derivatives | WHO Anatomical Therapeutic Chemical classification | | Barbiturates and derivatives |
0‑L | N03AA01 | methylphenobarbital | WHO Anatomical Therapeutic Chemical classification | | methylphenobarbital |
0‑L | N03AA02 | phenobarbital | WHO Anatomical Therapeutic Chemical classification | | phenobarbital |
0‑L | N03AA03 | primidone | WHO Anatomical Therapeutic Chemical classification | | primidone |
0‑L | N03AA04 | barbexaclone | WHO Anatomical Therapeutic Chemical classification | | barbexaclone |
0‑L | N03AA30 | metharbital | WHO Anatomical Therapeutic Chemical classification | | metharbital |
0‑L | N03AB | Hydantoin derivatives | WHO Anatomical Therapeutic Chemical classification | | Hydantoin derivatives |
0‑L | N03AB01 | ethotoin | WHO Anatomical Therapeutic Chemical classification | | ethotoin |
0‑L | N03AB02 | phenytoin | WHO Anatomical Therapeutic Chemical classification | | phenytoin |
0‑L | N03AB03 | amino(diphenylhydantoin) valeric acid | WHO Anatomical Therapeutic Chemical classification | | amino(diphenylhydantoin) valeric acid |
0‑L | N03AB04 | mephenytoin | WHO Anatomical Therapeutic Chemical classification | | mephenytoin |
0‑L | N03AB05 | fosphenytoin | WHO Anatomical Therapeutic Chemical classification | | fosphenytoin |
0‑L | N03AB52 | phenytoin, combinations | WHO Anatomical Therapeutic Chemical classification | | phenytoin, combinations |
0‑L | N03AB54 | mephenytoin, combinations | WHO Anatomical Therapeutic Chemical classification | | mephenytoin, combinations |
0‑L | N03AC | Oxazolidine derivatives | WHO Anatomical Therapeutic Chemical classification | | Oxazolidine derivatives |
0‑L | N03AC01 | paramethadione | WHO Anatomical Therapeutic Chemical classification | | paramethadione |
0‑L | N03AC02 | trimethadione | WHO Anatomical Therapeutic Chemical classification | | trimethadione |
0‑L | N03AC03 | ethadione | WHO Anatomical Therapeutic Chemical classification | | ethadione |
0‑L | N03AD | Succinimide derivatives | WHO Anatomical Therapeutic Chemical classification | | Succinimide derivatives |
0‑L | N03AD01 | ethosuximide | WHO Anatomical Therapeutic Chemical classification | | ethosuximide |
0‑L | N03AD02 | phensuximide | WHO Anatomical Therapeutic Chemical classification | | phensuximide |
0‑L | N03AD03 | mesuximide | WHO Anatomical Therapeutic Chemical classification | | mesuximide |
0‑L | N03AD51 | ethosuximide, combinations | WHO Anatomical Therapeutic Chemical classification | | ethosuximide, combinations |
0‑L | N03AE | Benzodiazepine derivatives | WHO Anatomical Therapeutic Chemical classification | | Benzodiazepine derivatives |
0‑L | N03AE01 | clonazepam | WHO Anatomical Therapeutic Chemical classification | | clonazepam |
0‑L | N03AF | Carboxamide derivatives | WHO Anatomical Therapeutic Chemical classification | | Carboxamide derivatives |
0‑L | N03AF01 | carbamazepine | WHO Anatomical Therapeutic Chemical classification | | carbamazepine |
0‑L | N03AF02 | oxcarbazepine | WHO Anatomical Therapeutic Chemical classification | | oxcarbazepine |
0‑L | N03AF03 | rufinamide | WHO Anatomical Therapeutic Chemical classification | | rufinamide |
0‑L | N03AF04 | eslicarbazepine | WHO Anatomical Therapeutic Chemical classification | | eslicarbazepine |
0‑L | N03AG | Fatty acid derivatives | WHO Anatomical Therapeutic Chemical classification | | Fatty acid derivatives |
0‑L | N03AG01 | valproic acid | WHO Anatomical Therapeutic Chemical classification | | valproic acid |
0‑L | N03AG02 | valpromide | WHO Anatomical Therapeutic Chemical classification | | valpromide |
0‑L | N03AG03 | aminobutyric acid | WHO Anatomical Therapeutic Chemical classification | | aminobutyric acid |
0‑L | N03AG04 | vigabatrin | WHO Anatomical Therapeutic Chemical classification | | vigabatrin |
0‑L | N03AG05 | progabide | WHO Anatomical Therapeutic Chemical classification | | progabide |
0‑L | N03AG06 | tiagabine | WHO Anatomical Therapeutic Chemical classification | | tiagabine |
0‑L | N03AX | Other antiepileptics | WHO Anatomical Therapeutic Chemical classification | | Other antiepileptics |
0‑L | N03AX03 | sultiame | WHO Anatomical Therapeutic Chemical classification | | sultiame |
0‑L | N03AX07 | phenacemide | WHO Anatomical Therapeutic Chemical classification | | phenacemide |
0‑L | N03AX09 | lamotrigine | WHO Anatomical Therapeutic Chemical classification | | lamotrigine |
0‑L | N03AX10 | felbamate | WHO Anatomical Therapeutic Chemical classification | | felbamate |
0‑L | N03AX11 | topiramate | WHO Anatomical Therapeutic Chemical classification | | topiramate |
0‑L | N03AX12 | gabapentin | WHO Anatomical Therapeutic Chemical classification | | gabapentin |
0‑L | N03AX13 | pheneturide | WHO Anatomical Therapeutic Chemical classification | | pheneturide |
0‑L | N03AX14 | levetiracetam | WHO Anatomical Therapeutic Chemical classification | | levetiracetam |
0‑L | N03AX15 | zonisamide | WHO Anatomical Therapeutic Chemical classification | | zonisamide |
0‑L | N03AX16 | pregabalin | WHO Anatomical Therapeutic Chemical classification | | pregabalin |
0‑L | N03AX17 | stiripentol | WHO Anatomical Therapeutic Chemical classification | | stiripentol |
0‑L | N03AX18 | lacosamide | WHO Anatomical Therapeutic Chemical classification | | lacosamide |
0‑L | N03AX19 | carisbamate | WHO Anatomical Therapeutic Chemical classification | | carisbamate |
0‑L | N03AX21 | retigabine | WHO Anatomical Therapeutic Chemical classification | | retigabine |
0‑L | N03AX22 | perampanel | WHO Anatomical Therapeutic Chemical classification | | perampanel |
0‑L | N03AX23 | brivaracetam | WHO Anatomical Therapeutic Chemical classification | | brivaracetam |
0‑L | N03AX30 | beclamide | WHO Anatomical Therapeutic Chemical classification | | beclamide |
0‑L | N04 | ANTI-PARKINSON DRUGS | WHO Anatomical Therapeutic Chemical classification | | ANTI-PARKINSON DRUGS |
0‑L | N04A | ANTICHOLINERGIC AGENTS | WHO Anatomical Therapeutic Chemical classification | | ANTICHOLINERGIC AGENTS |
0‑L | N04AA | Tertiary amines | WHO Anatomical Therapeutic Chemical classification | | Tertiary amines |
0‑L | N04AA01 | trihexyphenidyl | WHO Anatomical Therapeutic Chemical classification | | trihexyphenidyl |
0‑L | N04AA02 | biperiden | WHO Anatomical Therapeutic Chemical classification | | biperiden |
0‑L | N04AA03 | metixene | WHO Anatomical Therapeutic Chemical classification | | metixene |
0‑L | N04AA04 | procyclidine | WHO Anatomical Therapeutic Chemical classification | | procyclidine |
0‑L | N04AA05 | profenamine | WHO Anatomical Therapeutic Chemical classification | | profenamine |
0‑L | N04AA08 | dexetimide | WHO Anatomical Therapeutic Chemical classification | | dexetimide |
0‑L | N04AA09 | phenglutarimide | WHO Anatomical Therapeutic Chemical classification | | phenglutarimide |
0‑L | N04AA10 | mazaticol | WHO Anatomical Therapeutic Chemical classification | | mazaticol |
0‑L | N04AA11 | bornaprine | WHO Anatomical Therapeutic Chemical classification | | bornaprine |
0‑L | N04AA12 | tropatepine | WHO Anatomical Therapeutic Chemical classification | | tropatepine |
0‑L | N04AB | Ethers chemically close to antihistamines | WHO Anatomical Therapeutic Chemical classification | | Ethers chemically close to antihistamines |
0‑L | N04AB01 | etanautine | WHO Anatomical Therapeutic Chemical classification | | etanautine |
0‑L | N04AB02 | orphenadrine (chloride) | WHO Anatomical Therapeutic Chemical classification | | orphenadrine (chloride) |
0‑L | N04AC | Ethers of tropine or tropine derivatives | WHO Anatomical Therapeutic Chemical classification | | Ethers of tropine or tropine derivatives |
0‑L | N04AC01 | benzatropine | WHO Anatomical Therapeutic Chemical classification | | benzatropine |
0‑L | N04AC30 | etybenzatropine | WHO Anatomical Therapeutic Chemical classification | | etybenzatropine |
0‑L | N04B | DOPAMINERGIC AGENTS | WHO Anatomical Therapeutic Chemical classification | | DOPAMINERGIC AGENTS |
0‑L | N04BA | Dopa and dopa derivatives | WHO Anatomical Therapeutic Chemical classification | | Dopa and dopa derivatives |
0‑L | N04BA01 | levodopa | WHO Anatomical Therapeutic Chemical classification | | levodopa |
0‑L | N04BA02 | levodopa and decarboxylase inhibitor | WHO Anatomical Therapeutic Chemical classification | | levodopa and decarboxylase inhibitor |
0‑L | N04BA03 | levodopa, decarboxylase inhibitor and COMT inhibitor | WHO Anatomical Therapeutic Chemical classification | | levodopa, decarboxylase inhibitor and COMT inhibitor |
0‑L | N04BA04 | melevodopa | WHO Anatomical Therapeutic Chemical classification | | melevodopa |
0‑L | N04BA05 | melevodopa and decarboxylase inhibitor | WHO Anatomical Therapeutic Chemical classification | | melevodopa and decarboxylase inhibitor |
0‑L | N04BA06 | etilevodopa and decarboxylase inhibitor | WHO Anatomical Therapeutic Chemical classification | | etilevodopa and decarboxylase inhibitor |
0‑L | N04BB | Adamantane derivatives | WHO Anatomical Therapeutic Chemical classification | | Adamantane derivatives |
0‑L | N04BB01 | amantadine | WHO Anatomical Therapeutic Chemical classification | | amantadine |
0‑L | N04BC | Dopamine agonists | WHO Anatomical Therapeutic Chemical classification | | Dopamine agonists |
0‑L | N04BC01 | bromocriptine | WHO Anatomical Therapeutic Chemical classification | | bromocriptine |
0‑L | N04BC02 | pergolide | WHO Anatomical Therapeutic Chemical classification | | pergolide |
0‑L | N04BC03 | dihydroergocryptine mesylate | WHO Anatomical Therapeutic Chemical classification | | dihydroergocryptine mesylate |
0‑L | N04BC04 | ropinirole | WHO Anatomical Therapeutic Chemical classification | | ropinirole |
0‑L | N04BC05 | pramipexole | WHO Anatomical Therapeutic Chemical classification | | pramipexole |
0‑L | N04BC06 | cabergoline | WHO Anatomical Therapeutic Chemical classification | | cabergoline |
0‑L | N04BC07 | apomorphine | WHO Anatomical Therapeutic Chemical classification | | apomorphine |
0‑L | N04BC08 | piribedil | WHO Anatomical Therapeutic Chemical classification | | piribedil |
0‑L | N04BC09 | rotigotine | WHO Anatomical Therapeutic Chemical classification | | rotigotine |
0‑L | N04BD | Monoamine oxidase B inhibitors | WHO Anatomical Therapeutic Chemical classification | | Monoamine oxidase B inhibitors |
0‑L | N04BD01 | selegiline | WHO Anatomical Therapeutic Chemical classification | | selegiline |
0‑L | N04BD02 | rasagiline | WHO Anatomical Therapeutic Chemical classification | | rasagiline |
0‑L | N04BD03 | safinamide | WHO Anatomical Therapeutic Chemical classification | | safinamide |
0‑L | N04BX | Other dopaminergic agents | WHO Anatomical Therapeutic Chemical classification | | Other dopaminergic agents |
0‑L | N04BX01 | tolcapone | WHO Anatomical Therapeutic Chemical classification | | tolcapone |
0‑L | N04BX02 | entacapone | WHO Anatomical Therapeutic Chemical classification | | entacapone |
0‑L | N04BX03 | budipine | WHO Anatomical Therapeutic Chemical classification | | budipine |
0‑L | N05 | PSYCHOLEPTICS | WHO Anatomical Therapeutic Chemical classification | | PSYCHOLEPTICS |
0‑L | N05A | ANTIPSYCHOTICS | WHO Anatomical Therapeutic Chemical classification | | ANTIPSYCHOTICS |
0‑L | N05AA | Phenothiazines with aliphatic side-chain | WHO Anatomical Therapeutic Chemical classification | | Phenothiazines with aliphatic side-chain |
0‑L | N05AA01 | chlorpromazine | WHO Anatomical Therapeutic Chemical classification | | chlorpromazine |
0‑L | N05AA02 | levomepromazine | WHO Anatomical Therapeutic Chemical classification | | levomepromazine |
0‑L | N05AA03 | promazine | WHO Anatomical Therapeutic Chemical classification | | promazine |
0‑L | N05AA04 | acepromazine | WHO Anatomical Therapeutic Chemical classification | | acepromazine |
0‑L | N05AA05 | triflupromazine | WHO Anatomical Therapeutic Chemical classification | | triflupromazine |
0‑L | N05AA06 | cyamemazine | WHO Anatomical Therapeutic Chemical classification | | cyamemazine |
0‑L | N05AA07 | chlorproethazine | WHO Anatomical Therapeutic Chemical classification | | chlorproethazine |
0‑L | N05AB | Phenothiazines with piperazine structure | WHO Anatomical Therapeutic Chemical classification | | Phenothiazines with piperazine structure |
0‑L | N05AB01 | dixyrazine | WHO Anatomical Therapeutic Chemical classification | | dixyrazine |
0‑L | N05AB02 | fluphenazine | WHO Anatomical Therapeutic Chemical classification | | fluphenazine |
0‑L | N05AB03 | perphenazine | WHO Anatomical Therapeutic Chemical classification | | perphenazine |
0‑L | N05AB04 | prochlorperazine | WHO Anatomical Therapeutic Chemical classification | | prochlorperazine |
0‑L | N05AB05 | thiopropazate | WHO Anatomical Therapeutic Chemical classification | | thiopropazate |
0‑L | N05AB06 | trifluoperazine | WHO Anatomical Therapeutic Chemical classification | | trifluoperazine |
0‑L | N05AB07 | acetophenazine | WHO Anatomical Therapeutic Chemical classification | | acetophenazine |
0‑L | N05AB08 | thioproperazine | WHO Anatomical Therapeutic Chemical classification | | thioproperazine |
0‑L | N05AB09 | butaperazine | WHO Anatomical Therapeutic Chemical classification | | butaperazine |
0‑L | N05AB10 | perazine | WHO Anatomical Therapeutic Chemical classification | | perazine |
0‑L | N05AC | Phenothiazines with piperidine structure | WHO Anatomical Therapeutic Chemical classification | | Phenothiazines with piperidine structure |
0‑L | N05AC01 | periciazine | WHO Anatomical Therapeutic Chemical classification | | periciazine |
0‑L | N05AC02 | thioridazine | WHO Anatomical Therapeutic Chemical classification | | thioridazine |
0‑L | N05AC03 | mesoridazine | WHO Anatomical Therapeutic Chemical classification | | mesoridazine |
0‑L | N05AC04 | pipotiazine | WHO Anatomical Therapeutic Chemical classification | | pipotiazine |
0‑L | N05AD | Butyrophenone derivatives | WHO Anatomical Therapeutic Chemical classification | | Butyrophenone derivatives |
0‑L | N05AD01 | haloperidol | WHO Anatomical Therapeutic Chemical classification | | haloperidol |
0‑L | N05AD02 | trifluperidol | WHO Anatomical Therapeutic Chemical classification | | trifluperidol |
0‑L | N05AD03 | melperone | WHO Anatomical Therapeutic Chemical classification | | melperone |
0‑L | N05AD04 | moperone | WHO Anatomical Therapeutic Chemical classification | | moperone |
0‑L | N05AD05 | pipamperone | WHO Anatomical Therapeutic Chemical classification | | pipamperone |
0‑L | N05AD06 | bromperidol | WHO Anatomical Therapeutic Chemical classification | | bromperidol |
0‑L | N05AD07 | benperidol | WHO Anatomical Therapeutic Chemical classification | | benperidol |
0‑L | N05AD08 | droperidol | WHO Anatomical Therapeutic Chemical classification | | droperidol |
0‑L | N05AD09 | fluanisone | WHO Anatomical Therapeutic Chemical classification | | fluanisone |
0‑L | N05AE | Indole derivatives | WHO Anatomical Therapeutic Chemical classification | | Indole derivatives |
0‑L | N05AE01 | oxypertine | WHO Anatomical Therapeutic Chemical classification | | oxypertine |
0‑L | N05AE02 | molindone | WHO Anatomical Therapeutic Chemical classification | | molindone |
0‑L | N05AE03 | sertindole | WHO Anatomical Therapeutic Chemical classification | | sertindole |
0‑L | N05AE04 | ziprasidone | WHO Anatomical Therapeutic Chemical classification | | ziprasidone |
0‑L | N05AE05 | lurasidone | WHO Anatomical Therapeutic Chemical classification | | lurasidone |
0‑L | N05AF | Thioxanthene derivatives | WHO Anatomical Therapeutic Chemical classification | | Thioxanthene derivatives |
0‑L | N05AF01 | flupentixol | WHO Anatomical Therapeutic Chemical classification | | flupentixol |
0‑L | N05AF02 | clopenthixol | WHO Anatomical Therapeutic Chemical classification | | clopenthixol |
0‑L | N05AF03 | chlorprothixene | WHO Anatomical Therapeutic Chemical classification | | chlorprothixene |
0‑L | N05AF04 | tiotixene | WHO Anatomical Therapeutic Chemical classification | | tiotixene |
0‑L | N05AF05 | zuclopenthixol | WHO Anatomical Therapeutic Chemical classification | | zuclopenthixol |
0‑L | N05AG | Diphenylbutylpiperidine derivatives | WHO Anatomical Therapeutic Chemical classification | | Diphenylbutylpiperidine derivatives |
0‑L | N05AG01 | fluspirilene | WHO Anatomical Therapeutic Chemical classification | | fluspirilene |
0‑L | N05AG02 | pimozide | WHO Anatomical Therapeutic Chemical classification | | pimozide |
0‑L | N05AG03 | penfluridol | WHO Anatomical Therapeutic Chemical classification | | penfluridol |
0‑L | N05AH | Diazepines, oxazepines, thiazepines and oxepines | WHO Anatomical Therapeutic Chemical classification | | Diazepines, oxazepines, thiazepines and oxepines |
0‑L | N05AH01 | loxapine | WHO Anatomical Therapeutic Chemical classification | | loxapine |
0‑L | N05AH02 | clozapine | WHO Anatomical Therapeutic Chemical classification | | clozapine |
0‑L | N05AH03 | olanzapine | WHO Anatomical Therapeutic Chemical classification | | olanzapine |
0‑L | N05AH04 | quetiapine | WHO Anatomical Therapeutic Chemical classification | | quetiapine |
0‑L | N05AH05 | asenapine | WHO Anatomical Therapeutic Chemical classification | | asenapine |
0‑L | N05AH06 | clotiapine | WHO Anatomical Therapeutic Chemical classification | | clotiapine |
0‑L | N05AL | Benzamides | WHO Anatomical Therapeutic Chemical classification | | Benzamides |
0‑L | N05AL01 | sulpiride | WHO Anatomical Therapeutic Chemical classification | | sulpiride |
0‑L | N05AL02 | sultopride | WHO Anatomical Therapeutic Chemical classification | | sultopride |
0‑L | N05AL03 | tiapride | WHO Anatomical Therapeutic Chemical classification | | tiapride |
0‑L | N05AL04 | remoxipride | WHO Anatomical Therapeutic Chemical classification | | remoxipride |
0‑L | N05AL05 | amisulpride | WHO Anatomical Therapeutic Chemical classification | | amisulpride |
0‑L | N05AL06 | veralipride | WHO Anatomical Therapeutic Chemical classification | | veralipride |
0‑L | N05AL07 | levosulpiride | WHO Anatomical Therapeutic Chemical classification | | levosulpiride |
0‑L | N05AN | Lithium | WHO Anatomical Therapeutic Chemical classification | | Lithium |
0‑L | N05AN01 | lithium | WHO Anatomical Therapeutic Chemical classification | | lithium |
0‑L | N05AX | Other antipsychotics | WHO Anatomical Therapeutic Chemical classification | | Other antipsychotics |
0‑L | N05AX07 | prothipendyl | WHO Anatomical Therapeutic Chemical classification | | prothipendyl |
0‑L | N05AX08 | risperidone | WHO Anatomical Therapeutic Chemical classification | | risperidone |
0‑L | N05AX10 | mosapramine | WHO Anatomical Therapeutic Chemical classification | | mosapramine |
0‑L | N05AX11 | zotepine | WHO Anatomical Therapeutic Chemical classification | | zotepine |
0‑L | N05AX12 | aripiprazole | WHO Anatomical Therapeutic Chemical classification | | aripiprazole |
0‑L | N05AX13 | paliperidone | WHO Anatomical Therapeutic Chemical classification | | paliperidone |
0‑L | N05AX14 | iloperidone | WHO Anatomical Therapeutic Chemical classification | | iloperidone |
0‑L | N05AX15 | cariprazine | WHO Anatomical Therapeutic Chemical classification | | cariprazine |
0‑L | N05AX16 | brexpiprazole | WHO Anatomical Therapeutic Chemical classification | | brexpiprazole |
0‑L | N05AX17 | pimavanserin | WHO Anatomical Therapeutic Chemical classification | | pimavanserin |
0‑L | N05B | ANXIOLYTICS | WHO Anatomical Therapeutic Chemical classification | | ANXIOLYTICS |
0‑L | N05BA | Benzodiazepine derivatives | WHO Anatomical Therapeutic Chemical classification | | Benzodiazepine derivatives |
0‑L | N05BA01 | diazepam | WHO Anatomical Therapeutic Chemical classification | | diazepam |
0‑L | N05BA02 | chlordiazepoxide | WHO Anatomical Therapeutic Chemical classification | | chlordiazepoxide |
0‑L | N05BA03 | medazepam | WHO Anatomical Therapeutic Chemical classification | | medazepam |
0‑L | N05BA04 | oxazepam | WHO Anatomical Therapeutic Chemical classification | | oxazepam |
0‑L | N05BA05 | potassium clorazepate | WHO Anatomical Therapeutic Chemical classification | | potassium clorazepate |
0‑L | N05BA06 | lorazepam | WHO Anatomical Therapeutic Chemical classification | | lorazepam |
0‑L | N05BA07 | adinazolam | WHO Anatomical Therapeutic Chemical classification | | adinazolam |
0‑L | N05BA08 | bromazepam | WHO Anatomical Therapeutic Chemical classification | | bromazepam |
0‑L | N05BA09 | clobazam | WHO Anatomical Therapeutic Chemical classification | | clobazam |
0‑L | N05BA10 | ketazolam | WHO Anatomical Therapeutic Chemical classification | | ketazolam |
0‑L | N05BA11 | prazepam | WHO Anatomical Therapeutic Chemical classification | | prazepam |
0‑L | N05BA12 | alprazolam | WHO Anatomical Therapeutic Chemical classification | | alprazolam |
0‑L | N05BA13 | halazepam | WHO Anatomical Therapeutic Chemical classification | | halazepam |
0‑L | N05BA14 | pinazepam | WHO Anatomical Therapeutic Chemical classification | | pinazepam |
0‑L | N05BA15 | camazepam | WHO Anatomical Therapeutic Chemical classification | | camazepam |
0‑L | N05BA16 | nordazepam | WHO Anatomical Therapeutic Chemical classification | | nordazepam |
0‑L | N05BA17 | fludiazepam | WHO Anatomical Therapeutic Chemical classification | | fludiazepam |
0‑L | N05BA18 | ethyl loflazepate | WHO Anatomical Therapeutic Chemical classification | | ethyl loflazepate |
0‑L | N05BA19 | etizolam | WHO Anatomical Therapeutic Chemical classification | | etizolam |
0‑L | N05BA21 | clotiazepam | WHO Anatomical Therapeutic Chemical classification | | clotiazepam |
0‑L | N05BA22 | cloxazolam | WHO Anatomical Therapeutic Chemical classification | | cloxazolam |
0‑L | N05BA23 | tofisopam | WHO Anatomical Therapeutic Chemical classification | | tofisopam |
0‑L | N05BA24 | bentazepam | WHO Anatomical Therapeutic Chemical classification | | bentazepam |
0‑L | N05BA56 | lorazepam, combinations | WHO Anatomical Therapeutic Chemical classification | | lorazepam, combinations |
0‑L | N05BB | Diphenylmethane derivatives | WHO Anatomical Therapeutic Chemical classification | | Diphenylmethane derivatives |
0‑L | N05BB01 | hydroxyzine | WHO Anatomical Therapeutic Chemical classification | | hydroxyzine |
0‑L | N05BB02 | captodiame | WHO Anatomical Therapeutic Chemical classification | | captodiame |
0‑L | N05BB51 | hydroxyzine, combinations | WHO Anatomical Therapeutic Chemical classification | | hydroxyzine, combinations |
0‑L | N05BC | Carbamates | WHO Anatomical Therapeutic Chemical classification | | Carbamates |
0‑L | N05BC01 | meprobamate | WHO Anatomical Therapeutic Chemical classification | | meprobamate |
0‑L | N05BC03 | emylcamate | WHO Anatomical Therapeutic Chemical classification | | emylcamate |
0‑L | N05BC04 | mebutamate | WHO Anatomical Therapeutic Chemical classification | | mebutamate |
0‑L | N05BC51 | meprobamate, combinations | WHO Anatomical Therapeutic Chemical classification | | meprobamate, combinations |
0‑L | N05BD | Dibenzo-bicyclo-octadiene derivatives | WHO Anatomical Therapeutic Chemical classification | | Dibenzo-bicyclo-octadiene derivatives |
0‑L | N05BD01 | benzoctamine | WHO Anatomical Therapeutic Chemical classification | | benzoctamine |
0‑L | N05BE | Azaspirodecanedione derivatives | WHO Anatomical Therapeutic Chemical classification | | Azaspirodecanedione derivatives |
0‑L | N05BE01 | buspirone | WHO Anatomical Therapeutic Chemical classification | | buspirone |
0‑L | N05BX | Other anxiolytics | WHO Anatomical Therapeutic Chemical classification | | Other anxiolytics |
0‑L | N05BX01 | mephenoxalone | WHO Anatomical Therapeutic Chemical classification | | mephenoxalone |
0‑L | N05BX02 | gedocarnil | WHO Anatomical Therapeutic Chemical classification | | gedocarnil |
0‑L | N05BX03 | etifoxine | WHO Anatomical Therapeutic Chemical classification | | etifoxine |
0‑L | N05BX04 | fabomotizole | WHO Anatomical Therapeutic Chemical classification | | fabomotizole |
0‑L | N05C | HYPNOTICS AND SEDATIVES | WHO Anatomical Therapeutic Chemical classification | | HYPNOTICS AND SEDATIVES |
0‑L | N05CA | Barbiturates, plain | WHO Anatomical Therapeutic Chemical classification | | Barbiturates, plain |
0‑L | N05CA01 | pentobarbital | WHO Anatomical Therapeutic Chemical classification | | pentobarbital |
0‑L | N05CA02 | amobarbital | WHO Anatomical Therapeutic Chemical classification | | amobarbital |
0‑L | N05CA03 | butobarbital | WHO Anatomical Therapeutic Chemical classification | | butobarbital |
0‑L | N05CA04 | barbital | WHO Anatomical Therapeutic Chemical classification | | barbital |
0‑L | N05CA05 | aprobarbital | WHO Anatomical Therapeutic Chemical classification | | aprobarbital |
0‑L | N05CA06 | secobarbital | WHO Anatomical Therapeutic Chemical classification | | secobarbital |
0‑L | N05CA07 | talbutal | WHO Anatomical Therapeutic Chemical classification | | talbutal |
0‑L | N05CA08 | vinylbital | WHO Anatomical Therapeutic Chemical classification | | vinylbital |
0‑L | N05CA09 | vinbarbital | WHO Anatomical Therapeutic Chemical classification | | vinbarbital |
0‑L | N05CA10 | cyclobarbital | WHO Anatomical Therapeutic Chemical classification | | cyclobarbital |
0‑L | N05CA11 | heptabarbital | WHO Anatomical Therapeutic Chemical classification | | heptabarbital |
0‑L | N05CA12 | reposal | WHO Anatomical Therapeutic Chemical classification | | reposal |
0‑L | N05CA15 | methohexital | WHO Anatomical Therapeutic Chemical classification | | methohexital |
0‑L | N05CA16 | hexobarbital | WHO Anatomical Therapeutic Chemical classification | | hexobarbital |
0‑L | N05CA19 | thiopental | WHO Anatomical Therapeutic Chemical classification | | thiopental |
0‑L | N05CA20 | etallobarbital | WHO Anatomical Therapeutic Chemical classification | | etallobarbital |
0‑L | N05CA21 | allobarbital | WHO Anatomical Therapeutic Chemical classification | | allobarbital |
0‑L | N05CA22 | proxibarbal | WHO Anatomical Therapeutic Chemical classification | | proxibarbal |
0‑L | N05CB | Barbiturates, combinations | WHO Anatomical Therapeutic Chemical classification | | Barbiturates, combinations |
0‑L | N05CB01 | combinations of barbiturates | WHO Anatomical Therapeutic Chemical classification | | combinations of barbiturates |
0‑L | N05CB02 | barbiturates in combination with other drugs | WHO Anatomical Therapeutic Chemical classification | | barbiturates in combination with other drugs |
0‑L | N05CC | Aldehydes and derivatives | WHO Anatomical Therapeutic Chemical classification | | Aldehydes and derivatives |
0‑L | N05CC01 | chloral hydrate | WHO Anatomical Therapeutic Chemical classification | | chloral hydrate |
0‑L | N05CC02 | chloralodol | WHO Anatomical Therapeutic Chemical classification | | chloralodol |
0‑L | N05CC03 | acetylglycinamide chloral hydrate | WHO Anatomical Therapeutic Chemical classification | | acetylglycinamide chloral hydrate |
0‑L | N05CC04 | dichloralphenazone | WHO Anatomical Therapeutic Chemical classification | | dichloralphenazone |
0‑L | N05CC05 | paraldehyde | WHO Anatomical Therapeutic Chemical classification | | paraldehyde |
0‑L | N05CD | Benzodiazepine derivatives | WHO Anatomical Therapeutic Chemical classification | | Benzodiazepine derivatives |
0‑L | N05CD01 | flurazepam | WHO Anatomical Therapeutic Chemical classification | | flurazepam |
0‑L | N05CD02 | nitrazepam | WHO Anatomical Therapeutic Chemical classification | | nitrazepam |
0‑L | N05CD03 | flunitrazepam | WHO Anatomical Therapeutic Chemical classification | | flunitrazepam |
0‑L | N05CD04 | estazolam | WHO Anatomical Therapeutic Chemical classification | | estazolam |
0‑L | N05CD05 | triazolam | WHO Anatomical Therapeutic Chemical classification | | triazolam |
0‑L | N05CD06 | lormetazepam | WHO Anatomical Therapeutic Chemical classification | | lormetazepam |
0‑L | N05CD07 | temazepam | WHO Anatomical Therapeutic Chemical classification | | temazepam |
0‑L | N05CD08 | midazolam | WHO Anatomical Therapeutic Chemical classification | | midazolam |
0‑L | N05CD09 | brotizolam | WHO Anatomical Therapeutic Chemical classification | | brotizolam |
0‑L | N05CD10 | quazepam | WHO Anatomical Therapeutic Chemical classification | | quazepam |
0‑L | N05CD11 | loprazolam | WHO Anatomical Therapeutic Chemical classification | | loprazolam |
0‑L | N05CD12 | doxefazepam | WHO Anatomical Therapeutic Chemical classification | | doxefazepam |
0‑L | N05CD13 | cinolazepam | WHO Anatomical Therapeutic Chemical classification | | cinolazepam |
0‑L | N05CE | Piperidinedione derivatives | WHO Anatomical Therapeutic Chemical classification | | Piperidinedione derivatives |
0‑L | N05CE01 | glutethimide | WHO Anatomical Therapeutic Chemical classification | | glutethimide |
0‑L | N05CE02 | methyprylon | WHO Anatomical Therapeutic Chemical classification | | methyprylon |
0‑L | N05CE03 | pyrithyldione | WHO Anatomical Therapeutic Chemical classification | | pyrithyldione |
0‑L | N05CF | Benzodiazepine related drugs | WHO Anatomical Therapeutic Chemical classification | | Benzodiazepine related drugs |
0‑L | N05CF01 | zopiclone | WHO Anatomical Therapeutic Chemical classification | | zopiclone |
0‑L | N05CF02 | zolpidem | WHO Anatomical Therapeutic Chemical classification | | zolpidem |
0‑L | N05CF03 | zaleplon | WHO Anatomical Therapeutic Chemical classification | | zaleplon |
0‑L | N05CF04 | eszopiclone | WHO Anatomical Therapeutic Chemical classification | | eszopiclone |
0‑L | N05CH | Melatonin receptor agonists | WHO Anatomical Therapeutic Chemical classification | | Melatonin receptor agonists |
0‑L | N05CH01 | melatonin | WHO Anatomical Therapeutic Chemical classification | | melatonin |
0‑L | N05CH02 | ramelteon | WHO Anatomical Therapeutic Chemical classification | | ramelteon |
0‑L | N05CH03 | tasimelteon | WHO Anatomical Therapeutic Chemical classification | | tasimelteon |
0‑L | N05CM | Other hypnotics and sedatives | WHO Anatomical Therapeutic Chemical classification | | Other hypnotics and sedatives |
0‑L | N05CM01 | methaqualone | WHO Anatomical Therapeutic Chemical classification | | methaqualone |
0‑L | N05CM02 | clomethiazole | WHO Anatomical Therapeutic Chemical classification | | clomethiazole |
0‑L | N05CM03 | bromisoval | WHO Anatomical Therapeutic Chemical classification | | bromisoval |
0‑L | N05CM04 | carbromal | WHO Anatomical Therapeutic Chemical classification | | carbromal |
0‑L | N05CM05 | scopolamine | WHO Anatomical Therapeutic Chemical classification | | scopolamine |
0‑L | N05CM06 | propiomazine | WHO Anatomical Therapeutic Chemical classification | | propiomazine |
0‑L | N05CM07 | triclofos | WHO Anatomical Therapeutic Chemical classification | | triclofos |
0‑L | N05CM08 | ethchlorvynol | WHO Anatomical Therapeutic Chemical classification | | ethchlorvynol |
0‑L | N05CM09 | Valerianae radix | WHO Anatomical Therapeutic Chemical classification | | Valerianae radix |
0‑L | N05CM10 | hexapropymate | WHO Anatomical Therapeutic Chemical classification | | hexapropymate |
0‑L | N05CM11 | bromides | WHO Anatomical Therapeutic Chemical classification | | bromides |
0‑L | N05CM12 | apronal | WHO Anatomical Therapeutic Chemical classification | | apronal |
0‑L | N05CM13 | valnoctamide | WHO Anatomical Therapeutic Chemical classification | | valnoctamide |
0‑L | N05CM15 | methylpentynol | WHO Anatomical Therapeutic Chemical classification | | methylpentynol |
0‑L | N05CM16 | niaprazine | WHO Anatomical Therapeutic Chemical classification | | niaprazine |
0‑L | N05CM18 | dexmedetomidine | WHO Anatomical Therapeutic Chemical classification | | dexmedetomidine |
0‑L | N05CX | Hypnotics and sedatives in combination, excl. barbiturates | WHO Anatomical Therapeutic Chemical classification | | Hypnotics and sedatives in combination, excl. barbiturates |
0‑L | N05CX01 | meprobamate, combinations | WHO Anatomical Therapeutic Chemical classification | | meprobamate, combinations |
0‑L | N05CX02 | methaqualone, combinations | WHO Anatomical Therapeutic Chemical classification | | methaqualone, combinations |
0‑L | N05CX03 | methylpentynol, combinations | WHO Anatomical Therapeutic Chemical classification | | methylpentynol, combinations |
0‑L | N05CX04 | clomethiazole, combinations | WHO Anatomical Therapeutic Chemical classification | | clomethiazole, combinations |
0‑L | N05CX05 | emepronium, combinations | WHO Anatomical Therapeutic Chemical classification | | emepronium, combinations |
0‑L | N05CX06 | dipiperonylaminoethanol, combinations | WHO Anatomical Therapeutic Chemical classification | | dipiperonylaminoethanol, combinations |
0‑L | N06 | PSYCHOANALEPTICS | WHO Anatomical Therapeutic Chemical classification | | PSYCHOANALEPTICS |
0‑L | N06A | ANTIDEPRESSANTS | WHO Anatomical Therapeutic Chemical classification | | ANTIDEPRESSANTS |
0‑L | N06AA | Non-selective monoamine reuptake inhibitors | WHO Anatomical Therapeutic Chemical classification | | Non-selective monoamine reuptake inhibitors |
0‑L | N06AA01 | desipramine | WHO Anatomical Therapeutic Chemical classification | | desipramine |
0‑L | N06AA02 | imipramine | WHO Anatomical Therapeutic Chemical classification | | imipramine |
0‑L | N06AA03 | imipramine oxide | WHO Anatomical Therapeutic Chemical classification | | imipramine oxide |
0‑L | N06AA04 | clomipramine | WHO Anatomical Therapeutic Chemical classification | | clomipramine |
0‑L | N06AA05 | opipramol | WHO Anatomical Therapeutic Chemical classification | | opipramol |
0‑L | N06AA06 | trimipramine | WHO Anatomical Therapeutic Chemical classification | | trimipramine |
0‑L | N06AA07 | lofepramine | WHO Anatomical Therapeutic Chemical classification | | lofepramine |
0‑L | N06AA08 | dibenzepin | WHO Anatomical Therapeutic Chemical classification | | dibenzepin |
0‑L | N06AA09 | amitriptyline | WHO Anatomical Therapeutic Chemical classification | | amitriptyline |
0‑L | N06AA10 | nortriptyline | WHO Anatomical Therapeutic Chemical classification | | nortriptyline |
0‑L | N06AA11 | protriptyline | WHO Anatomical Therapeutic Chemical classification | | protriptyline |
0‑L | N06AA12 | doxepin | WHO Anatomical Therapeutic Chemical classification | | doxepin |
0‑L | N06AA13 | iprindole | WHO Anatomical Therapeutic Chemical classification | | iprindole |
0‑L | N06AA14 | melitracen | WHO Anatomical Therapeutic Chemical classification | | melitracen |
0‑L | N06AA15 | butriptyline | WHO Anatomical Therapeutic Chemical classification | | butriptyline |
0‑L | N06AA16 | dosulepin | WHO Anatomical Therapeutic Chemical classification | | dosulepin |
0‑L | N06AA17 | amoxapine | WHO Anatomical Therapeutic Chemical classification | | amoxapine |
0‑L | N06AA18 | dimetacrine | WHO Anatomical Therapeutic Chemical classification | | dimetacrine |
0‑L | N06AA19 | amineptine | WHO Anatomical Therapeutic Chemical classification | | amineptine |
0‑L | N06AA21 | maprotiline | WHO Anatomical Therapeutic Chemical classification | | maprotiline |
0‑L | N06AA23 | quinupramine | WHO Anatomical Therapeutic Chemical classification | | quinupramine |
0‑L | N06AB | Selective serotonin reuptake inhibitors | WHO Anatomical Therapeutic Chemical classification | | Selective serotonin reuptake inhibitors |
0‑L | N06AB02 | zimeldine | WHO Anatomical Therapeutic Chemical classification | | zimeldine |
0‑L | N06AB03 | fluoxetine | WHO Anatomical Therapeutic Chemical classification | | fluoxetine |
0‑L | N06AB04 | citalopram | WHO Anatomical Therapeutic Chemical classification | | citalopram |
0‑L | N06AB05 | paroxetine | WHO Anatomical Therapeutic Chemical classification | | paroxetine |
0‑L | N06AB06 | sertraline | WHO Anatomical Therapeutic Chemical classification | | sertraline |
0‑L | N06AB07 | alaproclate | WHO Anatomical Therapeutic Chemical classification | | alaproclate |
0‑L | N06AB08 | fluvoxamine | WHO Anatomical Therapeutic Chemical classification | | fluvoxamine |
0‑L | N06AB09 | etoperidone | WHO Anatomical Therapeutic Chemical classification | | etoperidone |
0‑L | N06AB10 | escitalopram | WHO Anatomical Therapeutic Chemical classification | | escitalopram |
0‑L | N06AF | Monoamine oxidase inhibitors, non-selective | WHO Anatomical Therapeutic Chemical classification | | Monoamine oxidase inhibitors, non-selective |
0‑L | N06AF01 | isocarboxazid | WHO Anatomical Therapeutic Chemical classification | | isocarboxazid |
0‑L | N06AF02 | nialamide | WHO Anatomical Therapeutic Chemical classification | | nialamide |
0‑L | N06AF03 | phenelzine | WHO Anatomical Therapeutic Chemical classification | | phenelzine |
0‑L | N06AF04 | tranylcypromine | WHO Anatomical Therapeutic Chemical classification | | tranylcypromine |
0‑L | N06AF05 | iproniazide | WHO Anatomical Therapeutic Chemical classification | | iproniazide |
0‑L | N06AF06 | iproclozide | WHO Anatomical Therapeutic Chemical classification | | iproclozide |
0‑L | N06AG | Monoamine oxidase A inhibitors | WHO Anatomical Therapeutic Chemical classification | | Monoamine oxidase A inhibitors |
0‑L | N06AG02 | moclobemide | WHO Anatomical Therapeutic Chemical classification | | moclobemide |
0‑L | N06AG03 | toloxatone | WHO Anatomical Therapeutic Chemical classification | | toloxatone |
0‑L | N06AX | Other antidepressants | WHO Anatomical Therapeutic Chemical classification | | Other antidepressants |
0‑L | N06AX01 | oxitriptan | WHO Anatomical Therapeutic Chemical classification | | oxitriptan |
0‑L | N06AX02 | tryptophan | WHO Anatomical Therapeutic Chemical classification | | tryptophan |
0‑L | N06AX03 | mianserin | WHO Anatomical Therapeutic Chemical classification | | mianserin |
0‑L | N06AX04 | nomifensine | WHO Anatomical Therapeutic Chemical classification | | nomifensine |
0‑L | N06AX05 | trazodone | WHO Anatomical Therapeutic Chemical classification | | trazodone |
0‑L | N06AX06 | nefazodone | WHO Anatomical Therapeutic Chemical classification | | nefazodone |
0‑L | N06AX07 | minaprine | WHO Anatomical Therapeutic Chemical classification | | minaprine |
0‑L | N06AX08 | bifemelane | WHO Anatomical Therapeutic Chemical classification | | bifemelane |
0‑L | N06AX09 | viloxazine | WHO Anatomical Therapeutic Chemical classification | | viloxazine |
0‑L | N06AX10 | oxaflozane | WHO Anatomical Therapeutic Chemical classification | | oxaflozane |
0‑L | N06AX11 | mirtazapine | WHO Anatomical Therapeutic Chemical classification | | mirtazapine |
0‑L | N06AX12 | bupropion | WHO Anatomical Therapeutic Chemical classification | | bupropion |
0‑L | N06AX13 | medifoxamine | WHO Anatomical Therapeutic Chemical classification | | medifoxamine |
0‑L | N06AX14 | tianeptine | WHO Anatomical Therapeutic Chemical classification | | tianeptine |
0‑L | N06AX15 | pivagabine | WHO Anatomical Therapeutic Chemical classification | | pivagabine |
0‑L | N06AX16 | venlafaxine | WHO Anatomical Therapeutic Chemical classification | | venlafaxine |
0‑L | N06AX17 | milnacipran | WHO Anatomical Therapeutic Chemical classification | | milnacipran |
0‑L | N06AX18 | reboxetine | WHO Anatomical Therapeutic Chemical classification | | reboxetine |
0‑L | N06AX19 | gepirone | WHO Anatomical Therapeutic Chemical classification | | gepirone |
0‑L | N06AX21 | duloxetine | WHO Anatomical Therapeutic Chemical classification | | duloxetine |
0‑L | N06AX22 | agomelatine | WHO Anatomical Therapeutic Chemical classification | | agomelatine |
0‑L | N06AX23 | desvenlafaxine | WHO Anatomical Therapeutic Chemical classification | | desvenlafaxine |
0‑L | N06AX24 | vilazodone | WHO Anatomical Therapeutic Chemical classification | | vilazodone |
0‑L | N06AX25 | Hyperici herba | WHO Anatomical Therapeutic Chemical classification | | Hyperici herba |
0‑L | N06AX26 | vortioxetine | WHO Anatomical Therapeutic Chemical classification | | vortioxetine |
0‑L | N06B | PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS | WHO Anatomical Therapeutic Chemical classification | | PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS |
0‑L | N06BA | Centrally acting sympathomimetics | WHO Anatomical Therapeutic Chemical classification | | Centrally acting sympathomimetics |
0‑L | N06BA01 | amfetamine | WHO Anatomical Therapeutic Chemical classification | | amfetamine |
0‑L | N06BA02 | dexamfetamine | WHO Anatomical Therapeutic Chemical classification | | dexamfetamine |
0‑L | N06BA03 | metamfetamine | WHO Anatomical Therapeutic Chemical classification | | metamfetamine |
0‑L | N06BA04 | methylphenidate | WHO Anatomical Therapeutic Chemical classification | | methylphenidate |
0‑L | N06BA05 | pemoline | WHO Anatomical Therapeutic Chemical classification | | pemoline |
0‑L | N06BA06 | fencamfamin | WHO Anatomical Therapeutic Chemical classification | | fencamfamin |
0‑L | N06BA07 | modafinil | WHO Anatomical Therapeutic Chemical classification | | modafinil |
0‑L | N06BA08 | fenozolone | WHO Anatomical Therapeutic Chemical classification | | fenozolone |
0‑L | N06BA09 | atomoxetine | WHO Anatomical Therapeutic Chemical classification | | atomoxetine |
0‑L | N06BA10 | fenetylline | WHO Anatomical Therapeutic Chemical classification | | fenetylline |
0‑L | N06BA11 | dexmethylphenidate | WHO Anatomical Therapeutic Chemical classification | | dexmethylphenidate |
0‑L | N06BA12 | lisdexamfetamine | WHO Anatomical Therapeutic Chemical classification | | lisdexamfetamine |
0‑L | N06BA13 | armodafinil | WHO Anatomical Therapeutic Chemical classification | | armodafinil |
0‑L | N06BC | Xanthine derivatives | WHO Anatomical Therapeutic Chemical classification | | Xanthine derivatives |
0‑L | N06BC01 | caffeine | WHO Anatomical Therapeutic Chemical classification | | caffeine |
0‑L | N06BC02 | propentofylline | WHO Anatomical Therapeutic Chemical classification | | propentofylline |
0‑L | N06BX | Other psychostimulants and nootropics | WHO Anatomical Therapeutic Chemical classification | | Other psychostimulants and nootropics |
0‑L | N06BX01 | meclofenoxate | WHO Anatomical Therapeutic Chemical classification | | meclofenoxate |
0‑L | N06BX02 | pyritinol | WHO Anatomical Therapeutic Chemical classification | | pyritinol |
0‑L | N06BX03 | piracetam | WHO Anatomical Therapeutic Chemical classification | | piracetam |
0‑L | N06BX04 | deanol | WHO Anatomical Therapeutic Chemical classification | | deanol |
0‑L | N06BX05 | fipexide | WHO Anatomical Therapeutic Chemical classification | | fipexide |
0‑L | N06BX06 | citicoline | WHO Anatomical Therapeutic Chemical classification | | citicoline |
0‑L | N06BX07 | oxiracetam | WHO Anatomical Therapeutic Chemical classification | | oxiracetam |
0‑L | N06BX08 | pirisudanol | WHO Anatomical Therapeutic Chemical classification | | pirisudanol |
0‑L | N06BX09 | linopirdine | WHO Anatomical Therapeutic Chemical classification | | linopirdine |
0‑L | N06BX10 | nizofenone | WHO Anatomical Therapeutic Chemical classification | | nizofenone |
0‑L | N06BX11 | aniracetam | WHO Anatomical Therapeutic Chemical classification | | aniracetam |
0‑L | N06BX12 | acetylcarnitine | WHO Anatomical Therapeutic Chemical classification | | acetylcarnitine |
0‑L | N06BX13 | idebenone | WHO Anatomical Therapeutic Chemical classification | | idebenone |
0‑L | N06BX14 | prolintane | WHO Anatomical Therapeutic Chemical classification | | prolintane |
0‑L | N06BX15 | pipradrol | WHO Anatomical Therapeutic Chemical classification | | pipradrol |
0‑L | N06BX16 | pramiracetam | WHO Anatomical Therapeutic Chemical classification | | pramiracetam |
0‑L | N06BX17 | adrafinil | WHO Anatomical Therapeutic Chemical classification | | adrafinil |
0‑L | N06BX18 | vinpocetine | WHO Anatomical Therapeutic Chemical classification | | vinpocetine |
0‑L | N06BX21 | mebicar | WHO Anatomical Therapeutic Chemical classification | | mebicar |
0‑L | N06BX22 | phenibut | WHO Anatomical Therapeutic Chemical classification | | phenibut |
0‑L | N06C | PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION | WHO Anatomical Therapeutic Chemical classification | | PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION |
0‑L | N06CA | Antidepressants in combination with psycholeptics | WHO Anatomical Therapeutic Chemical classification | | Antidepressants in combination with psycholeptics |
0‑L | N06CA01 | amitriptyline and psycholeptics | WHO Anatomical Therapeutic Chemical classification | | amitriptyline and psycholeptics |
0‑L | N06CA02 | melitracen and psycholeptics | WHO Anatomical Therapeutic Chemical classification | | melitracen and psycholeptics |
0‑L | N06CA03 | fluoxetine and psycholeptics | WHO Anatomical Therapeutic Chemical classification | | fluoxetine and psycholeptics |
0‑L | N06CB | Psychostimulants in combination with psycholeptics | WHO Anatomical Therapeutic Chemical classification | | Psychostimulants in combination with psycholeptics |
0‑L | N06D | ANTI-DEMENTIA DRUGS | WHO Anatomical Therapeutic Chemical classification | | ANTI-DEMENTIA DRUGS |
0‑L | N06DA | Anticholinesterases | WHO Anatomical Therapeutic Chemical classification | | Anticholinesterases |
0‑L | N06DA01 | tacrine | WHO Anatomical Therapeutic Chemical classification | | tacrine |
0‑L | N06DA02 | donepezil | WHO Anatomical Therapeutic Chemical classification | | donepezil |
0‑L | N06DA03 | rivastigmine | WHO Anatomical Therapeutic Chemical classification | | rivastigmine |
0‑L | N06DA04 | galantamine | WHO Anatomical Therapeutic Chemical classification | | galantamine |
0‑L | N06DA05 | ipidacrine | WHO Anatomical Therapeutic Chemical classification | | ipidacrine |
0‑L | N06DA52 | donepezil and memantine | WHO Anatomical Therapeutic Chemical classification | | donepezil and memantine |
0‑L | N06DA53 | donepezil, memantine and Ginkgo folium | WHO Anatomical Therapeutic Chemical classification | | donepezil, memantine and Ginkgo folium |
0‑L | N06DX | Other anti-dementia drugs | WHO Anatomical Therapeutic Chemical classification | | Other anti-dementia drugs |
0‑L | N06DX01 | memantine | WHO Anatomical Therapeutic Chemical classification | | memantine |
0‑L | N06DX02 | Ginkgo folium | WHO Anatomical Therapeutic Chemical classification | | Ginkgo folium |
0‑L | N06DX30 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | N07 | OTHER NERVOUS SYSTEM DRUGS | WHO Anatomical Therapeutic Chemical classification | | OTHER NERVOUS SYSTEM DRUGS |
0‑L | N07A | PARASYMPATHOMIMETICS | WHO Anatomical Therapeutic Chemical classification | | PARASYMPATHOMIMETICS |
0‑L | N07AA | Anticholinesterases | WHO Anatomical Therapeutic Chemical classification | | Anticholinesterases |
0‑L | N07AA01 | neostigmine | WHO Anatomical Therapeutic Chemical classification | | neostigmine |
0‑L | N07AA02 | pyridostigmine | WHO Anatomical Therapeutic Chemical classification | | pyridostigmine |
0‑L | N07AA03 | distigmine | WHO Anatomical Therapeutic Chemical classification | | distigmine |
0‑L | N07AA30 | ambenonium | WHO Anatomical Therapeutic Chemical classification | | ambenonium |
0‑L | N07AA51 | neostigmine, combinations | WHO Anatomical Therapeutic Chemical classification | | neostigmine, combinations |
0‑L | N07AB | Choline esters | WHO Anatomical Therapeutic Chemical classification | | Choline esters |
0‑L | N07AB01 | carbachol | WHO Anatomical Therapeutic Chemical classification | | carbachol |
0‑L | N07AB02 | bethanechol | WHO Anatomical Therapeutic Chemical classification | | bethanechol |
0‑L | N07AX | Other parasympathomimetics | WHO Anatomical Therapeutic Chemical classification | | Other parasympathomimetics |
0‑L | N07AX01 | pilocarpine | WHO Anatomical Therapeutic Chemical classification | | pilocarpine |
0‑L | N07AX02 | choline alfoscerate | WHO Anatomical Therapeutic Chemical classification | | choline alfoscerate |
0‑L | N07AX03 | cevimeline | WHO Anatomical Therapeutic Chemical classification | | cevimeline |
0‑L | N07B | DRUGS USED IN ADDICTIVE DISORDERS | WHO Anatomical Therapeutic Chemical classification | | DRUGS USED IN ADDICTIVE DISORDERS |
0‑L | N07BA | Drugs used in nicotine dependence | WHO Anatomical Therapeutic Chemical classification | | Drugs used in nicotine dependence |
0‑L | N07BA01 | nicotine | WHO Anatomical Therapeutic Chemical classification | | nicotine |
0‑L | N07BA03 | varenicline | WHO Anatomical Therapeutic Chemical classification | | varenicline |
0‑L | N07BB | Drugs used in alcohol dependence | WHO Anatomical Therapeutic Chemical classification | | Drugs used in alcohol dependence |
0‑L | N07BB01 | disulfiram | WHO Anatomical Therapeutic Chemical classification | | disulfiram |
0‑L | N07BB02 | calcium carbimide | WHO Anatomical Therapeutic Chemical classification | | calcium carbimide |
0‑L | N07BB03 | acamprosate | WHO Anatomical Therapeutic Chemical classification | | acamprosate |
0‑L | N07BB04 | naltrexone | WHO Anatomical Therapeutic Chemical classification | | naltrexone |
0‑L | N07BB05 | nalmefene | WHO Anatomical Therapeutic Chemical classification | | nalmefene |
0‑L | N07BC | Drugs used in opioid dependence | WHO Anatomical Therapeutic Chemical classification | | Drugs used in opioid dependence |
0‑L | N07BC01 | buprenorphine | WHO Anatomical Therapeutic Chemical classification | | buprenorphine |
0‑L | N07BC02 | methadone | WHO Anatomical Therapeutic Chemical classification | | methadone |
0‑L | N07BC03 | levacetylmethadol | WHO Anatomical Therapeutic Chemical classification | | levacetylmethadol |
0‑L | N07BC04 | lofexidine | WHO Anatomical Therapeutic Chemical classification | | lofexidine |
0‑L | N07BC05 | levomethadone | WHO Anatomical Therapeutic Chemical classification | | levomethadone |
0‑L | N07BC06 | diamorphine | WHO Anatomical Therapeutic Chemical classification | | diamorphine |
0‑L | N07BC51 | buprenorphine, combinations | WHO Anatomical Therapeutic Chemical classification | | buprenorphine, combinations |
0‑L | N07C | ANTIVERTIGO PREPARATIONS | WHO Anatomical Therapeutic Chemical classification | | ANTIVERTIGO PREPARATIONS |
0‑L | N07CA | Antivertigo preparations | WHO Anatomical Therapeutic Chemical classification | | Antivertigo preparations |
0‑L | N07CA01 | betahistine | WHO Anatomical Therapeutic Chemical classification | | betahistine |
0‑L | N07CA02 | cinnarizine | WHO Anatomical Therapeutic Chemical classification | | cinnarizine |
0‑L | N07CA03 | flunarizine | WHO Anatomical Therapeutic Chemical classification | | flunarizine |
0‑L | N07CA04 | acetylleucine | WHO Anatomical Therapeutic Chemical classification | | acetylleucine |
0‑L | N07CA52 | cinnarizine, combinations | WHO Anatomical Therapeutic Chemical classification | | cinnarizine, combinations |
0‑L | N07X | OTHER NERVOUS SYSTEM DRUGS | WHO Anatomical Therapeutic Chemical classification | | OTHER NERVOUS SYSTEM DRUGS |
0‑L | N07XA | Gangliosides and ganglioside derivatives | WHO Anatomical Therapeutic Chemical classification | | Gangliosides and ganglioside derivatives |
0‑L | N07XX | Other nervous system drugs | WHO Anatomical Therapeutic Chemical classification | | Other nervous system drugs |
0‑L | N07XX01 | tirilazad | WHO Anatomical Therapeutic Chemical classification | | tirilazad |
0‑L | N07XX02 | riluzole | WHO Anatomical Therapeutic Chemical classification | | riluzole |
0‑L | N07XX03 | xaliproden | WHO Anatomical Therapeutic Chemical classification | | xaliproden |
0‑L | N07XX04 | sodium oxybate | WHO Anatomical Therapeutic Chemical classification | | sodium oxybate |
0‑L | N07XX05 | amifampridine | WHO Anatomical Therapeutic Chemical classification | | amifampridine |
0‑L | N07XX06 | tetrabenazine | WHO Anatomical Therapeutic Chemical classification | | tetrabenazine |
0‑L | N07XX07 | fampridine | WHO Anatomical Therapeutic Chemical classification | | fampridine |
0‑L | N07XX08 | tafamidis | WHO Anatomical Therapeutic Chemical classification | | tafamidis |
0‑L | N07XX09 | dimethyl fumarate | WHO Anatomical Therapeutic Chemical classification | | dimethyl fumarate |
0‑L | N07XX10 | laquinimod | WHO Anatomical Therapeutic Chemical classification | | laquinimod |
0‑L | N07XX11 | pitolisant | WHO Anatomical Therapeutic Chemical classification | | pitolisant |
0‑L | N07XX59 | dextromethorphan, combinations | WHO Anatomical Therapeutic Chemical classification | | dextromethorphan, combinations |
0‑L | P | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS | WHO Anatomical Therapeutic Chemical classification | | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS |
0‑L | P01 | ANTIPROTOZOALS | WHO Anatomical Therapeutic Chemical classification | | ANTIPROTOZOALS |
0‑L | P01A | AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES | WHO Anatomical Therapeutic Chemical classification | | AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES |
0‑L | P01AA | Hydroxyquinoline derivatives | WHO Anatomical Therapeutic Chemical classification | | Hydroxyquinoline derivatives |
0‑L | P01AA01 | broxyquinoline | WHO Anatomical Therapeutic Chemical classification | | broxyquinoline |
0‑L | P01AA02 | clioquinol | WHO Anatomical Therapeutic Chemical classification | | clioquinol |
0‑L | P01AA04 | chlorquinaldol | WHO Anatomical Therapeutic Chemical classification | | chlorquinaldol |
0‑L | P01AA05 | tilbroquinol | WHO Anatomical Therapeutic Chemical classification | | tilbroquinol |
0‑L | P01AA52 | clioquinol, combinations | WHO Anatomical Therapeutic Chemical classification | | clioquinol, combinations |
0‑L | P01AB | Nitroimidazole derivatives | WHO Anatomical Therapeutic Chemical classification | | Nitroimidazole derivatives |
0‑L | P01AB01 | metronidazole | WHO Anatomical Therapeutic Chemical classification | | metronidazole |
0‑L | P01AB02 | tinidazole | WHO Anatomical Therapeutic Chemical classification | | tinidazole |
0‑L | P01AB03 | ornidazole | WHO Anatomical Therapeutic Chemical classification | | ornidazole |
0‑L | P01AB04 | azanidazole | WHO Anatomical Therapeutic Chemical classification | | azanidazole |
0‑L | P01AB05 | propenidazole | WHO Anatomical Therapeutic Chemical classification | | propenidazole |
0‑L | P01AB06 | nimorazole | WHO Anatomical Therapeutic Chemical classification | | nimorazole |
0‑L | P01AB07 | secnidazole | WHO Anatomical Therapeutic Chemical classification | | secnidazole |
0‑L | P01AB51 | metronidazole, combinations | WHO Anatomical Therapeutic Chemical classification | | metronidazole, combinations |
0‑L | P01AC | Dichloroacetamide derivatives | WHO Anatomical Therapeutic Chemical classification | | Dichloroacetamide derivatives |
0‑L | P01AC01 | diloxanide | WHO Anatomical Therapeutic Chemical classification | | diloxanide |
0‑L | P01AC02 | clefamide | WHO Anatomical Therapeutic Chemical classification | | clefamide |
0‑L | P01AC03 | etofamide | WHO Anatomical Therapeutic Chemical classification | | etofamide |
0‑L | P01AC04 | teclozan | WHO Anatomical Therapeutic Chemical classification | | teclozan |
0‑L | P01AR | Arsenic compounds | WHO Anatomical Therapeutic Chemical classification | | Arsenic compounds |
0‑L | P01AR01 | arsthinol | WHO Anatomical Therapeutic Chemical classification | | arsthinol |
0‑L | P01AR02 | difetarsone | WHO Anatomical Therapeutic Chemical classification | | difetarsone |
0‑L | P01AR03 | glycobiarsol | WHO Anatomical Therapeutic Chemical classification | | glycobiarsol |
0‑L | P01AR53 | glycobiarsol, combinations | WHO Anatomical Therapeutic Chemical classification | | glycobiarsol, combinations |
0‑L | P01AX | Other agents against amoebiasis and other protozoal diseases | WHO Anatomical Therapeutic Chemical classification | | Other agents against amoebiasis and other protozoal diseases |
0‑L | P01AX01 | chiniofon | WHO Anatomical Therapeutic Chemical classification | | chiniofon |
0‑L | P01AX02 | emetine | WHO Anatomical Therapeutic Chemical classification | | emetine |
0‑L | P01AX04 | phanquinone | WHO Anatomical Therapeutic Chemical classification | | phanquinone |
0‑L | P01AX05 | mepacrine | WHO Anatomical Therapeutic Chemical classification | | mepacrine |
0‑L | P01AX06 | atovaquone | WHO Anatomical Therapeutic Chemical classification | | atovaquone |
0‑L | P01AX07 | trimetrexate | WHO Anatomical Therapeutic Chemical classification | | trimetrexate |
0‑L | P01AX08 | tenonitrozole | WHO Anatomical Therapeutic Chemical classification | | tenonitrozole |
0‑L | P01AX09 | dehydroemetine | WHO Anatomical Therapeutic Chemical classification | | dehydroemetine |
0‑L | P01AX10 | fumagillin | WHO Anatomical Therapeutic Chemical classification | | fumagillin |
0‑L | P01AX11 | nitazoxanide | WHO Anatomical Therapeutic Chemical classification | | nitazoxanide |
0‑L | P01AX52 | emetine, combinations | WHO Anatomical Therapeutic Chemical classification | | emetine, combinations |
0‑L | P01B | ANTIMALARIALS | WHO Anatomical Therapeutic Chemical classification | | ANTIMALARIALS |
0‑L | P01BA | Aminoquinolines | WHO Anatomical Therapeutic Chemical classification | | Aminoquinolines |
0‑L | P01BA01 | chloroquine | WHO Anatomical Therapeutic Chemical classification | | chloroquine |
0‑L | P01BA02 | hydroxychloroquine | WHO Anatomical Therapeutic Chemical classification | | hydroxychloroquine |
0‑L | P01BA03 | primaquine | WHO Anatomical Therapeutic Chemical classification | | primaquine |
0‑L | P01BA06 | amodiaquine | WHO Anatomical Therapeutic Chemical classification | | amodiaquine |
0‑L | P01BB | Biguanides | WHO Anatomical Therapeutic Chemical classification | | Biguanides |
0‑L | P01BB01 | proguanil | WHO Anatomical Therapeutic Chemical classification | | proguanil |
0‑L | P01BB02 | cycloguanil embonate | WHO Anatomical Therapeutic Chemical classification | | cycloguanil embonate |
0‑L | P01BB51 | proguanil, combinations | WHO Anatomical Therapeutic Chemical classification | | proguanil, combinations |
0‑L | P01BC | Methanolquinolines | WHO Anatomical Therapeutic Chemical classification | | Methanolquinolines |
0‑L | P01BC01 | quinine | WHO Anatomical Therapeutic Chemical classification | | quinine |
0‑L | P01BC02 | mefloquine | WHO Anatomical Therapeutic Chemical classification | | mefloquine |
0‑L | P01BD | Diaminopyrimidines | WHO Anatomical Therapeutic Chemical classification | | Diaminopyrimidines |
0‑L | P01BD01 | pyrimethamine | WHO Anatomical Therapeutic Chemical classification | | pyrimethamine |
0‑L | P01BD51 | pyrimethamine, combinations | WHO Anatomical Therapeutic Chemical classification | | pyrimethamine, combinations |
0‑L | P01BE | Artemisinin and derivatives, plain | WHO Anatomical Therapeutic Chemical classification | | Artemisinin and derivatives, plain |
0‑L | P01BE01 | artemisinin | WHO Anatomical Therapeutic Chemical classification | | artemisinin |
0‑L | P01BE02 | artemether | WHO Anatomical Therapeutic Chemical classification | | artemether |
0‑L | P01BE03 | artesunate | WHO Anatomical Therapeutic Chemical classification | | artesunate |
0‑L | P01BE04 | artemotil | WHO Anatomical Therapeutic Chemical classification | | artemotil |
0‑L | P01BE05 | artenimol | WHO Anatomical Therapeutic Chemical classification | | artenimol |
0‑L | P01BF | Artemisinin and derivatives, combinations | WHO Anatomical Therapeutic Chemical classification | | Artemisinin and derivatives, combinations |
0‑L | P01BF01 | artemether and lumefantrine | WHO Anatomical Therapeutic Chemical classification | | artemether and lumefantrine |
0‑L | P01BF02 | artesunate and mefloquine | WHO Anatomical Therapeutic Chemical classification | | artesunate and mefloquine |
0‑L | P01BF03 | artesunate and amodiaquine | WHO Anatomical Therapeutic Chemical classification | | artesunate and amodiaquine |
0‑L | P01BF04 | artesunate, sulphamethopyrazine and pyrimethamine | WHO Anatomical Therapeutic Chemical classification | | artesunate, sulphamethopyrazine and pyrimethamine |
0‑L | P01BF05 | artenimol and piperaquine | WHO Anatomical Therapeutic Chemical classification | | artenimol and piperaquine |
0‑L | P01BF06 | artesunate and pyronaridine | WHO Anatomical Therapeutic Chemical classification | | artesunate and pyronaridine |
0‑L | P01BX | Other antimalarials | WHO Anatomical Therapeutic Chemical classification | | Other antimalarials |
0‑L | P01BX01 | halofantrine | WHO Anatomical Therapeutic Chemical classification | | halofantrine |
0‑L | P01BX02 | arterolane and piperaquine | WHO Anatomical Therapeutic Chemical classification | | arterolane and piperaquine |
0‑L | P01C | AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS | WHO Anatomical Therapeutic Chemical classification | | AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS |
0‑L | P01CA | Nitroimidazole derivatives | WHO Anatomical Therapeutic Chemical classification | | Nitroimidazole derivatives |
0‑L | P01CA02 | benznidazole | WHO Anatomical Therapeutic Chemical classification | | benznidazole |
0‑L | P01CB | Antimony compounds | WHO Anatomical Therapeutic Chemical classification | | Antimony compounds |
0‑L | P01CB01 | meglumine antimonate | WHO Anatomical Therapeutic Chemical classification | | meglumine antimonate |
0‑L | P01CB02 | sodium stibogluconate | WHO Anatomical Therapeutic Chemical classification | | sodium stibogluconate |
0‑L | P01CC | Nitrofuran derivatives | WHO Anatomical Therapeutic Chemical classification | | Nitrofuran derivatives |
0‑L | P01CC01 | nifurtimox | WHO Anatomical Therapeutic Chemical classification | | nifurtimox |
0‑L | P01CC02 | nitrofural | WHO Anatomical Therapeutic Chemical classification | | nitrofural |
0‑L | P01CD | Arsenic compounds | WHO Anatomical Therapeutic Chemical classification | | Arsenic compounds |
0‑L | P01CD01 | melarsoprol | WHO Anatomical Therapeutic Chemical classification | | melarsoprol |
0‑L | P01CD02 | acetarsol | WHO Anatomical Therapeutic Chemical classification | | acetarsol |
0‑L | P01CX | Other agents against leishmaniasis and trypanosomiasis | WHO Anatomical Therapeutic Chemical classification | | Other agents against leishmaniasis and trypanosomiasis |
0‑L | P01CX01 | pentamidine isethionate | WHO Anatomical Therapeutic Chemical classification | | pentamidine isethionate |
0‑L | P01CX02 | suramin sodium | WHO Anatomical Therapeutic Chemical classification | | suramin sodium |
0‑L | P01CX03 | eflornithine | WHO Anatomical Therapeutic Chemical classification | | eflornithine |
0‑L | P02 | ANTHELMINTICS | WHO Anatomical Therapeutic Chemical classification | | ANTHELMINTICS |
0‑L | P02B | ANTITREMATODALS | WHO Anatomical Therapeutic Chemical classification | | ANTITREMATODALS |
0‑L | P02BA | Quinoline derivatives and related substances | WHO Anatomical Therapeutic Chemical classification | | Quinoline derivatives and related substances |
0‑L | P02BA01 | praziquantel | WHO Anatomical Therapeutic Chemical classification | | praziquantel |
0‑L | P02BA02 | oxamniquine | WHO Anatomical Therapeutic Chemical classification | | oxamniquine |
0‑L | P02BB | Organophosphorous compounds | WHO Anatomical Therapeutic Chemical classification | | Organophosphorous compounds |
0‑L | P02BB01 | metrifonate | WHO Anatomical Therapeutic Chemical classification | | metrifonate |
0‑L | P02BX | Other antitrematodal agents | WHO Anatomical Therapeutic Chemical classification | | Other antitrematodal agents |
0‑L | P02BX01 | bithionol | WHO Anatomical Therapeutic Chemical classification | | bithionol |
0‑L | P02BX02 | niridazole | WHO Anatomical Therapeutic Chemical classification | | niridazole |
0‑L | P02BX03 | stibophen | WHO Anatomical Therapeutic Chemical classification | | stibophen |
0‑L | P02BX04 | triclabendazole | WHO Anatomical Therapeutic Chemical classification | | triclabendazole |
0‑L | P02C | ANTINEMATODAL AGENTS | WHO Anatomical Therapeutic Chemical classification | | ANTINEMATODAL AGENTS |
0‑L | P02CA | Benzimidazole derivatives | WHO Anatomical Therapeutic Chemical classification | | Benzimidazole derivatives |
0‑L | P02CA01 | mebendazole | WHO Anatomical Therapeutic Chemical classification | | mebendazole |
0‑L | P02CA02 | tiabendazole | WHO Anatomical Therapeutic Chemical classification | | tiabendazole |
0‑L | P02CA03 | albendazole | WHO Anatomical Therapeutic Chemical classification | | albendazole |
0‑L | P02CA04 | ciclobendazole | WHO Anatomical Therapeutic Chemical classification | | ciclobendazole |
0‑L | P02CA05 | flubendazole | WHO Anatomical Therapeutic Chemical classification | | flubendazole |
0‑L | P02CA06 | fenbendazole | WHO Anatomical Therapeutic Chemical classification | | fenbendazole |
0‑L | P02CA51 | mebendazole, combinations | WHO Anatomical Therapeutic Chemical classification | | mebendazole, combinations |
0‑L | P02CB | Piperazine and derivatives | WHO Anatomical Therapeutic Chemical classification | | Piperazine and derivatives |
0‑L | P02CB01 | piperazine | WHO Anatomical Therapeutic Chemical classification | | piperazine |
0‑L | P02CB02 | diethylcarbamazine | WHO Anatomical Therapeutic Chemical classification | | diethylcarbamazine |
0‑L | P02CC | Tetrahydropyrimidine derivatives | WHO Anatomical Therapeutic Chemical classification | | Tetrahydropyrimidine derivatives |
0‑L | P02CC01 | pyrantel | WHO Anatomical Therapeutic Chemical classification | | pyrantel |
0‑L | P02CC02 | oxantel | WHO Anatomical Therapeutic Chemical classification | | oxantel |
0‑L | P02CE | Imidazothiazole derivatives | WHO Anatomical Therapeutic Chemical classification | | Imidazothiazole derivatives |
0‑L | P02CE01 | levamisole | WHO Anatomical Therapeutic Chemical classification | | levamisole |
0‑L | P02CF | Avermectines | WHO Anatomical Therapeutic Chemical classification | | Avermectines |
0‑L | P02CF01 | ivermectin | WHO Anatomical Therapeutic Chemical classification | | ivermectin |
0‑L | P02CX | Other antinematodals | WHO Anatomical Therapeutic Chemical classification | | Other antinematodals |
0‑L | P02CX01 | pyrvinium | WHO Anatomical Therapeutic Chemical classification | | pyrvinium |
0‑L | P02CX02 | bephenium | WHO Anatomical Therapeutic Chemical classification | | bephenium |
0‑L | P02D | ANTICESTODALS | WHO Anatomical Therapeutic Chemical classification | | ANTICESTODALS |
0‑L | P02DA | Salicylic acid derivatives | WHO Anatomical Therapeutic Chemical classification | | Salicylic acid derivatives |
0‑L | P02DA01 | niclosamide | WHO Anatomical Therapeutic Chemical classification | | niclosamide |
0‑L | P02DX | Other anticestodals | WHO Anatomical Therapeutic Chemical classification | | Other anticestodals |
0‑L | P02DX01 | desaspidin | WHO Anatomical Therapeutic Chemical classification | | desaspidin |
0‑L | P02DX02 | dichlorophen | WHO Anatomical Therapeutic Chemical classification | | dichlorophen |
0‑L | P03 | ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS | WHO Anatomical Therapeutic Chemical classification | | ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS |
0‑L | P03A | ECTOPARASITICIDES, INCL. SCABICIDES | WHO Anatomical Therapeutic Chemical classification | | ECTOPARASITICIDES, INCL. SCABICIDES |
0‑L | P03AA | Sulfur containing products | WHO Anatomical Therapeutic Chemical classification | | Sulfur containing products |
0‑L | P03AA01 | dixanthogen | WHO Anatomical Therapeutic Chemical classification | | dixanthogen |
0‑L | P03AA02 | potassium polysulfide | WHO Anatomical Therapeutic Chemical classification | | potassium polysulfide |
0‑L | P03AA03 | mesulfen | WHO Anatomical Therapeutic Chemical classification | | mesulfen |
0‑L | P03AA04 | disulfiram | WHO Anatomical Therapeutic Chemical classification | | disulfiram |
0‑L | P03AA05 | thiram | WHO Anatomical Therapeutic Chemical classification | | thiram |
0‑L | P03AA54 | disulfiram, combinations | WHO Anatomical Therapeutic Chemical classification | | disulfiram, combinations |
0‑L | P03AB | Chlorine containing products | WHO Anatomical Therapeutic Chemical classification | | Chlorine containing products |
0‑L | P03AB01 | clofenotane | WHO Anatomical Therapeutic Chemical classification | | clofenotane |
0‑L | P03AB02 | lindane | WHO Anatomical Therapeutic Chemical classification | | lindane |
0‑L | P03AB51 | clofenotane, combinations | WHO Anatomical Therapeutic Chemical classification | | clofenotane, combinations |
0‑L | P03AC | Pyrethrines, incl. synthetic compounds | WHO Anatomical Therapeutic Chemical classification | | Pyrethrines, incl. synthetic compounds |
0‑L | P03AC01 | pyrethrum | WHO Anatomical Therapeutic Chemical classification | | pyrethrum |
0‑L | P03AC02 | bioallethrin | WHO Anatomical Therapeutic Chemical classification | | bioallethrin |
0‑L | P03AC03 | phenothrin | WHO Anatomical Therapeutic Chemical classification | | phenothrin |
0‑L | P03AC04 | permethrin | WHO Anatomical Therapeutic Chemical classification | | permethrin |
0‑L | P03AC51 | pyrethrum, combinations | WHO Anatomical Therapeutic Chemical classification | | pyrethrum, combinations |
0‑L | P03AC52 | bioallethrin, combinations | WHO Anatomical Therapeutic Chemical classification | | bioallethrin, combinations |
0‑L | P03AC53 | phenothrin, combinations | WHO Anatomical Therapeutic Chemical classification | | phenothrin, combinations |
0‑L | P03AC54 | permethrin, combinations | WHO Anatomical Therapeutic Chemical classification | | permethrin, combinations |
0‑L | P03AX | Other ectoparasiticides, incl. scabicides | WHO Anatomical Therapeutic Chemical classification | | Other ectoparasiticides, incl. scabicides |
0‑L | P03AX01 | benzyl benzoate | WHO Anatomical Therapeutic Chemical classification | | benzyl benzoate |
0‑L | P03AX02 | copper oleinate | WHO Anatomical Therapeutic Chemical classification | | copper oleinate |
0‑L | P03AX03 | malathion | WHO Anatomical Therapeutic Chemical classification | | malathion |
0‑L | P03AX04 | quassia | WHO Anatomical Therapeutic Chemical classification | | quassia |
0‑L | P03AX05 | dimeticone | WHO Anatomical Therapeutic Chemical classification | | dimeticone |
0‑L | P03AX06 | benzyl alcohol | WHO Anatomical Therapeutic Chemical classification | | benzyl alcohol |
0‑L | P03B | INSECTICIDES AND REPELLENTS | WHO Anatomical Therapeutic Chemical classification | | INSECTICIDES AND REPELLENTS |
0‑L | P03BA | Pyrethrines | WHO Anatomical Therapeutic Chemical classification | | Pyrethrines |
0‑L | P03BA01 | cyfluthrin | WHO Anatomical Therapeutic Chemical classification | | cyfluthrin |
0‑L | P03BA02 | cypermethrin | WHO Anatomical Therapeutic Chemical classification | | cypermethrin |
0‑L | P03BA03 | decamethrin | WHO Anatomical Therapeutic Chemical classification | | decamethrin |
0‑L | P03BA04 | tetramethrin | WHO Anatomical Therapeutic Chemical classification | | tetramethrin |
0‑L | P03BX | Other insecticides and repellents | WHO Anatomical Therapeutic Chemical classification | | Other insecticides and repellents |
0‑L | P03BX01 | diethyltoluamide | WHO Anatomical Therapeutic Chemical classification | | diethyltoluamide |
0‑L | P03BX02 | dimethylphthalate | WHO Anatomical Therapeutic Chemical classification | | dimethylphthalate |
0‑L | P03BX03 | dibutylphthalate | WHO Anatomical Therapeutic Chemical classification | | dibutylphthalate |
0‑L | P03BX04 | dibutylsuccinate | WHO Anatomical Therapeutic Chemical classification | | dibutylsuccinate |
0‑L | P03BX05 | dimethylcarbate | WHO Anatomical Therapeutic Chemical classification | | dimethylcarbate |
0‑L | P03BX06 | etohexadiol | WHO Anatomical Therapeutic Chemical classification | | etohexadiol |
0‑L | R | RESPIRATORY SYSTEM | WHO Anatomical Therapeutic Chemical classification | | RESPIRATORY SYSTEM |
0‑L | R01 | NASAL PREPARATIONS | WHO Anatomical Therapeutic Chemical classification | | NASAL PREPARATIONS |
0‑L | R01A | DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE | WHO Anatomical Therapeutic Chemical classification | | DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE |
0‑L | R01AA | Sympathomimetics, plain | WHO Anatomical Therapeutic Chemical classification | | Sympathomimetics, plain |
0‑L | R01AA02 | cyclopentamine | WHO Anatomical Therapeutic Chemical classification | | cyclopentamine |
0‑L | R01AA03 | ephedrine | WHO Anatomical Therapeutic Chemical classification | | ephedrine |
0‑L | R01AA04 | phenylephrine | WHO Anatomical Therapeutic Chemical classification | | phenylephrine |
0‑L | R01AA05 | oxymetazoline | WHO Anatomical Therapeutic Chemical classification | | oxymetazoline |
0‑L | R01AA06 | tetryzoline | WHO Anatomical Therapeutic Chemical classification | | tetryzoline |
0‑L | R01AA07 | xylometazoline | WHO Anatomical Therapeutic Chemical classification | | xylometazoline |
0‑L | R01AA08 | naphazoline | WHO Anatomical Therapeutic Chemical classification | | naphazoline |
0‑L | R01AA09 | tramazoline | WHO Anatomical Therapeutic Chemical classification | | tramazoline |
0‑L | R01AA10 | metizoline | WHO Anatomical Therapeutic Chemical classification | | metizoline |
0‑L | R01AA11 | tuaminoheptane | WHO Anatomical Therapeutic Chemical classification | | tuaminoheptane |
0‑L | R01AA12 | fenoxazoline | WHO Anatomical Therapeutic Chemical classification | | fenoxazoline |
0‑L | R01AA13 | tymazoline | WHO Anatomical Therapeutic Chemical classification | | tymazoline |
0‑L | R01AA14 | epinephrine | WHO Anatomical Therapeutic Chemical classification | | epinephrine |
0‑L | R01AA15 | indanazoline | WHO Anatomical Therapeutic Chemical classification | | indanazoline |
0‑L | R01AB | Sympathomimetics, combinations excl. corticosteroids | WHO Anatomical Therapeutic Chemical classification | | Sympathomimetics, combinations excl. corticosteroids |
0‑L | R01AB01 | phenylephrine | WHO Anatomical Therapeutic Chemical classification | | phenylephrine |
0‑L | R01AB02 | naphazoline | WHO Anatomical Therapeutic Chemical classification | | naphazoline |
0‑L | R01AB03 | tetryzoline | WHO Anatomical Therapeutic Chemical classification | | tetryzoline |
0‑L | R01AB05 | ephedrine | WHO Anatomical Therapeutic Chemical classification | | ephedrine |
0‑L | R01AB06 | xylometazoline | WHO Anatomical Therapeutic Chemical classification | | xylometazoline |
0‑L | R01AB07 | oxymetazoline | WHO Anatomical Therapeutic Chemical classification | | oxymetazoline |
0‑L | R01AB08 | tuaminoheptane | WHO Anatomical Therapeutic Chemical classification | | tuaminoheptane |
0‑L | R01AC | Antiallergic agents, excl. corticosteroids | WHO Anatomical Therapeutic Chemical classification | | Antiallergic agents, excl. corticosteroids |
0‑L | R01AC01 | cromoglicic acid | WHO Anatomical Therapeutic Chemical classification | | cromoglicic acid |
0‑L | R01AC02 | levocabastine | WHO Anatomical Therapeutic Chemical classification | | levocabastine |
0‑L | R01AC03 | azelastine | WHO Anatomical Therapeutic Chemical classification | | azelastine |
0‑L | R01AC04 | antazoline | WHO Anatomical Therapeutic Chemical classification | | antazoline |
0‑L | R01AC05 | spaglumic acid | WHO Anatomical Therapeutic Chemical classification | | spaglumic acid |
0‑L | R01AC06 | thonzylamine | WHO Anatomical Therapeutic Chemical classification | | thonzylamine |
0‑L | R01AC07 | nedocromil | WHO Anatomical Therapeutic Chemical classification | | nedocromil |
0‑L | R01AC08 | olopatadine | WHO Anatomical Therapeutic Chemical classification | | olopatadine |
0‑L | R01AC51 | cromoglicic acid, combinations | WHO Anatomical Therapeutic Chemical classification | | cromoglicic acid, combinations |
0‑L | R01AD | Corticosteroids | WHO Anatomical Therapeutic Chemical classification | | Corticosteroids |
0‑L | R01AD01 | beclometasone | WHO Anatomical Therapeutic Chemical classification | | beclometasone |
0‑L | R01AD02 | prednisolone | WHO Anatomical Therapeutic Chemical classification | | prednisolone |
0‑L | R01AD03 | dexamethasone | WHO Anatomical Therapeutic Chemical classification | | dexamethasone |
0‑L | R01AD04 | flunisolide | WHO Anatomical Therapeutic Chemical classification | | flunisolide |
0‑L | R01AD05 | budesonide | WHO Anatomical Therapeutic Chemical classification | | budesonide |
0‑L | R01AD06 | betamethasone | WHO Anatomical Therapeutic Chemical classification | | betamethasone |
0‑L | R01AD07 | tixocortol | WHO Anatomical Therapeutic Chemical classification | | tixocortol |
0‑L | R01AD08 | fluticasone | WHO Anatomical Therapeutic Chemical classification | | fluticasone |
0‑L | R01AD09 | mometasone | WHO Anatomical Therapeutic Chemical classification | | mometasone |
0‑L | R01AD11 | triamcinolone | WHO Anatomical Therapeutic Chemical classification | | triamcinolone |
0‑L | R01AD12 | fluticasone furoate | WHO Anatomical Therapeutic Chemical classification | | fluticasone furoate |
0‑L | R01AD13 | ciclesonide | WHO Anatomical Therapeutic Chemical classification | | ciclesonide |
0‑L | R01AD52 | prednisolone, combinations | WHO Anatomical Therapeutic Chemical classification | | prednisolone, combinations |
0‑L | R01AD53 | dexamethasone, combinations | WHO Anatomical Therapeutic Chemical classification | | dexamethasone, combinations |
0‑L | R01AD57 | tixocortol, combinations | WHO Anatomical Therapeutic Chemical classification | | tixocortol, combinations |
0‑L | R01AD58 | fluticasone, combinations | WHO Anatomical Therapeutic Chemical classification | | fluticasone, combinations |
0‑L | R01AD60 | hydrocortisone, combinations | WHO Anatomical Therapeutic Chemical classification | | hydrocortisone, combinations |
0‑L | R01AX | Other nasal preparations | WHO Anatomical Therapeutic Chemical classification | | Other nasal preparations |
0‑L | R01AX01 | calcium hexamine thiocyanate | WHO Anatomical Therapeutic Chemical classification | | calcium hexamine thiocyanate |
0‑L | R01AX02 | retinol | WHO Anatomical Therapeutic Chemical classification | | retinol |
0‑L | R01AX03 | ipratropium bromide | WHO Anatomical Therapeutic Chemical classification | | ipratropium bromide |
0‑L | R01AX05 | ritiometan | WHO Anatomical Therapeutic Chemical classification | | ritiometan |
0‑L | R01AX06 | mupirocin | WHO Anatomical Therapeutic Chemical classification | | mupirocin |
0‑L | R01AX07 | hexamidine | WHO Anatomical Therapeutic Chemical classification | | hexamidine |
0‑L | R01AX08 | framycetin | WHO Anatomical Therapeutic Chemical classification | | framycetin |
0‑L | R01AX09 | hyaluronic acid | WHO Anatomical Therapeutic Chemical classification | | hyaluronic acid |
0‑L | R01AX10 | various | WHO Anatomical Therapeutic Chemical classification | | various |
0‑L | R01AX30 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | R01B | NASAL DECONGESTANTS FOR SYSTEMIC USE | WHO Anatomical Therapeutic Chemical classification | | NASAL DECONGESTANTS FOR SYSTEMIC USE |
0‑L | R01BA | Sympathomimetics | WHO Anatomical Therapeutic Chemical classification | | Sympathomimetics |
0‑L | R01BA01 | phenylpropanolamine | WHO Anatomical Therapeutic Chemical classification | | phenylpropanolamine |
0‑L | R01BA02 | pseudoephedrine | WHO Anatomical Therapeutic Chemical classification | | pseudoephedrine |
0‑L | R01BA03 | phenylephrine | WHO Anatomical Therapeutic Chemical classification | | phenylephrine |
0‑L | R01BA51 | phenylpropanolamine, combinations | WHO Anatomical Therapeutic Chemical classification | | phenylpropanolamine, combinations |
0‑L | R01BA52 | pseudoephedrine, combinations | WHO Anatomical Therapeutic Chemical classification | | pseudoephedrine, combinations |
0‑L | R01BA53 | phenylephrine, combinations | WHO Anatomical Therapeutic Chemical classification | | phenylephrine, combinations |
0‑L | R02 | THROAT PREPARATIONS | WHO Anatomical Therapeutic Chemical classification | | THROAT PREPARATIONS |
0‑L | R02A | THROAT PREPARATIONS | WHO Anatomical Therapeutic Chemical classification | | THROAT PREPARATIONS |
0‑L | R02AA | Antiseptics | WHO Anatomical Therapeutic Chemical classification | | Antiseptics |
0‑L | R02AA01 | ambazone | WHO Anatomical Therapeutic Chemical classification | | ambazone |
0‑L | R02AA02 | dequalinium | WHO Anatomical Therapeutic Chemical classification | | dequalinium |
0‑L | R02AA03 | dichlorobenzyl alcohol | WHO Anatomical Therapeutic Chemical classification | | dichlorobenzyl alcohol |
0‑L | R02AA05 | chlorhexidine | WHO Anatomical Therapeutic Chemical classification | | chlorhexidine |
0‑L | R02AA06 | cetylpyridinium | WHO Anatomical Therapeutic Chemical classification | | cetylpyridinium |
0‑L | R02AA09 | benzethonium | WHO Anatomical Therapeutic Chemical classification | | benzethonium |
0‑L | R02AA10 | myristyl-benzalkonium | WHO Anatomical Therapeutic Chemical classification | | myristyl-benzalkonium |
0‑L | R02AA11 | chlorquinaldol | WHO Anatomical Therapeutic Chemical classification | | chlorquinaldol |
0‑L | R02AA12 | hexylresorcinol | WHO Anatomical Therapeutic Chemical classification | | hexylresorcinol |
0‑L | R02AA13 | acriflavinium chloride | WHO Anatomical Therapeutic Chemical classification | | acriflavinium chloride |
0‑L | R02AA14 | oxyquinoline | WHO Anatomical Therapeutic Chemical classification | | oxyquinoline |
0‑L | R02AA15 | povidone-iodine | WHO Anatomical Therapeutic Chemical classification | | povidone-iodine |
0‑L | R02AA16 | benzalkonium | WHO Anatomical Therapeutic Chemical classification | | benzalkonium |
0‑L | R02AA17 | cetrimonium | WHO Anatomical Therapeutic Chemical classification | | cetrimonium |
0‑L | R02AA18 | hexamidine | WHO Anatomical Therapeutic Chemical classification | | hexamidine |
0‑L | R02AA19 | phenol | WHO Anatomical Therapeutic Chemical classification | | phenol |
0‑L | R02AA20 | various | WHO Anatomical Therapeutic Chemical classification | | various |
0‑L | R02AA21 | octenidine | WHO Anatomical Therapeutic Chemical classification | | octenidine |
0‑L | R02AB | Antibiotics | WHO Anatomical Therapeutic Chemical classification | | Antibiotics |
0‑L | R02AB01 | neomycin | WHO Anatomical Therapeutic Chemical classification | | neomycin |
0‑L | R02AB02 | tyrothricin | WHO Anatomical Therapeutic Chemical classification | | tyrothricin |
0‑L | R02AB03 | fusafungine | WHO Anatomical Therapeutic Chemical classification | | fusafungine |
0‑L | R02AB04 | bacitracin | WHO Anatomical Therapeutic Chemical classification | | bacitracin |
0‑L | R02AB30 | gramicidin | WHO Anatomical Therapeutic Chemical classification | | gramicidin |
0‑L | R02AD | Anesthetics, local | WHO Anatomical Therapeutic Chemical classification | | Anesthetics, local |
0‑L | R02AD01 | benzocaine | WHO Anatomical Therapeutic Chemical classification | | benzocaine |
0‑L | R02AD02 | lidocaine | WHO Anatomical Therapeutic Chemical classification | | lidocaine |
0‑L | R02AD03 | cocaine | WHO Anatomical Therapeutic Chemical classification | | cocaine |
0‑L | R02AD04 | dyclonine | WHO Anatomical Therapeutic Chemical classification | | dyclonine |
0‑L | R02AX | Other throat preparations | WHO Anatomical Therapeutic Chemical classification | | Other throat preparations |
0‑L | R02AX01 | flurbiprofen | WHO Anatomical Therapeutic Chemical classification | | flurbiprofen |
0‑L | R02AX02 | ibuprofen | WHO Anatomical Therapeutic Chemical classification | | ibuprofen |
0‑L | R03 | DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES | WHO Anatomical Therapeutic Chemical classification | | DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES |
0‑L | R03A | ADRENERGICS, INHALANTS | WHO Anatomical Therapeutic Chemical classification | | ADRENERGICS, INHALANTS |
0‑L | R03AA | Alpha- and beta-adrenoreceptor agonists | WHO Anatomical Therapeutic Chemical classification | | Alpha- and beta-adrenoreceptor agonists |
0‑L | R03AA01 | epinephrine | WHO Anatomical Therapeutic Chemical classification | | epinephrine |
0‑L | R03AB | Non-selective beta-adrenoreceptor agonists | WHO Anatomical Therapeutic Chemical classification | | Non-selective beta-adrenoreceptor agonists |
0‑L | R03AB02 | isoprenaline | WHO Anatomical Therapeutic Chemical classification | | isoprenaline |
0‑L | R03AB03 | orciprenaline | WHO Anatomical Therapeutic Chemical classification | | orciprenaline |
0‑L | R03AC | Selective beta-2-adrenoreceptor agonists | WHO Anatomical Therapeutic Chemical classification | | Selective beta-2-adrenoreceptor agonists |
0‑L | R03AC02 | salbutamol | WHO Anatomical Therapeutic Chemical classification | | salbutamol |
0‑L | R03AC03 | terbutaline | WHO Anatomical Therapeutic Chemical classification | | terbutaline |
0‑L | R03AC04 | fenoterol | WHO Anatomical Therapeutic Chemical classification | | fenoterol |
0‑L | R03AC05 | rimiterol | WHO Anatomical Therapeutic Chemical classification | | rimiterol |
0‑L | R03AC06 | hexoprenaline | WHO Anatomical Therapeutic Chemical classification | | hexoprenaline |
0‑L | R03AC07 | isoetarine | WHO Anatomical Therapeutic Chemical classification | | isoetarine |
0‑L | R03AC08 | pirbuterol | WHO Anatomical Therapeutic Chemical classification | | pirbuterol |
0‑L | R03AC09 | tretoquinol | WHO Anatomical Therapeutic Chemical classification | | tretoquinol |
0‑L | R03AC10 | carbuterol | WHO Anatomical Therapeutic Chemical classification | | carbuterol |
0‑L | R03AC11 | tulobuterol | WHO Anatomical Therapeutic Chemical classification | | tulobuterol |
0‑L | R03AC12 | salmeterol | WHO Anatomical Therapeutic Chemical classification | | salmeterol |
0‑L | R03AC13 | formoterol | WHO Anatomical Therapeutic Chemical classification | | formoterol |
0‑L | R03AC14 | clenbuterol | WHO Anatomical Therapeutic Chemical classification | | clenbuterol |
0‑L | R03AC15 | reproterol | WHO Anatomical Therapeutic Chemical classification | | reproterol |
0‑L | R03AC16 | procaterol | WHO Anatomical Therapeutic Chemical classification | | procaterol |
0‑L | R03AC17 | bitolterol | WHO Anatomical Therapeutic Chemical classification | | bitolterol |
0‑L | R03AC18 | indacaterol | WHO Anatomical Therapeutic Chemical classification | | indacaterol |
0‑L | R03AC19 | olodaterol | WHO Anatomical Therapeutic Chemical classification | | olodaterol |
0‑L | R03AH | Combinations of adrenergics | WHO Anatomical Therapeutic Chemical classification | | Combinations of adrenergics |
0‑L | R03AK | Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics | WHO Anatomical Therapeutic Chemical classification | | Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics |
0‑L | R03AK01 | epinephrine and other drugs for obstructive airway diseases | WHO Anatomical Therapeutic Chemical classification | | epinephrine and other drugs for obstructive airway diseases |
0‑L | R03AK02 | isoprenaline and other drugs for obstructive airway diseases | WHO Anatomical Therapeutic Chemical classification | | isoprenaline and other drugs for obstructive airway diseases |
0‑L | R03AK04 | salbutamol and sodium cromoglicate | WHO Anatomical Therapeutic Chemical classification | | salbutamol and sodium cromoglicate |
0‑L | R03AK05 | reproterol and sodium cromoglicate | WHO Anatomical Therapeutic Chemical classification | | reproterol and sodium cromoglicate |
0‑L | R03AK06 | salmeterol and fluticasone | WHO Anatomical Therapeutic Chemical classification | | salmeterol and fluticasone |
0‑L | R03AK07 | formoterol and budesonide | WHO Anatomical Therapeutic Chemical classification | | formoterol and budesonide |
0‑L | R03AK08 | formoterol and beclometasone | WHO Anatomical Therapeutic Chemical classification | | formoterol and beclometasone |
0‑L | R03AK09 | formoterol and mometasone | WHO Anatomical Therapeutic Chemical classification | | formoterol and mometasone |
0‑L | R03AK10 | vilanterol and fluticasone furoate | WHO Anatomical Therapeutic Chemical classification | | vilanterol and fluticasone furoate |
0‑L | R03AK11 | formoterol and fluticasone | WHO Anatomical Therapeutic Chemical classification | | formoterol and fluticasone |
0‑L | R03AK12 | salmeterol and budesonide | WHO Anatomical Therapeutic Chemical classification | | salmeterol and budesonide |
0‑L | R03AK13 | salbutamol and beclometasone | WHO Anatomical Therapeutic Chemical classification | | salbutamol and beclometasone |
0‑L | R03AL | Adrenergics in combination with anticholinergics | WHO Anatomical Therapeutic Chemical classification | | Adrenergics in combination with anticholinergics |
0‑L | R03AL01 | fenoterol and ipratropium bromide | WHO Anatomical Therapeutic Chemical classification | | fenoterol and ipratropium bromide |
0‑L | R03AL02 | salbutamol and ipratropium bromide | WHO Anatomical Therapeutic Chemical classification | | salbutamol and ipratropium bromide |
0‑L | R03AL03 | vilanterol and umeclidinium bromide | WHO Anatomical Therapeutic Chemical classification | | vilanterol and umeclidinium bromide |
0‑L | R03AL04 | indacaterol and glycopyrronium bromide | WHO Anatomical Therapeutic Chemical classification | | indacaterol and glycopyrronium bromide |
0‑L | R03AL05 | formoterol and aclidinium bromide | WHO Anatomical Therapeutic Chemical classification | | formoterol and aclidinium bromide |
0‑L | R03AL06 | olodaterol and tiotropium bromide | WHO Anatomical Therapeutic Chemical classification | | olodaterol and tiotropium bromide |
0‑L | R03AL07 | formoterol and glycopyrronium bromide | WHO Anatomical Therapeutic Chemical classification | | formoterol and glycopyrronium bromide |
0‑L | R03B | OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS | WHO Anatomical Therapeutic Chemical classification | | OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS |
0‑L | R03BA | Glucocorticoids | WHO Anatomical Therapeutic Chemical classification | | Glucocorticoids |
0‑L | R03BA01 | beclometasone | WHO Anatomical Therapeutic Chemical classification | | beclometasone |
0‑L | R03BA02 | budesonide | WHO Anatomical Therapeutic Chemical classification | | budesonide |
0‑L | R03BA03 | flunisolide | WHO Anatomical Therapeutic Chemical classification | | flunisolide |
0‑L | R03BA04 | betamethasone | WHO Anatomical Therapeutic Chemical classification | | betamethasone |
0‑L | R03BA05 | fluticasone | WHO Anatomical Therapeutic Chemical classification | | fluticasone |
0‑L | R03BA06 | triamcinolone | WHO Anatomical Therapeutic Chemical classification | | triamcinolone |
0‑L | R03BA07 | mometasone | WHO Anatomical Therapeutic Chemical classification | | mometasone |
0‑L | R03BA08 | ciclesonide | WHO Anatomical Therapeutic Chemical classification | | ciclesonide |
0‑L | R03BA09 | fluticasone furoate | WHO Anatomical Therapeutic Chemical classification | | fluticasone furoate |
0‑L | R03BB | Anticholinergics | WHO Anatomical Therapeutic Chemical classification | | Anticholinergics |
0‑L | R03BB01 | ipratropium bromide | WHO Anatomical Therapeutic Chemical classification | | ipratropium bromide |
0‑L | R03BB02 | oxitropium bromide | WHO Anatomical Therapeutic Chemical classification | | oxitropium bromide |
0‑L | R03BB03 | stramoni preparations | WHO Anatomical Therapeutic Chemical classification | | stramoni preparations |
0‑L | R03BB04 | tiotropium bromide | WHO Anatomical Therapeutic Chemical classification | | tiotropium bromide |
0‑L | R03BB05 | aclidinium bromide | WHO Anatomical Therapeutic Chemical classification | | aclidinium bromide |
0‑L | R03BB06 | glycopyrronium bromide | WHO Anatomical Therapeutic Chemical classification | | glycopyrronium bromide |
0‑L | R03BB07 | umeclidinium bromide | WHO Anatomical Therapeutic Chemical classification | | umeclidinium bromide |
0‑L | R03BB54 | tiotropium bromide, combinations | WHO Anatomical Therapeutic Chemical classification | | tiotropium bromide, combinations |
0‑L | R03BC | Antiallergic agents, excl. corticosteroids | WHO Anatomical Therapeutic Chemical classification | | Antiallergic agents, excl. corticosteroids |
0‑L | R03BC01 | cromoglicic acid | WHO Anatomical Therapeutic Chemical classification | | cromoglicic acid |
0‑L | R03BC03 | nedocromil | WHO Anatomical Therapeutic Chemical classification | | nedocromil |
0‑L | R03BX | Other drugs for obstructive airway diseases, inhalants | WHO Anatomical Therapeutic Chemical classification | | Other drugs for obstructive airway diseases, inhalants |
0‑L | R03BX01 | fenspiride | WHO Anatomical Therapeutic Chemical classification | | fenspiride |
0‑L | R03C | ADRENERGICS FOR SYSTEMIC USE | WHO Anatomical Therapeutic Chemical classification | | ADRENERGICS FOR SYSTEMIC USE |
0‑L | R03CA | Alpha- and beta-adrenoreceptor agonists | WHO Anatomical Therapeutic Chemical classification | | Alpha- and beta-adrenoreceptor agonists |
0‑L | R03CA02 | ephedrine | WHO Anatomical Therapeutic Chemical classification | | ephedrine |
0‑L | R03CB | Non-selective beta-adrenoreceptor agonists | WHO Anatomical Therapeutic Chemical classification | | Non-selective beta-adrenoreceptor agonists |
0‑L | R03CB01 | isoprenaline | WHO Anatomical Therapeutic Chemical classification | | isoprenaline |
0‑L | R03CB02 | methoxyphenamine | WHO Anatomical Therapeutic Chemical classification | | methoxyphenamine |
0‑L | R03CB03 | orciprenaline | WHO Anatomical Therapeutic Chemical classification | | orciprenaline |
0‑L | R03CB51 | isoprenaline, combinations | WHO Anatomical Therapeutic Chemical classification | | isoprenaline, combinations |
0‑L | R03CB53 | orciprenaline, combinations | WHO Anatomical Therapeutic Chemical classification | | orciprenaline, combinations |
0‑L | R03CC | Selective beta-2-adrenoreceptor agonists | WHO Anatomical Therapeutic Chemical classification | | Selective beta-2-adrenoreceptor agonists |
0‑L | R03CC02 | salbutamol | WHO Anatomical Therapeutic Chemical classification | | salbutamol |
0‑L | R03CC03 | terbutaline | WHO Anatomical Therapeutic Chemical classification | | terbutaline |
0‑L | R03CC04 | fenoterol | WHO Anatomical Therapeutic Chemical classification | | fenoterol |
0‑L | R03CC05 | hexoprenaline | WHO Anatomical Therapeutic Chemical classification | | hexoprenaline |
0‑L | R03CC06 | isoetarine | WHO Anatomical Therapeutic Chemical classification | | isoetarine |
0‑L | R03CC07 | pirbuterol | WHO Anatomical Therapeutic Chemical classification | | pirbuterol |
0‑L | R03CC08 | procaterol | WHO Anatomical Therapeutic Chemical classification | | procaterol |
0‑L | R03CC09 | tretoquinol | WHO Anatomical Therapeutic Chemical classification | | tretoquinol |
0‑L | R03CC10 | carbuterol | WHO Anatomical Therapeutic Chemical classification | | carbuterol |
0‑L | R03CC11 | tulobuterol | WHO Anatomical Therapeutic Chemical classification | | tulobuterol |
0‑L | R03CC12 | bambuterol | WHO Anatomical Therapeutic Chemical classification | | bambuterol |
0‑L | R03CC13 | clenbuterol | WHO Anatomical Therapeutic Chemical classification | | clenbuterol |
0‑L | R03CC14 | reproterol | WHO Anatomical Therapeutic Chemical classification | | reproterol |
0‑L | R03CC53 | terbutaline, combinations | WHO Anatomical Therapeutic Chemical classification | | terbutaline, combinations |
0‑L | R03CK | Adrenergics and other drugs for obstructive airway diseases | WHO Anatomical Therapeutic Chemical classification | | Adrenergics and other drugs for obstructive airway diseases |
0‑L | R03D | OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES | WHO Anatomical Therapeutic Chemical classification | | OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES |
0‑L | R03DA | Xanthines | WHO Anatomical Therapeutic Chemical classification | | Xanthines |
0‑L | R03DA01 | diprophylline | WHO Anatomical Therapeutic Chemical classification | | diprophylline |
0‑L | R03DA02 | choline theophyllinate | WHO Anatomical Therapeutic Chemical classification | | choline theophyllinate |
0‑L | R03DA03 | proxyphylline | WHO Anatomical Therapeutic Chemical classification | | proxyphylline |
0‑L | R03DA04 | theophylline | WHO Anatomical Therapeutic Chemical classification | | theophylline |
0‑L | R03DA05 | aminophylline | WHO Anatomical Therapeutic Chemical classification | | aminophylline |
0‑L | R03DA06 | etamiphylline | WHO Anatomical Therapeutic Chemical classification | | etamiphylline |
0‑L | R03DA07 | theobromine | WHO Anatomical Therapeutic Chemical classification | | theobromine |
0‑L | R03DA08 | bamifylline | WHO Anatomical Therapeutic Chemical classification | | bamifylline |
0‑L | R03DA09 | acefylline piperazine | WHO Anatomical Therapeutic Chemical classification | | acefylline piperazine |
0‑L | R03DA10 | bufylline | WHO Anatomical Therapeutic Chemical classification | | bufylline |
0‑L | R03DA11 | doxofylline | WHO Anatomical Therapeutic Chemical classification | | doxofylline |
0‑L | R03DA20 | combinations of xanthines | WHO Anatomical Therapeutic Chemical classification | | combinations of xanthines |
0‑L | R03DA51 | diprophylline, combinations | WHO Anatomical Therapeutic Chemical classification | | diprophylline, combinations |
0‑L | R03DA54 | theophylline, combinations excl. psycholeptics | WHO Anatomical Therapeutic Chemical classification | | theophylline, combinations excl. psycholeptics |
0‑L | R03DA55 | aminophylline, combinations | WHO Anatomical Therapeutic Chemical classification | | aminophylline, combinations |
0‑L | R03DA57 | theobromine, combinations | WHO Anatomical Therapeutic Chemical classification | | theobromine, combinations |
0‑L | R03DA74 | theophylline, combinations with psycholeptics | WHO Anatomical Therapeutic Chemical classification | | theophylline, combinations with psycholeptics |
0‑L | R03DB | Xanthines and adrenergics | WHO Anatomical Therapeutic Chemical classification | | Xanthines and adrenergics |
0‑L | R03DB01 | diprophylline and adrenergics | WHO Anatomical Therapeutic Chemical classification | | diprophylline and adrenergics |
0‑L | R03DB02 | choline theophyllinate and adrenergics | WHO Anatomical Therapeutic Chemical classification | | choline theophyllinate and adrenergics |
0‑L | R03DB03 | proxyphylline and adrenergics | WHO Anatomical Therapeutic Chemical classification | | proxyphylline and adrenergics |
0‑L | R03DB04 | theophylline and adrenergics | WHO Anatomical Therapeutic Chemical classification | | theophylline and adrenergics |
0‑L | R03DB05 | aminophylline and adrenergics | WHO Anatomical Therapeutic Chemical classification | | aminophylline and adrenergics |
0‑L | R03DB06 | etamiphylline and adrenergics | WHO Anatomical Therapeutic Chemical classification | | etamiphylline and adrenergics |
0‑L | R03DC | Leukotriene receptor antagonists | WHO Anatomical Therapeutic Chemical classification | | Leukotriene receptor antagonists |
0‑L | R03DC01 | zafirlukast | WHO Anatomical Therapeutic Chemical classification | | zafirlukast |
0‑L | R03DC02 | pranlukast | WHO Anatomical Therapeutic Chemical classification | | pranlukast |
0‑L | R03DC03 | montelukast | WHO Anatomical Therapeutic Chemical classification | | montelukast |
0‑L | R03DC04 | ibudilast | WHO Anatomical Therapeutic Chemical classification | | ibudilast |
0‑L | R03DC53 | montelukast, combinations | WHO Anatomical Therapeutic Chemical classification | | montelukast, combinations |
0‑L | R03DX | Other systemic drugs for obstructive airway diseases | WHO Anatomical Therapeutic Chemical classification | | Other systemic drugs for obstructive airway diseases |
0‑L | R03DX01 | amlexanox | WHO Anatomical Therapeutic Chemical classification | | amlexanox |
0‑L | R03DX02 | eprozinol | WHO Anatomical Therapeutic Chemical classification | | eprozinol |
0‑L | R03DX03 | fenspiride | WHO Anatomical Therapeutic Chemical classification | | fenspiride |
0‑L | R03DX05 | omalizumab | WHO Anatomical Therapeutic Chemical classification | | omalizumab |
0‑L | R03DX06 | seratrodast | WHO Anatomical Therapeutic Chemical classification | | seratrodast |
0‑L | R03DX07 | roflumilast | WHO Anatomical Therapeutic Chemical classification | | roflumilast |
0‑L | R03DX08 | reslizumab | WHO Anatomical Therapeutic Chemical classification | | reslizumab |
0‑L | R03DX09 | mepolizumab | WHO Anatomical Therapeutic Chemical classification | | mepolizumab |
0‑L | R05 | COUGH AND COLD PREPARATIONS | WHO Anatomical Therapeutic Chemical classification | | COUGH AND COLD PREPARATIONS |
0‑L | R05C | EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS | WHO Anatomical Therapeutic Chemical classification | | EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS |
0‑L | R05CA | Expectorants | WHO Anatomical Therapeutic Chemical classification | | Expectorants |
0‑L | R05CA01 | tyloxapol | WHO Anatomical Therapeutic Chemical classification | | tyloxapol |
0‑L | R05CA02 | potassium iodide | WHO Anatomical Therapeutic Chemical classification | | potassium iodide |
0‑L | R05CA03 | guaifenesin | WHO Anatomical Therapeutic Chemical classification | | guaifenesin |
0‑L | R05CA04 | ipecacuanha | WHO Anatomical Therapeutic Chemical classification | | ipecacuanha |
0‑L | R05CA05 | althea root | WHO Anatomical Therapeutic Chemical classification | | althea root |
0‑L | R05CA06 | senega | WHO Anatomical Therapeutic Chemical classification | | senega |
0‑L | R05CA07 | antimony pentasulfide | WHO Anatomical Therapeutic Chemical classification | | antimony pentasulfide |
0‑L | R05CA08 | creosote | WHO Anatomical Therapeutic Chemical classification | | creosote |
0‑L | R05CA09 | guaiacolsulfonate | WHO Anatomical Therapeutic Chemical classification | | guaiacolsulfonate |
0‑L | R05CA10 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | R05CA11 | levoverbenone | WHO Anatomical Therapeutic Chemical classification | | levoverbenone |
0‑L | R05CA12 | Hederae helicis folium | WHO Anatomical Therapeutic Chemical classification | | Hederae helicis folium |
0‑L | R05CA13 | cineole | WHO Anatomical Therapeutic Chemical classification | | cineole |
0‑L | R05CB | Mucolytics | WHO Anatomical Therapeutic Chemical classification | | Mucolytics |
0‑L | R05CB01 | acetylcysteine | WHO Anatomical Therapeutic Chemical classification | | acetylcysteine |
0‑L | R05CB02 | bromhexine | WHO Anatomical Therapeutic Chemical classification | | bromhexine |
0‑L | R05CB03 | carbocisteine | WHO Anatomical Therapeutic Chemical classification | | carbocisteine |
0‑L | R05CB04 | eprazinone | WHO Anatomical Therapeutic Chemical classification | | eprazinone |
0‑L | R05CB05 | mesna | WHO Anatomical Therapeutic Chemical classification | | mesna |
0‑L | R05CB06 | ambroxol | WHO Anatomical Therapeutic Chemical classification | | ambroxol |
0‑L | R05CB07 | sobrerol | WHO Anatomical Therapeutic Chemical classification | | sobrerol |
0‑L | R05CB08 | domiodol | WHO Anatomical Therapeutic Chemical classification | | domiodol |
0‑L | R05CB09 | letosteine | WHO Anatomical Therapeutic Chemical classification | | letosteine |
0‑L | R05CB10 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | R05CB11 | stepronin | WHO Anatomical Therapeutic Chemical classification | | stepronin |
0‑L | R05CB13 | dornase alfa (desoxyribonuclease) | WHO Anatomical Therapeutic Chemical classification | | dornase alfa (desoxyribonuclease) |
0‑L | R05CB14 | neltenexine | WHO Anatomical Therapeutic Chemical classification | | neltenexine |
0‑L | R05CB15 | erdosteine | WHO Anatomical Therapeutic Chemical classification | | erdosteine |
0‑L | R05CB16 | mannitol | WHO Anatomical Therapeutic Chemical classification | | mannitol |
0‑L | R05D | COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS | WHO Anatomical Therapeutic Chemical classification | | COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS |
0‑L | R05DA | Opium alkaloids and derivatives | WHO Anatomical Therapeutic Chemical classification | | Opium alkaloids and derivatives |
0‑L | R05DA01 | ethylmorphine | WHO Anatomical Therapeutic Chemical classification | | ethylmorphine |
0‑L | R05DA03 | hydrocodone | WHO Anatomical Therapeutic Chemical classification | | hydrocodone |
0‑L | R05DA04 | codeine | WHO Anatomical Therapeutic Chemical classification | | codeine |
0‑L | R05DA05 | opium alkaloids with morphine | WHO Anatomical Therapeutic Chemical classification | | opium alkaloids with morphine |
0‑L | R05DA06 | normethadone | WHO Anatomical Therapeutic Chemical classification | | normethadone |
0‑L | R05DA07 | noscapine | WHO Anatomical Therapeutic Chemical classification | | noscapine |
0‑L | R05DA08 | pholcodine | WHO Anatomical Therapeutic Chemical classification | | pholcodine |
0‑L | R05DA09 | dextromethorphan | WHO Anatomical Therapeutic Chemical classification | | dextromethorphan |
0‑L | R05DA10 | thebacon | WHO Anatomical Therapeutic Chemical classification | | thebacon |
0‑L | R05DA11 | dimemorfan | WHO Anatomical Therapeutic Chemical classification | | dimemorfan |
0‑L | R05DA12 | acetyldihydrocodeine | WHO Anatomical Therapeutic Chemical classification | | acetyldihydrocodeine |
0‑L | R05DA20 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | R05DB | Other cough suppressants | WHO Anatomical Therapeutic Chemical classification | | Other cough suppressants |
0‑L | R05DB01 | benzonatate | WHO Anatomical Therapeutic Chemical classification | | benzonatate |
0‑L | R05DB02 | benproperine | WHO Anatomical Therapeutic Chemical classification | | benproperine |
0‑L | R05DB03 | clobutinol | WHO Anatomical Therapeutic Chemical classification | | clobutinol |
0‑L | R05DB04 | isoaminile | WHO Anatomical Therapeutic Chemical classification | | isoaminile |
0‑L | R05DB05 | pentoxyverine | WHO Anatomical Therapeutic Chemical classification | | pentoxyverine |
0‑L | R05DB07 | oxolamine | WHO Anatomical Therapeutic Chemical classification | | oxolamine |
0‑L | R05DB09 | oxeladin | WHO Anatomical Therapeutic Chemical classification | | oxeladin |
0‑L | R05DB10 | clofedanol | WHO Anatomical Therapeutic Chemical classification | | clofedanol |
0‑L | R05DB11 | pipazetate | WHO Anatomical Therapeutic Chemical classification | | pipazetate |
0‑L | R05DB12 | bibenzonium bromide | WHO Anatomical Therapeutic Chemical classification | | bibenzonium bromide |
0‑L | R05DB13 | butamirate | WHO Anatomical Therapeutic Chemical classification | | butamirate |
0‑L | R05DB14 | fedrilate | WHO Anatomical Therapeutic Chemical classification | | fedrilate |
0‑L | R05DB15 | zipeprol | WHO Anatomical Therapeutic Chemical classification | | zipeprol |
0‑L | R05DB16 | dibunate | WHO Anatomical Therapeutic Chemical classification | | dibunate |
0‑L | R05DB17 | droxypropine | WHO Anatomical Therapeutic Chemical classification | | droxypropine |
0‑L | R05DB18 | prenoxdiazine | WHO Anatomical Therapeutic Chemical classification | | prenoxdiazine |
0‑L | R05DB19 | dropropizine | WHO Anatomical Therapeutic Chemical classification | | dropropizine |
0‑L | R05DB20 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | R05DB21 | cloperastine | WHO Anatomical Therapeutic Chemical classification | | cloperastine |
0‑L | R05DB22 | meprotixol | WHO Anatomical Therapeutic Chemical classification | | meprotixol |
0‑L | R05DB23 | piperidione | WHO Anatomical Therapeutic Chemical classification | | piperidione |
0‑L | R05DB24 | tipepidine | WHO Anatomical Therapeutic Chemical classification | | tipepidine |
0‑L | R05DB25 | morclofone | WHO Anatomical Therapeutic Chemical classification | | morclofone |
0‑L | R05DB26 | nepinalone | WHO Anatomical Therapeutic Chemical classification | | nepinalone |
0‑L | R05DB27 | levodropropizine | WHO Anatomical Therapeutic Chemical classification | | levodropropizine |
0‑L | R05DB28 | dimethoxanate | WHO Anatomical Therapeutic Chemical classification | | dimethoxanate |
0‑L | R05F | COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS | WHO Anatomical Therapeutic Chemical classification | | COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS |
0‑L | R05FA | Opium derivatives and expectorants | WHO Anatomical Therapeutic Chemical classification | | Opium derivatives and expectorants |
0‑L | R05FA01 | opium derivatives and mucolytics | WHO Anatomical Therapeutic Chemical classification | | opium derivatives and mucolytics |
0‑L | R05FA02 | opium derivatives and expectorants | WHO Anatomical Therapeutic Chemical classification | | opium derivatives and expectorants |
0‑L | R05FB | Other cough suppressants and expectorants | WHO Anatomical Therapeutic Chemical classification | | Other cough suppressants and expectorants |
0‑L | R05FB01 | cough suppressants and mucolytics | WHO Anatomical Therapeutic Chemical classification | | cough suppressants and mucolytics |
0‑L | R05FB02 | cough suppressants and expectorants | WHO Anatomical Therapeutic Chemical classification | | cough suppressants and expectorants |
0‑L | R05X | OTHER COLD PREPARATIONS | WHO Anatomical Therapeutic Chemical classification | | OTHER COLD PREPARATIONS |
0‑L | R06 | ANTIHISTAMINES FOR SYSTEMIC USE | WHO Anatomical Therapeutic Chemical classification | | ANTIHISTAMINES FOR SYSTEMIC USE |
0‑L | R06A | ANTIHISTAMINES FOR SYSTEMIC USE | WHO Anatomical Therapeutic Chemical classification | | ANTIHISTAMINES FOR SYSTEMIC USE |
0‑L | R06AA | Aminoalkyl ethers | WHO Anatomical Therapeutic Chemical classification | | Aminoalkyl ethers |
0‑L | R06AA01 | bromazine | WHO Anatomical Therapeutic Chemical classification | | bromazine |
0‑L | R06AA02 | diphenhydramine | WHO Anatomical Therapeutic Chemical classification | | diphenhydramine |
0‑L | R06AA04 | clemastine | WHO Anatomical Therapeutic Chemical classification | | clemastine |
0‑L | R06AA06 | chlorphenoxamine | WHO Anatomical Therapeutic Chemical classification | | chlorphenoxamine |
0‑L | R06AA07 | diphenylpyraline | WHO Anatomical Therapeutic Chemical classification | | diphenylpyraline |
0‑L | R06AA08 | carbinoxamine | WHO Anatomical Therapeutic Chemical classification | | carbinoxamine |
0‑L | R06AA09 | doxylamine | WHO Anatomical Therapeutic Chemical classification | | doxylamine |
0‑L | R06AA10 | trimethobenzamide | WHO Anatomical Therapeutic Chemical classification | | trimethobenzamide |
0‑L | R06AA52 | diphenhydramine, combinations | WHO Anatomical Therapeutic Chemical classification | | diphenhydramine, combinations |
0‑L | R06AA54 | clemastine, combinations | WHO Anatomical Therapeutic Chemical classification | | clemastine, combinations |
0‑L | R06AA56 | chlorphenoxamine, combinations | WHO Anatomical Therapeutic Chemical classification | | chlorphenoxamine, combinations |
0‑L | R06AA57 | diphenylpyraline, combinations | WHO Anatomical Therapeutic Chemical classification | | diphenylpyraline, combinations |
0‑L | R06AA59 | doxylamine, combinations | WHO Anatomical Therapeutic Chemical classification | | doxylamine, combinations |
0‑L | R06AB | Substituted alkylamines | WHO Anatomical Therapeutic Chemical classification | | Substituted alkylamines |
0‑L | R06AB01 | brompheniramine | WHO Anatomical Therapeutic Chemical classification | | brompheniramine |
0‑L | R06AB02 | dexchlorpheniramine | WHO Anatomical Therapeutic Chemical classification | | dexchlorpheniramine |
0‑L | R06AB03 | dimetindene | WHO Anatomical Therapeutic Chemical classification | | dimetindene |
0‑L | R06AB04 | chlorphenamine | WHO Anatomical Therapeutic Chemical classification | | chlorphenamine |
0‑L | R06AB05 | pheniramine | WHO Anatomical Therapeutic Chemical classification | | pheniramine |
0‑L | R06AB06 | dexbrompheniramine | WHO Anatomical Therapeutic Chemical classification | | dexbrompheniramine |
0‑L | R06AB07 | talastine | WHO Anatomical Therapeutic Chemical classification | | talastine |
0‑L | R06AB51 | brompheniramine, combinations | WHO Anatomical Therapeutic Chemical classification | | brompheniramine, combinations |
0‑L | R06AB52 | dexchlorpheniramine, combinations | WHO Anatomical Therapeutic Chemical classification | | dexchlorpheniramine, combinations |
0‑L | R06AB54 | chlorphenamine, combinations | WHO Anatomical Therapeutic Chemical classification | | chlorphenamine, combinations |
0‑L | R06AB56 | dexbrompheniramine, combinations | WHO Anatomical Therapeutic Chemical classification | | dexbrompheniramine, combinations |
0‑L | R06AC | Substituted ethylene diamines | WHO Anatomical Therapeutic Chemical classification | | Substituted ethylene diamines |
0‑L | R06AC01 | mepyramine | WHO Anatomical Therapeutic Chemical classification | | mepyramine |
0‑L | R06AC02 | histapyrrodine | WHO Anatomical Therapeutic Chemical classification | | histapyrrodine |
0‑L | R06AC03 | chloropyramine | WHO Anatomical Therapeutic Chemical classification | | chloropyramine |
0‑L | R06AC04 | tripelennamine | WHO Anatomical Therapeutic Chemical classification | | tripelennamine |
0‑L | R06AC05 | methapyrilene | WHO Anatomical Therapeutic Chemical classification | | methapyrilene |
0‑L | R06AC06 | thonzylamine | WHO Anatomical Therapeutic Chemical classification | | thonzylamine |
0‑L | R06AC52 | histapyrrodine, combinations | WHO Anatomical Therapeutic Chemical classification | | histapyrrodine, combinations |
0‑L | R06AC53 | chloropyramine, combinations | WHO Anatomical Therapeutic Chemical classification | | chloropyramine, combinations |
0‑L | R06AD | Phenothiazine derivatives | WHO Anatomical Therapeutic Chemical classification | | Phenothiazine derivatives |
0‑L | R06AD01 | alimemazine | WHO Anatomical Therapeutic Chemical classification | | alimemazine |
0‑L | R06AD02 | promethazine | WHO Anatomical Therapeutic Chemical classification | | promethazine |
0‑L | R06AD03 | thiethylperazine | WHO Anatomical Therapeutic Chemical classification | | thiethylperazine |
0‑L | R06AD04 | methdilazine | WHO Anatomical Therapeutic Chemical classification | | methdilazine |
0‑L | R06AD05 | hydroxyethylpromethazine | WHO Anatomical Therapeutic Chemical classification | | hydroxyethylpromethazine |
0‑L | R06AD06 | thiazinam | WHO Anatomical Therapeutic Chemical classification | | thiazinam |
0‑L | R06AD07 | mequitazine | WHO Anatomical Therapeutic Chemical classification | | mequitazine |
0‑L | R06AD08 | oxomemazine | WHO Anatomical Therapeutic Chemical classification | | oxomemazine |
0‑L | R06AD09 | isothipendyl | WHO Anatomical Therapeutic Chemical classification | | isothipendyl |
0‑L | R06AD52 | promethazine, combinations | WHO Anatomical Therapeutic Chemical classification | | promethazine, combinations |
0‑L | R06AD55 | hydroxyethylpromethazine, combinations | WHO Anatomical Therapeutic Chemical classification | | hydroxyethylpromethazine, combinations |
0‑L | R06AE | Piperazine derivatives | WHO Anatomical Therapeutic Chemical classification | | Piperazine derivatives |
0‑L | R06AE01 | buclizine | WHO Anatomical Therapeutic Chemical classification | | buclizine |
0‑L | R06AE03 | cyclizine | WHO Anatomical Therapeutic Chemical classification | | cyclizine |
0‑L | R06AE04 | chlorcyclizine | WHO Anatomical Therapeutic Chemical classification | | chlorcyclizine |
0‑L | R06AE05 | meclozine | WHO Anatomical Therapeutic Chemical classification | | meclozine |
0‑L | R06AE06 | oxatomide | WHO Anatomical Therapeutic Chemical classification | | oxatomide |
0‑L | R06AE07 | cetirizine | WHO Anatomical Therapeutic Chemical classification | | cetirizine |
0‑L | R06AE09 | levocetirizine | WHO Anatomical Therapeutic Chemical classification | | levocetirizine |
0‑L | R06AE51 | buclizine, combinations | WHO Anatomical Therapeutic Chemical classification | | buclizine, combinations |
0‑L | R06AE53 | cyclizine, combinations | WHO Anatomical Therapeutic Chemical classification | | cyclizine, combinations |
0‑L | R06AE55 | meclozine, combinations | WHO Anatomical Therapeutic Chemical classification | | meclozine, combinations |
0‑L | R06AK | Combinations of antihistamines | WHO Anatomical Therapeutic Chemical classification | | Combinations of antihistamines |
0‑L | R06AX | Other antihistamines for systemic use | WHO Anatomical Therapeutic Chemical classification | | Other antihistamines for systemic use |
0‑L | R06AX01 | bamipine | WHO Anatomical Therapeutic Chemical classification | | bamipine |
0‑L | R06AX02 | cyproheptadine | WHO Anatomical Therapeutic Chemical classification | | cyproheptadine |
0‑L | R06AX03 | thenalidine | WHO Anatomical Therapeutic Chemical classification | | thenalidine |
0‑L | R06AX04 | phenindamine | WHO Anatomical Therapeutic Chemical classification | | phenindamine |
0‑L | R06AX05 | antazoline | WHO Anatomical Therapeutic Chemical classification | | antazoline |
0‑L | R06AX07 | triprolidine | WHO Anatomical Therapeutic Chemical classification | | triprolidine |
0‑L | R06AX08 | pyrrobutamine | WHO Anatomical Therapeutic Chemical classification | | pyrrobutamine |
0‑L | R06AX09 | azatadine | WHO Anatomical Therapeutic Chemical classification | | azatadine |
0‑L | R06AX11 | astemizole | WHO Anatomical Therapeutic Chemical classification | | astemizole |
0‑L | R06AX12 | terfenadine | WHO Anatomical Therapeutic Chemical classification | | terfenadine |
0‑L | R06AX13 | loratadine | WHO Anatomical Therapeutic Chemical classification | | loratadine |
0‑L | R06AX15 | mebhydrolin | WHO Anatomical Therapeutic Chemical classification | | mebhydrolin |
0‑L | R06AX16 | deptropine | WHO Anatomical Therapeutic Chemical classification | | deptropine |
0‑L | R06AX17 | ketotifen | WHO Anatomical Therapeutic Chemical classification | | ketotifen |
0‑L | R06AX18 | acrivastine | WHO Anatomical Therapeutic Chemical classification | | acrivastine |
0‑L | R06AX19 | azelastine | WHO Anatomical Therapeutic Chemical classification | | azelastine |
0‑L | R06AX21 | tritoqualine | WHO Anatomical Therapeutic Chemical classification | | tritoqualine |
0‑L | R06AX22 | ebastine | WHO Anatomical Therapeutic Chemical classification | | ebastine |
0‑L | R06AX23 | pimethixene | WHO Anatomical Therapeutic Chemical classification | | pimethixene |
0‑L | R06AX24 | epinastine | WHO Anatomical Therapeutic Chemical classification | | epinastine |
0‑L | R06AX25 | mizolastine | WHO Anatomical Therapeutic Chemical classification | | mizolastine |
0‑L | R06AX26 | fexofenadine | WHO Anatomical Therapeutic Chemical classification | | fexofenadine |
0‑L | R06AX27 | desloratadine | WHO Anatomical Therapeutic Chemical classification | | desloratadine |
0‑L | R06AX28 | rupatadine | WHO Anatomical Therapeutic Chemical classification | | rupatadine |
0‑L | R06AX29 | bilastine | WHO Anatomical Therapeutic Chemical classification | | bilastine |
0‑L | R06AX31 | quifenadine | WHO Anatomical Therapeutic Chemical classification | | quifenadine |
0‑L | R06AX32 | sequifenadine | WHO Anatomical Therapeutic Chemical classification | | sequifenadine |
0‑L | R06AX53 | thenalidine, combinations | WHO Anatomical Therapeutic Chemical classification | | thenalidine, combinations |
0‑L | R06AX58 | pyrrobutamine, combinations | WHO Anatomical Therapeutic Chemical classification | | pyrrobutamine, combinations |
0‑L | R07 | OTHER RESPIRATORY SYSTEM PRODUCTS | WHO Anatomical Therapeutic Chemical classification | | OTHER RESPIRATORY SYSTEM PRODUCTS |
0‑L | R07A | OTHER RESPIRATORY SYSTEM PRODUCTS | WHO Anatomical Therapeutic Chemical classification | | OTHER RESPIRATORY SYSTEM PRODUCTS |
0‑L | R07AA | Lung surfactants | WHO Anatomical Therapeutic Chemical classification | | Lung surfactants |
0‑L | R07AA01 | colfosceril palmitate | WHO Anatomical Therapeutic Chemical classification | | colfosceril palmitate |
0‑L | R07AA02 | natural phospholipids | WHO Anatomical Therapeutic Chemical classification | | natural phospholipids |
0‑L | R07AA30 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | R07AB | Respiratory stimulants | WHO Anatomical Therapeutic Chemical classification | | Respiratory stimulants |
0‑L | R07AB01 | doxapram | WHO Anatomical Therapeutic Chemical classification | | doxapram |
0‑L | R07AB02 | nikethamide | WHO Anatomical Therapeutic Chemical classification | | nikethamide |
0‑L | R07AB03 | pentetrazol | WHO Anatomical Therapeutic Chemical classification | | pentetrazol |
0‑L | R07AB04 | etamivan | WHO Anatomical Therapeutic Chemical classification | | etamivan |
0‑L | R07AB05 | bemegride | WHO Anatomical Therapeutic Chemical classification | | bemegride |
0‑L | R07AB06 | prethcamide | WHO Anatomical Therapeutic Chemical classification | | prethcamide |
0‑L | R07AB07 | almitrine | WHO Anatomical Therapeutic Chemical classification | | almitrine |
0‑L | R07AB08 | dimefline | WHO Anatomical Therapeutic Chemical classification | | dimefline |
0‑L | R07AB09 | mepixanox | WHO Anatomical Therapeutic Chemical classification | | mepixanox |
0‑L | R07AB52 | nikethamide, combinations | WHO Anatomical Therapeutic Chemical classification | | nikethamide, combinations |
0‑L | R07AB53 | pentetrazol, combinations | WHO Anatomical Therapeutic Chemical classification | | pentetrazol, combinations |
0‑L | R07AX | Other respiratory system products | WHO Anatomical Therapeutic Chemical classification | | Other respiratory system products |
0‑L | R07AX01 | nitric oxide | WHO Anatomical Therapeutic Chemical classification | | nitric oxide |
0‑L | R07AX02 | ivacaftor | WHO Anatomical Therapeutic Chemical classification | | ivacaftor |
0‑L | R07AX30 | ivacaftor and lumacaftor | WHO Anatomical Therapeutic Chemical classification | | ivacaftor and lumacaftor |
0‑L | S | SENSORY ORGANS | WHO Anatomical Therapeutic Chemical classification | | SENSORY ORGANS |
0‑L | S01 | OPHTHALMOLOGICALS | WHO Anatomical Therapeutic Chemical classification | | OPHTHALMOLOGICALS |
0‑L | S01A | ANTIINFECTIVES | WHO Anatomical Therapeutic Chemical classification | | ANTIINFECTIVES |
0‑L | S01AA | Antibiotics | WHO Anatomical Therapeutic Chemical classification | | Antibiotics |
0‑L | S01AA01 | chloramphenicol | WHO Anatomical Therapeutic Chemical classification | | chloramphenicol |
0‑L | S01AA02 | chlortetracycline | WHO Anatomical Therapeutic Chemical classification | | chlortetracycline |
0‑L | S01AA03 | neomycin | WHO Anatomical Therapeutic Chemical classification | | neomycin |
0‑L | S01AA04 | oxytetracycline | WHO Anatomical Therapeutic Chemical classification | | oxytetracycline |
0‑L | S01AA05 | tyrothricin | WHO Anatomical Therapeutic Chemical classification | | tyrothricin |
0‑L | S01AA07 | framycetin | WHO Anatomical Therapeutic Chemical classification | | framycetin |
0‑L | S01AA09 | tetracycline | WHO Anatomical Therapeutic Chemical classification | | tetracycline |
0‑L | S01AA10 | natamycin | WHO Anatomical Therapeutic Chemical classification | | natamycin |
0‑L | S01AA11 | gentamicin | WHO Anatomical Therapeutic Chemical classification | | gentamicin |
0‑L | S01AA12 | tobramycin | WHO Anatomical Therapeutic Chemical classification | | tobramycin |
0‑L | S01AA13 | fusidic acid | WHO Anatomical Therapeutic Chemical classification | | fusidic acid |
0‑L | S01AA14 | benzylpenicillin | WHO Anatomical Therapeutic Chemical classification | | benzylpenicillin |
0‑L | S01AA15 | dihydrostreptomycin | WHO Anatomical Therapeutic Chemical classification | | dihydrostreptomycin |
0‑L | S01AA16 | rifamycin | WHO Anatomical Therapeutic Chemical classification | | rifamycin |
0‑L | S01AA17 | erythromycin | WHO Anatomical Therapeutic Chemical classification | | erythromycin |
0‑L | S01AA18 | polymyxin B | WHO Anatomical Therapeutic Chemical classification | | polymyxin B |
0‑L | S01AA19 | ampicillin | WHO Anatomical Therapeutic Chemical classification | | ampicillin |
0‑L | S01AA20 | antibiotics in combination with other drugs | WHO Anatomical Therapeutic Chemical classification | | antibiotics in combination with other drugs |
0‑L | S01AA21 | amikacin | WHO Anatomical Therapeutic Chemical classification | | amikacin |
0‑L | S01AA22 | micronomicin | WHO Anatomical Therapeutic Chemical classification | | micronomicin |
0‑L | S01AA23 | netilmicin | WHO Anatomical Therapeutic Chemical classification | | netilmicin |
0‑L | S01AA24 | kanamycin | WHO Anatomical Therapeutic Chemical classification | | kanamycin |
0‑L | S01AA25 | azidamfenicol | WHO Anatomical Therapeutic Chemical classification | | azidamfenicol |
0‑L | S01AA26 | azithromycin | WHO Anatomical Therapeutic Chemical classification | | azithromycin |
0‑L | S01AA27 | cefuroxime | WHO Anatomical Therapeutic Chemical classification | | cefuroxime |
0‑L | S01AA30 | combinations of different antibiotics | WHO Anatomical Therapeutic Chemical classification | | combinations of different antibiotics |
0‑L | S01AB | Sulfonamides | WHO Anatomical Therapeutic Chemical classification | | Sulfonamides |
0‑L | S01AB01 | sulfamethizole | WHO Anatomical Therapeutic Chemical classification | | sulfamethizole |
0‑L | S01AB02 | sulfafurazole | WHO Anatomical Therapeutic Chemical classification | | sulfafurazole |
0‑L | S01AB03 | sulfadicramide | WHO Anatomical Therapeutic Chemical classification | | sulfadicramide |
0‑L | S01AB04 | sulfacetamide | WHO Anatomical Therapeutic Chemical classification | | sulfacetamide |
0‑L | S01AB05 | sulfafenazol | WHO Anatomical Therapeutic Chemical classification | | sulfafenazol |
0‑L | S01AD | Antivirals | WHO Anatomical Therapeutic Chemical classification | | Antivirals |
0‑L | S01AD01 | idoxuridine | WHO Anatomical Therapeutic Chemical classification | | idoxuridine |
0‑L | S01AD02 | trifluridine | WHO Anatomical Therapeutic Chemical classification | | trifluridine |
0‑L | S01AD03 | aciclovir | WHO Anatomical Therapeutic Chemical classification | | aciclovir |
0‑L | S01AD05 | interferon | WHO Anatomical Therapeutic Chemical classification | | interferon |
0‑L | S01AD06 | vidarabine | WHO Anatomical Therapeutic Chemical classification | | vidarabine |
0‑L | S01AD07 | famciclovir | WHO Anatomical Therapeutic Chemical classification | | famciclovir |
0‑L | S01AD08 | fomivirsen | WHO Anatomical Therapeutic Chemical classification | | fomivirsen |
0‑L | S01AD09 | ganciclovir | WHO Anatomical Therapeutic Chemical classification | | ganciclovir |
0‑L | S01AE | Fluoroquinolones | WHO Anatomical Therapeutic Chemical classification | | Fluoroquinolones |
0‑L | S01AE01 | ofloxacin | WHO Anatomical Therapeutic Chemical classification | | ofloxacin |
0‑L | S01AE02 | norfloxacin | WHO Anatomical Therapeutic Chemical classification | | norfloxacin |
0‑L | S01AE03 | ciprofloxacin | WHO Anatomical Therapeutic Chemical classification | | ciprofloxacin |
0‑L | S01AE04 | lomefloxacin | WHO Anatomical Therapeutic Chemical classification | | lomefloxacin |
0‑L | S01AE05 | levofloxacin | WHO Anatomical Therapeutic Chemical classification | | levofloxacin |
0‑L | S01AE06 | gatifloxacin | WHO Anatomical Therapeutic Chemical classification | | gatifloxacin |
0‑L | S01AE07 | moxifloxacin | WHO Anatomical Therapeutic Chemical classification | | moxifloxacin |
0‑L | S01AE08 | besifloxacin | WHO Anatomical Therapeutic Chemical classification | | besifloxacin |
0‑L | S01AX | Other antiinfectives | WHO Anatomical Therapeutic Chemical classification | | Other antiinfectives |
0‑L | S01AX01 | mercury compounds | WHO Anatomical Therapeutic Chemical classification | | mercury compounds |
0‑L | S01AX02 | silver compounds | WHO Anatomical Therapeutic Chemical classification | | silver compounds |
0‑L | S01AX03 | zinc compounds | WHO Anatomical Therapeutic Chemical classification | | zinc compounds |
0‑L | S01AX04 | nitrofural | WHO Anatomical Therapeutic Chemical classification | | nitrofural |
0‑L | S01AX05 | bibrocathol | WHO Anatomical Therapeutic Chemical classification | | bibrocathol |
0‑L | S01AX06 | resorcinol | WHO Anatomical Therapeutic Chemical classification | | resorcinol |
0‑L | S01AX07 | sodium borate | WHO Anatomical Therapeutic Chemical classification | | sodium borate |
0‑L | S01AX08 | hexamidine | WHO Anatomical Therapeutic Chemical classification | | hexamidine |
0‑L | S01AX09 | chlorhexidine | WHO Anatomical Therapeutic Chemical classification | | chlorhexidine |
0‑L | S01AX10 | sodium propionate | WHO Anatomical Therapeutic Chemical classification | | sodium propionate |
0‑L | S01AX14 | dibrompropamidine | WHO Anatomical Therapeutic Chemical classification | | dibrompropamidine |
0‑L | S01AX15 | propamidine | WHO Anatomical Therapeutic Chemical classification | | propamidine |
0‑L | S01AX16 | picloxydine | WHO Anatomical Therapeutic Chemical classification | | picloxydine |
0‑L | S01AX18 | povidone-iodine | WHO Anatomical Therapeutic Chemical classification | | povidone-iodine |
0‑L | S01B | ANTIINFLAMMATORY AGENTS | WHO Anatomical Therapeutic Chemical classification | | ANTIINFLAMMATORY AGENTS |
0‑L | S01BA | Corticosteroids, plain | WHO Anatomical Therapeutic Chemical classification | | Corticosteroids, plain |
0‑L | S01BA01 | dexamethasone | WHO Anatomical Therapeutic Chemical classification | | dexamethasone |
0‑L | S01BA02 | hydrocortisone | WHO Anatomical Therapeutic Chemical classification | | hydrocortisone |
0‑L | S01BA03 | cortisone | WHO Anatomical Therapeutic Chemical classification | | cortisone |
0‑L | S01BA04 | prednisolone | WHO Anatomical Therapeutic Chemical classification | | prednisolone |
0‑L | S01BA05 | triamcinolone | WHO Anatomical Therapeutic Chemical classification | | triamcinolone |
0‑L | S01BA06 | betamethasone | WHO Anatomical Therapeutic Chemical classification | | betamethasone |
0‑L | S01BA07 | fluorometholone | WHO Anatomical Therapeutic Chemical classification | | fluorometholone |
0‑L | S01BA08 | medrysone | WHO Anatomical Therapeutic Chemical classification | | medrysone |
0‑L | S01BA09 | clobetasone | WHO Anatomical Therapeutic Chemical classification | | clobetasone |
0‑L | S01BA10 | alclometasone | WHO Anatomical Therapeutic Chemical classification | | alclometasone |
0‑L | S01BA11 | desonide | WHO Anatomical Therapeutic Chemical classification | | desonide |
0‑L | S01BA12 | formocortal | WHO Anatomical Therapeutic Chemical classification | | formocortal |
0‑L | S01BA13 | rimexolone | WHO Anatomical Therapeutic Chemical classification | | rimexolone |
0‑L | S01BA14 | loteprednol | WHO Anatomical Therapeutic Chemical classification | | loteprednol |
0‑L | S01BA15 | fluocinolone acetonide | WHO Anatomical Therapeutic Chemical classification | | fluocinolone acetonide |
0‑L | S01BB | Corticosteroids and mydriatics in combination | WHO Anatomical Therapeutic Chemical classification | | Corticosteroids and mydriatics in combination |
0‑L | S01BB01 | hydrocortisone and mydriatics | WHO Anatomical Therapeutic Chemical classification | | hydrocortisone and mydriatics |
0‑L | S01BB02 | prednisolone and mydriatics | WHO Anatomical Therapeutic Chemical classification | | prednisolone and mydriatics |
0‑L | S01BB03 | fluorometholone and mydriatics | WHO Anatomical Therapeutic Chemical classification | | fluorometholone and mydriatics |
0‑L | S01BB04 | betamethasone and mydriatics | WHO Anatomical Therapeutic Chemical classification | | betamethasone and mydriatics |
0‑L | S01BC | Antiinflammatory agents, non-steroids | WHO Anatomical Therapeutic Chemical classification | | Antiinflammatory agents, non-steroids |
0‑L | S01BC01 | indometacin | WHO Anatomical Therapeutic Chemical classification | | indometacin |
0‑L | S01BC02 | oxyphenbutazone | WHO Anatomical Therapeutic Chemical classification | | oxyphenbutazone |
0‑L | S01BC03 | diclofenac | WHO Anatomical Therapeutic Chemical classification | | diclofenac |
0‑L | S01BC04 | flurbiprofen | WHO Anatomical Therapeutic Chemical classification | | flurbiprofen |
0‑L | S01BC05 | ketorolac | WHO Anatomical Therapeutic Chemical classification | | ketorolac |
0‑L | S01BC06 | piroxicam | WHO Anatomical Therapeutic Chemical classification | | piroxicam |
0‑L | S01BC07 | bendazac | WHO Anatomical Therapeutic Chemical classification | | bendazac |
0‑L | S01BC08 | salicylic acid | WHO Anatomical Therapeutic Chemical classification | | salicylic acid |
0‑L | S01BC09 | pranoprofen | WHO Anatomical Therapeutic Chemical classification | | pranoprofen |
0‑L | S01BC10 | nepafenac | WHO Anatomical Therapeutic Chemical classification | | nepafenac |
0‑L | S01BC11 | bromfenac | WHO Anatomical Therapeutic Chemical classification | | bromfenac |
0‑L | S01C | ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION | WHO Anatomical Therapeutic Chemical classification | | ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION |
0‑L | S01CA | Corticosteroids and antiinfectives in combination | WHO Anatomical Therapeutic Chemical classification | | Corticosteroids and antiinfectives in combination |
0‑L | S01CA01 | dexamethasone and antiinfectives | WHO Anatomical Therapeutic Chemical classification | | dexamethasone and antiinfectives |
0‑L | S01CA02 | prednisolone and antiinfectives | WHO Anatomical Therapeutic Chemical classification | | prednisolone and antiinfectives |
0‑L | S01CA03 | hydrocortisone and antiinfectives | WHO Anatomical Therapeutic Chemical classification | | hydrocortisone and antiinfectives |
0‑L | S01CA04 | fluocortolone and antiinfectives | WHO Anatomical Therapeutic Chemical classification | | fluocortolone and antiinfectives |
0‑L | S01CA05 | betamethasone and antiinfectives | WHO Anatomical Therapeutic Chemical classification | | betamethasone and antiinfectives |
0‑L | S01CA06 | fludrocortisone and antiinfectives | WHO Anatomical Therapeutic Chemical classification | | fludrocortisone and antiinfectives |
0‑L | S01CA07 | fluorometholone and antiinfectives | WHO Anatomical Therapeutic Chemical classification | | fluorometholone and antiinfectives |
0‑L | S01CA08 | methylprednisolone and antiinfectives | WHO Anatomical Therapeutic Chemical classification | | methylprednisolone and antiinfectives |
0‑L | S01CA09 | chloroprednisone and antiinfectives | WHO Anatomical Therapeutic Chemical classification | | chloroprednisone and antiinfectives |
0‑L | S01CA10 | fluocinolone acetonide and antiinfectives | WHO Anatomical Therapeutic Chemical classification | | fluocinolone acetonide and antiinfectives |
0‑L | S01CA11 | clobetasone and antiinfectives | WHO Anatomical Therapeutic Chemical classification | | clobetasone and antiinfectives |
0‑L | S01CB | Corticosteroids/antiinfectives/mydriatics in combination | WHO Anatomical Therapeutic Chemical classification | | Corticosteroids/antiinfectives/mydriatics in combination |
0‑L | S01CB01 | dexamethasone | WHO Anatomical Therapeutic Chemical classification | | dexamethasone |
0‑L | S01CB02 | prednisolone | WHO Anatomical Therapeutic Chemical classification | | prednisolone |
0‑L | S01CB03 | hydrocortisone | WHO Anatomical Therapeutic Chemical classification | | hydrocortisone |
0‑L | S01CB04 | betamethasone | WHO Anatomical Therapeutic Chemical classification | | betamethasone |
0‑L | S01CB05 | fluorometholone | WHO Anatomical Therapeutic Chemical classification | | fluorometholone |
0‑L | S01CC | Antiinflammatory agents, non-steroids and antiinfectives in combination | WHO Anatomical Therapeutic Chemical classification | | Antiinflammatory agents, non-steroids and antiinfectives in combination |
0‑L | S01CC01 | diclofenac and antiinfectives | WHO Anatomical Therapeutic Chemical classification | | diclofenac and antiinfectives |
0‑L | S01CC02 | indometacin and antiinfectives | WHO Anatomical Therapeutic Chemical classification | | indometacin and antiinfectives |
0‑L | S01E | ANTIGLAUCOMA PREPARATIONS AND MIOTICS | WHO Anatomical Therapeutic Chemical classification | | ANTIGLAUCOMA PREPARATIONS AND MIOTICS |
0‑L | S01EA | Sympathomimetics in glaucoma therapy1) | WHO Anatomical Therapeutic Chemical classification | | Sympathomimetics in glaucoma therapy1) |
0‑L | S01EA01 | epinephrine | WHO Anatomical Therapeutic Chemical classification | | epinephrine |
0‑L | S01EA02 | dipivefrine | WHO Anatomical Therapeutic Chemical classification | | dipivefrine |
0‑L | S01EA03 | apraclonidine | WHO Anatomical Therapeutic Chemical classification | | apraclonidine |
0‑L | S01EA04 | clonidine | WHO Anatomical Therapeutic Chemical classification | | clonidine |
0‑L | S01EA05 | brimonidine | WHO Anatomical Therapeutic Chemical classification | | brimonidine |
0‑L | S01EA51 | epinephrine, combinations | WHO Anatomical Therapeutic Chemical classification | | epinephrine, combinations |
0‑L | S01EB | Parasympathomimetics | WHO Anatomical Therapeutic Chemical classification | | Parasympathomimetics |
0‑L | S01EB01 | pilocarpine | WHO Anatomical Therapeutic Chemical classification | | pilocarpine |
0‑L | S01EB02 | carbachol | WHO Anatomical Therapeutic Chemical classification | | carbachol |
0‑L | S01EB03 | ecothiopate | WHO Anatomical Therapeutic Chemical classification | | ecothiopate |
0‑L | S01EB04 | demecarium | WHO Anatomical Therapeutic Chemical classification | | demecarium |
0‑L | S01EB05 | physostigmine | WHO Anatomical Therapeutic Chemical classification | | physostigmine |
0‑L | S01EB06 | neostigmine | WHO Anatomical Therapeutic Chemical classification | | neostigmine |
0‑L | S01EB07 | fluostigmine | WHO Anatomical Therapeutic Chemical classification | | fluostigmine |
0‑L | S01EB08 | aceclidine | WHO Anatomical Therapeutic Chemical classification | | aceclidine |
0‑L | S01EB09 | acetylcholine | WHO Anatomical Therapeutic Chemical classification | | acetylcholine |
0‑L | S01EB10 | paraoxon | WHO Anatomical Therapeutic Chemical classification | | paraoxon |
0‑L | S01EB51 | pilocarpine, combinations | WHO Anatomical Therapeutic Chemical classification | | pilocarpine, combinations |
0‑L | S01EB58 | aceclidine, combinations | WHO Anatomical Therapeutic Chemical classification | | aceclidine, combinations |
0‑L | S01EC | Carbonic anhydrase inhibitors | WHO Anatomical Therapeutic Chemical classification | | Carbonic anhydrase inhibitors |
0‑L | S01EC01 | acetazolamide | WHO Anatomical Therapeutic Chemical classification | | acetazolamide |
0‑L | S01EC02 | diclofenamide | WHO Anatomical Therapeutic Chemical classification | | diclofenamide |
0‑L | S01EC03 | dorzolamide | WHO Anatomical Therapeutic Chemical classification | | dorzolamide |
0‑L | S01EC04 | brinzolamide | WHO Anatomical Therapeutic Chemical classification | | brinzolamide |
0‑L | S01EC05 | methazolamide | WHO Anatomical Therapeutic Chemical classification | | methazolamide |
0‑L | S01EC54 | brinzolamide, combinations | WHO Anatomical Therapeutic Chemical classification | | brinzolamide, combinations |
0‑L | S01ED | Beta blocking agents1) | WHO Anatomical Therapeutic Chemical classification | | Beta blocking agents1) |
0‑L | S01ED01 | timolol | WHO Anatomical Therapeutic Chemical classification | | timolol |
0‑L | S01ED02 | betaxolol | WHO Anatomical Therapeutic Chemical classification | | betaxolol |
0‑L | S01ED03 | levobunolol | WHO Anatomical Therapeutic Chemical classification | | levobunolol |
0‑L | S01ED04 | metipranolol | WHO Anatomical Therapeutic Chemical classification | | metipranolol |
0‑L | S01ED05 | carteolol | WHO Anatomical Therapeutic Chemical classification | | carteolol |
0‑L | S01ED06 | befunolol | WHO Anatomical Therapeutic Chemical classification | | befunolol |
0‑L | S01ED51 | timolol, combinations | WHO Anatomical Therapeutic Chemical classification | | timolol, combinations |
0‑L | S01ED52 | betaxolol, combinations | WHO Anatomical Therapeutic Chemical classification | | betaxolol, combinations |
0‑L | S01ED54 | metipranolol, combinations | WHO Anatomical Therapeutic Chemical classification | | metipranolol, combinations |
0‑L | S01ED55 | carteolol, combinations | WHO Anatomical Therapeutic Chemical classification | | carteolol, combinations |
0‑L | S01EE | Prostaglandin analogues1) | WHO Anatomical Therapeutic Chemical classification | | Prostaglandin analogues1) |
0‑L | S01EE01 | latanoprost | WHO Anatomical Therapeutic Chemical classification | | latanoprost |
0‑L | S01EE02 | unoprostone | WHO Anatomical Therapeutic Chemical classification | | unoprostone |
0‑L | S01EE03 | bimatoprost | WHO Anatomical Therapeutic Chemical classification | | bimatoprost |
0‑L | S01EE04 | travoprost | WHO Anatomical Therapeutic Chemical classification | | travoprost |
0‑L | S01EE05 | tafluprost | WHO Anatomical Therapeutic Chemical classification | | tafluprost |
0‑L | S01EX | Other antiglaucoma preparations | WHO Anatomical Therapeutic Chemical classification | | Other antiglaucoma preparations |
0‑L | S01EX01 | guanethidine | WHO Anatomical Therapeutic Chemical classification | | guanethidine |
0‑L | S01EX02 | dapiprazole | WHO Anatomical Therapeutic Chemical classification | | dapiprazole |
0‑L | S01F | MYDRIATICS AND CYCLOPLEGICS | WHO Anatomical Therapeutic Chemical classification | | MYDRIATICS AND CYCLOPLEGICS |
0‑L | S01FA | Anticholinergics | WHO Anatomical Therapeutic Chemical classification | | Anticholinergics |
0‑L | S01FA01 | atropine | WHO Anatomical Therapeutic Chemical classification | | atropine |
0‑L | S01FA02 | scopolamine | WHO Anatomical Therapeutic Chemical classification | | scopolamine |
0‑L | S01FA03 | methylscopolamine | WHO Anatomical Therapeutic Chemical classification | | methylscopolamine |
0‑L | S01FA04 | cyclopentolate | WHO Anatomical Therapeutic Chemical classification | | cyclopentolate |
0‑L | S01FA05 | homatropine | WHO Anatomical Therapeutic Chemical classification | | homatropine |
0‑L | S01FA06 | tropicamide | WHO Anatomical Therapeutic Chemical classification | | tropicamide |
0‑L | S01FA54 | cyclopentolate, combinations | WHO Anatomical Therapeutic Chemical classification | | cyclopentolate, combinations |
0‑L | S01FA56 | tropicamide, combinations | WHO Anatomical Therapeutic Chemical classification | | tropicamide, combinations |
0‑L | S01FB | Sympathomimetics excl. antiglaucoma preparations | WHO Anatomical Therapeutic Chemical classification | | Sympathomimetics excl. antiglaucoma preparations |
0‑L | S01FB01 | phenylephrine | WHO Anatomical Therapeutic Chemical classification | | phenylephrine |
0‑L | S01FB02 | ephedrine | WHO Anatomical Therapeutic Chemical classification | | ephedrine |
0‑L | S01FB03 | ibopamine | WHO Anatomical Therapeutic Chemical classification | | ibopamine |
0‑L | S01FB51 | phenylephrine and ketorolac | WHO Anatomical Therapeutic Chemical classification | | phenylephrine and ketorolac |
0‑L | S01G | DECONGESTANTS AND ANTIALLERGICS | WHO Anatomical Therapeutic Chemical classification | | DECONGESTANTS AND ANTIALLERGICS |
0‑L | S01GA | Sympathomimetics used as decongestants | WHO Anatomical Therapeutic Chemical classification | | Sympathomimetics used as decongestants |
0‑L | S01GA01 | naphazoline | WHO Anatomical Therapeutic Chemical classification | | naphazoline |
0‑L | S01GA02 | tetryzoline | WHO Anatomical Therapeutic Chemical classification | | tetryzoline |
0‑L | S01GA03 | xylometazoline | WHO Anatomical Therapeutic Chemical classification | | xylometazoline |
0‑L | S01GA04 | oxymetazoline | WHO Anatomical Therapeutic Chemical classification | | oxymetazoline |
0‑L | S01GA05 | phenylephrine | WHO Anatomical Therapeutic Chemical classification | | phenylephrine |
0‑L | S01GA06 | oxedrine | WHO Anatomical Therapeutic Chemical classification | | oxedrine |
0‑L | S01GA51 | naphazoline, combinations | WHO Anatomical Therapeutic Chemical classification | | naphazoline, combinations |
0‑L | S01GA52 | tetryzoline, combinations | WHO Anatomical Therapeutic Chemical classification | | tetryzoline, combinations |
0‑L | S01GA53 | xylometazoline, combinations | WHO Anatomical Therapeutic Chemical classification | | xylometazoline, combinations |
0‑L | S01GA55 | phenylephrine, combinations | WHO Anatomical Therapeutic Chemical classification | | phenylephrine, combinations |
0‑L | S01GA56 | oxedrine, combinations | WHO Anatomical Therapeutic Chemical classification | | oxedrine, combinations |
0‑L | S01GX | Other antiallergics | WHO Anatomical Therapeutic Chemical classification | | Other antiallergics |
0‑L | S01GX01 | cromoglicic acid | WHO Anatomical Therapeutic Chemical classification | | cromoglicic acid |
0‑L | S01GX02 | levocabastine | WHO Anatomical Therapeutic Chemical classification | | levocabastine |
0‑L | S01GX03 | spaglumic acid | WHO Anatomical Therapeutic Chemical classification | | spaglumic acid |
0‑L | S01GX04 | nedocromil | WHO Anatomical Therapeutic Chemical classification | | nedocromil |
0‑L | S01GX05 | lodoxamide | WHO Anatomical Therapeutic Chemical classification | | lodoxamide |
0‑L | S01GX06 | emedastine | WHO Anatomical Therapeutic Chemical classification | | emedastine |
0‑L | S01GX07 | azelastine | WHO Anatomical Therapeutic Chemical classification | | azelastine |
0‑L | S01GX08 | ketotifen | WHO Anatomical Therapeutic Chemical classification | | ketotifen |
0‑L | S01GX09 | olopatadine | WHO Anatomical Therapeutic Chemical classification | | olopatadine |
0‑L | S01GX10 | epinastine | WHO Anatomical Therapeutic Chemical classification | | epinastine |
0‑L | S01GX11 | alcaftadine | WHO Anatomical Therapeutic Chemical classification | | alcaftadine |
0‑L | S01GX51 | cromoglicic acid, combinations | WHO Anatomical Therapeutic Chemical classification | | cromoglicic acid, combinations |
0‑L | S01H | LOCAL ANESTHETICS | WHO Anatomical Therapeutic Chemical classification | | LOCAL ANESTHETICS |
0‑L | S01HA | Local anesthetics | WHO Anatomical Therapeutic Chemical classification | | Local anesthetics |
0‑L | S01HA01 | cocaine | WHO Anatomical Therapeutic Chemical classification | | cocaine |
0‑L | S01HA02 | oxybuprocaine | WHO Anatomical Therapeutic Chemical classification | | oxybuprocaine |
0‑L | S01HA03 | tetracaine | WHO Anatomical Therapeutic Chemical classification | | tetracaine |
0‑L | S01HA04 | proxymetacaine | WHO Anatomical Therapeutic Chemical classification | | proxymetacaine |
0‑L | S01HA05 | procaine | WHO Anatomical Therapeutic Chemical classification | | procaine |
0‑L | S01HA06 | cinchocaine | WHO Anatomical Therapeutic Chemical classification | | cinchocaine |
0‑L | S01HA07 | lidocaine | WHO Anatomical Therapeutic Chemical classification | | lidocaine |
0‑L | S01HA30 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | S01J | DIAGNOSTIC AGENTS | WHO Anatomical Therapeutic Chemical classification | | DIAGNOSTIC AGENTS |
0‑L | S01JA | Colouring agents | WHO Anatomical Therapeutic Chemical classification | | Colouring agents |
0‑L | S01JA01 | fluorescein | WHO Anatomical Therapeutic Chemical classification | | fluorescein |
0‑L | S01JA02 | rose bengal sodium | WHO Anatomical Therapeutic Chemical classification | | rose bengal sodium |
0‑L | S01JA51 | fluorescein, combinations | WHO Anatomical Therapeutic Chemical classification | | fluorescein, combinations |
0‑L | S01JX | Other ophthalmological diagnostic agents | WHO Anatomical Therapeutic Chemical classification | | Other ophthalmological diagnostic agents |
0‑L | S01K | SURGICAL AIDS | WHO Anatomical Therapeutic Chemical classification | | SURGICAL AIDS |
0‑L | S01KA | Viscoelastic substances | WHO Anatomical Therapeutic Chemical classification | | Viscoelastic substances |
0‑L | S01KA01 | hyaluronic acid | WHO Anatomical Therapeutic Chemical classification | | hyaluronic acid |
0‑L | S01KA02 | hypromellose | WHO Anatomical Therapeutic Chemical classification | | hypromellose |
0‑L | S01KA51 | hyaluronic acid, combinations | WHO Anatomical Therapeutic Chemical classification | | hyaluronic acid, combinations |
0‑L | S01KX | Other surgical aids | WHO Anatomical Therapeutic Chemical classification | | Other surgical aids |
0‑L | S01KX01 | chymotrypsin | WHO Anatomical Therapeutic Chemical classification | | chymotrypsin |
0‑L | S01L | OCULAR VASCULAR DISORDER AGENTS | WHO Anatomical Therapeutic Chemical classification | | OCULAR VASCULAR DISORDER AGENTS |
0‑L | S01LA | Antineovascularisation agents | WHO Anatomical Therapeutic Chemical classification | | Antineovascularisation agents |
0‑L | S01LA01 | verteporfin | WHO Anatomical Therapeutic Chemical classification | | verteporfin |
0‑L | S01LA02 | anecortave | WHO Anatomical Therapeutic Chemical classification | | anecortave |
0‑L | S01LA03 | pegaptanib | WHO Anatomical Therapeutic Chemical classification | | pegaptanib |
0‑L | S01LA04 | ranibizumab | WHO Anatomical Therapeutic Chemical classification | | ranibizumab |
0‑L | S01LA05 | aflibercept | WHO Anatomical Therapeutic Chemical classification | | aflibercept |
0‑L | S01X | OTHER OPHTHALMOLOGICALS | WHO Anatomical Therapeutic Chemical classification | | OTHER OPHTHALMOLOGICALS |
0‑L | S01XA | Other ophthalmologicals | WHO Anatomical Therapeutic Chemical classification | | Other ophthalmologicals |
0‑L | S01XA01 | guaiazulen | WHO Anatomical Therapeutic Chemical classification | | guaiazulen |
0‑L | S01XA02 | retinol | WHO Anatomical Therapeutic Chemical classification | | retinol |
0‑L | S01XA03 | sodium chloride, hypertonic | WHO Anatomical Therapeutic Chemical classification | | sodium chloride, hypertonic |
0‑L | S01XA04 | potassium iodide | WHO Anatomical Therapeutic Chemical classification | | potassium iodide |
0‑L | S01XA05 | sodium edetate | WHO Anatomical Therapeutic Chemical classification | | sodium edetate |
0‑L | S01XA06 | ethylmorphine | WHO Anatomical Therapeutic Chemical classification | | ethylmorphine |
0‑L | S01XA07 | alum | WHO Anatomical Therapeutic Chemical classification | | alum |
0‑L | S01XA08 | acetylcysteine | WHO Anatomical Therapeutic Chemical classification | | acetylcysteine |
0‑L | S01XA09 | iodoheparinate | WHO Anatomical Therapeutic Chemical classification | | iodoheparinate |
0‑L | S01XA10 | inosine | WHO Anatomical Therapeutic Chemical classification | | inosine |
0‑L | S01XA11 | nandrolone | WHO Anatomical Therapeutic Chemical classification | | nandrolone |
0‑L | S01XA12 | dexpanthenol | WHO Anatomical Therapeutic Chemical classification | | dexpanthenol |
0‑L | S01XA13 | alteplase | WHO Anatomical Therapeutic Chemical classification | | alteplase |
0‑L | S01XA14 | heparin | WHO Anatomical Therapeutic Chemical classification | | heparin |
0‑L | S01XA15 | ascorbic acid | WHO Anatomical Therapeutic Chemical classification | | ascorbic acid |
0‑L | S01XA18 | ciclosporin | WHO Anatomical Therapeutic Chemical classification | | ciclosporin |
0‑L | S01XA19 | limbal stems cells, autologous | WHO Anatomical Therapeutic Chemical classification | | limbal stems cells, autologous |
0‑L | S01XA20 | artificial tears and other indifferent preparations | WHO Anatomical Therapeutic Chemical classification | | artificial tears and other indifferent preparations |
0‑L | S01XA21 | mercaptamine | WHO Anatomical Therapeutic Chemical classification | | mercaptamine |
0‑L | S01XA22 | ocriplasmin | WHO Anatomical Therapeutic Chemical classification | | ocriplasmin |
0‑L | S01XA23 | sirolimus | WHO Anatomical Therapeutic Chemical classification | | sirolimus |
0‑L | S02 | OTOLOGICALS | WHO Anatomical Therapeutic Chemical classification | | OTOLOGICALS |
0‑L | S02A | ANTIINFECTIVES | WHO Anatomical Therapeutic Chemical classification | | ANTIINFECTIVES |
0‑L | S02AA | Antiinfectives | WHO Anatomical Therapeutic Chemical classification | | Antiinfectives |
0‑L | S02AA01 | chloramphenicol | WHO Anatomical Therapeutic Chemical classification | | chloramphenicol |
0‑L | S02AA02 | nitrofural | WHO Anatomical Therapeutic Chemical classification | | nitrofural |
0‑L | S02AA03 | boric acid | WHO Anatomical Therapeutic Chemical classification | | boric acid |
0‑L | S02AA04 | aluminium acetotartrate | WHO Anatomical Therapeutic Chemical classification | | aluminium acetotartrate |
0‑L | S02AA05 | clioquinol | WHO Anatomical Therapeutic Chemical classification | | clioquinol |
0‑L | S02AA06 | hydrogen peroxide | WHO Anatomical Therapeutic Chemical classification | | hydrogen peroxide |
0‑L | S02AA07 | neomycin | WHO Anatomical Therapeutic Chemical classification | | neomycin |
0‑L | S02AA08 | tetracycline | WHO Anatomical Therapeutic Chemical classification | | tetracycline |
0‑L | S02AA09 | chlorhexidine | WHO Anatomical Therapeutic Chemical classification | | chlorhexidine |
0‑L | S02AA10 | acetic acid | WHO Anatomical Therapeutic Chemical classification | | acetic acid |
0‑L | S02AA11 | polymyxin B | WHO Anatomical Therapeutic Chemical classification | | polymyxin B |
0‑L | S02AA12 | rifamycin | WHO Anatomical Therapeutic Chemical classification | | rifamycin |
0‑L | S02AA13 | miconazole | WHO Anatomical Therapeutic Chemical classification | | miconazole |
0‑L | S02AA14 | gentamicin | WHO Anatomical Therapeutic Chemical classification | | gentamicin |
0‑L | S02AA15 | ciprofloxacin | WHO Anatomical Therapeutic Chemical classification | | ciprofloxacin |
0‑L | S02AA16 | ofloxacin | WHO Anatomical Therapeutic Chemical classification | | ofloxacin |
0‑L | S02AA30 | antiinfectives, combinations | WHO Anatomical Therapeutic Chemical classification | | antiinfectives, combinations |
0‑L | S02B | CORTICOSTEROIDS | WHO Anatomical Therapeutic Chemical classification | | CORTICOSTEROIDS |
0‑L | S02BA | Corticosteroids | WHO Anatomical Therapeutic Chemical classification | | Corticosteroids |
0‑L | S02BA01 | hydrocortisone | WHO Anatomical Therapeutic Chemical classification | | hydrocortisone |
0‑L | S02BA03 | prednisolone | WHO Anatomical Therapeutic Chemical classification | | prednisolone |
0‑L | S02BA06 | dexamethasone | WHO Anatomical Therapeutic Chemical classification | | dexamethasone |
0‑L | S02BA07 | betamethasone | WHO Anatomical Therapeutic Chemical classification | | betamethasone |
0‑L | S02BA08 | fluocinolone acetonide | WHO Anatomical Therapeutic Chemical classification | | fluocinolone acetonide |
0‑L | S02C | CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION | WHO Anatomical Therapeutic Chemical classification | | CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION |
0‑L | S02CA | Corticosteroids and antiinfectives in combination | WHO Anatomical Therapeutic Chemical classification | | Corticosteroids and antiinfectives in combination |
0‑L | S02CA01 | prednisolone and antiinfectives | WHO Anatomical Therapeutic Chemical classification | | prednisolone and antiinfectives |
0‑L | S02CA02 | flumetasone and antiinfectives | WHO Anatomical Therapeutic Chemical classification | | flumetasone and antiinfectives |
0‑L | S02CA03 | hydrocortisone and antiinfectives | WHO Anatomical Therapeutic Chemical classification | | hydrocortisone and antiinfectives |
0‑L | S02CA04 | triamcinolone and antiinfectives | WHO Anatomical Therapeutic Chemical classification | | triamcinolone and antiinfectives |
0‑L | S02CA05 | fluocinolone acetonide and antiinfectives | WHO Anatomical Therapeutic Chemical classification | | fluocinolone acetonide and antiinfectives |
0‑L | S02CA06 | dexamethasone and antiinfectives | WHO Anatomical Therapeutic Chemical classification | | dexamethasone and antiinfectives |
0‑L | S02CA07 | fludrocortisone and antiinfectives | WHO Anatomical Therapeutic Chemical classification | | fludrocortisone and antiinfectives |
0‑L | S02D | OTHER OTOLOGICALS | WHO Anatomical Therapeutic Chemical classification | | OTHER OTOLOGICALS |
0‑L | S02DA | Analgesics and anesthetics | WHO Anatomical Therapeutic Chemical classification | | Analgesics and anesthetics |
0‑L | S02DA01 | lidocaine | WHO Anatomical Therapeutic Chemical classification | | lidocaine |
0‑L | S02DA02 | cocaine | WHO Anatomical Therapeutic Chemical classification | | cocaine |
0‑L | S02DA03 | phenazone | WHO Anatomical Therapeutic Chemical classification | | phenazone |
0‑L | S02DA04 | cinchocaine | WHO Anatomical Therapeutic Chemical classification | | cinchocaine |
0‑L | S02DA30 | combinations | WHO Anatomical Therapeutic Chemical classification | | combinations |
0‑L | S02DC | Indifferent preparations | WHO Anatomical Therapeutic Chemical classification | | Indifferent preparations |
0‑L | S03 | OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS | WHO Anatomical Therapeutic Chemical classification | | OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS |
0‑L | S03A | ANTIINFECTIVES | WHO Anatomical Therapeutic Chemical classification | | ANTIINFECTIVES |
0‑L | S03AA | Antiinfectives | WHO Anatomical Therapeutic Chemical classification | | Antiinfectives |
0‑L | S03AA01 | neomycin | WHO Anatomical Therapeutic Chemical classification | | neomycin |
0‑L | S03AA02 | tetracycline | WHO Anatomical Therapeutic Chemical classification | | tetracycline |
0‑L | S03AA03 | polymyxin B | WHO Anatomical Therapeutic Chemical classification | | polymyxin B |
0‑L | S03AA04 | chlorhexidine | WHO Anatomical Therapeutic Chemical classification | | chlorhexidine |
0‑L | S03AA05 | hexamidine | WHO Anatomical Therapeutic Chemical classification | | hexamidine |
0‑L | S03AA06 | gentamicin | WHO Anatomical Therapeutic Chemical classification | | gentamicin |
0‑L | S03AA07 | ciprofloxacin | WHO Anatomical Therapeutic Chemical classification | | ciprofloxacin |
0‑L | S03AA08 | chloramphenicol | WHO Anatomical Therapeutic Chemical classification | | chloramphenicol |
0‑L | S03AA30 | antiinfectives, combinations | WHO Anatomical Therapeutic Chemical classification | | antiinfectives, combinations |
0‑L | S03B | CORTICOSTEROIDS | WHO Anatomical Therapeutic Chemical classification | | CORTICOSTEROIDS |
0‑L | S03BA | Corticosteroids | WHO Anatomical Therapeutic Chemical classification | | Corticosteroids |
0‑L | S03BA01 | dexamethasone | WHO Anatomical Therapeutic Chemical classification | | dexamethasone |
0‑L | S03BA02 | prednisolone | WHO Anatomical Therapeutic Chemical classification | | prednisolone |
0‑L | S03BA03 | betamethasone | WHO Anatomical Therapeutic Chemical classification | | betamethasone |
0‑L | S03C | CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION | WHO Anatomical Therapeutic Chemical classification | | CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION |
0‑L | S03CA | Corticosteroids and antiinfectives in combination | WHO Anatomical Therapeutic Chemical classification | | Corticosteroids and antiinfectives in combination |
0‑L | S03CA01 | dexamethasone and antiinfectives | WHO Anatomical Therapeutic Chemical classification | | dexamethasone and antiinfectives |
0‑L | S03CA02 | prednisolone and antiinfectives | WHO Anatomical Therapeutic Chemical classification | | prednisolone and antiinfectives |
0‑L | S03CA04 | hydrocortisone and antiinfectives | WHO Anatomical Therapeutic Chemical classification | | hydrocortisone and antiinfectives |
0‑L | S03CA05 | fludrocortisone and antiinfectives | WHO Anatomical Therapeutic Chemical classification | | fludrocortisone and antiinfectives |
0‑L | S03CA06 | betamethasone and antiinfectives | WHO Anatomical Therapeutic Chemical classification | | betamethasone and antiinfectives |
0‑L | S03D | OTHER OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS | WHO Anatomical Therapeutic Chemical classification | | OTHER OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS |
0‑L | V | VARIOUS | WHO Anatomical Therapeutic Chemical classification | | VARIOUS |
0‑L | V01 | ALLERGENS | WHO Anatomical Therapeutic Chemical classification | | ALLERGENS |
0‑L | V01A | ALLERGENS | WHO Anatomical Therapeutic Chemical classification | | ALLERGENS |
0‑L | V01AA | Allergen extracts | WHO Anatomical Therapeutic Chemical classification | | Allergen extracts |
0‑L | V01AA01 | feather | WHO Anatomical Therapeutic Chemical classification | | feather |
0‑L | V01AA02 | grass pollen | WHO Anatomical Therapeutic Chemical classification | | grass pollen |
0‑L | V01AA03 | house dust mites | WHO Anatomical Therapeutic Chemical classification | | house dust mites |
0‑L | V01AA04 | mould fungus and yeast fungus | WHO Anatomical Therapeutic Chemical classification | | mould fungus and yeast fungus |
0‑L | V01AA05 | tree pollen | WHO Anatomical Therapeutic Chemical classification | | tree pollen |
0‑L | V01AA07 | insects | WHO Anatomical Therapeutic Chemical classification | | insects |
0‑L | V01AA08 | food | WHO Anatomical Therapeutic Chemical classification | | food |
0‑L | V01AA09 | textiles | WHO Anatomical Therapeutic Chemical classification | | textiles |
0‑L | V01AA10 | flowers | WHO Anatomical Therapeutic Chemical classification | | flowers |
0‑L | V01AA11 | animals | WHO Anatomical Therapeutic Chemical classification | | animals |
0‑L | V01AA20 | various | WHO Anatomical Therapeutic Chemical classification | | various |
0‑L | V03 | ALL OTHER THERAPEUTIC PRODUCTS | WHO Anatomical Therapeutic Chemical classification | | ALL OTHER THERAPEUTIC PRODUCTS |
0‑L | V03A | ALL OTHER THERAPEUTIC PRODUCTS | WHO Anatomical Therapeutic Chemical classification | | ALL OTHER THERAPEUTIC PRODUCTS |
0‑L | V03AB | Antidotes | WHO Anatomical Therapeutic Chemical classification | | Antidotes |
0‑L | V03AB01 | ipecacuanha | WHO Anatomical Therapeutic Chemical classification | | ipecacuanha |
0‑L | V03AB02 | nalorphine | WHO Anatomical Therapeutic Chemical classification | | nalorphine |
0‑L | V03AB03 | edetates | WHO Anatomical Therapeutic Chemical classification | | edetates |
0‑L | V03AB04 | pralidoxime | WHO Anatomical Therapeutic Chemical classification | | pralidoxime |
0‑L | V03AB05 | prednisolone and promethazine | WHO Anatomical Therapeutic Chemical classification | | prednisolone and promethazine |
0‑L | V03AB06 | thiosulfate | WHO Anatomical Therapeutic Chemical classification | | thiosulfate |
0‑L | V03AB08 | sodium nitrite | WHO Anatomical Therapeutic Chemical classification | | sodium nitrite |
0‑L | V03AB09 | dimercaprol | WHO Anatomical Therapeutic Chemical classification | | dimercaprol |
0‑L | V03AB13 | obidoxime | WHO Anatomical Therapeutic Chemical classification | | obidoxime |
0‑L | V03AB14 | protamine | WHO Anatomical Therapeutic Chemical classification | | protamine |
0‑L | V03AB15 | naloxone | WHO Anatomical Therapeutic Chemical classification | | naloxone |
0‑L | V03AB16 | ethanol | WHO Anatomical Therapeutic Chemical classification | | ethanol |
0‑L | V03AB17 | methylthioninium chloride | WHO Anatomical Therapeutic Chemical classification | | methylthioninium chloride |
0‑L | V03AB18 | potassium permanganate | WHO Anatomical Therapeutic Chemical classification | | potassium permanganate |
0‑L | V03AB19 | physostigmine | WHO Anatomical Therapeutic Chemical classification | | physostigmine |
0‑L | V03AB20 | copper sulfate | WHO Anatomical Therapeutic Chemical classification | | copper sulfate |
0‑L | V03AB21 | potassium iodide | WHO Anatomical Therapeutic Chemical classification | | potassium iodide |
0‑L | V03AB22 | amyl nitrite | WHO Anatomical Therapeutic Chemical classification | | amyl nitrite |
0‑L | V03AB23 | acetylcysteine | WHO Anatomical Therapeutic Chemical classification | | acetylcysteine |
0‑L | V03AB24 | digitalis antitoxin | WHO Anatomical Therapeutic Chemical classification | | digitalis antitoxin |
0‑L | V03AB25 | flumazenil | WHO Anatomical Therapeutic Chemical classification | | flumazenil |
0‑L | V03AB26 | methionine | WHO Anatomical Therapeutic Chemical classification | | methionine |
0‑L | V03AB27 | 4-dimethylaminophenol | WHO Anatomical Therapeutic Chemical classification | | 4-dimethylaminophenol |
0‑L | V03AB29 | cholinesterase | WHO Anatomical Therapeutic Chemical classification | | cholinesterase |
0‑L | V03AB31 | prussian blue | WHO Anatomical Therapeutic Chemical classification | | prussian blue |
0‑L | V03AB32 | glutathione | WHO Anatomical Therapeutic Chemical classification | | glutathione |
0‑L | V03AB33 | hydroxocobalamin | WHO Anatomical Therapeutic Chemical classification | | hydroxocobalamin |
0‑L | V03AB34 | fomepizole | WHO Anatomical Therapeutic Chemical classification | | fomepizole |
0‑L | V03AB35 | sugammadex | WHO Anatomical Therapeutic Chemical classification | | sugammadex |
0‑L | V03AB36 | phentolamine | WHO Anatomical Therapeutic Chemical classification | | phentolamine |
0‑L | V03AB37 | idarucizumab | WHO Anatomical Therapeutic Chemical classification | | idarucizumab |
0‑L | V03AC | Iron chelating agents | WHO Anatomical Therapeutic Chemical classification | | Iron chelating agents |
0‑L | V03AC01 | deferoxamine | WHO Anatomical Therapeutic Chemical classification | | deferoxamine |
0‑L | V03AC02 | deferiprone | WHO Anatomical Therapeutic Chemical classification | | deferiprone |
0‑L | V03AC03 | deferasirox | WHO Anatomical Therapeutic Chemical classification | | deferasirox |
0‑L | V03AE | Drugs for treatment of hyperkalemia and hyperphosphatemia | WHO Anatomical Therapeutic Chemical classification | | Drugs for treatment of hyperkalemia and hyperphosphatemia |
0‑L | V03AE01 | polystyrene sulfonate | WHO Anatomical Therapeutic Chemical classification | | polystyrene sulfonate |
0‑L | V03AE02 | sevelamer | WHO Anatomical Therapeutic Chemical classification | | sevelamer |
0‑L | V03AE03 | lanthanum carbonate | WHO Anatomical Therapeutic Chemical classification | | lanthanum carbonate |
0‑L | V03AE04 | calcium acetate and magnesium carbonate | WHO Anatomical Therapeutic Chemical classification | | calcium acetate and magnesium carbonate |
0‑L | V03AE05 | sucroferric oxyhydroxide | WHO Anatomical Therapeutic Chemical classification | | sucroferric oxyhydroxide |
0‑L | V03AE06 | colestilan | WHO Anatomical Therapeutic Chemical classification | | colestilan |
0‑L | V03AE07 | calcium acetate | WHO Anatomical Therapeutic Chemical classification | | calcium acetate |
0‑L | V03AE08 | ferric citrate | WHO Anatomical Therapeutic Chemical classification | | ferric citrate |
0‑L | V03AE09 | patiromer calcium | WHO Anatomical Therapeutic Chemical classification | | patiromer calcium |
0‑L | V03AF | Detoxifying agents for antineoplastic treatment | WHO Anatomical Therapeutic Chemical classification | | Detoxifying agents for antineoplastic treatment |
0‑L | V03AF01 | mesna | WHO Anatomical Therapeutic Chemical classification | | mesna |
0‑L | V03AF02 | dexrazoxane | WHO Anatomical Therapeutic Chemical classification | | dexrazoxane |
0‑L | V03AF03 | calcium folinate | WHO Anatomical Therapeutic Chemical classification | | calcium folinate |
0‑L | V03AF04 | calcium levofolinate | WHO Anatomical Therapeutic Chemical classification | | calcium levofolinate |
0‑L | V03AF05 | amifostine | WHO Anatomical Therapeutic Chemical classification | | amifostine |
0‑L | V03AF06 | sodium folinate | WHO Anatomical Therapeutic Chemical classification | | sodium folinate |
0‑L | V03AF07 | rasburicase | WHO Anatomical Therapeutic Chemical classification | | rasburicase |
0‑L | V03AF08 | palifermin | WHO Anatomical Therapeutic Chemical classification | | palifermin |
0‑L | V03AF09 | glucarpidase | WHO Anatomical Therapeutic Chemical classification | | glucarpidase |
0‑L | V03AF10 | sodium levofolinate | WHO Anatomical Therapeutic Chemical classification | | sodium levofolinate |
0‑L | V03AG | Drugs for treatment of hypercalcemia | WHO Anatomical Therapeutic Chemical classification | | Drugs for treatment of hypercalcemia |
0‑L | V03AG01 | sodium cellulose phosphate | WHO Anatomical Therapeutic Chemical classification | | sodium cellulose phosphate |
0‑L | V03AH | Drugs for treatment of hypoglycemia | WHO Anatomical Therapeutic Chemical classification | | Drugs for treatment of hypoglycemia |
0‑L | V03AH01 | diazoxide | WHO Anatomical Therapeutic Chemical classification | | diazoxide |
0‑L | V03AK | Tissue adhesives | WHO Anatomical Therapeutic Chemical classification | | Tissue adhesives |
0‑L | V03AM | Drugs for embolisation | WHO Anatomical Therapeutic Chemical classification | | Drugs for embolisation |
0‑L | V03AN | Medical gases | WHO Anatomical Therapeutic Chemical classification | | Medical gases |
0‑L | V03AN01 | oxygen | WHO Anatomical Therapeutic Chemical classification | | oxygen |
0‑L | V03AN02 | carbon dioxide | WHO Anatomical Therapeutic Chemical classification | | carbon dioxide |
0‑L | V03AN03 | helium | WHO Anatomical Therapeutic Chemical classification | | helium |
0‑L | V03AN04 | nitrogen | WHO Anatomical Therapeutic Chemical classification | | nitrogen |
0‑L | V03AN05 | medical air | WHO Anatomical Therapeutic Chemical classification | | medical air |
0‑L | V03AX | Other therapeutic products | WHO Anatomical Therapeutic Chemical classification | | Other therapeutic products |
0‑L | V03AX02 | nalfurafine | WHO Anatomical Therapeutic Chemical classification | | nalfurafine |
0‑L | V03AX03 | cobicistat | WHO Anatomical Therapeutic Chemical classification | | cobicistat |
0‑L | V03AZ | Nerve depressants | WHO Anatomical Therapeutic Chemical classification | | Nerve depressants |
0‑L | V03AZ01 | ethanol | WHO Anatomical Therapeutic Chemical classification | | ethanol |
0‑L | V04 | DIAGNOSTIC AGENTS | WHO Anatomical Therapeutic Chemical classification | | DIAGNOSTIC AGENTS |
0‑L | V04B | URINE TESTS | WHO Anatomical Therapeutic Chemical classification | | URINE TESTS |
0‑L | V04C | OTHER DIAGNOSTIC AGENTS | WHO Anatomical Therapeutic Chemical classification | | OTHER DIAGNOSTIC AGENTS |
0‑L | V04CA | Tests for diabetes | WHO Anatomical Therapeutic Chemical classification | | Tests for diabetes |
0‑L | V04CA01 | tolbutamide | WHO Anatomical Therapeutic Chemical classification | | tolbutamide |
0‑L | V04CA02 | glucose | WHO Anatomical Therapeutic Chemical classification | | glucose |
0‑L | V04CB | Tests for fat absorption | WHO Anatomical Therapeutic Chemical classification | | Tests for fat absorption |
0‑L | V04CB01 | vitamin A concentrates | WHO Anatomical Therapeutic Chemical classification | | vitamin A concentrates |
0‑L | V04CC | Tests for bile duct patency | WHO Anatomical Therapeutic Chemical classification | | Tests for bile duct patency |
0‑L | V04CC01 | sorbitol | WHO Anatomical Therapeutic Chemical classification | | sorbitol |
0‑L | V04CC02 | magnesium sulfate | WHO Anatomical Therapeutic Chemical classification | | magnesium sulfate |
0‑L | V04CC03 | sincalide | WHO Anatomical Therapeutic Chemical classification | | sincalide |
0‑L | V04CC04 | ceruletide | WHO Anatomical Therapeutic Chemical classification | | ceruletide |
0‑L | V04CD | Tests for pituitary function | WHO Anatomical Therapeutic Chemical classification | | Tests for pituitary function |
0‑L | V04CD01 | metyrapone | WHO Anatomical Therapeutic Chemical classification | | metyrapone |
0‑L | V04CD03 | sermorelin | WHO Anatomical Therapeutic Chemical classification | | sermorelin |
0‑L | V04CD04 | corticorelin | WHO Anatomical Therapeutic Chemical classification | | corticorelin |
0‑L | V04CD05 | somatorelin | WHO Anatomical Therapeutic Chemical classification | | somatorelin |
0‑L | V04CD06 | macimorelin | WHO Anatomical Therapeutic Chemical classification | | macimorelin |
0‑L | V04CE | Tests for liver functional capacity | WHO Anatomical Therapeutic Chemical classification | | Tests for liver functional capacity |
0‑L | V04CE01 | galactose | WHO Anatomical Therapeutic Chemical classification | | galactose |
0‑L | V04CE02 | sulfobromophthalein | WHO Anatomical Therapeutic Chemical classification | | sulfobromophthalein |
0‑L | V04CE03 | methacetin (13C) | WHO Anatomical Therapeutic Chemical classification | | methacetin (13C) |
0‑L | V04CF | Tuberculosis diagnostics | WHO Anatomical Therapeutic Chemical classification | | Tuberculosis diagnostics |
0‑L | V04CF01 | tuberculin | WHO Anatomical Therapeutic Chemical classification | | tuberculin |
0‑L | V04CG | Tests for gastric secretion | WHO Anatomical Therapeutic Chemical classification | | Tests for gastric secretion |
0‑L | V04CG01 | cation exchange resins | WHO Anatomical Therapeutic Chemical classification | | cation exchange resins |
0‑L | V04CG02 | betazole | WHO Anatomical Therapeutic Chemical classification | | betazole |
0‑L | V04CG03 | histamine phosphate | WHO Anatomical Therapeutic Chemical classification | | histamine phosphate |
0‑L | V04CG04 | pentagastrin | WHO Anatomical Therapeutic Chemical classification | | pentagastrin |
0‑L | V04CG05 | methylthioninium chloride | WHO Anatomical Therapeutic Chemical classification | | methylthioninium chloride |
0‑L | V04CG30 | caffeine and sodium benzoate | WHO Anatomical Therapeutic Chemical classification | | caffeine and sodium benzoate |
0‑L | V04CH | Tests for renal function and ureteral injuries | WHO Anatomical Therapeutic Chemical classification | | Tests for renal function and ureteral injuries |
0‑L | V04CH01 | inulin and other polyfructosans | WHO Anatomical Therapeutic Chemical classification | | inulin and other polyfructosans |
0‑L | V04CH02 | indigo carmine | WHO Anatomical Therapeutic Chemical classification | | indigo carmine |
0‑L | V04CH03 | phenolsulfonphthalein | WHO Anatomical Therapeutic Chemical classification | | phenolsulfonphthalein |
0‑L | V04CH04 | alsactide | WHO Anatomical Therapeutic Chemical classification | | alsactide |
0‑L | V04CH30 | aminohippuric acid | WHO Anatomical Therapeutic Chemical classification | | aminohippuric acid |
0‑L | V04CJ | Tests for thyreoidea function | WHO Anatomical Therapeutic Chemical classification | | Tests for thyreoidea function |
0‑L | V04CJ01 | thyrotropin | WHO Anatomical Therapeutic Chemical classification | | thyrotropin |
0‑L | V04CJ02 | protirelin | WHO Anatomical Therapeutic Chemical classification | | protirelin |
0‑L | V04CK | Tests for pancreatic function | WHO Anatomical Therapeutic Chemical classification | | Tests for pancreatic function |
0‑L | V04CK01 | secretin | WHO Anatomical Therapeutic Chemical classification | | secretin |
0‑L | V04CK02 | pancreozymin (cholecystokinin) | WHO Anatomical Therapeutic Chemical classification | | pancreozymin (cholecystokinin) |
0‑L | V04CK03 | bentiromide | WHO Anatomical Therapeutic Chemical classification | | bentiromide |
0‑L | V04CL | Tests for allergic diseases | WHO Anatomical Therapeutic Chemical classification | | Tests for allergic diseases |
0‑L | V04CM | Tests for fertility disturbances | WHO Anatomical Therapeutic Chemical classification | | Tests for fertility disturbances |
0‑L | V04CM01 | gonadorelin | WHO Anatomical Therapeutic Chemical classification | | gonadorelin |
0‑L | V04CX | Other diagnostic agents | WHO Anatomical Therapeutic Chemical classification | | Other diagnostic agents |
0‑L | V06 | GENERAL NUTRIENTS | WHO Anatomical Therapeutic Chemical classification | | GENERAL NUTRIENTS |
0‑L | V06A | DIET FORMULATIONS FOR TREATMENT OF OBESITY | WHO Anatomical Therapeutic Chemical classification | | DIET FORMULATIONS FOR TREATMENT OF OBESITY |
0‑L | V06AA | Low-energy diets | WHO Anatomical Therapeutic Chemical classification | | Low-energy diets |
0‑L | V06B | PROTEIN SUPPLEMENTS | WHO Anatomical Therapeutic Chemical classification | | PROTEIN SUPPLEMENTS |
0‑L | V06C | INFANT FORMULAS | WHO Anatomical Therapeutic Chemical classification | | INFANT FORMULAS |
0‑L | V06CA | Nutrients without phenylalanine | WHO Anatomical Therapeutic Chemical classification | | Nutrients without phenylalanine |
0‑L | V06D | OTHER NUTRIENTS | WHO Anatomical Therapeutic Chemical classification | | OTHER NUTRIENTS |
0‑L | V06DA | Carbohydrates/proteins/minerals/vitamins, combinations | WHO Anatomical Therapeutic Chemical classification | | Carbohydrates/proteins/minerals/vitamins, combinations |
0‑L | V06DB | Fat/carbohydrates/proteins/minerals/vitamins, combinations | WHO Anatomical Therapeutic Chemical classification | | Fat/carbohydrates/proteins/minerals/vitamins, combinations |
0‑L | V06DC | Carbohydrates | WHO Anatomical Therapeutic Chemical classification | | Carbohydrates |
0‑L | V06DC01 | glucose | WHO Anatomical Therapeutic Chemical classification | | glucose |
0‑L | V06DC02 | fructose | WHO Anatomical Therapeutic Chemical classification | | fructose |
0‑L | V06DD | Amino acids, incl. combinations with polypeptides | WHO Anatomical Therapeutic Chemical classification | | Amino acids, incl. combinations with polypeptides |
0‑L | V06DE | Amino acids/carbohydrates/minerals/vitamins, combinations | WHO Anatomical Therapeutic Chemical classification | | Amino acids/carbohydrates/minerals/vitamins, combinations |
0‑L | V06DF | Milk substitutes | WHO Anatomical Therapeutic Chemical classification | | Milk substitutes |
0‑L | V06DX | Other combinations of nutrients | WHO Anatomical Therapeutic Chemical classification | | Other combinations of nutrients |
0‑L | V07 | ALL OTHER NON-THERAPEUTIC PRODUCTS | WHO Anatomical Therapeutic Chemical classification | | ALL OTHER NON-THERAPEUTIC PRODUCTS |
0‑L | V07A | ALL OTHER NON-THERAPEUTIC PRODUCTS | WHO Anatomical Therapeutic Chemical classification | | ALL OTHER NON-THERAPEUTIC PRODUCTS |
0‑L | V07AA | Plasters | WHO Anatomical Therapeutic Chemical classification | | Plasters |
0‑L | V07AB | Solvents and diluting agents, incl. irrigating solutions | WHO Anatomical Therapeutic Chemical classification | | Solvents and diluting agents, incl. irrigating solutions |
0‑L | V07AC | Blood transfusion, auxiliary products | WHO Anatomical Therapeutic Chemical classification | | Blood transfusion, auxiliary products |
0‑L | V07AD | Blood tests, auxiliary products | WHO Anatomical Therapeutic Chemical classification | | Blood tests, auxiliary products |
0‑L | V07AN | Incontinence equipment | WHO Anatomical Therapeutic Chemical classification | | Incontinence equipment |
0‑L | V07AR | Sensitivity tests, discs and tablets | WHO Anatomical Therapeutic Chemical classification | | Sensitivity tests, discs and tablets |
0‑L | V07AS | Stomi equipment | WHO Anatomical Therapeutic Chemical classification | | Stomi equipment |
0‑L | V07AT | Cosmetics | WHO Anatomical Therapeutic Chemical classification | | Cosmetics |
0‑L | V07AV | Technical disinfectants | WHO Anatomical Therapeutic Chemical classification | | Technical disinfectants |
0‑L | V07AX | Washing agents etc. | WHO Anatomical Therapeutic Chemical classification | | Washing agents etc. |
0‑L | V07AY | Other non-therapeutic auxiliary products | WHO Anatomical Therapeutic Chemical classification | | Other non-therapeutic auxiliary products |
0‑L | V07AZ | Chemicals and reagents for analysis | WHO Anatomical Therapeutic Chemical classification | | Chemicals and reagents for analysis |
0‑L | V08 | CONTRAST MEDIA | WHO Anatomical Therapeutic Chemical classification | | CONTRAST MEDIA |
0‑L | V08A | X-RAY CONTRAST MEDIA, IODINATED | WHO Anatomical Therapeutic Chemical classification | | X-RAY CONTRAST MEDIA, IODINATED |
0‑L | V08AA | Watersoluble, nephrotropic, high osmolar X-ray contrast media | WHO Anatomical Therapeutic Chemical classification | | Watersoluble, nephrotropic, high osmolar X-ray contrast media |
0‑L | V08AA01 | diatrizoic acid | WHO Anatomical Therapeutic Chemical classification | | diatrizoic acid |
0‑L | V08AA02 | metrizoic acid | WHO Anatomical Therapeutic Chemical classification | | metrizoic acid |
0‑L | V08AA03 | iodamide | WHO Anatomical Therapeutic Chemical classification | | iodamide |
0‑L | V08AA04 | iotalamic acid | WHO Anatomical Therapeutic Chemical classification | | iotalamic acid |
0‑L | V08AA05 | ioxitalamic acid | WHO Anatomical Therapeutic Chemical classification | | ioxitalamic acid |
0‑L | V08AA06 | ioglicic acid | WHO Anatomical Therapeutic Chemical classification | | ioglicic acid |
0‑L | V08AA07 | acetrizoic acid | WHO Anatomical Therapeutic Chemical classification | | acetrizoic acid |
0‑L | V08AA08 | iocarmic acid | WHO Anatomical Therapeutic Chemical classification | | iocarmic acid |
0‑L | V08AA09 | methiodal | WHO Anatomical Therapeutic Chemical classification | | methiodal |
0‑L | V08AA10 | diodone | WHO Anatomical Therapeutic Chemical classification | | diodone |
0‑L | V08AB | Watersoluble, nephrotropic, low osmolar X-ray contrast media | WHO Anatomical Therapeutic Chemical classification | | Watersoluble, nephrotropic, low osmolar X-ray contrast media |
0‑L | V08AB01 | metrizamide | WHO Anatomical Therapeutic Chemical classification | | metrizamide |
0‑L | V08AB02 | iohexol | WHO Anatomical Therapeutic Chemical classification | | iohexol |
0‑L | V08AB03 | ioxaglic acid | WHO Anatomical Therapeutic Chemical classification | | ioxaglic acid |
0‑L | V08AB04 | iopamidol | WHO Anatomical Therapeutic Chemical classification | | iopamidol |
0‑L | V08AB05 | iopromide | WHO Anatomical Therapeutic Chemical classification | | iopromide |
0‑L | V08AB06 | iotrolan | WHO Anatomical Therapeutic Chemical classification | | iotrolan |
0‑L | V08AB07 | ioversol | WHO Anatomical Therapeutic Chemical classification | | ioversol |
0‑L | V08AB08 | iopentol | WHO Anatomical Therapeutic Chemical classification | | iopentol |
0‑L | V08AB09 | iodixanol | WHO Anatomical Therapeutic Chemical classification | | iodixanol |
0‑L | V08AB10 | iomeprol | WHO Anatomical Therapeutic Chemical classification | | iomeprol |
0‑L | V08AB11 | iobitridol | WHO Anatomical Therapeutic Chemical classification | | iobitridol |
0‑L | V08AB12 | ioxilan | WHO Anatomical Therapeutic Chemical classification | | ioxilan |
0‑L | V08AC | Watersoluble, hepatotropic X-ray contrast media | WHO Anatomical Therapeutic Chemical classification | | Watersoluble, hepatotropic X-ray contrast media |
0‑L | V08AC01 | iodoxamic acid | WHO Anatomical Therapeutic Chemical classification | | iodoxamic acid |
0‑L | V08AC02 | iotroxic acid | WHO Anatomical Therapeutic Chemical classification | | iotroxic acid |
0‑L | V08AC03 | ioglycamic acid | WHO Anatomical Therapeutic Chemical classification | | ioglycamic acid |
0‑L | V08AC04 | adipiodone | WHO Anatomical Therapeutic Chemical classification | | adipiodone |
0‑L | V08AC05 | iobenzamic acid | WHO Anatomical Therapeutic Chemical classification | | iobenzamic acid |
0‑L | V08AC06 | iopanoic acid | WHO Anatomical Therapeutic Chemical classification | | iopanoic acid |
0‑L | V08AC07 | iocetamic acid | WHO Anatomical Therapeutic Chemical classification | | iocetamic acid |
0‑L | V08AC08 | sodium iopodate | WHO Anatomical Therapeutic Chemical classification | | sodium iopodate |
0‑L | V08AC09 | tyropanoic acid | WHO Anatomical Therapeutic Chemical classification | | tyropanoic acid |
0‑L | V08AC10 | calcium iopodate | WHO Anatomical Therapeutic Chemical classification | | calcium iopodate |
0‑L | V08AD | Non-watersoluble X-ray contrast media | WHO Anatomical Therapeutic Chemical classification | | Non-watersoluble X-ray contrast media |
0‑L | V08AD01 | ethyl esters of iodised fatty acids | WHO Anatomical Therapeutic Chemical classification | | ethyl esters of iodised fatty acids |
0‑L | V08AD02 | iopydol | WHO Anatomical Therapeutic Chemical classification | | iopydol |
0‑L | V08AD03 | propyliodone | WHO Anatomical Therapeutic Chemical classification | | propyliodone |
0‑L | V08AD04 | iofendylate | WHO Anatomical Therapeutic Chemical classification | | iofendylate |
0‑L | V08B | X-RAY CONTRAST MEDIA, NON-IODINATED | WHO Anatomical Therapeutic Chemical classification | | X-RAY CONTRAST MEDIA, NON-IODINATED |
0‑L | V08BA | Barium sulfate containing X-ray contrast media | WHO Anatomical Therapeutic Chemical classification | | Barium sulfate containing X-ray contrast media |
0‑L | V08BA01 | barium sulfate with suspending agents | WHO Anatomical Therapeutic Chemical classification | | barium sulfate with suspending agents |
0‑L | V08BA02 | barium sulfate without suspending agents | WHO Anatomical Therapeutic Chemical classification | | barium sulfate without suspending agents |
0‑L | V08C | MAGNETIC RESONANCE IMAGING CONTRAST MEDIA | WHO Anatomical Therapeutic Chemical classification | | MAGNETIC RESONANCE IMAGING CONTRAST MEDIA |
0‑L | V08CA | Paramagnetic contrast media | WHO Anatomical Therapeutic Chemical classification | | Paramagnetic contrast media |
0‑L | V08CA01 | gadopentetic acid | WHO Anatomical Therapeutic Chemical classification | | gadopentetic acid |
0‑L | V08CA02 | gadoteric acid | WHO Anatomical Therapeutic Chemical classification | | gadoteric acid |
0‑L | V08CA03 | gadodiamide | WHO Anatomical Therapeutic Chemical classification | | gadodiamide |
0‑L | V08CA04 | gadoteridol | WHO Anatomical Therapeutic Chemical classification | | gadoteridol |
0‑L | V08CA05 | mangafodipir | WHO Anatomical Therapeutic Chemical classification | | mangafodipir |
0‑L | V08CA06 | gadoversetamide | WHO Anatomical Therapeutic Chemical classification | | gadoversetamide |
0‑L | V08CA07 | ferric ammonium citrate | WHO Anatomical Therapeutic Chemical classification | | ferric ammonium citrate |
0‑L | V08CA08 | gadobenic acid | WHO Anatomical Therapeutic Chemical classification | | gadobenic acid |
0‑L | V08CA09 | gadobutrol | WHO Anatomical Therapeutic Chemical classification | | gadobutrol |
0‑L | V08CA10 | gadoxetic acid | WHO Anatomical Therapeutic Chemical classification | | gadoxetic acid |
0‑L | V08CA11 | gadofosveset | WHO Anatomical Therapeutic Chemical classification | | gadofosveset |
0‑L | V08CB | Superparamagnetic contrast media | WHO Anatomical Therapeutic Chemical classification | | Superparamagnetic contrast media |
0‑L | V08CB01 | ferumoxsil | WHO Anatomical Therapeutic Chemical classification | | ferumoxsil |
0‑L | V08CB02 | ferristene | WHO Anatomical Therapeutic Chemical classification | | ferristene |
0‑L | V08CB03 | iron oxide, nanoparticles | WHO Anatomical Therapeutic Chemical classification | | iron oxide, nanoparticles |
0‑L | V08CX | Other magnetic resonance imaging contrast media | WHO Anatomical Therapeutic Chemical classification | | Other magnetic resonance imaging contrast media |
0‑L | V08CX01 | perflubron | WHO Anatomical Therapeutic Chemical classification | | perflubron |
0‑L | V08D | ULTRASOUND CONTRAST MEDIA | WHO Anatomical Therapeutic Chemical classification | | ULTRASOUND CONTRAST MEDIA |
0‑L | V08DA | Ultrasound contrast media | WHO Anatomical Therapeutic Chemical classification | | Ultrasound contrast media |
0‑L | V08DA01 | microspheres of human albumin | WHO Anatomical Therapeutic Chemical classification | | microspheres of human albumin |
0‑L | V08DA02 | microparticles of galactose | WHO Anatomical Therapeutic Chemical classification | | microparticles of galactose |
0‑L | V08DA03 | perflenapent | WHO Anatomical Therapeutic Chemical classification | | perflenapent |
0‑L | V08DA04 | microspheres of phospholipids | WHO Anatomical Therapeutic Chemical classification | | microspheres of phospholipids |
0‑L | V08DA05 | sulfur hexafluoride | WHO Anatomical Therapeutic Chemical classification | | sulfur hexafluoride |
0‑L | V08DA06 | perflubutane polymer microspheres | WHO Anatomical Therapeutic Chemical classification | | perflubutane polymer microspheres |
0‑L | V09 | DIAGNOSTIC RADIOPHARMACEUTICALS | WHO Anatomical Therapeutic Chemical classification | | DIAGNOSTIC RADIOPHARMACEUTICALS |
0‑L | V09A | CENTRAL NERVOUS SYSTEM | WHO Anatomical Therapeutic Chemical classification | | CENTRAL NERVOUS SYSTEM |
0‑L | V09AA | Technetium (99mTc) compounds | WHO Anatomical Therapeutic Chemical classification | | Technetium (99mTc) compounds |
0‑L | V09AA01 | technetium (99mTc) exametazime | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) exametazime |
0‑L | V09AA02 | technetium (99mTc) bicisate | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) bicisate |
0‑L | V09AB | Iodine (123I) compounds | WHO Anatomical Therapeutic Chemical classification | | Iodine (123I) compounds |
0‑L | V09AB01 | iodine iofetamine (123I) | WHO Anatomical Therapeutic Chemical classification | | iodine iofetamine (123I) |
0‑L | V09AB02 | iodine iolopride (123I) | WHO Anatomical Therapeutic Chemical classification | | iodine iolopride (123I) |
0‑L | V09AB03 | iodine ioflupane (123I) | WHO Anatomical Therapeutic Chemical classification | | iodine ioflupane (123I) |
0‑L | V09AX | Other central nervous system diagnostic radiopharmaceuticals | WHO Anatomical Therapeutic Chemical classification | | Other central nervous system diagnostic radiopharmaceuticals |
0‑L | V09AX01 | indium (111In) pentetic acid | WHO Anatomical Therapeutic Chemical classification | | indium (111In) pentetic acid |
0‑L | V09AX03 | iodine (124I) 2beta-carbomethoxy-3beta-(4 iodophenyl)-tropane | WHO Anatomical Therapeutic Chemical classification | | iodine (124I) 2beta-carbomethoxy-3beta-(4 iodophenyl)-tropane |
0‑L | V09AX04 | flutemetamol (18F) | WHO Anatomical Therapeutic Chemical classification | | flutemetamol (18F) |
0‑L | V09AX05 | florbetapir (18F) | WHO Anatomical Therapeutic Chemical classification | | florbetapir (18F) |
0‑L | V09AX06 | florbetaben (18F) | WHO Anatomical Therapeutic Chemical classification | | florbetaben (18F) |
0‑L | V09B | SKELETON | WHO Anatomical Therapeutic Chemical classification | | SKELETON |
0‑L | V09BA | Technetium (99mTc) compounds | WHO Anatomical Therapeutic Chemical classification | | Technetium (99mTc) compounds |
0‑L | V09BA01 | technetium (99mTc) oxidronic acid | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) oxidronic acid |
0‑L | V09BA02 | technetium (99mTc) medronic acid | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) medronic acid |
0‑L | V09BA03 | technetium (99mTc) pyrophosphate | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) pyrophosphate |
0‑L | V09BA04 | technetium (99mTc) butedronic acid | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) butedronic acid |
0‑L | V09C | RENAL SYSTEM | WHO Anatomical Therapeutic Chemical classification | | RENAL SYSTEM |
0‑L | V09CA | Technetium (99mTc) compounds | WHO Anatomical Therapeutic Chemical classification | | Technetium (99mTc) compounds |
0‑L | V09CA01 | technetium (99mTc) pentetic acid | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) pentetic acid |
0‑L | V09CA02 | technetium (99mTc) succimer | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) succimer |
0‑L | V09CA03 | technetium (99mTc) mertiatide | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) mertiatide |
0‑L | V09CA04 | technetium (99mTc) gluceptate | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) gluceptate |
0‑L | V09CA05 | technetium (99mTc) gluconate | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) gluconate |
0‑L | V09CA06 | technetium (99mTc) ethylenedicysteine | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) ethylenedicysteine |
0‑L | V09CX | Other renal system diagnostic radiopharmaceuticals | WHO Anatomical Therapeutic Chemical classification | | Other renal system diagnostic radiopharmaceuticals |
0‑L | V09CX01 | sodium iodohippurate (123I) | WHO Anatomical Therapeutic Chemical classification | | sodium iodohippurate (123I) |
0‑L | V09CX02 | sodium iodohippurate (131I) | WHO Anatomical Therapeutic Chemical classification | | sodium iodohippurate (131I) |
0‑L | V09CX03 | sodium iothalamate (125I) | WHO Anatomical Therapeutic Chemical classification | | sodium iothalamate (125I) |
0‑L | V09CX04 | chromium (51Cr) edetate | WHO Anatomical Therapeutic Chemical classification | | chromium (51Cr) edetate |
0‑L | V09D | HEPATIC AND RETICULO ENDOTHELIAL SYSTEM | WHO Anatomical Therapeutic Chemical classification | | HEPATIC AND RETICULO ENDOTHELIAL SYSTEM |
0‑L | V09DA | Technetium (99mTc) compounds | WHO Anatomical Therapeutic Chemical classification | | Technetium (99mTc) compounds |
0‑L | V09DA01 | technetium (99mTc) disofenin | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) disofenin |
0‑L | V09DA02 | technetium (99mTc) etifenin | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) etifenin |
0‑L | V09DA03 | technetium (99mTc) lidofenin | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) lidofenin |
0‑L | V09DA04 | technetium (99mTc) mebrofenin | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) mebrofenin |
0‑L | V09DA05 | technetium (99mTc) galtifenin | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) galtifenin |
0‑L | V09DB | Technetium (99mTc), particles and colloids | WHO Anatomical Therapeutic Chemical classification | | Technetium (99mTc), particles and colloids |
0‑L | V09DB01 | technetium (99mTc) nanocolloid | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) nanocolloid |
0‑L | V09DB02 | technetium (99mTc) microcolloid | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) microcolloid |
0‑L | V09DB03 | technetium (99mTc) millimicrospheres | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) millimicrospheres |
0‑L | V09DB04 | technetium (99mTc) tin colloid | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) tin colloid |
0‑L | V09DB05 | technetium (99mTc) sulfur colloid | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) sulfur colloid |
0‑L | V09DB06 | technetium (99mTc) rheniumsulfide colloid | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) rheniumsulfide colloid |
0‑L | V09DB07 | technetium (99mTc) phytate | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) phytate |
0‑L | V09DX | Other hepatic and reticulo endothelial system diagnostic radiopharmaceuticals | WHO Anatomical Therapeutic Chemical classification | | Other hepatic and reticulo endothelial system diagnostic radiopharmaceuticals |
0‑L | V09DX01 | selenium (75Se) tauroselcholic acid | WHO Anatomical Therapeutic Chemical classification | | selenium (75Se) tauroselcholic acid |
0‑L | V09E | RESPIRATORY SYSTEM | WHO Anatomical Therapeutic Chemical classification | | RESPIRATORY SYSTEM |
0‑L | V09EA | Technetium (99mTc), inhalants | WHO Anatomical Therapeutic Chemical classification | | Technetium (99mTc), inhalants |
0‑L | V09EA01 | technetium (99mTc) pentetic acid | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) pentetic acid |
0‑L | V09EA02 | technetium (99mTc) technegas | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) technegas |
0‑L | V09EA03 | technetium (99mTc) nanocolloid | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) nanocolloid |
0‑L | V09EB | Technetium (99mTc), particles for injection | WHO Anatomical Therapeutic Chemical classification | | Technetium (99mTc), particles for injection |
0‑L | V09EB01 | technetium (99mTc) macrosalb | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) macrosalb |
0‑L | V09EB02 | technetium (99mTc) microspheres | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) microspheres |
0‑L | V09EX | Other respiratory system diagnostic radiopharmaceuticals | WHO Anatomical Therapeutic Chemical classification | | Other respiratory system diagnostic radiopharmaceuticals |
0‑L | V09EX01 | krypton (81mKr) gas | WHO Anatomical Therapeutic Chemical classification | | krypton (81mKr) gas |
0‑L | V09EX02 | xenon (127Xe) gas | WHO Anatomical Therapeutic Chemical classification | | xenon (127Xe) gas |
0‑L | V09EX03 | xenon (133Xe) gas | WHO Anatomical Therapeutic Chemical classification | | xenon (133Xe) gas |
0‑L | V09F | THYROID | WHO Anatomical Therapeutic Chemical classification | | THYROID |
0‑L | V09FX | Various thyroid diagnostic radiopharmaceuticals | WHO Anatomical Therapeutic Chemical classification | | Various thyroid diagnostic radiopharmaceuticals |
0‑L | V09FX01 | technetium (99mTc) pertechnetate | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) pertechnetate |
0‑L | V09FX02 | sodium iodide (123I) | WHO Anatomical Therapeutic Chemical classification | | sodium iodide (123I) |
0‑L | V09FX03 | sodium iodide (131I) | WHO Anatomical Therapeutic Chemical classification | | sodium iodide (131I) |
0‑L | V09FX04 | sodium iodide (124I) | WHO Anatomical Therapeutic Chemical classification | | sodium iodide (124I) |
0‑L | V09G | CARDIOVASCULAR SYSTEM | WHO Anatomical Therapeutic Chemical classification | | CARDIOVASCULAR SYSTEM |
0‑L | V09GA | Technetium (99mTc) compounds | WHO Anatomical Therapeutic Chemical classification | | Technetium (99mTc) compounds |
0‑L | V09GA01 | technetium (99mTc) sestamibi | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) sestamibi |
0‑L | V09GA02 | technetium (99mTc) tetrofosmin | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) tetrofosmin |
0‑L | V09GA03 | technetium (99mTc) teboroxime | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) teboroxime |
0‑L | V09GA04 | technetium (99mTc) human albumin | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) human albumin |
0‑L | V09GA05 | technetium (99mTc) furifosmin | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) furifosmin |
0‑L | V09GA06 | technetium (99mTc) stannous agent labelled cells | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) stannous agent labelled cells |
0‑L | V09GA07 | technetium (99mTc) apcitide | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) apcitide |
0‑L | V09GB | Iodine (125I) compounds | WHO Anatomical Therapeutic Chemical classification | | Iodine (125I) compounds |
0‑L | V09GB01 | fibrinogen (125I) | WHO Anatomical Therapeutic Chemical classification | | fibrinogen (125I) |
0‑L | V09GB02 | iodine (125I) human albumin | WHO Anatomical Therapeutic Chemical classification | | iodine (125I) human albumin |
0‑L | V09GX | Other cardiovascular system diagnostic radiopharmaceuticals | WHO Anatomical Therapeutic Chemical classification | | Other cardiovascular system diagnostic radiopharmaceuticals |
0‑L | V09GX01 | thallium (201Tl) chloride | WHO Anatomical Therapeutic Chemical classification | | thallium (201Tl) chloride |
0‑L | V09GX02 | indium (111In) imciromab | WHO Anatomical Therapeutic Chemical classification | | indium (111In) imciromab |
0‑L | V09GX03 | chromium (51Cr) chromate labelled cells | WHO Anatomical Therapeutic Chemical classification | | chromium (51Cr) chromate labelled cells |
0‑L | V09GX04 | rubidium (82Rb) chloride | WHO Anatomical Therapeutic Chemical classification | | rubidium (82Rb) chloride |
0‑L | V09H | INFLAMMATION AND INFECTION DETECTION | WHO Anatomical Therapeutic Chemical classification | | INFLAMMATION AND INFECTION DETECTION |
0‑L | V09HA | Technetium (99mTc) compounds | WHO Anatomical Therapeutic Chemical classification | | Technetium (99mTc) compounds |
0‑L | V09HA01 | technetium (99mTc) human immunoglobulin | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) human immunoglobulin |
0‑L | V09HA02 | technetium (99mTc) exametazime labelled cells | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) exametazime labelled cells |
0‑L | V09HA03 | technetium (99mTc) antigranulocyte antibody | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) antigranulocyte antibody |
0‑L | V09HA04 | technetium (99mTc) sulesomab | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) sulesomab |
0‑L | V09HB | Indium (111In) compounds | WHO Anatomical Therapeutic Chemical classification | | Indium (111In) compounds |
0‑L | V09HB01 | indium (111In) oxinate labelled cells | WHO Anatomical Therapeutic Chemical classification | | indium (111In) oxinate labelled cells |
0‑L | V09HB02 | indium (111In) tropolonate labelled cells | WHO Anatomical Therapeutic Chemical classification | | indium (111In) tropolonate labelled cells |
0‑L | V09HX | Other diagnostic radiopharmaceuticals for inflammation and infection detection | WHO Anatomical Therapeutic Chemical classification | | Other diagnostic radiopharmaceuticals for inflammation and infection detection |
0‑L | V09HX01 | gallium (67Ga) citrate | WHO Anatomical Therapeutic Chemical classification | | gallium (67Ga) citrate |
0‑L | V09I | TUMOUR DETECTION | WHO Anatomical Therapeutic Chemical classification | | TUMOUR DETECTION |
0‑L | V09IA | Technetium (99mTc) compounds | WHO Anatomical Therapeutic Chemical classification | | Technetium (99mTc) compounds |
0‑L | V09IA01 | technetium (99mTc) antiCarcinoEmbryonicAntigen antibody | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) antiCarcinoEmbryonicAntigen antibody |
0‑L | V09IA02 | technetium (99mTc) antimelanoma antibody | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) antimelanoma antibody |
0‑L | V09IA03 | technetium (99mTc) pentavalent succimer | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) pentavalent succimer |
0‑L | V09IA04 | technetium (99mTc) votumumab | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) votumumab |
0‑L | V09IA05 | technetium (99mTc) depreotide | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) depreotide |
0‑L | V09IA06 | technetium (99mTc) arcitumomab | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) arcitumomab |
0‑L | V09IA07 | technetium (99mTc) hynic-octreotide | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) hynic-octreotide |
0‑L | V09IA08 | technetium (99mTc) etarfolatide | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) etarfolatide |
0‑L | V09IA09 | technetium (99mTc) tilmanocept | WHO Anatomical Therapeutic Chemical classification | | technetium (99mTc) tilmanocept |
0‑L | V09IB | Indium (111In) compounds | WHO Anatomical Therapeutic Chemical classification | | Indium (111In) compounds |
0‑L | V09IB01 | indium (111In) pentetreotide | WHO Anatomical Therapeutic Chemical classification | | indium (111In) pentetreotide |
0‑L | V09IB02 | indium (111In) satumomab pendetide | WHO Anatomical Therapeutic Chemical classification | | indium (111In) satumomab pendetide |
0‑L | V09IB03 | indium (111In) antiovariumcarcinoma antibody | WHO Anatomical Therapeutic Chemical classification | | indium (111In) antiovariumcarcinoma antibody |
0‑L | V09IB04 | indium (111In) capromab pendetide | WHO Anatomical Therapeutic Chemical classification | | indium (111In) capromab pendetide |
0‑L | V09IX | Other diagnostic radiopharmaceuticals for tumour detection | WHO Anatomical Therapeutic Chemical classification | | Other diagnostic radiopharmaceuticals for tumour detection |
0‑L | V09IX01 | iobenguane (123I) | WHO Anatomical Therapeutic Chemical classification | | iobenguane (123I) |
0‑L | V09IX02 | iobenguane (131I) | WHO Anatomical Therapeutic Chemical classification | | iobenguane (131I) |
0‑L | V09IX03 | iodine (125I) CC49-monoclonal antibody | WHO Anatomical Therapeutic Chemical classification | | iodine (125I) CC49-monoclonal antibody |
0‑L | V09IX04 | fludeoxyglucose (18F) | WHO Anatomical Therapeutic Chemical classification | | fludeoxyglucose (18F) |
0‑L | V09IX05 | fluorodopa (18F) | WHO Anatomical Therapeutic Chemical classification | | fluorodopa (18F) |
0‑L | V09IX06 | sodium fluoride (18F) | WHO Anatomical Therapeutic Chemical classification | | sodium fluoride (18F) |
0‑L | V09IX07 | fluoromethylcholine (18F) | WHO Anatomical Therapeutic Chemical classification | | fluoromethylcholine (18F) |
0‑L | V09IX08 | fluoroethylcholine (18F) | WHO Anatomical Therapeutic Chemical classification | | fluoroethylcholine (18F) |
0‑L | V09IX09 | gallium (68Ga) edotreotide | WHO Anatomical Therapeutic Chemical classification | | gallium (68Ga) edotreotide |
0‑L | V09IX10 | fluoroethyl-L-tyrosine (18F) | WHO Anatomical Therapeutic Chemical classification | | fluoroethyl-L-tyrosine (18F) |
0‑L | V09IX11 | fluoroestradiol (18F) | WHO Anatomical Therapeutic Chemical classification | | fluoroestradiol (18F) |
0‑L | V09IX12 | fluciclovine (18F) | WHO Anatomical Therapeutic Chemical classification | | fluciclovine (18F) |
0‑L | V09X | OTHER DIAGNOSTIC RADIOPHARMACEUTICALS | WHO Anatomical Therapeutic Chemical classification | | OTHER DIAGNOSTIC RADIOPHARMACEUTICALS |
0‑L | V09XA | Iodine (131I) compounds | WHO Anatomical Therapeutic Chemical classification | | Iodine (131I) compounds |
0‑L | V09XA01 | iodine (131I) norcholesterol | WHO Anatomical Therapeutic Chemical classification | | iodine (131I) norcholesterol |
0‑L | V09XA02 | iodocholesterol (131I) | WHO Anatomical Therapeutic Chemical classification | | iodocholesterol (131I) |
0‑L | V09XA03 | iodine (131I) human albumin | WHO Anatomical Therapeutic Chemical classification | | iodine (131I) human albumin |
0‑L | V09XX | Various diagnostic radiopharmaceuticals | WHO Anatomical Therapeutic Chemical classification | | Various diagnostic radiopharmaceuticals |
0‑L | V09XX01 | cobalt (57Co) cyanocobalamine | WHO Anatomical Therapeutic Chemical classification | | cobalt (57Co) cyanocobalamine |
0‑L | V09XX02 | cobalt (58Co) cyanocobalamine | WHO Anatomical Therapeutic Chemical classification | | cobalt (58Co) cyanocobalamine |
0‑L | V09XX03 | selenium (75Se) norcholesterol | WHO Anatomical Therapeutic Chemical classification | | selenium (75Se) norcholesterol |
0‑L | V09XX04 | ferric (59Fe) citrate | WHO Anatomical Therapeutic Chemical classification | | ferric (59Fe) citrate |
0‑L | V10 | THERAPEUTIC RADIOPHARMACEUTICALS | WHO Anatomical Therapeutic Chemical classification | | THERAPEUTIC RADIOPHARMACEUTICALS |
0‑L | V10A | ANTIINFLAMMATORY AGENTS | WHO Anatomical Therapeutic Chemical classification | | ANTIINFLAMMATORY AGENTS |
0‑L | V10AA | Yttrium (90Y) compounds | WHO Anatomical Therapeutic Chemical classification | | Yttrium (90Y) compounds |
0‑L | V10AA01 | yttrium (90Y) citrate colloid | WHO Anatomical Therapeutic Chemical classification | | yttrium (90Y) citrate colloid |
0‑L | V10AA02 | yttrium (90Y) ferrihydroxide colloid | WHO Anatomical Therapeutic Chemical classification | | yttrium (90Y) ferrihydroxide colloid |
0‑L | V10AA03 | yttrium (90Y) silicate colloid | WHO Anatomical Therapeutic Chemical classification | | yttrium (90Y) silicate colloid |
0‑L | V10AX | Other antiinflammatory therapeutic radiopharmaceuticals | WHO Anatomical Therapeutic Chemical classification | | Other antiinflammatory therapeutic radiopharmaceuticals |
0‑L | V10AX01 | phosphorous (32P) chromicphosphate colloid | WHO Anatomical Therapeutic Chemical classification | | phosphorous (32P) chromicphosphate colloid |
0‑L | V10AX02 | samarium (153Sm) hydroxyapatite colloid | WHO Anatomical Therapeutic Chemical classification | | samarium (153Sm) hydroxyapatite colloid |
0‑L | V10AX03 | dysprosium (165Dy) colloid | WHO Anatomical Therapeutic Chemical classification | | dysprosium (165Dy) colloid |
0‑L | V10AX04 | erbium (169Er) citrate colloid | WHO Anatomical Therapeutic Chemical classification | | erbium (169Er) citrate colloid |
0‑L | V10AX05 | rhenium (186Re) sulfide colloid | WHO Anatomical Therapeutic Chemical classification | | rhenium (186Re) sulfide colloid |
0‑L | V10AX06 | gold (198Au) colloidal | WHO Anatomical Therapeutic Chemical classification | | gold (198Au) colloidal |
0‑L | V10B | PAIN PALLIATION (BONE SEEKING AGENTS) | WHO Anatomical Therapeutic Chemical classification | | PAIN PALLIATION (BONE SEEKING AGENTS) |
0‑L | V10BX | Various pain palliation radiopharmaceuticals | WHO Anatomical Therapeutic Chemical classification | | Various pain palliation radiopharmaceuticals |
0‑L | V10BX01 | strontium (89Sr) chloride | WHO Anatomical Therapeutic Chemical classification | | strontium (89Sr) chloride |
0‑L | V10BX02 | samarium (153Sm) lexidronam | WHO Anatomical Therapeutic Chemical classification | | samarium (153Sm) lexidronam |
0‑L | V10BX03 | rhenium (186Re) etidronic acid | WHO Anatomical Therapeutic Chemical classification | | rhenium (186Re) etidronic acid |
0‑L | V10X | OTHER THERAPEUTIC RADIOPHARMACEUTICALS | WHO Anatomical Therapeutic Chemical classification | | OTHER THERAPEUTIC RADIOPHARMACEUTICALS |
0‑L | V10XA | Iodine (131I) compounds | WHO Anatomical Therapeutic Chemical classification | | Iodine (131I) compounds |
0‑L | V10XA01 | sodium iodide (131I) | WHO Anatomical Therapeutic Chemical classification | | sodium iodide (131I) |
0‑L | V10XA02 | iobenguane (131I) | WHO Anatomical Therapeutic Chemical classification | | iobenguane (131I) |
0‑L | V10XA53 | tositumomab/iodine (131I) tositumomab | WHO Anatomical Therapeutic Chemical classification | | tositumomab/iodine (131I) tositumomab |
0‑L | V10XX | Various therapeutic radiopharmaceuticals | WHO Anatomical Therapeutic Chemical classification | | Various therapeutic radiopharmaceuticals |
0‑L | V10XX01 | sodium phosphate (32P) | WHO Anatomical Therapeutic Chemical classification | | sodium phosphate (32P) |
0‑L | V10XX02 | ibritumomab tiuxetan (90Y) | WHO Anatomical Therapeutic Chemical classification | | ibritumomab tiuxetan (90Y) |
0‑L | V10XX03 | radium (223Ra) dichloride | WHO Anatomical Therapeutic Chemical classification | | radium (223Ra) dichloride |
0‑L | V20 | SURGICAL DRESSINGS | WHO Anatomical Therapeutic Chemical classification | | SURGICAL DRESSINGS |
|